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Melanomas are considered as the most aggressive and treatment resistant human cancers 
since, once the melanoma reaches its advanced stages, it starts to resist chemotherapy. 
Melanomas account for 48,000 deaths worldwide with the highest rates of incidences in 
Australia and New Zealand. It has been reported that the resistance to chemotherapeutics 
or the multi-drug resistance (MDR) is generally mediated by oncogenic mutations and 
increased expression of drug resistance markers in melanoma. Mutation in the tumour 
suppressor protein p53 is one of the most common reasons that lead to tumour progression 
and development, due to dysregulation of apoptosis. While, rapidly accelerated 
fibrosarcoma homolog-B (BRAF) and rapidly accelerated fibrosarcoma homolog-N (NRAS) 
are the most commonly associated mutations with melanomas that lead to drug resistance. 
P-glycoprotein (P-gp) is also a critical marker that is further associated with resistance to 
chemotherapeutics. BRAF, NRAS, p53 mutations and P-gp overexpression together lead to 
multi-drug resistant (MDR) melanomas.  
This study employed the use of p53 mutant SK-MEL-2 (missense mutation), SK-MEL-28 (loss 
of function mutation) and patient derived BRAF mutant (LM-MEL-24 and LM-MEL-62), NRAS 
mutant (LM-MEL-1a), wild-type BRAF and NRAS (LM-MEL-12) and drug-resistant cell line 
(Mel-007), in order to investigate the anti-cancer potential of bovine lactoferrin (bLf), in its 
different iron saturation forms; Native-bLf (natural form of bLf), iron-free form of bLf (Apo-
bLf) and iron-saturated form of bLf (Fe-bLf). The aim of the present study was delineating 
the mechanism of apoptosis that was caused by bLf, and its ability to target P-gp in order to 
overcome MDR in melanomas with mutant p53, BRAF, NRAS and drug-resistant status. bLf, 
a multifunctional iron binding glycoprotein has been shown to have anti-cancer activity 
against several forms of cancer however, its ability to target melanomas with different 
mutational status and drug-resistant markers remains unexplored. Therefore, this is the first 
study to report on the anti-cancer efficacies of Native-bLf, Apo-bLf and Fe-bLf in  p53 
mutant (SK-MEL-2 and SK-MEL-28) and patient derived BRAF mutants (LM-MEL-24 and LM-
MEL-62), NRAS mutant (LM-MEL-1a), wild-type BRAF and NRAS (LM-MEL-12) and cisplatin 
drug-resistant cell line (Mel-007) melanoma cells. 
                                                                                                                                                  Abstract 
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The Native-bLf and its iron free and iron saturated forms were successfully prepared as per 
the well-established procedure, from the laboratory. The purity and immunoreactivity of the 
prepared proteins were confirmed using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting. The iron content in the three forms of bLf 
samples namely Native-bLf, Apo-bLf and Fe-bLf, was 19 %, 2.3 % and 98.5 %, respectively 
which was in accordance with the previously published ranges from our laboratory and 
worldwide.  
Before studying the anticancer activities of bLf, attempts were made to investigate if bLf 
forms differ in their internalisation (cellular uptake) and modulate the gene expression 
levels of different types of lactoferrin receptors present on melanoma cells. Quantitative 
real time polymerase chain reaction (qRT-PCR) was performed in order to analyse the 
modulation of mRNA expression levels of various Lf receptors when cells were grown with 
bLf forms. A differential Lf receptor expression pattern was observed in the case of all the 
cell lines. In particular, in SK-MEL-28, Native-bLf significantly (p< 0.01) upregulated the 
transferrin receptor 1 and 2 (TfR1 and TfR2) expression while Apo-bLf significantly (p< 0.01) 
upregulated TfR2 and TfR1 (p< 0.05), Fe-bLf on the other hand significantly (p< 0.05) 
upregulated TfR. Interestingly, gene expression levels of other receptors such as low-density 
lipoprotein receptors (LRP) 1 and 2 and lactoferrin receptor (LfR) showed significant 
downregulation. In SK-MEL-2 cells, Native-bLf significantly upregulated the expression of LfR 
(p≤ 0.01) and TfR1 at 40 nM (p< 0.05) while Apo-bLf upregulated the expression of LRP-1 (p< 
0.05) at higher concentration, Fe-bLf significantly upregulated (p≤ 0.01) LRP-1, LRP-2, LfR 
and (p< 0.05) TfR1. As observed in SK-MEL-28, SK-MEL-2 also showed a significant 
downregulation of TfR and TfR2. An interesting observation was the downregulation of TfR1 
with Fe-bLf treatments in both SK-MEL-2 and SK-MEL-28 cells. Similar observations of 
differentially regulated Lf receptor expression were noted in the patient-derived primary 
melanoma and drug-resistant cells. Native-bLf significantly upregulated the expression of 
TfR1 and LRP-1 (p≤ 0.01), Apo-bLf significantly upregulated TfR1 (p≤ 0.01), TfR2 and LfR (p< 
0.05) and Fe-bLf caused significant upregulation (p≤ 0.01) of TfR1, LfR and LRP-2 (p< 0.05) in 
LM-MEL-12 (WT BRAF and NRAS) cells. Significant downregulation of TfR, LRP-1 (with Apo-
bLf and Fe-bLf) and LfR2 (p≤ 0.01) were also observed in LM-MEL-12 (WT BRAF and NRAS) 
cells. In LM-MEL-1a (NRAS Q16K) cells, significant upregulation of LfR (p≤ 0.01) with Apo-bLf 
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and Fe-bLf upregulated the expression of LfR (p≤ 0.001) and LRP-2 (p< 0.05) was observed. 
Significant downregulation of TfR, TfR1, LfR1 and LfR2 was observed in LM-MEL-1a (NRAS 
Q16K) cells. LM-MEL-62 (BRAF G469E) cells, showed a significant upregulation (p< 0.05) of 
LfR with Native-bLf and Apo-bLf. Fe-bLf significantly upregulated TfR, TfR2 and LfR (p< 0.05), 
however; downregulation of TfR1, LfR1, LfR2, LRP-1 and LRP-2 (with Native-bLf and Apo-bLf) 
was observed in LM-MEL-62 (BRAF G469E) cells. The expression of LRP-1 was significantly 
upregulated (p< 0.05) with Native-bLf in LM-MEL-24 (BRAF V600K) cells. Apo-bLf treatment 
led to a significant upregulation of TfR1, LfR2 (p≤ 0.01) and LfR (p< 0.05). Significant 
upregulation (p< 0.05) of LfR2 and LRP-1 was observed with Fe-bLf and TfR, TfR2, LfR1 were 
all downregulated in LM-MEL-24 (BRAF V600K) cells. Drug-resistant Mel-007 (DR) cells 
showed a significant upregulation (p< 0.05) of TfR1 and LfR2 with Native-bLf, LfR, LRP-2 (p≤ 
0.01) and TfR and TfR1 (p< 0.05) with Apo-bLf and TfR, TfR1, LfR, LfR2, LRP-1 and LRP-2 with 
Fe-bLf. Downregulation of only TfR2 was observed which was significant (p≤ 0.01) with Apo-
bLf treatment in Mel-007 (DR) cells. 
The internalisation studies were further performed using laser immunoconfocal microscopy. 
Even though Apo-bLf was not as efficient as Native-bLf and Fe-bLf in being able to 
internalise within 30 min, the internalisation efficacy of all the three bLf forms was found to 
be equivalent following 6 h incubation in SK-MEL-2. On the other hand, Apo-bLf showed the 
most effective internalisation efficacy in SK-MEL-28 cells at 30 min, while at 6 h all the three 
forms of bLf again showed equivalent internalisation efficacy. A time-dependent increase in 
the internalisation efficacy of all three forms of bLf was observed in case of LM-MEL-12 (WT 
BRAF and NRAS), LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF G469E) cells. In LM-MEL-
24 (BRAF V600K) cells, both Native-bLf and Apo-bLf showed lower internalisation efficacy 
when compared to Fe-bLf, whereas; all the three forms of bLf showed very high 
internalisation efficacy in Mel-007 (DR) cells. A membrane-specific immunoreactivity of the 
bLf forms was observed, suggesting, receptor-mediated internalisation of bLf forms. It was 
also observed that bLf forms were able to internalise in the nucleus of the melanoma cells. 
Irrespective of the variation in the Lf receptor expression with the bLf forms in the 
melanoma cells tested, it was observed that all the three forms of bLf were able to 
internalise efficiently at 6 h.  
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To investigate the effect of bLf forms on targeting melanoma cell growth, CyQUANT cell 
proliferation assay, tumour spheroid assay and clonogenic assay were used. CyQUANT assay 
findings revealed that at the highest concentration (80 nM) among the three bLf forms,  Fe-
bLf  showed the highest anti-cell proliferative ability in SK-MEL-2 cells (p≤ 0.001) whereas; 
Apo-bLf (p≤ 0.001)  proved the most effective in reducing the cell proliferation of SK-MEL-28 
cells. While at 80 nM, all the three forms, Native-bLf, Apo-bLf and Fe-bLf were significant (p≤ 
0.01) in reducing cell proliferation  of three cell lines with mutations namely LM-MEL-12 (WT 
BRAF and NRAS), LM-MEL-1a (NRAS Q16K) LM-MEL-24 (BRAF V600K) and cisplatin resistant  
Mel-007 (DR); Fe-bLf  at the same concentration proved most effective with  significant (p≤ 
0.001) downregulation of  cell proliferation in LM-MEL-62 (BRAF G469E). On the other hand, 
even at the lower concentration 40nM Apo-bLf  had highly significant effect (p≤ 0.01) in 
reducing the cell proliferation in LM-MEL-1a (NRAS Q16K) and both Apo-bLf and Fe-bLf 
showed significant (p≤ 0.01) in reducing cell proliferation of LM-MEL-24 (BRAF V600K) and 
Mel-007 (DR) cells even at 40nM.  
The results from 3 dimensional tumour spheroid assay further  revealed that, Fe-bLf was the 
most significant in reducing the tumour spheroid size in SK-MEL-2 (p≤ 0.001), SK-MEL-28 (p≤ 
0.01), LM-MEL-1a (NRAS Q16K) (p≤ 0.001), LM-MEL-62 (BRAF G469E) (p≤ 0.01) and Mel-007 
(DR) cells, whereas; Native-bLf was the most effective in LM-MEL-12 (WT BRAF and NRAS) 
(p≤ 0.01)  and in LM-MEL-24 (BRAF V600K) (p≤ 0.001) cells. An increase in the necrotic 
regions in the tumour spheroids was observed with the treatments. Native-bLf led to 
degradation and disintegration of tumour spheroids rather than reducing their surface area.  
Colony forming assay was performed to investigate the effects of bLf forms on clonogenic 
potential of melanoma cells. Native-bLf was the most significant (p≤ 0.001) in reducing the 
clonogenic potential of SK-MEL-2, SK-MEL-28 and LM-MEL-1a (NRAS Q16K) cells. The most 
effective and significant (p≤ 0.001)  downregulation in clonogenicity of LM-MEL-12 (WT 
BRAF and NRAS) and LM-MEL-24 (BRAF V600K) cells was noted with all the three forms of 
bLf  (40nM). In LM-MEL-62 (BRAF V600K) and Mel-007 (DR) treatments of Native-bLf and Fe-
bLf were most significant (p≤ 0.001). Both Apo-bLf and Native-bLf also showed significant 
comparatively significant effect at 20 nM, LM-MEL-24 (BRAFV600K). 
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The cytotoxic effects of bLf forms (10 nM, 20 nM and 40 nM) on melanoma cells and normal 
primary epidermal melanocytes were further studied using lactate dehydrogenase (LDH 
release assay). Native-bLf and Fe-bLf was most significant (p≤ 0.001) in SK-MEL-2 cells while 
Native-bLf and Apo-bLf was most significant (p≤ 0.001) in causing cytotoxicity to SK-MEL-28. 
Both Fe-bLf and Native-bLf showed non-significant cytotoxicity in the primary epidermal 
melanocytes, whereas; higher treatments of 40nM Apo-bLf led to a significant cytotoxicity 
(p< 0.05) in these cells. However, this cytotoxicity was comparatively much lower than the 
cytotoxicity caused in melanoma cells at the same concentration.  
For patient derived cell lines, it was found that in preliminary screening experiments, that a 
further higher concentration of 80 nM was required to induce comparable level of 
cytotoxicity observed with SK-MEL-2 and SK-MEL-28. All the three bLf forms at 80 nM 
induced significant levels (p≤ 0.001) of cytotoxicity in LM-MEL-24 (BRAF V600K), LM-MEL-62 
(BRAF G469E) cells. It was observed that both Apo-bLf and Fe-bLf were effective (p≤ 0.001) 
in LM-MEL-12 (WT BRAF and NRAS), while, both Native-bLf and Fe-bLf were effective (p≤ 
0.001) in LM-MEL-1a (NRAS Q16K). Only Native-bLf was found to be the most significant (p≤ 
0.001) in causing cytotoxicity in Mel-007 (DR) cells.  
To determine the nature of cell death, annexin-V assay was performed. In SK-MEL-2 cells, 
there was significant (p≤ 0.001) induction of apoptosis with Fe-bLf. Both Native-bLf and Apo-
bLf proved most effective as it caused significant upregulation of late apoptosis and necrosis 
(p≤ 0.01) in SK-MEL-28 cells. In LM-MEL-12 (WT BRAF and NRAS) cells, both Apo-bLf and Fe-
bLf caused significant increase (p≤ 0.001) in the early apoptotic cells when compared to 
untreated cells. Native-bLf was found to be the most effective treatment as it lead to a 
significant (p≤ 0.001) increase in the late apoptotic cells in LM-MEL-1a (NRAS Q16K), and 
more necrosis (p≤ 0.01) in LM-MEL-62 (BRAF G469E) cells, and early apoptosis (p≤ 0.01) in 
LM-MEL-24 (BRAF V600K) and (p≤ 0.001) in Mel-007 (DR).   
The protein expression profiling of key molecules involved in the apoptotic pathway using 
apoptosis array revealed that the apoptotic pathway induced by bLf forms in SK-MEL-2 and 
SK-MEL-28 was the same irrespective of the treatment with different forms of bLf that were  
proved earlier effective in targeting melanoma cell growth and inducing cell death.   At 40 
nM, significant downregulation in the survivin protein expression was observed with Apo-
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bLf (p≤ 0.01) in SK-MEL-2, and with Native-bLf and Fe-bLf (p< 0.05) in SK-MEL-28. 
Upregulation of death receptors namely, tumour necrosis factor related apoptosis inducing 
ligand (TRAIL) and tumour necrosis factor receptor superfamily member 6 (Fas/TNFRSF6) 
was observed in SK-MEL-2 (with Apo-bLf and Fe-bLf) and in SK-MEL-28 (with all the three 
forms of bLf). Fas- associated protein with death domain (FADD) was upregulated with Apo-
bLf in SK-MEL-2 and with both Native-bLf and Apo-bLf in SK-MEL-28 cells. The mechanisms 
of apoptosis involved significant upregulation of pro-apoptotic markers such as phospho-
p53 (S15), B-cell lymphoma -2 associated X protein (Bax) and Bcl-2 associated death 
promoter (Bad) in both SK-MEL-2 and SK-MEL-28 cell lines. The caspase-3 release assay 
confirmed upregulation of the final activator of apoptosis (caspase-3) with Fe-bLf 40 nM in 
SK-MEL-2 and both Native-bLf and Fe-bLf (40 nM) in SK-MEL-28, whereas; at 20 nM Native-
bLf caused significant (p≤ 0.001) increase in caspase-3 release in SK-MEL-2 and (p≤ 0.01) in 
SK-MEL-28. 
In order to reconfirm the importance of p53 in the induction of apoptosis in melanoma cells 
with different BRAF and NRAS mutations and drug resistance, the study was therefore,  
extended to visualize the cellular localisation (cytoplasmic/nuclear) of p53 expression 
through immunoconfocal microscopy, following treatment with different bLf forms at 40nM 
in  patient derived melanoma cell lines. In the untreated cells, the localisation of p53 was 
mainly cytoplasmic in all the cells. With treatment of Native-bLf, Apo-bLf and Fe-bLf in LM-
MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and LM-
MEL-24 (BRAF V600K) cells, there was an increase in the expression of p53 and the 
expression was mainly observed in the nucleus of the cells. In Mel-007 (DR) cells alone, 
Native-bLf and Apo-bLf were not as effective as Fe-bLf in causing nuclear localisation of p53 
whereas the cytoplasmic and perinuclear expression of p53 had increased with both Native-
bLf and Fe-bLf. 
Western blotting analysis was further performed to delineate the effect of Apo-bLf and Fe-
bLf at 40 nM, on the protein expression of key molecules involved in p53- pathway leading 
to apoptosis.  In LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells, 
Fe-bLf was the most effective form in upregulating p53. The phospho-p53 levels were found 
to increase with Fe-bLf in LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF G469E) cells, and 
Apo-bLf was comparatively more effective in upregulation of phospho-p53 in Mel-007 (DR). 
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Downstream regulators of the p53 pathway such as Numb were found to be upregulated by 
both Apo-bLf and Fe-bLf in LM-MEL-1a (NRAS Q16K) and Mel-007 (DR) cells, whereas; only 
Fe-bLf was effective in LM-MEL-62 (BRAF G469E) cells. Downregulation of mouse double 
minute homolog 2 (MDM2) was observed with Fe-bLf in LM-MEL-1a (NRAS Q16K) and with 
both Apo-bLf and Fe-bLf in Mel-007 (DR). Both Apo-bLf and Fe-bLf showed downregulation 
of survivin, Bcl-2 and upregulation of Bax protein expression in all the three cell lines. By 
employing siRNA technology and treating these three cell lines post p53 silencing, with Apo-
bLf and Fe-bLf, it was observed that anti-apoptotic functions of Apo-bLf and Fe-bLf were 
p53-dependent and the absence of p53 did not cause apoptosis in LM-MEL-1a (NRAS Q16K), 
LM-MEL-62 (BRAF G469E) and Mel-007 (DR) melanoma cell lines, further validating the 
potential use of bLf in melanomas with varying clinical phenotypes that include mutations 
and drug-resistant status. 
Since melanoma cells with p53, BRAF and NRAS mutations are known to induce drug-
resistance in melanoma cells, study of critical drug-resistance marker P-gp was performed 
using flow cytometry, confocal microscopy and Western blotting. The above mentioned 
assays, confirmed that overall all the iron containing bLf forms (both Native-bLf and Fe-bLf) 
were effective in downregulating P-gp expression in SK-MEL-2 and, SK-MEL-28 cells. Both 
Native-bLf and Fe-bLf again proved comparatively effective in downregulating P-gp 
expression in LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF G469E), whereas; all the three 
forms of bLf showed an effective downregulation of P-gp in LM-MEL-12 (WT BRAF and 
NRAS) and LM-MEL-24 (BRAF V600K). In case of Mel-007 (DR) cells, both Apo-bLf and Fe-bLf 
were found to be effective in downregulating P-gp. However, the effective treatment time 
varied between the cell lines varying in their p53 mutational and BRAF/NRAS status. 
Downregulation of P-gp expression was significant (p≤ 0.01) with Fe- bLf treatments in the 
patient-derived primary melanoma cell lines where the reduction in P-gp protein expression 
was seen upto 120 h of treatment. On the contrary, chemotherapeutic drugs, including 
Dacarbazine (DTIC), Doxorubicin (Dox) and Melphalan were able to downregulate the P-gp 
protein expression from 48 h to 72 h of treatment. After 96 h and 120 h the protein 
expression levels of P-gp were significantly upregulated (p< 0.05) proving limited effect of 
DTIC, Dox and Melphalan on P-gp expression. An anti-hypertensive drug, atenolol was also 
employed in this study for studying the modulation of P-gp expression in the melanoma cell 
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lines. This drug was used as a treatment strategy for malignant melanoma patients hence it 
would be interesting to check its effect on P-gp expression in vitro. Atenolol proved to be 
significant (p≤ 0.01) in downregulating P-gp expression in both SK-MEL-2 and SK-MEL-28 
cells, however, in case on the patient derived melanoma cells with varying BRAF/NRAS 
status and drug-resistant cell line, atenolol did not show a highly significant effect in 
downregulating P-gp even at concentration of 1 mg/mL.  
Taken together, from the data derived from all the assays (cell growth , cell death and P-gp 
marker) performed, Fe-bLf (iron saturated) was the most effective in SK-MEL-2, whereas; 
Apo-bLf (iron free) was the most effective in SK-MEL-28 cells. These results indicate that the 
activity of bLf forms varied in SK-MEL-2 (missense mutation) and SK-MEL-28 (loss of function 
mutation) might be due to the difference in iron saturation of bLf forms.  
In LM-MEL-12 (WT BRAF and NRAS) cells, the overall anti-cancer efficacy was high with both 
Apo-bLf and Fe-bLf. Fe-bLf showed highest anti-cancer efficacy in LM-MEL-1a (NRAS Q16K) 
and LM-MEL-62 (BRAF G469E), whereas; Apo-bLf was most effective in LM-MEL-24 (BRAF 
V600K) cells. In Mel-007 (DR) cells, both Native-bLf and Fe-bLf were equally effective. 
Interestingly, in LM-MEL-1a (WT BRAF and NRAS) no difference in the effect between the 
iron free and iron saturated forms were observed, whereas; in cell lines that harboured 
BRAF or NRAS mutations only either the iron free or iron saturated form of bLf was 
effective. In drug-resistant cells (Mel-007 (DR)), only the bLf forms that contained iron 
proved effective in terms of overall anti-cancer activity. These current study findings are 
novel and indicate a possible relationship of the BRAF/NRAS mutations with the regulation 
of iron metabolism in the melanoma cell lines which could further cause a difference in the 
actions of the iron free and iron containing forms of bLf. However, further studies both in 
vivo and in vitro need to be performed, in order to establish the true anti-cancer potential of 
bLf against melanoma for translational impact to clinics.   
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1.1 MELANOMA- AN OVERVIEW 
1.1.1 Melanoma: the highly aggressive skin cancer 
Melanoma, also known as skin cancer is one of the most rapidly increasing cancers 
worldwide, making it a global health problem. One in every three cancers that is diagnosed 
is a skin cancer. Melanoma accounts for only 2% of the skin cancers worldwide but causes 
majority of deaths due to skin cancer (www.cance.org, 2014). Being a highly aggressive form 
of cancer, melanoma metastasis is a common phenomenon that leads to a decrease in the 
5-year survival rate by 16 % and a median survival rate of 6-15 months (Thompson et al. 
2011). Melanoma is described as a malignant tumor of the melanocytes (skin cells), which 
synthesize melanin. Melanin is a dark pigment, responsible for the colour of the skin. 
Melanoma can occur in any part of the body where there is a presence of melanocytes. 
Melanocytes are present mostly in the skin but can also be found in the bowel and in the 
eye.  
1.1.2 Statistics 
Melanoma is most predominant in women, more commonly detected in Caucasians who 
live in sunny climates. The incidence of melanoma is rising worldwide (Jemal et al. 2001a). 
World Health Organisation (WHO) statistics state that there are 48,000 deaths due to 
melanoma every year (Lucas et al. 2006). The highest rates of incidence of melanoma are in 
Australia and New Zealand (Parkin et al. 2005). It is the fifth most common cause of cancer 
among men and seventh most common cause of cancer in women in Australia (Australian 
Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries 
(AACR) 2008). Overall, melanoma is the third most common cancer that occurs in Australia, 
and is the most common cancer that is detected in the age group of 15-24 year old 
Australians (AIHW 2010). As per national statistics, melanoma was accountable for 14 % and 
23 % of all the cancers that were diagnosed in 2006 and 2010, respectively 
(http://www.aihw.gov.au/cancer/skin/). Moreover, according to the statistics, in 2014, two 
in three Australians will be diagnosed with skin cancer by the time they are 70, and the five 
year relative survival rate for melanoma is 90 % for Australian men and 94 % for Australian 
women ('Australian Institute of Health and Welfare , Canberra'  2014).  
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It also accounts for 7000 deaths per year in the USA (http://www.cancer.net/cancer-
types/melanoma/statistics). With these figures, melanoma has been regarded as one of the 
most expensive cancers in terms of mortality and morbidity (Balch et al. 2001a). Melanoma 
is currently the fifth most common cancer diagnosed in America, and the incidence is 
increasing with an estimate of 9710 deaths in the USA and 1050 deaths in Canada in 2014 
(Hamilton et al. 2014; Siegel et al. 2014).  
1.1.3 Risk factors 
A number of factors play a role in the development and progression of melanoma (Figure 1). 
Some of the important factors that pose as major risk factors for melanoma are a 
persistently changed or changing mole, irregular patterns of pigmented lesions, a congenital 
mole, and family history of cutaneous melanoma, excessive exposure to the sun leading to 
exposure to ultraviolet (UV) radiation, immunosuppression, and Caucasian race. Fair skin, 
tendency of the skin to burn rather than tan when exposed to sun rays, freckles on the skin, 
light eye and light hair colour are also some minor factors that are responsible for 
melanoma (Azoury & Lange 2014). 
 
Figure 1. Hypothetical model of melanoma development. In 25% of cases, melanoma 
derives from a pre-existing nevus through a multistep process regulated by a key set of 
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genes. Cells must acquire successive genetic lesions prior to forming tumors and 
metastases. Asterisks indicate genes mutated in the germline (Bertolotto C et al., Scientifica, 
635203 (2013)). These include, neuroblastoma rat sarcoma viral oncogene homology 
(NRAS), rapidly accelerated fibrosarcoma homolog B (BRAF), phosphatase and tensin 
homolog (PTEN), cyclin-dependent kinase 4 (CDK4), tumour-suppressor protein p53 (TP53), 
cyclin D1 (CCND1), telomerase reverse transcriptase (TERT), microphthalmia-associated 
transcription factor (MITF), matrix metalloproteinases 2 (MMP2), Wingless-type mouse 
mammary tumour virus integration site family member 5A (WNT5A), transient receptor 
potential cation channel subfamily M member 1 (TRPM1), epithelial-mesenchymal transition 
(EMT).  Source: (Bertolotto 2013). 
Genetic factors: Melanoma is argued to be a genetic disease, as 10 % of the melanoma 
patients have a family history of melanoma (Montella et al. 2014). An example of a gene 
that is associated with high-risk of occurrence of melanoma is the cyclin-dependent kinase 
N2A (CDKN2A) that has been recognised in the families with an increased occurrence of 
melanoma for decades (Hawkes et al. 2013). Germline mutations in the CDKN2A genes that 
involve chromosome locus p14, p16 lead to an inactivation of the p53, posing a risk of 
melanoma (Hyland et al. 2014). CDK4 (Molven et al. 2005) and retinoblastoma 1 (RB1) 
mutations are also linked to be present in melanoma-prone families. These RB1 mutations 
are also germline leading to loss of heterozygosity for the allele posing an 80-fold elevated 
risk to develop melanoma (Fletcher et al. 2004).  
Biological factors: A number of receptor tyrosine kinases (RTK) have been studied in 
association with melanoma biology. Copy number imbalances in the c-KIT gene (Curtin et al. 
2006), and loss of c-KIT that are associated with UV-induced sun damage (Isabel Zhu & 
Fitzpatrick 2006), lead to an increased risk of melanoma. Activation of the epidermal growth 
factor receptor (EGFR) signaling pathway (Udart et al. 2001) and the rat sarcoma (Ras) 
family mutations, (Ji, Flaherty & Tsao 2012) that get triggered by extracellular growth 
factors, lead to an increase in the metastatic potential and disease occurrence of melanoma.  
1.1.4 Prognosis and treatment challenges 
Melanoma begins to form from the surface of the skin hence it can often be detected at a 
very early stage. Regular examination of the total skin should be done. Melanoma occurs in 
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various stages and the stage of melanoma is important for its prognosis and treatment 
(Table1.1). When treated at the early stages, melanoma is often curable by surgical excision. 
Besides surgical excision of the primary tumour, other treatment strategies include 
chemotherapy, radiotherapy, and a combination of both immunotherapy and 
chemotherapy, treating metastatic melanomas in particular, are all included for melanoma 
treatment (Garibyan & Fisher 2010; Nashan et al. 2007). Melanoma prognosis is often very 
poor in patients that have visceral metastasis and their median survival rate is only a few 
months (Balch et al. 2001b). The prognosis of stage IV melanomas has been poor, with a 
median survival rate less than 1 year and an overall 5-year survival rate of < 10 %.  
Table 1.1. Stages of melanoma progression.  
S.no. Stage of 
melanoma 
Tumour thickness Symptoms 
1.  Stage 0 ---- Abnormal melanocytes in epidermis 
2.  Stage IA  ≤1mm No ulceration 
3.  Stage IB 1mm-2mm With or without ulceration 
4.  Stage IIA ˃ 2mm Ulceration that spreads in the skin 
5.  Stage IIB 2mm-4mm With or without ulceration 
6.  Stage IIC ˃ 4mm With or without ulceration 
7.  Stage III Any thickness Cancer spread to lymph nodes 
Cancer may be in a lymph vessel between 
the primary tumour and nearby lymph 
nodes 
Small tumours found under the skin 
8.  Stage IV Any thickness Cancer spread to lung, liver, brain, soft 
tissue, bone, gastrointestinal (GI tract) 
 
Melanomas are considered as the most aggressive and treatment resistant human cancers 
(Tsao et al. 2012). Traditional chemotherapy works the best for majority of patients in order 
to treat melanoma upto stage II in their progression (Walsh, Gibbs & Gonzalez 2000).The 
general mechanism by which anti-cancer drugs, such as, mitocan act on melanoma is by 
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inducing apoptosis in the melanocytes (Fisher 1994; Wang et al. 2014). However, low 
therapeutic efficacies of the chemotherapeutic agents are usually due to the fact that their 
ability to induce apoptosis in melanoma is relatively weak when compared to other 
malignant cell types (Li et al. 1998; Wäster, Rosdahl & Öllinger 2014). In melanoma, there is 
a very low level of spontaneous apoptosis which is due to the increased metastatic potential 
(Glinsky et al. 1997; Staunton & Gaffney 1995). Developing resistance to apoptosis is an 
early step in malignant transformation from normal melanocytes to melanoma. This holds 
true as resistance to apoptosis is observed more in melanocytic nevi when compared to 
isolated melanocytes (Alanko, Rosenberg & Saksela 1999). 
Though chemotherapy is the most common therapeutic measure available for treating 
melanoma but once the melanoma reaches its advanced stages, it starts to resist 
chemotherapy. The most important concern for the treatment of melanoma is to overcome 
this resistance that is acquired by the melanocytes.  
One of the major impediments and drawbacks in the effective use of chemotherapy and 
drug delivery to cancer cells is the phenomenon of multiple drug resistance (MDR) which 
was first observed in micro-organisms like bacteria and virus (Goossens et al. 2005). 
Designing anti-cancer chemotherapy is a very challenging task as none of the treatments 
available for cancer are 100 percent effective. Also, the efficacy of the treatment depends 
on the individual and their somatic cell genetic differences in the tumor (Gottesman 2002a). 
Each and every cancer has its own array of drug resistant genes; hence the mechanism of 
drug resistance differs in every type of cancer. A number of pathways, for example the 
RAF/MEK/ERK pathway play an important role in conferring MDR to cancer (McCubrey et al. 
2007). Understanding the mechanism(s) by which cancer cells become insensitive to 
chemotherapy, is important in developing therapeutics for drug-resistant tumours.  
Overcoming the mechanisms by which these cancer cells become insensitive to drug 
toxication has been commonly studied. Malignant melanomas have a response rate to 
chemotherapy of 5-12 %  (Weide et al. 2012) which is very low and 50-70 % of  melanomas 
that reject therapy harbor BRAF mutations (Chapman et al. 2011). The phenomenon of MDR 
plays a very critical role in melanoma or skin cancer and the drug resistance mechanisms 
with altered apoptotic pathways and fewer pro-apoptotic molecules have been widely 
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analysed. MDR is a result of a number of distinct mechanisms and processes that occur in 
the tumor and tumor environment. 
1.2 POTENTIAL MECHANISMS OF DRUG RESISTANCE IN MELANOMA 
A number of mechanisms have been hypothesised and worked upon in developing clarity 
for the basis of drug resistance in melanoma patients (Figure 2). A number of mechanisms 
including drug transport, detoxification of glutathione conjugation, topoisomerases, DNA 
repair, Ras mutations and dysregulation of apoptosis have been identified as potential 
factors for causing drug resistance in melanoma cells called melanosomes (Osieka 1984). 
 
Figure 2. Potential mechanisms of drug resistance in melanoma. There are numerous 
reasons why melanomas are resistant to chemotherapy. Some of the mechanisms that are 
involved in making the cells resistant to anti-cancer drugs are drug detoxifying properties of 
melanosomes, over expression of inhibitors of apoptosis (IAP), altered expressions of 
oncogenes or tumour suppressor genes,  endogenous nitric oxide and energy dependent 
drug efflux pumps. This figure shows the potential mechanisms by which melanoma cells 
                                                                                                       Chapter 1- Review of Literature                  
8 
 
become drug resistant. Various factors like the involvement of the V600E mutation in the 
BRAF gene, the MDR-1 (P-glycoprotein (P-gp)) which effluxes anti-cancer agents out of the 
cancer cells, topoisomerases- the enzymes that repair DNA of the tumor causing its survival, 
tenascin-C and glutathione-S-transferase (GST) that are upregulated with the increased P-gp 
expression, and micro RNA regulate the expression of drug transporters on the membranes 
of tumor cells, and the cancer stem cells (CSCs) which show a very high expression of P-gp in 
them, all contribute towards making a cancer cell drug resistant. Source: (Kanwar, Singh & 
Kanwar 2014). 
1.2.1 ABC transporters- the drug-efflux pumps 
A super family of transporters called the adenosine tri phosphate (ATP) binding cassette 
(ABC) transporters are present on the membranes of almost all the cells. These are 
multifunctional efflux transporters that transport molecules by binding and/or hydrolysing a 
pair of ATP molecule and efflux compounds from the inner to the outer leaf of the 
membranes (Higgins 1992). Classification of these transporters is done based on the 
sequence of amino acids that are present in the ATP binding domain (Dean & Allikmets 
1995). A number of evidences suggest the role of the ABC transporters in MDR. P-
glycoprotein (P-gp) which is encoded by the ATP-binding cassette, sub-family B (ABCB1) 
gene was the first ABC transporter, that was found to be over expressed in the MDR tumour 
cells (Kartner et al. 1985). The gene for P-gp called MDR-1, was cloned in 1985 (Kartner et al. 
1985). P-gp also known as MDR Protein 1, is a molecular pump present in the membrane 
which actively effluxes the drugs and other foreign substrates from the interior and has a 
broad substrate specificity (Deeley & Cole 2006). Specific correlations between the 
transport pump and the drug resistant cell lines was made with a study on Chinese hamster 
ovary (CH0) cancer cell line, where P-gp levels were directly proportional to the degree of 
drug resistance in the cells (Juliano & Ling 1976; Ren et al. 2014). P-gp has now become 
target of various anti-cancer efforts.  
P-gp and multidrug resistance-associated proteins (MRPs) that belong to the ABC super 
family, efflux the drug out of the cells in order to prevent drug accumulation. The ABC 
transporters are made up of two ATP binding domains (ABD) also known as nucleotide 
binding folds (NBF) Walker A and Walker B motifs (Figure 3). NBF has an additional 
signature C motif that is present upstream to the Walker B motif (Hyde et al. 1990). NBF 
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also consists of two transmembrane domains (TM) which is made up of 6-11 membrane 
spanning helices. A transporter that consists of all these domains is called as a full 
transporter. When a drug that is rendered into the system comes into contact with the 
transporter (such as P-gp), there is an activation in one of the ATP binding domains, this 
leads to the hydrolysis of ATP which causes a major change in the shape of the P-gp 
transporter structure (Ramachandra et al. 1998). This causes the release of the drug into the 
extracellular space. A second ATP hydrolysis is required to restore the P-gp to its original 
shape so that the cycle can take place again (Sauna & Ambudkar 2001). 
 
Figure 3. Structure and mechanism of action of ABC transporters. Mechanism of drug 
efflux by the P-gp membrane transporter, when an anti-cancer drug enters the cell. (A) The 
P-gp and the entire cell that is causing the efflux of the internalised drug (B) The detailed 
structure of the P-gp and the entry of the drug into the cell through the cell membrane. (C) 
The drug on binding to the ABD causes a conformational change in the nucleotide-binding 
domain (NBD) of the P-gp by utilizing one molecule of ATP. (D) This conformational change 
causes the efflux of the drug from the intracellular space to the extracellular space. (E) After 
the efflux of the drug, another molecule of ATP is hydrolyzed into ADP, causing the release 
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of Pi and thereby, bringing back the conformation of the NBD to normal. Source (Kanwar, 
Singh & Kanwar 2011). 
Cancer cells that are drug resistant often have high levels of P-gp expression on their cell 
surface and P-gp are also found in different types of tumours (Childs et al. 1998). Altered 
levels of the P-gp are always found in patients who have recently undergone chemotherapy 
which subjects them to the anti-cancer drugs such as paclitaxel, cyclosporine and opioids 
etc. (Zhou 2008).Melanoma cells do not express P-gp when they are not subjected to 
chemotherapy (Schandendorf et al. 1994). Once a patient undergoes chemotherapy for 
melanoma, due to the exposure to drug molecules the expression of P-gp is induced in the 
melanoma cells (Schandendorf et al. 1995).  
Cole et al. recognised the second kind of ABC transporters in lung cancer cell line which was 
different from the P-gp in a way that it had a broader substrate specificity of the drugs 
binding to it (Cole & Deeley 2006). This transporter was the multi-drug associated protein 1 
(MRP1). This lead to the finding of more ABC transporters that are associated with the 
multi-drug resistance cell lines.  
The third kind of ABC transporters for anti-cancer drugs were multixenobiotic resistance 
(MXR), breast cancer resistance protein (BCRP) or placenta-specific ATP-binding cassette 
gene (ABC-P) (Cole et al. 1992). These were over expressed on the surface of those cells that 
showed resistance to anthracyclines or mitoxantrone. MDR2 gene products (Dean & 
Allikmets 1995), ATP-binding cassette transporter A2 (ABCA2) (Borst, Zelcer & vanHelvoort 
2000) and sister of P-gp (SPGP) (Laing et al. 1998) could possibly play a role in implementing 
drug resistance but their role was not considered as significant as the other transporters. 
1.2.3 Inhibitors of the ABC transporter proteins 
Recent studies on the effect of MRP-1 in drug resistance have shown that when MRP-1 is 
over expressed in correlation with GST, it increases the ability of melanoma cells to acquire 
resistance to anti-cancer agents (Morrow et al. 1998). Therefore, inhibitors of glutathione 
synthesis and GST’s were developed, for example, curcumin, ethacrynic acid, and MRP’s 
were inhibited by using MK571 and sulphinpyrazone. When GST and MRP were targeted 
with their respective inhibitors they protected the melanoma cells from the toxic effects of 
etoposide (Figure 4) (Depeille et al. 2005).  
                                                                                                       Chapter 1- Review of Literature                  
11 
 
In melanoma, where the phenomenon of multi-drug resistance is most commonly observed, 
P-gp is said to play a dominant role in melanoma as well. One such example is the HCT-15 
drug resistant melanoma cells where drug resistance is conferred because of the P-gp. 
Ingenole-3-angelate (Ing3A) which is extracted from Euphorbia peplus has been tested on 
HCT-15 melanoma cell line. It was observed that Ing3A was bound to and was transported 
by P-gp. Ing3A also blocked the efflux of the drug molecule(Li, Shukla & Lee 2010).  
Dipyridamole is another drug molecule that was used to treat MDR melanoma cells. When 
treated with this agent it was observed that these cells accumulated more amounts of 
doxorubicin and paclitaxel, thereby dipyridamole induced chemosensitivity. This process of 
chemosensitization involved an interaction of this dipyridamole  molecule with P-gp but its 
exact role and mechanism is not known (Damle & Desai 1994). Gemcitabine has also been 
used to study its effect on melanoma cells that are resistant to doxorubicin. It was seen that 
gemcitabine downregulated the expression of P-gp, thereby increasing the uptake of 
doxorubicin by the melanoma cells allowing its action on the cells (Bergman et al. 2003).  
P-gp suppressive cyclosporine (PSC), a non-immunosuppressive cyclosporine analogue, also 
called as valspodar, can inhibit multiple non P-gp transporters in melanoma cells which 
include a cluster of ABC transporters. Some of the transporters that are inhibited are ATP-
biding cassette transporter A9 (ABCA9), ATP-binding cassette transporter B5 (ABCB5), ATP-
binding cassette, sub-family C (ABCC2) and ATP-binding cassette, sub-family D1 (ABCD1) 
(Szakacs et al. 2004). ABCB5 has 60-70% homology with the P-gp membrane transporters 
which attributes it the property of drug-resistance (Chen et al. 2005). PSC or verapamil has 
been shown to increase vinblastine induced cytotoxicity in the human melanotic melanoma 
cell lines, by reflecting the inhibition of P-gp like transporters that are associated with 
melanogenesis (Chen et al. 2009a). 




Figure 4. MDR-1 (P-gp), its enhancers and inhibitors. MDR-1 (P-gp) plays a very important 
role in conferring drug resistance by effluxing the drugs out of the cancer cells. A number of 
proteins and other molecules contribute to the function of MDR-1 in conferring drug 
resistance or restoring the drug sensitivity. MDR-1 inhibitors and anti-cancer agents used 
along with siRNA for MDR-1 (Xiong & Lavasanifar 2011), help in inhibiting the action of 
MDR-1 and make the cancer cells sensitive to treatment with anticancer drugs. Lysosomal 
associated transmembrane beta 4 (LAPTM4B), epidermal growth factor receptor (EGFR), 
cyclooxygenase-2 (COX-2) and the mitogen activate protein kinase (MAPK) pathway, get 
upregulated in case of drug resistant cancers. These molecules either work in co-ordination 
with MDR-1 or help in the activation of it to make cancer cells resistant to chemotherapy. 
Source: (Kanwar, Singh & Kanwar 2014).  
1.2.4 Mechanism of drug resistance in melanocytes 
There are numerous reasons why melanomas are resistant to chemotherapy(Figure 2)., 
Some of the mechanisms that are involved in making the cells resistant to anti-cancer drugs 
are drug detoxifying properties of melanosomes (Grossman & Alteri 2001), over expression 
of inhibitors of apoptosis (IAP) (Soengas & Lowe 2003), altered expressions of oncogenes or 
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tumour suppressor genes (Chin, Garraway & Fisher 2006), endogenous nitric oxide and 
energy dependent drug efflux pumps (Frank et al. 2003). Overexpression of proton pump 
inhibitors leads to decreased pH in the intracellular compartments of a cell when compared 
to the extracellular compartments. As it has been shown that inhibition of lysosomal 
vacuolar H+ ATP activity by proton pump inhibitors leads to reduced expression of proton 
pumps that alters the pH in the intracellular region, thereby increasing cytoplasmic 
retention and import of the cytotoxic drugs. This increase in pH of the intracellular region 
helps  the tumour become resistant to the effects of cisplatin, 5 fluorouracil and vinblastine 
and inhibition of the proton pumps reduces the intracellular pH rendering the cells sensitive 
to therapy by allowing the retention of the above mentioned drugs (Luciani et al. 2004).   
Chemotherapy for metastatic malignant melanoma involves the use of only one approved 
drug by the Food and Drug Administration (FDA) called dacarbazine (DTIC). Experimental 
studies on melanoma xenografts have proved the resistance of melanoma cells, MNT-1 and 
SK-MEL-28 to DTIC, and other chemotherapeutic drug (cisplatin) in vivo (Chen et al. 2006). 
Melanosomes are intracellular organelles of the melanocytes where the synthesis and 
storage of the melanin pigment takes place. It has been proposed that these melanosomes 
might be one of the reasons for conferring drug resistance to melanoma cells by alteration 
of the intracellular drug distribution. This is done either by drug efflux or sequestration into 
intracellular organelles. There are various genes that are responsible for the formation of 
melanosomes, and the mutations in these genes are responsible for increasing the drug 
sensitivity of the cells (Chen et al. 2009b).  
Both drug resistance and drug sensitivity in melanomas and pigment producing cells involve 
the melanosomes biogenesis pathway. Stage IV melanosomes are more sensitive towards 
the drugs because they are highly pigmented. These melanosomes are filled with the 
melanin pigment and frequently exhibit defective membrane structure when compared to 
the stage I, II and III melanosomes (Chen et al. 2009a). This defective membrane structure 
allows the permeability of the drug inside the cell hence making it more effective for 
treatment (Figure 5). As these melanosomes are filled with melanin pigment, they 
sometimes release the toxic substances (which are intermediates in the melanogenic 
biosynthesis pathway) into the cytoplasm which causes endogenous melanogenic 
cytotoxicity (EMC). The stage II and stage III melanosomes are said to exhibit a drug 
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resistance mechanism by trapping the drugs in their organelles (Chen et al. 2009b).  Other 
studies proved that mutations in the BRAF (Lo & Shi 2014), NRAS (Lidsky et al. 2014), p53 
(Jochemsen 2014) and RAF-1 genes (Nissan et al. 2014), are responsible for the synthesis of 
melanosomes (melanoma cells) can alter drug resistance and increase their sensitivity to 
chemotherapy.   
 
Figure 5. Mechanism of drug resistance in melanosomes (melanocytes). The schematic 
figure displays the proposed mechanism showing the relationship between the melanosome 
biosynthetic pathway and drug resistance in melanosomes. Drug resistance is conferred to 
melanosomes depending upon the stage in which they are present. Stage I melanosomes 
are known as premelanosomes and the synthesis of melanin pigment is just initiating. Stage 
II and stage III melanosomes have a sufficient amount of melanin present, which traps the 
drug that enters the melanosomes, hence inhibiting the action of the drug in the 
melanosomes making them drug resistant. In stage IV, there is an overproduction of 
melanin pigment, which leads to the efflux of the drug to the extracellular matrix and 
disruption of the cell membrane. This causes release of melanin pigment and makes the 
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cells more susceptible to the drugs to which they are subjected. Source: (Kanwar, Singh & 
Kanwar 2011).  
Regulation of melanosome formation is influenced by proteins like Hermansky Pudlak 
Syndrome (HPS) proteins (Wei 2006), gp100/Pmel17. It is a structural melanosome protein 
and tyrosinase which are membrane proteins for melanosomal integration (Granholm, Japs 
& Kappenman 1990). It has been studied that, genes like Dtnbp1, Pldn, Vsps33a that 
regulate the formation of mature melanosomes can modulate drug resistance, and 
amelanotic melanosomes (melanomas lacking pigment) are more susceptible to 
chemotherapy to cisplatin.  
1.2.5 Role of BRAF mutations in conferring drug resistance to melanoma 
BRAF belongs to rapidly accelerated fibrosarcoma (RAF) kinases which play role in the 
MAPK/ERKs signaling pathways implicated in cell division, differentiation and secretion. 
MAPK signal transduction pathway  is responsible for transmitting mitogenic signals from 
the cell surface growth factor receptors under normal physiological conditions (Bamford, 
Dawson & Forbes 2004). The highest expression of BRAF gene is seen in cells that originate 
from neuronal crest, mainly in neuronal cells and melanocytes. The best described substrate 
for BRAF till date, is MAP kinase MEK (Garnett & Marais 2004; Holderfield et al. 2014). 
Mutations in BRAF can be both inherited or acquired. The acquired mutations in BRAF make 
it function as an oncogene, and lead to the development of cancer (Davies et al. 2009). 
Activation and amplification of BRAF and its mutations have been confirmed in patient 
biopsies where 4 out of 20 patients with relapse, showed activation of the MAPK pathway 
due to BRAF mutations in melanoma (Horn et al. 2013). The most common mutation that 
has been studied in the BRAF gene is the V600E mutation which is present in 50% of 
malignant melanomas (Rodolfo, Daniotti & Vallacchi 2004). This mutation involves the 
substitution of glutamic acid (E) for valine (V) at the 600 position of the amino acid 
sequence. Lesions that arise from continuous exposure of the skin to sun are said to have a 
high amount of BRAF mutations when compared to melanomas that arise with no relation 
to sun exposure of the skin (Curtin et al. 2005). Apart from BRAF V600E mutations, that 
contribute to 70- 80% of all BRAF mutations that occur in cancer, other BRAF mutations at 
the V600 position include V600K, V600D and V600R which account for a total of 5 -15 % of 
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all BRAF mutations. All the V600 mutations in BRAF gene are a consequence of alternate 
amino acid substitutions (Shtivelman et al. 2014). 
Researchers at Jonnson Comprehensive Cancer Center based at University of California, Los 
Angeles (UCLA) have concluded that patients who developed a melanoma due to mutations 
in the BRAF gene acquire resistance to a targeted treatment by developing a secondary 
mutation in the melanocytes (Chapman et al. 2011). Targeting the messenger RNA (mRNA) 
specifically for V600E with BRAF-specific short-interfering RNA (siRNA) have inhibited the 
synthesis of DNA in the cancer cells, leading to apoptosis of these cells (Hingorani et al. 
2003). Four BRAF mutations have been identified by The Sanger Institute Group that can 
cause MEK- dependant cell proliferation and transformation of fibroblasts, being totally 
independent of the Ras activation of extracellular signal-regulated kinase (ERK) (Karasarides, 
Chiloeches & Hayward 2004). Weinstein et al, stated that BRAF V600E mutation, induces a 
state on “oncogene addiction” (Weinstein, Begemann & Zhou 1997) which indicates that 
once BRAFV600E mutation occurs in melanoma, it will always lead to the development of 
mutations in the Ras oncogene is one of the most common mutation associated with cancer 
(Hassel et al. 2014) which also leads to an increased metastatic potential of melanomas 
(Sanchez-Laorden et al. 2014). Ras mutations are observed in 15% of melanomas (Jansen et 
al. 1996). The neuroblastoma Ras (N-RAS) mutations are particularly linked to the 
development of chemoresistance in melanoma cells (Holderfield et al. 2014) (Jansen et al. 
1997). Borner et al described the mechanism of Ras-mediated drug resistance in melanoma 
cells is due to the increased levels of B-cell lymphoma (Bcl-2) which does not allow the 
melanoma cells to undergo apoptosis (Borner et al. 1999). Dysregulation of apoptosis is one 
of the most important features in developing therapeutic targets for melanoma. Almost all 
the chemotherapeutic drugs induce pro-apoptotic signalling in cells, inhibiting tumor 
progression in those targeted cells (Fisher 1994).  
Although BRAF mutations are most commonly associated with resistance in melanoma, a 
number of other molecules are considered critical that are altered in melanoma. A few of 
them are listen in the table (Table 1.2) below (Adapted from (Shtivelman et al. 2014)).  
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Table 1.2. Commonly occurring gene alterations in melanoma.  
Name of the 
gene 







Mutations, Loss of 
heterozygosity 
85 % and 67 % RHO/RAC/MAPK SiRNA against 
MEK and ERK 
TERT Mutations in the 
promoter of 
catalytic subunit 
70 % - 80 % 






Telomerase TERT inhibitors 
in preclinical 
studies 
MDM4 Overexpression  65 % Negative 
regulator of p53 
SiRNA against 
p53-MDM4 





PTEN Point mutation or 
deletion 





Point mutation or 
deletion  
30 % - 40 %  Negative 
regulator of 
TP53 and RB 
SiRNA against 
CDK 
AKT3 Amplification 25 % PI3K SiRNA against 
AKT, PI3K and 
mTOR 
MYC Amplification 20 % – 40 %  Transcription Possible use of 
siRNA against 
mTOR 
TP53 Point mutation 10 % - 20 % Cell cycle, 
apoptosis 
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ETV1 Amplification 15 % Transcription  
 
MAP3K5- Mitogen activated protein kinase kinase kinase 5, MAP3K9- Mitogen activated 
protein kinase kinase kinase 9, MEK- Mitogen activated ERK, ERK- Extracellular regulated 
kinases, TERT- Telomerase reverse transcriptase, MDM4- Mouse double minute 4, NEDD9- 
Neural precursor cell expressed developmentally down-regulated 9, EMT- Epithelial 
mesenchymal transition, PTEN- Phosphatase and tensin homolog, PI3K- Phosphatidylinositol-
4,5 bisphosphate 3-kinase, CDKN2A- Cyclin-dependent kinase inhibitor 2A, TP53- Tumour 
suppressor protein 53, RB- Retinoblastoma protein, AKT-3- Thyoma viral oncogene homolog 
3, mTOR- Mechanistic target of rapamycin (serine/threonine kinase), MYC- 
Myelocytomatosis oncogene, ETV1- ETS translocation variant 1 
1.2.5.1 BRAF inhibitors/drugs, their side effects and limitations 
A number of therapeutic strategies have been directed towards RAF kinases and the first 
RAF inhibitor that was tested was sorafenib. In clinical trials, sorafenib showed very little 
effect as the median-progression free survival of 3 months (Eisen et al. 2006). Phase III trials 
also failed to show any benefit of using sorafenib alone or sorafenib in combination with 
chemotherapy (Hauschild et al. 2009).  
Considering the importance of BRAF mutations in developing resistance in melanoma cells, 
specific inhibitors that target this gene have been used to suppress the mutations and 
confer drug sensitivity to the melanoma cells. Among these inhibitors PLX4032, has now 
reached clinical trials, and has been tested in a number of studies. In the phase I of the 
clinical trials, it has been observed that 56% of the patients had shown tumor regression 
when they were treated with PLX4032 (Flaherty, Puzanov & Sosman 2009). It was observed 
that at an inhibitory concentration of 50 (IC50) of 1µM PLX403 caused growth inhibition, cell 
cycle arrest at the G0/G1 phase, and also restored apoptosis in the drug sensitive breast 
cancer cell lines (Tap et al. 2010). A complication arose when it was observed that 
melanoma cells acquired resistance to this inhibitor by an alternative survival pathway. A 
second oncogene NRAS mutation started occurring in the melanoma cells which made it 
resistant to treatment with PLX4032 (Sondergaard et al. 2010). A very dominating feature 
found in the cells, that all the PLX4032-resistant melanoma cells showed induction of 
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platelet-derived growth factor receptor β (PDGFRβ) RNA, protein and tyrosine 
phosphorylation. Knockdown of PDGFRβ or N-RAS reduced the growth of the melanoma cell 
lines that were showing resistance to PLX4032 (Nazarian et al. 2010).  
Another FDA approved drug, vemurafenib for the treatment of metastatic melanomas, and 
melanomas with BRAFV600E mutation has been able to target the ERK pathway that is a 
downstream regulator of RAF (Bollag et al. 2010). Vemurafenib proved effective over DTIC 
where there was an increase in the overall survival for vemurafenib was 13.2 months 
compared to 9.6 months in case of DTIC (Chapman et al. 2011). Irrespective of its success in 
clinical trials, vemurafenib was associated with a number of side effects like fatigue, 
alopecia, nausea, rash, photosensitivity and diarrhea due to which there was a need in 
modification of the dosage (Su et al. 2012b). Moreover, it was also associated with 
upregulation of C-rapidly accelerated fibrosarcoma (CRAF) protein which led to drug 
resistance (Oberholzer et al. 2012).  
Dabrafenib, another inhibitor of melanomas with BRAFV600 mutations was approved by the 
FDA in 2013 that had a similar mode of action as vemurafenib but had a shorter half-life 
when compared to vemurafenib (Falchook et al. 2012b). Other BRAF and MEK inhibitors 
named tratmetinib (Falchook et al. 2012a) and LGX818 (Dummer et al. 2013) are in 
development stages to target BRAF mutant melanomas; however, all these inhibitors had 
common side effects like reaction in the skin of hand and feet, keratosis pilaris, pain in 
extremities, alopecia, fatigue and arthralgia.  
Therapeutics that have been developed for BRAF inhibitors have further lead to resistance 
towards BRAF inhibitors within one year of treatment and 20 % of the patients treated with 
BRAF inhibitors developed cutaneous squamous cell carcinoma (Sosman et al. 2012). 
Vemurafenib when used for leukemia patients, showed the development of Ras-mutant 
leukemia showing secondary resistant mechanisms further to BRAF mutations in cancer 
(Callahan et al. 2012). 
 It was hypothesised that treatment with BRAF and MEK inhibitors leads to conformational 
changes in the wild-type BRAF protein that leads to MEK activation and promotion of 
formation of BRAF heterodimers with other RAF isoforms (Poulikakos et al. 2010). For 
example, use of MEK inhibitors in vitro increased transforming growth factor β (TGF- β) 
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signaling that which was then counteracted by the resistant melanoma cells. This resistance 
was acquired due to the overexpression of the SMAD specific E3 ubiquitin protein ligase 2 
(SMURF2) that further leads to overexpression of paired box-3 (PAX-3) and MITF, 
transcription factors helping cells survive (Smith et al. 2012). Activation of survival pathways 
such as PI3K, new mutations in the RAF-MAPK pathway are the two major mechanisms that 
have been related to the development of resistance with BRAF targeting agents (Sullivan & 
Flaherty 2013).  
1.2.6 Role of CD133, Nestin, ABCB5 and CD271 positive cancer stem cells in melanoma 
MDR 
Stem cells are unique because of three distinct properties that they acquire. They undergo 
self-renewal, have the capacity to develop into any kind of cell and can proliferate 
continuously. It is observed that in some tumors, the cancer cells also have similar 
properties and these cells are termed as “cancer stem cells” (CSC) that exhibit tumour 
initiating and self-renewal properties (Zabierowski et al. 2011). CSC could be the reason why 
a tumor becomes malignant from its benign form and lead to heterogeneity in the cancer 
population making it difficult to target. A few CSC are drug resistant cells which give rise to 
distant metastasis or they are responsible for relapse after chemotherapy. A very common 
feature of the CSC is the expression of ABC transporters on their membranes. Some of the 
ABC transporters present in the CSC are BCRP1 and MDR-1 (Zhou et al. 2001). 
 One of the most commonly identified stem cell marker in melanomas is cluster of 
differentiation 133 (CD133), a transmembrane glycoprotein also termed as prominin 1 
(Bertolini et al. 2009; Gedye et al. 2009). In recent studies, CD133 has been shown to have 
stem cell properties confirming its role as a stem cell  marker in melanomas (Monzani et al. 
2007). Recent studies prove that malignant melanoma biopsies contain a subset of cells that 
express CD133 and ABCG2 markers and these markers are also expressed in the xenograft 
models, and the cells that are grown from these tumour biopsies (Monzani et al. 2007). To 
examine the effect of CD133 positive melanoma tumour initiating cells in attributing stem 
cell properties to melanoma, the effect of taxol was tested on them. CD133+ cells were 
resistant to taxol-induced apoptosis whereas CD133- cells were able to undergo apoptosis 
by activation of the apoptosis signal-regulating kinase 1 (ASK1)/ c-jun-N-terminal kinase 
(JNK), p38 extracellular signaling regulated kinase (ERK) pathways which led to an increased 
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expression of B-cell lymphoma associated protein X (Bax). In CD133+ cells, this cascade of 
signaling pathways was not activated and Bax expression was not affected leading to 
resistance in chemotherapy in the CD133+ cells (El-Khattouti et al. 2014).  
A further study conducted on tumour-initiating cells isolated from blood samples, collected 
from 32 metastatic melanoma patients, which were screened for the presence of CD133 and 
nestin (an intermediate filament protein). The percentage of nestin positive cells was 
positively correlated with tumour burden and the number of metastatic sites. This matched 
with the CD133 profiles on the circulating melanoma cells and both these molecules lead to 
a poor prognosis of melanoma (Fusi et al. 2010).  
Another population of tumour initiating cells or cancer stem cells (CSCs), enriched with 
ABCB5 protein and were identified as a population of cells, leading to chemoresistance in 
malignant melanomas (Frank et al. 2005; Huang et al. 2004). The presence of this ABCB5 
was further checked for, in benign melanocytic nevi, primary cutaneous melanoma, 
metastases to lymph nodes and metastases to viscera tumour types. Amongst these tumour 
types tested, ABCB5 was identified as and found to be significantly upregulated with 
metastatic melanomas and thick melanomas. Xenotransplantation experiments proved that, 
cells enriched with ABCB5 showed a greater tumorigenic and proliferative capacity when 
compared to cells that lacked ABCB5 (Schatton et al. 2008). It was also observed that 
melanoma-initiating cells that were stained positive for ABCB5 also showed a preferential 
expression of vascular endothelial growth factor receptor-1 (VEGFR-1) in melanoma cell 
lines as well as in clinical melanoma samples. In vitro, the presence of VEGF induced the 
expression of CD144 (VE-Cadherin) in cells that were enriched with ABCB5 whereas this 
phenomenon did not occur in the ABCB5- cells. VEGFR and ABCB5 are markers that have 
been shown to help with progression of cancer. Knockdown of VEGFR-1 in these cells, 
showed a decrease in the development of ABCB5 that further led to a decrease in the 
tumour growth by 90 % (Frank et al. 2011).  
A similar study, involved the isolation of neural crest nerve growth factor receptor or cluster 
of differentiation (CD271) positive tumor initiating cells from melanomas, also called as 
melanoma tumour stem cells (MTSCs). A number of tumour samples from human patient 
biopsies, were screened for the presence of CD271 out of which, 90% of the melanomas 
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tested were stained positive for this marker. CD271 enriched population of cells when 
engrafted into the human skin or bone in mice resulted in melanoma tumour formation. No 
formation of melanoma was noted in mice that were transplanted with CD271 negative 
melanoma cells. The cells that stained positive for CD271 were negative for the expression 
of tyrosine (TYR), melanoma-associated antigen recognised by T cells (MART1) and 
melanoma antigen gene (MAGE) in 86 %, 69 % and 68 % of melanoma patients, respectively. 
Importantly, all these molecules are involved in T-cell mediated immune response that leads 
to upregulation of anti-tumour immunity in case of cancer. The absence of these markers in 
the CD271 positive cells indicates the reason for failure of T-cell directed therapies in the 
case of melanomas (Boiko et al. 2010). Recently, this was further confirmed, where positive 
expression of CD271 was a crucial determinant of tumorigenicity, plasticity and stem-cell 
like properties to patient-derived samples of metastatic melanoma patients (Redmer et al. 
2014). 
1.2.7 Molecular basis of chemosensitivity: the role of inhibitor of apoptosis family 
member- survivin 
IAP family consists of proteins that are structurally and functionally related and inhibit the 
occurrence of apoptosis (Table 1.3). This family consists of 8 members and their homologs 
have been identified in a number of organisms.  Survivin, the smallest member of this 
family, (Altieri & Marchisio 1999), is the most important cancer target (Guha & Altieri 2009; 
Kanwar et al. 2001). IAP proteins protect the cells from undergoing apoptosis by protecting 
the cells from a number of apoptotic stimuli like UV radiation, cytochrome C, growth factor 
withdrawal and various chemotherapeutic drugs (LaCasse et al. 1998a).  
Table 1.3. Members of the IAP family and their functions (Deveraux & Reed 1999; Vucic 
2014). 
S.no. Name of the protein Function 
1.  Baculoviral inhibitor of apoptosis  Inhibits caspases and inhibits apoptosis 
2.  Cydia pomonella granulosis virus 
inhibitor of apoptosis (Cp-IAP)  
Binds to and inhibits caspases 
3.  Orgyia pseudotsugata inhibitor of 
apoptosis (Op-IAP) 
Binds to caspases, inhibiting apoptosis 
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4.  X-linked inhibitor of apoptosis 
(XIAP)/ inhibitor of apoptosis 
protein 3 (IAP3) 
Binds to caspase-3, 7 and 9 causing 
degradation of caspases leading to reduced 
apoptosis 
5.  C-linked inhibitor of apoptosis (c-
IAP)/ baculoviral IAP repeat-
containing protein 2 (BIRC2) 
Inhibit apoptosis by interfering with activation 
of caspases 
6.  Livin/ baculoviral IAP repeat-
containing protein 7 (BIRC7)/ 
melanoma-inhibitor of apoptosis 
protein (ML-IAP) 
Isoform A- protects cells from apoptosis 
induced by staursporine 
Isoform B- protects cells from apoptosis by 
etoposide  
7.  Survivin/ baculoviral inhibitor of 
apoptosis repeat-containing 5 
(BIRC5) 
Stabilizes the formation of mitotic spindle 
apparatus  
Upregulates beta-catenin  
Interacts with caspase-3 and -7 
Inhibits Bax and Fas mediated apoptosis 
8.  NOD-like receptor family, 
apoptosis inhibitory protein 
(NIAP) 
Inhibits apoptosis by various pathways 
including Wnt signaling 
 
Survivin is a member of IAP family of proteins encoded by baculoviral inverted repeats (BIR) 
C5 gene that plays a key role in cell division and apoptosis (Alteri DC 2008). The molecular 
weight of survivin is 16.5 kDa, it has 142 amino acids with a gene span of 14.7Kb on the 
telomeric portion on chromosome 17 (Chiodino C et al. 1999). Survivin exists as a dimer and 
is different from other IAP proteins as it contains single zinc binding BIR domain at the 
amino terminus followed by a long amphipathic α helix instead of a new gene (RING) finger 
(Chantalat L et al. 2000; Muchmore SW et al. 2000; Verdecia MA et al. 2000). It is expressed 
during human embryonic and foetal development but is absent in most adult tissue (Konno 
R et al. 2000). Survivin is characterised by a single baculoviral IAP repeat (BIR) and does not 
contain a really interesting new gene (RING) finger domain which is the characteristic of 
other IAP family molecules (LaCasse et al. 1998b). There are five different and distinct 
isoforms of survivin, namely wild-type survivin, survivin-2α, survivin-2B, survivin-3 and 
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survivin-ΔEx3, but the only form that has been studied extensively in melanoma is the wild-
type full length survivin.  
Several studies have shown that knockdown of endogenous survivin expression leads to 
repressed cancer cell proliferation, enhanced apoptotic vulnerability, arrested cell cycle in 
G1 phase and apparent mitotic catastrophe (Zhang et al. 2010), and that overexpression of 
survivin can rescue cancer cells from apoptosis and cell cycle arrest (Bian et al. 2012). This is 
mainly because several important molecules involved in various cell signalling pathways act 
as modulators for survivin (Kanwar, Kamalapuram & Kanwar 2011b). Increase in survivin 
expression reduces apoptosis induced by activators of both extrinsic and intrinsic pathways 
and tumour suppressor gene i.e. Fas ligand (Sisson et al. 2012), Bax (Nardiello et al. 2011), 
p53(Wang et al. 2013), casapse-3,7 and 8 (Shin et al. 2001; Tamm et al. 1998).  
Survivin has been reported to be oncogenic, since it overcomes G₂/M phase of the cell cycle 
and causes mitotic progression once over-expressed in most cancers found in adults (Li F et 
al. 1998). Expression of WT survivin has been observed to be 10-fold higher in G₂/M phase 
when compared to G₂ or S phase (Altieri DC & Marchisio C 1999). The anti-apoptotic 
property of survivin can be regulated by various mechanisms, which mainly involve 
inactivation of the caspase-cascade, leading to the inhibition of apoptosis. The BIR domain 
of survivin interferes with caspase-3 and caspase-7 and induces inhibition of apoptosis 
(Tamm I et al. 1998). Survivin, when overexpressed in cancer cells, binds to X-linked 
inhibitor of apoptosis protein (XIAP), that leads to inhibition of caspase-9 activation, 
preventing apoptosis in melanoma cells (Mckenzie & Grossman 2012). In vitro, studies show 
that survivin, in its homodimer form, binds directly to caspase-3 and caspase-7 thereby, 
preventing the activity of caspases in inducing cell death and leading to dysregulation of 
apoptosis (Shin et al. 2001). It inhibits caspase-3 that is essential for prevention from 
apoptosis (Alteri DC 2003). Survivin’s ability to associate with caspase-9 and second 
mitochondria-derived activator of caspases/ direct IAP binding protein with low pI 
(Smac/DIABLO) shows that survivin inhibits apoptosis via the intrinsic pathway by interfering 
with the post mitochondrial events (Song Z, Yao X & Wu M 2003).   
Survivin is detectable in most types of cancer and the presence of survivin is associated with 
poor prognosis. It is well established by several publications that WT survivin is highly over 
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expressed in most cancer types including colon (Kim PJ et al. 2003), liver (Fields AC et al. 
2004), skin (Grossman D et al. 2001), prostate (Zhang M et al. 2005), breast (Vegran F et al. 
2011), ovarian (Liguang Z et al. 2007), lung (Olie RA et al. 2000), pancreas (Lee MA et al. 
2005) and neuronal (Shankar SL et al. 2001) cancers.  During the process of tumor 
development, the expression of survivin leads to the inhibition of apoptosis and increases 
tumor proliferation, drug resistance and angiogenesis. Hence therapies inhibiting survivin 
expression have been considered to prevent tumors from acquiring adequate blood supply 
(Yamamoto T & Tanigawa N 2001). 
Survivin expression has been reported to be upregulated with increase in tumour volume, In 
preclinical mouse models, large tumours of EL-4 lymphomas (1cm in diameter) showed a 10-
fold increase in the levels of survivin when compared to tumours that were 0.2 cm in 
diameter (Kanwar et al. 2001). It has been reviewed that survivin overexpression in clinical 
specimens of prostate tumours was associated with resistance to radiation therapy and 
chemotherapy  (Coumar et al. 2013; Kanwar, Kamalapuram & Kanwar 2011a). Upregulation 
of survivin was noted in cisplatin resistant gastric cancer, where a correlation between AKT 
and hypoxia-inducible factor-α (HIF-1α) upregulation caused an upregulation of survivin 
(Sun et al. 2014b).  
Survivin is known to localise in three different subcellular components, namely, the nucleus, 
the cytoplasm and the mitochondria (Dohi et al. 2004; Rodríguez et al. 2002). The 
localisation of survivin in various subcellular components indicates its functional aspect. The 
nuclear localisation of survivin aids in the role of survivin in the spindle forming assembly in 
mitosis, and the cytoplasmic and mitochondrial localisation (Dohi et al. 2004) of survivin is 
responsible for attributing the anti-apoptotic function (Colnaghi et al. 2006). In a tumour 
cell, survivin is restricted to the mitochondrial membrane aiding in its anti-apoptotic activity. 
When localization of survivin was investigated in mitochondria along with its role in cell 
death pathways, it was observed that a large amount of survivin localizes in mitochondria in 
tumour cells but not in healthy tissues and that cancer cells lacking mitochondrial survivin 
were more susceptible to apoptosis when compared to cells having mitochondrial survivin 
(Dohi et al. 2004). Later research led to the findings that mitochondrial survivin plays a 
crucial role in cytoprotection by preventing the activation of initiator caspase-9 thus 
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blocking activation of caspase-9 and in-turn caspase-3 (Lens SMA, Vader G & Medema RH 
2006).  
1.2.7.1 Survivin in melanoma  
In melanoma, the presence of survivin at every stage of melanogenesis has been identified 
and characterized. Molecular profiling of melanomas has shown the nuclear localisation of 
survivin in melanomas leads to poor prognosis and the role of survivin as an indicator of 
drug resistance in melanomas, where previously treated cisplatin-resistant tumours showed 
an increase in survivin expression in the survived cells (Gao et al. 2010). It has also been 
proved that survivin is absent in normal primary melanocytes but is highly expressed in both 
localised and metastatic melanomas and dysplastic, intradermal and Spitz nevi melanocytic 
nevi (Florell et al. 2005). Presence of survivin in the sentinel lymph nodes in melanoma is 
inversely correlated with patient survival as 61.5 % of the stage III patients who stained 
positive for survivin in the sentinel lymph nodes, died from melanoma (Gradilone et al. 
2003). 
Presence of survivin in melanomas was also correlated with the metastatic potential of 
melanoma cells and lowering the levels of survivin improved the survival rate (Takeuchi et 
al. 2005). Another interesting observation is the overexpression of survivin in melanomas 
that had a mutation or alteration in the tumour protein 53 (TP53) tumour suppressor and 
RB genes (Raj et al. 2008). Mutation in either of these genes occurring due to the loss of 
alternative reading frame or p16 proteins in melanoma can result in the overexpression of 
survivin (Sharpless & Chin 2003).  
In melanoma cells, survivin overexpression also leads to activation of the AKT pathway that 
is responsible for cell survival and blocks apoptosis (Qiu et al. 2005). Survivin overexpression 
in cisplatin-resistant 451Lu, SK-MEL-28, WM852, 1205Lu, SK-MEL-19 and Mewo, melanoma 
cells, show an increase in the PI3K-AKT-mTOR signaling pathway that leads to inhibition of 
apoptosis and development of resistance due to survivin overexpression (Sinnberg et al. 
2008). 
1.2.8 Survivin targeting strategies 
The functional importance of survivin is known to extend from simple processes such as 
inhibition of apoptosis and autophagy to complicated and interlinked pathways including 
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mitosis, DNA repair, cell proliferation and drug resistance (Altieri 2001; Kanwar, 
Kamalapuram & Kanwar 2011a, 2013; Kanwar et al. 2010). With increase in the number of 
studies implying the importance of survivin in cancer survival and targeting, there is  lot of 
emphasis on development of survivin inhibitors or survivin related molecular therapies as 
compared to other therapeutics in cancer treatment (Coumar et al. 2013). Some of the 
successful survivin inhibitor strategies used for survivin targeting are discussed in this 
section.  
1.2.8.1 Dominant negative survivin mutants as gene therapy 
Various dominant negative mutant forms of survivin (DNS) have been used to target wild-
type survivin in cancers, the function of which is to competitively inhibit the expression of 
wild-type survivin (Cheung et al. 2010b; Hartman & Czyz 2013; Kanwar, Kamalapuram & 
Kanwar 2013; Kanwar et al. 2001). Earlier studies performed with survivin antisense 
oligonucleotides 4003 have reported that down-regulation of survivin expression sensitizes 
cells to induction of apoptosis in lung cancer cells via the intrinsic pathway of apoptosis 
(mitochondrial pathway). The survivin antisense oligonucleotide 4003 failed to induce any 
significant apoptosis in a normal cell population lacking survivin expression; therefore, this 
confirmed that targeting survivin can offer a cancer explicit therapy (Olie RA et al. 2000). 
There are several dominant-negative forms of survivin that have been developed in order to 
target survivin in cancer. Dominant negative survivin inhibits the action of survivin in cancer 
cells by binding to it and deactivating the active function of survivin (Alteri 2001; Kanwar et 
al. 2001). The two most researched dominant-negative forms of survivin include the survivin 
T34A and survivin C84A mutants. The survivin T34A dominant-negative mutant is known to 
be incapable of interacting with wild-type survivin, however, it prevents phosphorylation of 
Thr34 by Cdc2 that results in disassociation of survivin caspase-9 complex allowing 
activation of apoptosis (O'Connor et al. 2000).  
A key residue positioned at the amino-terminal of the second helix of the BIR domain on 
survivin is Threonine 34 (Thr34). Thr34 is enclosed by a sequence that resembles the 
consensus phosphorylation site S/T-P-X-R present on the mitotic kinase complex (p34Cdc2-
cyclin B1). The activation of cyclin B1 dependent Cdc2 kinases is known to trigger the 
transition from G₂ phase to M phase (Choi, Fukui & Zhu 2011). Earlier studies have reported 
that the Thr34 to Ala (T34A) mutation removes the above mentioned phosphorylation site 
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and, therefore prevents binding of survivin to the activated form of caspase-9, in turn 
generating a dominant-negative survivin molecule that is capable of disrupting cell division 
and induction of apoptosis (Shen et al. 2009).  
By generating a construct of replication-deficient adenovirus encoding a T34A survivin 
mutant (pAd-T34A), DNS mutant form was earlier tested as potential cancer gene therapy 
approach, to target tumor cells viability, both in vitro and in vivo. When compared to the 
normal chemotherapeutic regimens, pAd-T34A was  more efficient in inducing spontaneous 
apoptosis, and inhibiting the  growth of breast, prostate, cervical, colorectal and lung cancer 
(Mesri et al. 2001). 
The T34A recombinant form of survivin represented as TmSm (T34A) was used to enhance 
the action of doxorubicin to treat cancer. The strategy of this development was avoiding the 
side effects of chemotherapeutics in order to sensitize the tumor cells to apoptosis.  TmSm 
(T34A) in combination with doxorubicin induced apoptosis of three different breast cancer 
cell lines. The use of a mutant form of survivin alongside and anti-cancer drug molecule was, 
as a potential strengthening agent to enhance chemotherapy in cancer patients (Xu et al. 
2012).  
On the other hand, Kanwar et al. 2001 induced a point mutation in the BIR domain at the 
84th position (C84A) which forms a dominant-negative form of survivin (Kanwar et al. 2001). 
Research on C84A form of dominant-negative survivin as both gene therapy (Kanwar et al. 
2001) and protein therapy (Cheung et al. 2010b; Sriramoju, Kanwar & Kanwar 2014) has 
been conducted. When tumours originated from the mouse EL-4 thymic lymphoma cells 
were injected into mice with plasmids encoding a new form of antisense survivin, (survivin-
C84A) along with B7-1, a co-stimulator of T-cells. The growth of small (p=0.006 and 
p=0.0018) and large tumours (p≤ 0.001) was inhibited significantly by intra-tumoral injection 
with anti-sense survivin and B7-1. It was also observed that tumours injected with survivin-
based plasmids showed increased apoptosis and generated higher levels of anti-tumour 
cytotoxic T lymphocytes (CTLs). Therefore, it was inferred that inhibition of survivin 
expression increases the susceptibility of large tumours to B7-1 mediated immunotherapy 
(Kanwar et al. 2001).  
                                                                                                       Chapter 1- Review of Literature                  
29 
 
 Another interesting approach for targeting tumors via survivin targeting has been the use of 
dendritic cells in combination with adenoviral vector containing a full-length DNS T34A gene 
for cancer immunotherapy. Dendritic cells when transduced with full length DNS T34A gene 
produced efficient activity against breast cancer cell lines. This combination of treatment 
was able to generate specific CTL response that targeted only tumor cells by recognizing 
them and killing the cancer cells (Pisarev, Yu & Salup 2003). It also showed an increase in the 
production of IFN-γ and MHC-I peptides in the tumor environment confirming the specific 
anti-tumor response obtained from this treatment. The efficacy of survivin-T34A plasmid 
encapsulated with liposomes was evaluated in C57BL/6 mice model with TRAMP-C1 
prostate cancer cells. It was found that the mice injected with survivin-T34A plasmid-
liposome complex showed smaller tumour volumes compared to the vector control and a 
significant increase (p≤ 0.05) of apoptosis in the tumours (Pan et al. 2010). 
Another study from the same group used the mouse survivin T34A plasmid (indicated as mS-
T34A) to check its effect on a mouse model of prostate cancer. MS-T34A plasmid was 
introduced into liposomal forms to achieve specific delivery. In vitro and in vivo studies 
showed that TRAMP-C1 cells transfected with mS-T34A had a significant inhibition of 
growth. It was associated with increased tumor cell apoptosis and decreased microvessel 
density (Pan et al. 2011). Mutant survivin-T34A  conjugated with liposomes  triggered 
apoptosis in breast cancer  cells, inhibited angiogenesis, and induced a specific tumor cell 
immune response (Peng et al. 2008). This holds true for ovarian carcinoma (McKay et al. 
2003) and  Lewis lung carcinoma where enhanced sensitivity to cisplatin was observed after 
treatment with DNA mutant T34A (Yu et al. 2010).  
Another study has been done to determine the inhibitory and therapeutic activity of an 
adenovirus expressing survivin double point mutant (TC34, 84AA) in hepatocellular cancer 
cells via gene therapy. It was reported that when compared to the survivin mutants T34A or 
C84A alone, the cancer killing effect of adenovirus-delivered dominant-negative survivin 
TC34, C84AA was much stronger (Zhang et al. 2008).  
1.2.8.2 Survivin mutant protein therapy 
Synthesis of survivin mutant GST-Surv-D53A protein using a single amino acid change (Asp 
53 to Ala 53) has been reported, that converted the anti-apoptotic survivin to pro-apoptotic 
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and induced apoptosis in p53 independent manner mainly induced by TRAIL (death receptor 
or extrinsic apoptotic pathway). The Surv-D53A was able to interact with wild type (WT) 
survivin to form survivin-Surv-D53A heterodimer and was also capable to interact with itself 
and form a homodimer (Song et al. 2004). It was also reported that Surv-D53A was less 
stable than WT survivin and prone to degradation by the ubiquitination pathway. 
It is known that survivin is a chromosomal passenger protein generally released from 
kinetochores at the beginning of anaphase and found to congregate at the telophase where 
it endures phosphorylation for the execution of cytokinesis (cell division). It has been 
reported that survivin-T34A DsRed (a red fluorescent protein), destabilizes the organisation 
of the chromosomal passenger complex at the cleavage furrow, resulting in abnormal 
cleavage of cells (Temme et al. 2003). Another cell permeable dominant negative survivin 
(dNSurRC84A) protein was developed and its anticancer activity was determined against 
cervical and prostate cancer cells in three dimensional cultures. The dominant negative 
survivin (replacing cysteine by alanine at 84th position, SurC84A) protein was fused with the 
cell penetrating peptide poly-arginine (9 residues of arginine, R9). DNSurRC84A successfully 
penetrated into 3D-cultured HeLa and DU145 cells and induced cancer cell death. Caspase-9 
and caspase-3 were found to be upregulated and dNSurRC84A rendered DU145 cells 
sensitive to TNF-α by activating caspase-8 suggesting that survivin blocks the extrinsic 
pathway of apoptosis (Cheung et al. 2010b). 
Another recent study from our laboratory has shown that the dominant-negative mutant 
(SurR9-C84A) has dual actions. On one hand it leads to proliferation in the differentiated 
neurons, while on the other it is cytotoxic towards the cancer cells (Baratchi, Kanwar & 
Kanwar 2011; Sriramoju, Kanwar & Kanwar 2014).  This phenomenon can be explained as 
targeting survivin has major advantages since it is specifically overexpressed only in 
tumours, hence targeting survivin avoids toxic effects of drugs towards primary cells 
(Grossman et al. 2001b; Grossman et al. 1999). 
1.2.8.3 Anti-survivin gene and protein therapies in targeting melanoma 
Melanoma is by far the most challenging cancer to achieve a chemotherapeutic regimen for. 
The presence of survivin in melanocytes and its role in conferring drug resistance to 
melanoma cells has provided hope for the development of an effective therapeutic measure 
for overcoming this challenge. Gene therapy with adenoviral vector, using the GFP-
                                                                                                       Chapter 1- Review of Literature                  
31 
 
conjugates of T34A mutant form of survivin gene was used to induce apoptosis in melanoma 
cells. The use of GFP-survivin (T34A) for targeting melanoma was found beneficial as it  
suppressed the tumor growth both in vitro and in vivo (Grossman et al. 2001a). A 
recombinant survivin protein (TAT-Surv-T34A) fused with cell penetrating TAT peptide was 
found to internalise in YUSAC2 and WM793 melanoma cells within 30 min. Intraperitoneal 
injection of 10 mg/Kg of TAT-SurvT-34A resulted in 30-40% reduction in the tumour mass in 
vivo (Yan et al. 2006).  
1.2.8.4 Other survivin inhibitors 
The molecular chaperone Hsp90 is known to bind to and stabilize the WT survivin hence 
therapies targeting Hsp90 using small molecule inhibitors such as geldanamycin have been 
used in order to observe the effect of Hsp90 inhibition on survivin. It has been reported that 
Hsp90 inhibitors failed to induce any significant inhibition in expression of survivin, in fact 
over-expression of survivin in certain cancer cells, and subsequent enhancement in cell 
survival ability was observed (Cheung et al. 2010a). 
Eli Lilly and Co. has developed an antisense oligonucleotide named LY2181308 that has been 
designed to specifically target survivin mRNA in tumour cells. This molecule is capable of 
binding to the translation initiation codon on the survivin mRNA leading to degradation of 
survivin transcript, downregulating the expression of survivin (Pennati, Folini & Zaffaroni 
2007). LY2181308 was tested in castration-resistant prostate cancer (CRPC) that is usually 
characterized by overexpression of a number of anti-apoptotic proteins like survivin. Phase 
II study of combining LY2181308 with docetaxel/prednisone showed an increase in the 
progression-free survival and reduction in the circulating tumour cells (CTCs) (Wiechno et al. 
2014). Recently, LY2181308 has also been used as a molecule to target survivin mRNA, for 
oral cancer patients. Downregulation of survivin is associated with decrease in Bcl-2 and 
increase in the caspase-3 leading to apoptosis in oral cancer patients (Khan, Blanco-
Codesido & Molife 2014).  
Another small molecule inhibitor termed YM155, that supresses the transcription of survivin 
by binding to its promoter has been developed. A number of in vitro and pre-clinical studies 
have been conducted to evaluate the activity of YM155 and recent studies with melanoma 
xenografts have proved that this molecule can cause apoptosis in melanoma (Nakahara et 
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al. 2011). However, in unresectable stage III and stage IV melanoma, this molecule was not 
effective as a single agent as only partial response was noted with these melanomas (Lewis 
et al. 2011).  
An anti-sense oligonucleotide (ASO) against survivin recognized as EZN-3042 has been 
studied sumptuously, and its anti-cancer effects were determined in a neuroblastoma 
model (Lamers et al. 2011). EZN-3042 was found to work in synergy with docetaxel for 
down-regulation of survivin expression and inhibition of tumour growth (Sapra et al. 2010). 
In Phase I of clinical trials, a combination of EZN-3042 docetaxel was well tolerated in 
patients with advanced malignancies and studies are still ongoing 
(http://enzon.com/files/Survivin-4.pdf). 
Another molecule that has been linked with the overexpression of survivin in cancer is the 
tumour suppressor p53. Increase in survivin expression neutralizes the p53-induced p21 
expression and promoter activity, further leading to blocked expression of cells 
(overexpressing survivin in the G1 phase. Gene silencing of survivin leads to upregulation of 
p21 and wild-type p53 in cancer cells (Tang et al. 2012). A number of studies have thereby, 
employed targeting survivin and p53 in non-small cell lung carcinoma (NSCLC) and acute 
lymphoblastic leukemia (PORĘBSKA et al. 2010; Tyner et al. 2011).  
Targeting survivin has been a commonly researched topic as this protein is overexpressed in 
all types of cancer and is also responsible for drug resistance in many cancer types. Studying 
the expression patterns of survivin and its importance as a survival factor for cancer cells 
has demanded more focus and attention on targeting survivin for cancer regression and 
treatment. As described earlier in this section, a number of dominant mutant forms of 
survivin, siRNA based therapeutics; vaccination strategies, peptide based targets and 
chemotherapeutics have been designed and developed to achieve downregulation of wild-
type survivin protein. The shift from synthetic drugs to natural proteins/peptides and 
nucleic acid based cancer therapeutics is mainly due to their lack of non-specific 
cytotoxicity, immunogenicity and biodegradability.  
Curcumin, a diarylheptanoid is the principal compound isolated from turmeric. This 
naturally available compound has been tested for its effect on survivin inhibition in human 
pancreatic cancer cell lines Panc-1 and AsPC-1, where treatment with curcumin leads to 
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downregulation of proliferation in all the cell lines that were tested. This effect was due to 
reduced expression of survivin and blocking of signal transducer and activator of 
transcription 3 (STAT3) that is usually upregulated in cancer (Glienke et al. 2009).Similar 
effect of curcumin was established in another study with melanoma cell lines A375, HT144 
and Hs294T (Glienke et al. 2009) which was accompanied by upregulation of NK cells and 
immunostimulatory cytokines like IFN-γ. Further studies with curcumin in melanoma cells 
showed that curcumin is a potent inducer of apoptosis as it arrests the growth of the cells in 
the G2/M phase of the cell cycle by targeting survivin in the G2/M phase. This leads to 
increased expression of p53 and DNA fragmentation causing susceptibility to platinum-
based drugs in melanoma (Zheng et al. 2004). 
Another naturally available protein that has been recently shown to be a   survivin targeting 
agent is bovine milk derived lactoferrin (bLf).  More recently, its iron-saturated form  (Fe-
bLf) as a  nanoformulation has been used to target  tumour growth in xenograft model of  
human colon cancer  that leads to reduction in tumour size  and induction of apoptosis in 
xenograft models of colon cancer (Kanwar, Mahidhara & Kanwar 2012b). Further studies 
with nanoformulated Fe-bLf have proved that Fe-bLf targets survivin that helps in 
eliminating colon cancer stem cells helping induce apoptosis in xenograft models of colon 
cancer (Kanwar et al. 2014).  
1.3 P53, UV RADIATIONS AND SKIN CANCER 
Tumour protein p53 (TP53) is coded by the p53 gene which is also known as the “guardian 
of the genome” or the tumour suppressor gene (May 1999). P53 was first identified as a 
cellular antigen that co-precipitated with anti-sera against the T antigen of the simian virus 
SV40 (Tegtmeyer et al. 1975)1977 (Tegtmeyer, Rundell & Collins 1977).  In 1980, Rotter et al 
found  a specific protein (molecular weight of 50 kDa), which was present in the sera of 
tumour bearing mice, and also present at a very high concentration in mice which rejected 
the tumours, suggesting that identified p50 had a role in tumour suppression (Rotter et al. 
1980). It was further reported that p53 played a role in regulating cell division mainly acting 
during the entry into cell cycle (G1) from the resting phase (G0)(Milner & Milner 1981).  
In 1984, a cDNA clone for human p53 gene was isolated and characterized; found that the 
p53 mRNA was reported to be 2.8 kb in length. It was present in cell lines of kidney 
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carcinoma, irrespective of the p53 protein expression (Matlashewski et al. 1984). In 1986, 
another study cloned human p53 gene and found that it is located on chromosome 17 p13 
(Mcbride, Merry & Givol 1986). Later, in 1991, it was found that p53 mainly functions due to 
its ability to bind to specific DNA sequences which is altered by the mutations that occur in 
tumours (Kern et al. 1991). It was shown that apoptosis can be induced in cell lines that 
have lost the endogenous p53 activity by introducing wild type p53 protein (Lowe et al. 
1993b). Using mouse embryonic fibroblast cells from p53 deficient mouse, it was found that 
the cells acquired cross resistance to anti-cancer agents’ 5-fluorouracil, etoposide and 
adriamycin. Therefore, it was found that tumour suppressor p53 was essential for execution 
of apoptosis (Lowe et al. 1993a).  
 P21/WAF1 was the first p53 target gene to be identified that showed relation of p53 with 
cell cycle arrest (El-Deiry et al. 1993). In 1993, a study claimed that temperature sensitive 
form of p53 showed efficient binding with a proto-oncogene mouse double minute 2 
homolog (MDM2). Using gene expression studies, it was found that MDM2 was a target 
gene for activation by wild type p53 (Barak et al. 1993). Another study reported that the 
growth regulation of most human cancers is regulated by RB protein and p53. It is the loss of 
RB which leads to abnormal proliferation due to deregulation of eukaryote transcription 
factor 2 (E2F) and results in the activation of tumour suppressor p53 which results in 
apoptosis (Palmero & Peters 1995). In 1998, a study showed that E2F-1 leads to the 
activation of p14ARF which is another tumour suppressor gene that binds to MDM2-p53 
complex, and prevents the degradation of p53. This mechanism acts as a fail-safe 
mechanism to protect against aberrant cell growth (Bates et al. 1998). However, MDM2 is 
found to be overexpressed in several types of human tumours and its overexpression has 
been reported to impair the p53 function.  
It has been reported that even though an increase in the expression of MDM2 did not lower 
the DNA damage due to p53 expression, it led to a reduction in ability of cells to be arrested 
in G1 phase (Chen et al. 1994). Therefore, studies have been performed to prevent the 
binding of MDM2 with p53 in order to activate the p53 pathway in cancer cells that may 
lead to cell cycle arrest, apoptosis and growth inhibition (Vassilev et al. 2004). Due to the 
importance of MDM2 in cancer cell proliferation, studies were further conducted in order to 
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identify the MDM2 binding proteins. It was found that MDM2 associated strongly with 
Numb which was involved in the determination of cell fate (Juven-Gershon et al. 1998). 
Numb mainly acts as an inhibitor of Notch signalling, controls the balance between 
proliferation and differentiation. Studies have shown that loss of Numb leads to activation 
of potential oncogene Notch and reduction of p53 (Carter & Vousden 2008). It has also been 
reported that Numb has the capability to interact with MDM2 and p53 to form a trimeric 
complex (Colaluca et al. 2008). Numb is also reported to prevent the ubiquitination of p53 
by MDM2 by inhibiting the E3 ligase activity of MDM2 (Figure 6). Therefore, it is 
hypothesized that Numb regulates the p53 tumour suppressor activity (Ma et al. 2006).   
 
Figure 6. Mechanism of action of p53 and its inactivation leads to cancer cell proliferation. 
This schematic figure is developed on the basis of the literature collected which shows that 
expression of Numb in the cells lead to activation of p53, helping cells undergo apoptosis. 
Inhibition of Numb expression in the cancer cells causes activation of MDM2, which further 
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leads to ubiquitin based degradation of p53, which helps in cancer cell proliferation. Loss of 
Numb also leads to activation of notch intracellular domain (NICD) that binds to DNA and 
causes activation of the target genes allowing proliferation and survival of cancer cells.  
Another study has shown that UV induced p53 mutations mainly lead to a high frequency of 
CC---TT double-base change (substitutions) known to be specifically induced by UV.  This 
dipyrimidine specificity also leads to formation of dipyrimidine photoproducts containing 
cytosine as an oncogenic photoproduct  (Brash et al. 1991). Since more than 90% of the p53 
mutations are known to be induced by UV radiations, studies were conducted to identify 
the stage of squamous cell carcinoma at which the p53 mutations are most likely to occur 
and it was reported that occurrence of actinic keratosis (AK) in the skin promoted 
differentiation and proliferation of  melanoma  (Ziegler et al. 1994).  
Role of p53 tumour suppressor gene has been studied in UV induced skin cancer. 
Susceptibility of p53 knockout and wild type mice to UV induced carcinogenesis was tested 
and it was found that the p53 knockout mice were highly susceptible to UV induced skin 
cancer. Tumours induced in wild type mice were mainly due to UV-induced mutations in 
p53. The type of tumour also varied amongst the two types of mice. The knockout mice 
showed development of squamous cell carcinoma and ocular tumours whereas the wild 
type mice showed mainly sarcomas (Jiang et al. 1999).  
Tumour supressor p53 has been suggested to define molecular tumour subtypes, where p53 
mutational status can determine therapeutic approach to the tumour (Vidwans et al. 2011). 
Mutations in the p53 gene in melanoma could be caused due to the stress responses to 
various stimuli like oncogene activation and/or exposure to UV radiation (Hocker & Tsao 
2007).  
In melanomas, 90 % of the tumours harbor an inactive p53 gene and 10 % of the tumours 
carry a point mutation which disables the activity of p53 as a tumour supressor and confers 
oncogenic potential to melanocytes (Hodis et al. 2012). A number of therapeutic options for 
melanoma have focussed on functionally activating the p53 protein to enhance the anti-
tumour activity of p53 for clinical benefit. DTIC although beneficial alkylating agent for 
melanoma induces p53-dependent apoptosis in melanoma cells but does not have any 
effect in extending the life in melanoma patients with metastasis.  
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With the complex mechanisms involved with p53 mutations leading to melanomas, “a 
targeted p53 therapy will take its place in the emerging cocktail of drugs that will ultimately 
be needed to treat metastatic melanoma” (Box, Vukmer & Terzian 2014). 
1.4 NATURAL COMPOUNDS USED FOR THERAPY OF DRUG RESISTANT MELANOMA 
Development of MDR with the use of chemotherapeutics and the occurrence of mutations 
with chemotherapeutic regimens, for examples, occurrence of BRAFV600E mutations with 
the use of vemurafenib and overexpression of drug-resistant markers like P-gp is one of the 
most challenging aspects of developing therapeutics for melanoma. As described earlier in 
this chapter (section 1.1.4), these chemotherapeutics that have been tested for targeting 
other molecules in melanoma, like BRAF V600E mutations, lead to a number of side effects 
that included rashes, keratitis etc. Keeping this in mind there has been focus on the use of 
natural compounds for the treatment of drug resistant cancers including melanoma to avoid 
the side-effects and cytotoxicity to primary non-tumour cells.  
1.4.1 Dandelion extracts/constituents 
Taraxacum officinale, commonly known as dandelion has been used previously for the 
treatment of chronic skin disorders (Frawley & Lad 1988). Lupeol-a triterpine, a constituent 
of Chinese dandelion showed upregulation of melanogenesis and decreased cell 
proliferation when tested on mouse melanoma (Hata et al. 2002). A375 melanoma cells 
were treated with the water extract of dandelion roots and it reduced the cell viability upto 
50% against control in 24 h. These extracts did not have any effects on the normal cells and 
did not cause any damage to the cell structure and cell viability (Chatterjee et al. 2010). 
Ethanolic extracts of dandelion reduced the levels of reactive oxygen species (ROS), nitric 
oxide production and inhibit, COX-2 expression hence it has the properties of being an anti-
inflammatory, anti-carcinogenic, anti-angiogenic and anti-nociceptive (Jeon, Kang & Jung 
2008). 
1.4.2 Pothomorphe umbelleta components 
The root extracts of this plant have been used for the treatment of skin lesions and for the 
wound healing on skin.  They exert anti-oxidant activity on the skin when it is affected by UV 
radiation stopping the photoaging of the skin (Ropke et al. 2003). At a later stage, it was also 
proved that the hypermethanolic extract of the root of Pothomorphe umbelleta inhibits the 
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activity of the metalloproteinases (MMP’s) namely MMP-2 and MMP-9 of the skin (Ropke et 
al. 2006). 4-nerolidylcatechol is the main component of the plant that has been attributed 
to play a role in the protection of the skin from damage by UV radiation.  This compound 
not only plays a role in the anti-oxidant activity but by inhibiting the matrix 
metalloproteinases (MMP’s), also sensitizes the melanoma cells to undergo apoptosis by 
stopping the cell cycle at the G1 phase thereby preventing its proliferation  (Brohem et al. 
2009). 
1.4.3 Celastrol 
Temozolomide (TMZ) was previously used for the treatment of melanomas and had proved 
to be as successful as DTIC. Over time melanomas have acquired the property of drug 
resistance temozolomide (Bafaloukos, Tsoutsos & Fountzilas 2004). Celastrol (CEL) is a 
traditional Chinese herbal medicine that has been used as an anti-inflammatory agent. To 
test the efficacy of this agent drug resistant melanoma cell lines were treated with CEL to 
check if it inhibits the tumour proteosame activity that is critical for tumour development. 
CEL was able to reduce the proteasome activity and increase induction of apoptosis in 
human prostate PC-3 xenografts (Goldberg 1995). Recently it has been shown that 
treatment of glioblastoma with CEL inhibits the tumor necrosis factor- α induced IκB 
activation and sensitizes the drug resistant cells to temozolomide (Chen, Rose & Doudican 
2009).   
1.4.4 Centaurothamnus maximus 
Centaurothamnus maximus is a plant found in the southern part of Saudi Arabia. It is a leafy 
scrub with magenta coloured flowers. These plants yield a very high amount of 
sesquiterpene lactones (Wang, Hamberger & Cheng 1993) and guaianoilides (Oksuz, Serin & 
Topcu 1994). Initial experiments using the ethanolic crude extracts of C. maximus showed a 
potential effect of the components against cancer cells. Most of the sesquiterpene lactones 
and a few guaianolides isolated from the plant  were also tested on the drug resistant 
melanoma cells which showed a cytotoxicity towards SK-MEL cell lines (Muhammad et al. 
2003).  




Guggulsterone is another traditional Chinese medicine that has been used to treat obesity, 
diabetes, atherosclerosis and osteoarthritis. It is polyphenol compound obtained from the 
gum resin of Commiphora mukul tree (Uriza & Moore 2003). Its mechanism of anti-
inflammatory activity is by inhibiting the inducible nitric oxide synthase (iNOS) (Meselhy 
2003). It suppresses the activation of inflammatory transcription factors like nuclear factor 
κB (NF-κB) which are a product of carcinogenesis and tumor promoters (Shishodia et al. 
2005). The most critical role of guggulsterone is that it inhibits proliferation of drug-resistant 
cancer cells including leukemia, head and neck carcinoma, multiple myeloma, lung 
carcinoma, breast carcinoma, ovarian carcinoma and melanoma hence sensitizing these 
cells to treatment and therapy (Shishodia et al. 2007).  
1.4.6 Tea tree oil 
Tea tree oil is extracted from Melaleuca alternifolia, a species found in the northern region 
of New South Wales, Australia. Terpenin-4-ol is the main component of tea tree oil which 
shows anti-tumor activity. It was reported that this compound can inhibit the invasive and 
metastatic properties of both drug sensitive and drug resistant melanoma cells (Bozzuto et 
al. 2011a).  
1.5 LACTOFERRIN AS A SAFE THERAPEUTIC   
1.5.1 Lactoferrin 
Lactoferrin (Lf) also called translactoferrin is a 75-80 kDa multifunctional globular 
glycoprotein, known to be present in various mammalian body fluids like milk, saliva, nasal 
secretions and tears (Kanwar & Kanwar 2013; Levay & Viljoen 1995). The size of the protein 
depends upon the glycosylation levels of the protein which also depends on the stability of 
Lf (Håkansson et al. 1995). Lf was first discovered as “red protein” that was isolated from 
both human and bovine milk as early as 1939 (Groves 1960; Johanson 1960; Sorensen & 
Sorensen 1939). Lf is called the “red milk protein” because in its native form Lf is red 
coloured due to the presence of ferric ion molecule. Although, ferric (+3) is the most 
common metal ion that is associated with Lf (Sawyer & Holt 1993), however, Lf can also bind 
to other metal ions, such as copper, manganese, and aluminium in biological systems 
(Harrington 1992). Binding of Fe3+ to Lf, is a pH dependent process. For each cation bound to 
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Lf, one atom of bicarbonate is incorporated into the iron-binding crevice which is essential 
for metal binding which facilitates iron saturation (Haridas, Anderson & Baker 1995). Higher 
concentrations of Lf are obtained from the colostrum where 10 mg/mL Lf is present in the 
colostrum when compared to 1-2 mg/mL in the milk in case of humans (Houghton et al. 
1985). From bovine source, less than 0.2mg/mL of Lf is present in mature milk and less than 
1.5 mg/mL is present in the colostrum (Steijns & Van Hooijdonk 2000). Although, both 
recombinant human lactoferrin (hLf) and bovine milk-derived bovine lactoferrin (bLf) have 
been studied and tested for their anti-cancer efficacies,  bLf has also proven to be less 
cytotoxic and has lesser adverse effects on both infants and adults (Tetens 2012). Another 
disadvantage of hLf, is that it has not been approved for use in food anywhere in the world 
whereas (http://www.nutraingredients.com/Research/Human-lactoferrin-safety-backed-in-
study) bLf has been approved “generally recommended as safe” (GRAS) by the FDA, USA 
(http://www.fda.gov/food/ingredientspackaginglabeling/gras/noticeinventory/ucm154188.
htm) (Table1.4, Figure 8).  
1.5.2 Structure of Lf 
Lf is made up of a single polypeptide chain and glycan. Both hLf and bLf have a homology of 
60-65% in their amino acid sequence consisting of 692 and 689 amino acids, respectively 
(Rey & Woloshuk 1990). Lf consists of two globular domains, the N-lobe and the C-lobe with 
40 % homology (Figure 7) that have the same polypeptide-folding pattern and one metal 
binding site. Both these lobes have two sub-domain structures N1 and N2 for the N lobe and 
C1 and C2 for the C lobe. The two sub-domains have a metal ion binding site (a metal ion 
with bicarbonate) (Baker, Baker & Kidd 2002). Three different forms of Lf a) Apo-Lf (iron free 
form of Lf), Fe-Lf (Fe saturated form of Lf that has two Fe3+) and holo Lf (one Fe3+) are 
present depending on their iron saturation status. The tertiary structures of Apo-Lf is 
characterized by open conformation of the N-lobe and the closed conformation of the C-
lobe, and both the lobes are closed in holo-Lf (Jameson et al. 1998).  




Figure 7. Structure of Lf. Predicted structure of bLf shows the two lobes- N lobe and C lobe 
in bLf structure. It also represents the two sub-domains of the N lobes and the C lobes and 
the α-helix structure that joins the two lobes. Predicted structure of Lf from the EU812318 
(bLf) sequence using PDB ID: 1FCK (human) as a template showing a two-lobed, four domain 
polypeptide. Source: (Siqueiros-Cendón et al. 2014). 
Table 1.4. Comparison of structural and functional aspects of bLf and hLf. 
Properties Bovine Lactoferrin (bLf) Human Lactoferrin (hLf) 




 Glycosylated at 
four sites, 
Asn233, 368, 476 
and 545 
 N-lobe of bLf is 
5.3o more closed 
than hLf and the 
 Glycosylated at only 
one site 476 and has an 
extra disulphide bridge 
at 160-183 position 
(Spik 1998) 
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 Iron release from 




 High degree of 
iron saturation in 
bLf (˃ 20 %) 
 Iron release from hLf 
begins at pH 4 and is 
completed at pH 2.5 
 hLf has lower degree of 






Approved as generally 
regarded as safe (GRAS) 
Chills, Fatigue, Rashes, 
Constipation, Diarrhoea, Loss 
of appetite. Not approved by 




 No adverse toxic 
effects of bLf 
were noted in 
chronic thirteen 
week high-dose 
fed rats. 100 
times lower 
proposed intake 




level (NOAEL) is 
2000 mg/kg body 
weight 
 Study on Wistar rats 
with recombinant 
human lactoferrin 
produced in the milk of 
transgenic cows, 
showed lower urinary 
pH in high-dose fed 
males and slightly 
higher kidney weight in 
high-dose fed females 
 NOAEL is 450mg/kg 
body weight 
  





bLf can resist digestion in 
the presence of infant 
Milk-derived hLf could not 
resist digestion in presence of 
(Bhatia 2011) 
(Takayama 
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digestion formula infant formula 2011) 
Antigenic 
determinants 
hLf and bLf share 
common antigenic 
determinants 
hLf and bLf share common 






bLf has more activity 
against Helicobacter  
pylori 









Same as milk-derived  
hLf against hepatitis C 
virus (HCV) 
Same as bovine lactoferrin 
against HCV 
(EL-Fakharany 




activity in B16 melanoma 
Recombinant hLf had 
comparatively lower anti-
cancer activity in melanoma 
(Kanwar et al. 




bLf is better defined than 
hLf 
Lesser studies have been 
conducted for hLf when 
compared to bLf 
 
 




Figure 8. Advantages of bovine lactoferrin (bLf) over human lactoferrin (hLf). This figure is 
drawn on the basis of the current findings that bovine lactoferrin (bLf) has 4 glycosylated 
sites and the N lobes are more closed, moreover the iron saturation in bLf is higher on the 
other hand, human lactoferrin (hLf) has only 1 glycosylation site and more open N lobes 
with comparatively lower iron saturation which makes it more prone to enzymatic 
degradation. Both bLf and hLf have similar structure, share common antigenic determinants 
and use the same receptors to internalize in cells and boosts the host immune system. 
However, the no-observed-adverse-effect level (NOAEL) dosage (maximum dosage which 
does not induce any toxicity) for bLf is 2000 mg/kg body weight (bw) is 4.4 fold higher when 
compared to recombinant hLf (450 mg/kg/bw). Higher dosages (>450 mg/kg/bw) of 
recombinant hLf has shown to induce chills, fatigue, diarrhoea, loss of appetite, constipation 
and rashes. bLf has been accredited as generally regarded as safe (GRAS) whereas hLf has no 
such accreditation. 
1.5.3 Various functions of Lf 
1.5.3.1 Iron transporter: Lf, like other transferrin family members (ovotransferrin and 
melanotransferrin) is responsible for maintaining the iron levels in various cell and cell 
components by regulating the levels of free iron in the body fluids (Baker, Anderson & Baker 
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2003). Due to its ability to transport iron, milk-derived  hLf acts as a bacteriostatic agent in 
being able to deplete the iron essential for bacterial growth (Bullen, Rogers & Leigh 1972). 
1.5.3.2 Immune modulator and chemoprevention activities: Phase I and II clinical studies, in 
lung cancer, showed that oral administration of recombinant human Lf (talactoferrin) 
increased the expression of interleukin-18 (IL-18), CD8+ T cells and natural killer (NK) cell 
activity (Hayes, Falchook & Varadhachary 2010). Talactoferrin employed in previously 
known metastatic renal cell carcinoma (RCC), showed an increase in the lymphokine-
activated killer cells and NK cell activity leading to macrophage cytotoxicity in RCC (Jonasch 
et al. 2008). Similar effects with hLf were also observed in head and neck squamous cell 
carcinoma where T-cell dependent tumour inhibition (Wolf et al. 2007). Clinical trials with 
talactoferrin failed in clinical phase II and III trials due to increase in the death rates.  
More recently, n malignant melanomas, hLf-derived cationic anti-microbial peptides (CAPs) 
have been employed to study their anti-cancer activity. Intradermally established B16-F10 
melanoma, in syngeneic mice and showed that intratumoral administration of LTX-315 lead 
to necrosis. This further caused infiltration of immune cells in the tumour environment 
leading to complete regression of tumour in the animals. Pro-inflammatory cytokines like 
interleukin 1 β (IL-1β), IL-6 and IL-8 were upregulated in the tumours. This anti-tumour 
response helped form a protective immune response and proposed to  be used as a newly 
formulated immunotherapeutic (Camilio et al. 2014).  
bLf has also proved to have a role in the immune response, as it has the ability to bind to 
various immune cells likes macrophages, neutrophils, dendritic cells, natural  killer cells, 
enterocytes, fibroblasts, osteoblasts and platelets helping regulate migration, growth and 
differentiation (Actor, Hwang & Kruzel 2009; Kanwar & Kanwar 2013). Iron-saturated form 
of bLf has been identified as an adjuvant for augmenting chemotherapy (Kanwar et al. 
2008). This study proves the role of iron-saturated Fe-bLf in being able to enhance anti-
tumour immunity by increasing the production of Th1 and Th2 (T helper) cytokines, TNF and 
interferon-γ (IFN-γ). Upregulation of these markers helps in reducing tumour size and 
sensitize tumours to chemotherapy. Fe-bLf was further found to act as an adjuvant to 
chemotherapeutic drugs like taxol and 5-Fluoruracil in EL-4 lymphomas and B16-F10 mouse 
melanomas. In mouse melanomas it was noted that bLf served as an immunomodulatory 
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protein by promoting tumour apoptosis through infiltrating leukocytes. The binding of bLf to 
the Peyer’s patches proved that bLf was preferentially taken up by the intestinal epithelium. 
This increased the production of Th1, Th2 within the tumour and also promoted 
upregulation of TFN and IFN-γ depleting tumours in the mice (Kanwar et al. 2008).  
Oral administration of bLf and its digested peptides known as lactoferricin are known to 
induce protective immunity in the intestine (Tomita et al. 2002). Strong chemopreventive 
effects of bLf were noted in colon carcinoma and the effect of bLf on other organs was 
tested in a multi-organ carcinogenesis model and the protective effect of bLf was extended 
to the esophagus and lung in addition to the colon (Ushida et al. 1999). Chemopreventive 
effects of bLf were extended to N-Butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder 
carcinogenesis model and 4-Nitroquinoline 1-Oxide-induced tongue carcinogenesis, by 
upregulating the bacteriostatic and anti-inflammatory effects of bLf (Masuda et al. 2000; 
Tanaka et al. 2000).  
An ancillary study of participants, who received 3 g of bLf per day for 12 months, further 
revealed that suppression of growth in colorectal polyps was complementary to the levels of 
human Lf in the serum of the patients. It was also found that bLf increased the expression of 
IFN-α in the colon of the patients (Alexander et al. 2014).  
1.5.3.3 Anti-oxidant: Iron-binding capacity of Lf helps in preventing lipid peroxidation of 
milk proteins preventing rancidity of milk (Gutteridge et al. 1981). Our group has proved the 
role of four different forms of bLf namely natural bLf, Apo-bLf, iron saturated bLf and 
selenium saturated bLf in combating oxidative stress in the gut epithelial cells (Burrow et al. 
2011). When these proteins were used to check the anti-oxidant activity of bLf on hydrogen 
peroxide-induced colon carcinogenesis in HT-29 cells, it was observed that there were 
changes in the HT29 colon cancer cells which would protect them against oxidative stress 
thereby help in targeting cancer where the oxygen levels are compromised due to the 
tumour microenvironment. Various antioxidant enzymes like glutathione transferase, 
catalase, and superoxidase dismutase show increased activity in gut epithelial cells when 
treated with these forms of bLf, and the oxidative stress molecules showed downregulation 
proving the role of various forms of this protein in targeting cancer cells and its oxidative 
stress levels (Burrow et al. 2011). Supplementation of bLf to check its antioxidant levels in 8 
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healthy human males showed an increase in the hydrophilic antioxidant capacity (Mulder et 
al. 2008). In erythrocytes, Lf participated in oxido-reductive reactions that maintain the 
optimal ion gradient in erythrocytes. This helps in protection of cells against oxidative stress 
by regulating glycolysis (Maneva, Taleva & Maneva 2003). Clinical trials in patients with 
hepatocellular carcinoma (HCC) when treated with bLf showed a significant increase in the 
cytotoxic T cells and NK cells, reducing ROS, increasing anti-oxidant capacity in HCC (Tsuda 
et al. 2002).   
1.5.3.4 Anti-cancer activity of bLf: The anti-cancer activity of bLf has been proved by a 
number of studies from all over the globe. In vitro and pre-clinical observations have 
confirmed the role of bLf as an anti-cancer agent. A few examples are as follows: HS578T 
and T47D breast cancer cell lines when treated with bLf showed 47 % and 54 %  reduction in 
cell proliferation and increased apoptosis by 2-fold in both the cell lines. It also caused a 
decrease in the cell migration (Duarte et al. 2011).Induction of apoptosis in SGC-7901 
stomach cancer cells by the inhibition of the Akt signaling pathway with 50 µmM bLf was 
observed. Expressions of Akt, phosphorylated Akt Ser473, phosphorylated Akt Thr308 and 
Bcl-2 were significantly decreased leading to upregulation of caspase-9 Ser196 (Xu et al. 
2010).  
Human lung cancer cell line, A549 expresses a high level of vascular endothelial growth 
factor (VEGF) that causes angiogenesis leading to increased tumour survival. Expression 
levels of VEGF are increased under conditions of hypoxia, an aspect that has been targeted 
by bLf for in vitro treatment. A549 cells, when treated with bLf showed an increase in the 
levels of anti-inflammatory cytokines such as IL-4 and IL-10 and a decrease in the levels of 
TNF-α which is a pro-inflammatory cytokine inhibiting angiogenesis and blocking lung cell 
inflammation (Tung et al. 2013).  
Various studies conducted by our laboratory and others have proved the role of bLf as an 
anti-cancer agent. Fe-bLf encapsulated in alginate coated chitosan nanocarriers when given 
orally has proved to treat xenograft of human colon cancer when given orally. A significant 
regression in tumour size and complete inhibition of tumour growth was observed with Fe-
bLf treatments. These nanocarriers loaded with Fe-bLf enhanced the absorption of iron and 
increase iron uptake during iron deficiency without interfering in the absorption of calcium 
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(Kanwar, Mahidhara & Kanwar 2012a). Further in vitro and in vivo studies with these 
nanocarriers confirmed that Fe-bLf was able to target stem cell markers like survivin, CD133 
and CD44 in colon cancer xenograft model. An increase in the microRNA that is responsible 
for absorption of iron was also observed. It was also proved that bLf was able to enter the 
cells through transferrin, Lf receptors, low-density lipoprotein receptor (LRP) and dimethyl 
transferrin 1 (DMT1) proving receptor mediated internalisation of bLf in colon cancer cells. 
Finally, the apoptotic pathways targeted by nanocarriers loaded with Fe-bLf proved to be 
both intrinsic and extrinsic. An important aspect of this study was the role of Fe-bLf in being 
able to target survivin (Kanwar et al. 2014) that has gained the importance of hot cancer 
target  (Kanwar, Mahidhara & Kanwar 2012a).   
Earlier, randomized, double-blind, controlled trial conducted on 104 patients with colorectal 
adenomatous polyps was given 1.5 g bLf or 3 g bLf daily for 12 months. Colonoscopy was 
done to monitor the growth patterns of the polyps, which was significantly retarded in 
participants who were 63 years or younger when given 3 g of bLf daily. Mode of 
administration of bLf was oral and it was concluded that bLf can be clinically relevant 
adjunct for treating colorectal polyps when compared to polypectomy that is not a 100 % 
effective in eradicating the polyp growth (Kozu et al. 2009). 
Subcutaneous administration of bovine Apo-bLf and lactoferricin (Lf peptide) inhibited lung 
metastasis of B16-BL6 melanoma cells when tested in a spontaneous mouse metastasis 
model. This effect was observed only with the Apo-bLf and not holo-Lf (Yoo et al. 1998). In 
this case the activity of bLf was due to activation of natural killer (NK) cells proving the role 
of bLf in enhancing anti-tumour response in melanoma cells. Liposomal bLf, when orally 
administered in melanoma cells, lead to the upregulation of TNF-α and IL-1β leading to 
increased anti-cancer effect of bLf (Ishikado et al. 2005b). 
1.5.3 (E) bLf in recent clinical trials: Over 1300 peer reviewed medical and scientific journals 
have put forth the inherent ability of Lf as anti-cancer, anti-viral, anti-bacterial and as anti-
fungal agent. This astounding research captivated many pharmaceuticals to hover around 
this protein. Based on the findings by Kanwar et al., 2008, that Fe-bLf, enhanced the 
production of Th1, Th2, IFN-γ and TNF cytokines, thereby sensitizing the tumors to 
chemotherapy in vivo; Fonterra, a leading multinational diary company in New Zealand and 
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the world’s largest exporter of dairy products has produced “ReCharge” ice-cream made of 
Fe-bLf. Phase 2 clinical trial of this innovative ice-cream is expected to increase the immune 
system in patients undergoing chemotherapy. Another study on bLf led to the discovery of 
curing iron deficiency in complicated pregnancies with improved Hb levels (Paesano 2010). 
bLf restores the physiological transport of iron from tissues to circulation thus enhancing 
iron homeostasis. Pregnant women are at high risk of iron deficiency since the developing 
fetus requires enormous iron for its development. Hepicidin, a master regulator of iron 
homeostasis helps to increase iron storage in cells. Lf administration decreased IL-6 
concentration and increased prohepcidin in pregnant women while in non-pregnant 
women; Lf did not change IL-6 levels while it increased prohepcidin. Earlier, a  beverage that 
contains iron saturated bLf to fortify iron has been shown to improve haematocrit (Ht) 
levels, RBC number and Hb levels (Tanaka 1992). bLf was also proved effective in modulating 
blood glucose levels by increasing insulin content in diabetes mellitus patients (Mohamad 
2009). Thus a vast clinical need for an effective treatment can be envisaged by the use of 
this multifunctional protein. 
Lactoferrin is commonly found in the saliva. An ongoing research study in phase II trials, in 
colorectal cancer patients who are receiving oxiplatin-based chemotherapy was aimed at 
investigating if bovine lactoferrin supplement would improve taste perception in these 
patients. (http://clinicaltrials.gov/show/NCT01941810).  
To summarise, the effectiveness of bLf in preclinical studies proved its potential as an anti-
cancer agent. bLf, a natural therapeutic has not shown to cause any health concerns and 
side-effects leading to clinical trials that have employed the use of bLf for anti-cancer 
therapeutics. Therefore, importance of bLf as an anti-cancer therapeutic is gradually 
increasing.   
1.6 CONCLUSIONS  
Irrespective of attaining knowledge about the development and mechanism of resistance in 
melanomas and also formulating various therapeutic targets in melanoma, the overall 
therapeutic efficacy in targeting metastatic and drug-resistant melanoma is still lacking. A 
number of factors like P-gp, p53, survivin and BRAF mutations that play a critical role in the 
progression of melanoma have been reviewed, studied and targeted. The varying 
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chemotherapeutic and immunotherapeutic options available for melanoma are restricted 
due to their inability to target heterogeneity of melanoma cell population. The 
multifunctional protein of interest bLf could provide a much-needed potential application of 
a natural therapeutic in targeting the various aspects of melanoma. Promising effects of bLf 
in other cancer types and initial studies as reviewed here, with mouse melanoma cell lines 
and xenograft models (Ishikado et al. 2005a; Kanwar et al. 2008; Yoo et al. 1998) provide 
the opportunity to explore the role of this naturally derived milk protein in melanoma cell 
lines with varying p53, BRAF, NRAS and drug resistant status.  
1.7 KNOWLEDGE GAPS  
 What would be the mechanism(s) of action of bLf forms with different iron 
saturation status in targeting melanoma cell growth and cell death? 
 How does bLf forms with different iron saturation status act on patient-derived 
melanoma cell lines with p53, BRAF and NRAS mutations?  
 Does bLf have a role in targeting p53? 
 Can bLf target P-gp, an important drug-resistant marker? 
1.8 NOVELTY OF THE PROJECT 
Majority of the cancer patients including melanoma patients, develop drug resistance and 
not responded well to chemotherapy, after prolonged treatments. This is the major 
drawback in providing anti-cancer therapeutics that are patient-friendly and target all types 
of melanoma cells. To make therapy available to the patients, a natural nontoxic anti-cancer 
molecule is in dire need that can target various markers such P-gp, survivin, BRAF 
mutations, stem cells, involved in conferring MDR to malignant melanoma cells. This is a 
first-of-a-kind study to explore the mechanism and pathway of actions of iron-free (Apo-
bLf), iron saturated (Fe-bLf) and native (naturally available)-bLf, in causing apoptosis and 
targeting P-gp in 7 different types of  melanoma cell lines  obtained from ATCC, and patients 
with varying mutational status. ATCC established, SK-MEL-2, SK-MEL-28, primary patient-
derived LM-MEL-1a (NRAS mutant Q16K and WT BRAF), LM-MEL-12 (WT BRAF and NRAS), 
LM-MEL-62 (BRAF G469E mutant and NRAS WT), LM-MEL-24 (BRAF V600K mutant and NRAS 
WT) and Mel-007 (cisplatin drug-resistant) melanoma cell lines were used for this study. By 
employing robust cell based bioassays, this study has explored the activity of bLf as a 
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potential biodrug in targeting various aspects of malignant melanoma, including metastasis, 
cancer-stem cell markers, drug-resistant markers and mutations.  
1.9 HYPOTHESIS  
 The main hypothesis tested in the study is that bLf in its various iron saturation forms 
(Native-bLf, Apo-bLf and Fe-bLf) will be able to target melanoma cells’ growth and death 
irrespective of their mutational and p53 status. Stem cell markers and drug-resistant 
molecule P-gp can also be targeted by bLf in a differential manner due to its iron saturation 
status.  
1.10 AIMS  
 Prepare and characterize three forms of bLf samples. 
 Investigate the role of bLf as an anti-cancer agent in well-established ATCC human 
melanoma cell lines, SK-MEL-2 and SK-MEL-28. 
 Investigate the role of bLf as an anti-cancer agent in patient tumour-derived primary 
melanoma cell lines with varying BRAF and NRAS mutational status. 
 To study the effect of bLf in inhibiting P-gp expression, an important drug efflux 
transporter in melanoma. 
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All the reagents and chemicals used in this study were of analytical grade and were cell 
culture tested. 
A brief outline of the methodology employed through the study has been highlighted in 
the flow chart given below: 
 
 




A) Preparation and characterization of bLf 
2.1.1 Different iron-saturated forms of Native-bLf 
Bovine lactoferrin (bLf) were prepared using the standardized methods in the laboratory 
(Kanwar 2008; Kanwar, Mahidhara & Kanwar 2012b) (Figure 2.1). All the glassware required 
for preparation of bLf was incubated in 30 % nitric acid (HNO3) for atleast 30 min prior to 
use. This was done to eliminate all the free metal ions present in the beakers. The glassware 
was then rinsed with distilled water and air dried. Three forms of bLf namely Native-bLf, 
Apo-bLf (iron free) and Fe-bLf (iron saturated) were prepared from purified LPS free native 
form of bLf, by the methods standardized in our laboratory. Native-bLf was dissolved in 
Milli-Q at an initial concentration of 80 mg/mL and stored.  
2.1.2 Preparation of iron-free form of bLf 
Iron-free (Apo-bLf) was prepared by changing the pH of Native-bLf to 2.06 with 6M HCl. This 
removes all the iron that is bound to Native-bLf which was indicated by change in colour 
from reddish brown to ivory white. This solution was dialysed against 0.1M citric acid using 
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a 50 kDa molecular weight cut-off Spectra/pro dialysis tube (Pacific Laboratory, Blackburn, 
Australia). The solution was dialysed for 48 h at 40C and the citric acid solution was changed 
every 12 h. After dialysis, Apo-bLf was prepared by adjusting the pH of the solution to 8 with 
10M sodium hydroxide (NaOH). 
2.1.3 Preparation of iron-saturated bLf 
To prepare iron-saturated bLf, Apo-bLf was used as the starting material. 0.1M sodium 
bicarbonate in powder form was added to Apo-bLf solution and the pH was adjusted using 
6M NaOH. Fe-NTA solution was freshly prepared by adding 300 mM of ferric nonahydrate 
and 600 mM nitriloacetic acid disodium salt that was used to saturate the Apo-bLf solution 
with iron. The Fe-NTA solution was added dropwise to Apo-bLf and the solution was stirred 
continuously. Change in colour from ivory white to deep marrow red was noted, confirming 
the formation of iron complexes. The solution was stirred for an hour and the pH was 
adjusted to 8 with 6M NaOH. The solution was dialysed against Milli-Q for 48 h at 4oC and 
the Milli-Q was changed every 12 h. The prepared proteins were lyophilised (freeze dried) 
for long term storage.  
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Figure 2.1. The steps involved in the preparation of three forms of bLf. This schematic was 
drawn to represent the process of bLf preparation. bLf powder was dissolved in milli-Q at an 
initial concentration of 80 mg/mL. This solution of protein in milli-Q was dialysed against 
milli-Q for 48 h and stored as Native-bLf. The pH of Native-bLf was brought down to 2.8 with 
the help of HCl. The solution changed colour and this solution was then dialysed against 0.1 
M citric acid for 40 h. After dialysis, the protein was collected and the pH was set to 8.2 and 
stored as Apo-bLf. To Apo-bLf, a mixture of ferric nonahydrate and ferric trinitriloacetate 
was added in the ratio of 2:1 dropwise and stirred for 2 h. After stirring it was dialysed 
against milli-Q for 48 h and stored as Fe-bLf 
2.1.4 Iron estimation  
The procedure to measure the iron content in each of the three bLf forms prepared, the 
ratio method for measurement of iron content was performed as described by Yang et al. 
Briefly, all the three forms of bLf samples prepared were diluted with milli-Q at a 
concentration of 1:100 (bLf: milli-Q). The diluted samples were then checked for their 
absorbance at 280 nm and 465 nm using a Hitachi UV spectrophotometer. Only Milli-Q was 
used as the negative absorbance control and Fe-NTA standard was prepared to be used as a 
positive control. The concentration of iron-free bLf from the total bLf sample added was 
calculated using the equation mentioned below.  
Iron concentration= (A280-1.4 X (A 465 /0.058))/1.1  
2.1.5 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS- PAGE)  
Separation of proteins according to their molecular weight was achieved using a technique 
called sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The SDS 
used in this technique is a detergent that imparts uniform negative charge on the proteins 
without causing any alterations to the primary structure of the protein. Polyacrylamide is 
used to separate the protein according to their size under the influence of an electric field.  
The components and reagents used in the preparation of an SDS-PAGE gel were followed as 
mentioned in the Table 2.1. SDS-PAGE gel has two components namely separating gel at the 
bottom and the stacking gel at the top. Stacking gel is to ensure that the desired protein 
arrives at the separating gel at the same time to ensure they migrate as a tight band. In the 
separating gel, low molecular weight proteins run faster than the high molecular weight 
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proteins. In accordance to that, high molecular weight proteins such as bLf (̴ 75 kDa) were 
analysed using an 8 % gel. The gels once casted were allowed to set at RT for 1 h. Protein 
samples were initially heated to 95oC for 5 min and then separated using a SDS-PAGE gel 
depending upon the size of the protein being studied. The gel was run at 200 Volts for 45 
min in a Mini PROTEAN gel tank (Bio-Rad, Gladsville, NSW, Australia) with 1X Running 
buffer. Gel was then stained by a staining buffer which contained Commassie brilliant blue 
in glacial acetic acid, methanol and water for 20 min. Gel was de-stained using destaining 
solution with methanol and glacial acetic acid overnight. The gel was then viewed using 
ChemiDoc (Bio-Rad ChemiDoc XRS camera) and images were processed using Quantity one 
software. 
Table 2.1. Reagents used for separating and stacking gels for SDS-PAGE. 








Milli-Q water 1.92 mL 4.32 mL 3.92 mL 3.42 mL 
O.5M Tris pH 
6.8 
0.75 mL --- --- --- 
1.5M Tris 
pH 8.8 
--- 2 mL 2 mL 2 mL 
40% 
acrylamide 
0.3 mL 1.6 mL  2 mL 2.5 mL  
20% SDS 15 µL 40 µL 40 µL 40 µL 
10% APS 15 µL 40 µL 40 µL 40 µL 
TEMED 5 µL 10 µL 10 µL 10 µL 
2.1.6 Western blotting analysis 
Western blotting is used to identify the presence of a specific protein from a pool of 
proteins. Transfer of proteins from the SDS-PAGE gel to PVDF membrane (AmershamTM 
HybondTM-ECL, GE Health Care and Life Sciences, Australia) was done using the Transblot 
Turbo Transfer system (Bio-Rad, Australia) depending upon the size of the desired protein. 
Pre-set protocols were maintained on the system for quick transfer. PVDF membranes were 
soaked in methanol for 1 min before use, in order to charge the membrane and then 
washed with milli-Q twice for 10 min each. Following transfer, membranes were washed 
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briefly in 1x TBS for 5 min, and incubated in 3% porcein gelatin (used specifically for probing 
bLf) (Sigma Aldrich, Australia) solution for 1 h on a rocking platform. This served as a 
blocking agent. This was followed by one wash with 1x TBST for 5 min and 3 washes with 1x 
TBS for 5 min each. The blots were then probed with the appropriate primary antibody 
(1oAb) (Table 2.6) overnight at 4oC on a rocking platform. Following primary antibody 
incubation the membranes were washed with 1x TBS four times for 5 min to remove any 
unbound 1o Ab. Appropriate secondary antibody (2o Ab) (Table 2.6) conjugated to horse 
radish peroxidase (HRP) was then added to the membranes. The membranes were 
incubated with the 2o Ab for 1 h at RT on a rocking platform. Post-incubation the 
membranes were washed with 4 times with TBS-T and with 1x TBS three times. The 
membranes were then viewed for antigen-antibody reaction using the solutions from 
enhanced chemiluminescence (ECL) kit (GE Healthcare, Australia) which were applied to the 
membranes. The membrane was imaged using the ChemiDoc-XRS system (Bio-Rad 
ChemiDoc XRS camera) and the images were processed using the Quantity One software.  
B) Cell culture 
2.2.1 Cell line and culture conditions 
Human skin cancer (melanoma) cell lines SK-MEL-2 and SK-MEL-28 were purchased from 
American type culture collection (ATCC, USA) and were grown in Eagle’s Essential Medium 
(EMEM) with 10% of fetal bovine serum (FBS) and 1% of penicillin-streptomycin (P/S). 
Primary epidermal melanocytes (PEM) were also purchased from ATCC and were grown in 
dermal basal cell media with melanocyte growth kit components (rh insulin, ascorbic acid, L-
glutamine, epinephrine, calcium chloride and M8 supplement). Patient-derived cell lines 
with different BRAF and NRAS mutational status namely LM-MEL-1a (NRAS Q16K mutant 
and BRAF WT), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K, NRAS WT) and 
LM-MEL-62 (BRAF G469E and NRAS WT) were obtained from The Ludwig Institute of Cancer 
Research in Melbourne, Australia (Ludwig Institute of Cancer Research Ltd, Austin Hospital, 
Studley Road, Heidelberg, Victoria, 3084, Australia). These cell lines were cultured in Roswell 
Park Memorial Institute (RPMI) medium with 10% FBS and 1 % Penicillin-streptomycin. 
Mel007, a cisplatin drug resistant human skin cancer cell line was a gift from The University 
of Sydney, Sydney, Australia (The University of Sydney, NSW, 2006, Australia) that were 
cultured in Dulbecco’s modified Eagles’ Essential Medium (DMEM) with 5% FBS and 1% P/S. 
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Optimum conditions for cell culture were maintained at 5% CO2 and 37
oC in a humidified 
incubator. Cell densities were maintained at 5x105 cells/mL. All cell culture reagents were 
purchased from GIBCOTM, Life Technologies, Australia, except for FBS that was purchased 
from Bovogen Biologicals and Interpath Pty Ltd. (Vic, Australia).  
2.2.2 Cell culture and maintenance  
Cell lines were routinely cultured in both 25cm2 and 75cm2 flasks (Greiner BioOne, Australia) 
with appropriate growth medium. On 80-90% confluency, cells were prepared for 
subculturing by replacing the old medium and washing them with sterile PBS. Trypsin-EDTA 
solution (Sigma-Aldrich, Australia) was added to the flasks and was incubated at 37°C for 5-7 
min to allow detaching of cells. Trypsin neutralisation was carried out by adding fresh 
growth medium and cells were centrifuged at 1600 rpm for 6 min. On centrifugation, single 
cell suspension was prepared by gentle pipetting and counted under haemocytometer. 
Appropriate numbers of cells were added back to the flasks for further culturing. Cell 
viability was always checked by trypan blue exclusion assay. 
2.2.3 Quantitative Real-Time PCR (qRT-PCR) studies 
2.2.3.1 Total RNA isolation 
Cells were grown in 6 well plates until they reached the desired confluence. Following 
washing with PBS, the cells were then treated with 20 nM and 40 nM concentrations of 
Native-bLf, Apo-bLf and Fe-bLf according to Table 2.4. After the cells were incubated with 
the desired treatments, total RNA was isolated from the cell lines using TriZol reagent (Life 
Technologies, Australia) method, as per kit instructions.  Briefly, to the cell monolayer 1mL 
TriZol reagent was added according to the plate size and manufacturer’s instructions. This 
was then mixed thoroughly for 5 min as RT. Lysed cells were then collected into 
microcentrifuge tubes and 200 μL of chloroform was added. The tubes were shaken and 
incubated at RT for 3 min. The lysates were then centrifuged at 11,200 rpm for 15 min at 
4oC. The lysates were separated into an upper aqueous phase and lower organic phase. The 
aqueous phase was collected into a fresh microcentrifuge tube and the organic phase was 
stored for protein extraction. To the aqueous phase 500 μL of isopropanol was added. The 
samples were incubated at RT for 10 min and then centrifuged at 11,200 rpm for 10 min at 
4oC. Post-centrifugation, the supernatant was removed and the RNA pellet was washed with 
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75% ethanol via vortexing. This was again centrifuged at 8,000 rpm for 5 min at 4oC. The 
RNA pellet was then dried and dissolved in RNase-free water (Sigma Aldrich, Australia). The 
isolated RNA concentration was determined using a Hitachi UV spectrophotometer at an 
absorbance on 260 nm. The quality of RNA was checked by running it on a 1% agarose gel 
with SYBR safe (Life Technologies, Australia) at 100 volts for 35 min, and then viewed using a 
Chemidoc XRS system from Bio-Rad.  
2.2.3.2. Reverse Transcriptase PCR for cDNA synthesis 
SuperScriptTM III first strand synthesis system (Life Technologies (previously Invitrogen), 
Australia) was used to convert the isolated RNA into cDNA. The assay was carried out as per 
manufacturer’s instructions.  In brief, a concentration of 8 μg of total RNA was used from 
each sample and transferred into 0.2 mL microcentrifuge tubes. To this, 1 µL of 50 μM oligo 
(dT) 20 and 1 μL of 10 mM dNTP mix (Life Technologies, Australia) was added. This mixture 
was made up to 10 μL by adding nuclease-free water (Applied biosystems, Australia). The 
tubes were then incubated at 65oC for 5 min in a Takara PCR thermal cycler (Scientifix, 
Australia) and then placed in ice for 1 min. The cDNA synthesis mixture was prepared as per 
kit instructions and 10 μL was added to each tube. Tubes were mixed and collected by brief 
centrifugation. They were then incubated in a PCR thermal cycler for 50 min at 50oC after 
incubation; reactions were stopped by incubating the tubes at 85oC for 5 min, and were 
then placed on ice. The prepared cDNA mixtures were stored at -20oC until further use.      
2.2.3.3. Real time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
assay 
The prepared cDNA was amplified by qRT-PCR according to the protocol given in the 
SybrGreen RT-PCR kit (Bio-Rad, Australia). The PCR reaction mixture was prepared in 0.2 mL 
microcentrifuge tubes by mixing 7.5 μL of SYBR Premix Ex TaqTM, approximately 450 ng/mL 
of cDNA, and 0.4 μL of both sense and antisense primers (as described in Table 2.5) for the 
required PCR product at a concentration of 0.2 µM. This mixture was made up to 15µL by 
adding nuclease-free water. The tubes were briefly centrifuged and placed in the PCR 
thermal cycler. Briefly, PCR cycle involved an initial denaturation step at 94oC for 5 min 
followed by 50 cycles of denaturation step at 94oC for 30 sec then an annealing step for 30 
sec (as shown in Table 2.5) at the recommended and appropriate temperatures for the 
primers being used and an extension step at 72oC for 1 min. All the samples were run in 
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triplicate and a mean Ct value for the samples was used for further calculations. The relative 
gene expression was calculated as ΔΔct values to check the fold changes in the expression of 
genes when compared to an untreated control. These values were plotted in a graph for 
representation. The PCR product of all the samples were run on a 1% agarose gel prepared 
in 1x TBS for 35 min at 100 Volts. The gel was then imaged using a UV filter on a ChemiDoc 
XRS.  
2.2.4 Immunofluorescence (IF) staining 
 
Figure 2.2. Showing the principle of staining using IF. This figure was drawn to explain the 
principle of IF staining. Cells with protein of interest can be detected by fluorescent labelled 
antibodies. Unlabelled primary antibody that binds to the protein of interest can be 
detected when a fluorophore (either FITC or TRITC) labelled secondary antibody binds to the 
primary antibody producing fluorescence 
Cellular internalisation assay: The cells were cultured at a cell density of 105 cells/mL in 8 –
chamber slides and incubated at 37oC at 5% CO2 and were treated as mentioned in Table 
2.4. After incubation the media was removed and the cell layer was washed with PBS. The 
cells were then treated with 20 nM of Native-bLf, Apo-bLf and Fe-bLf for 30 min, 2 h, 4 h and 
6 h. This was done to check the time-dependent internalisation of all forms of bLf. For the 
experimental setup, a primary antibody control and a secondary antibody control were 
included. Primary antibody control well was maintained by following all the steps without 
the addition of primary antibody. For the secondary antibody control, all the steps were 
followed upto the primary antibody incubation and no secondary antibody was added to the 
control well to confirm the immunoreactivity. The slides were incubated at 37oC for 24 h at 
5% CO2.After incubation, the supernatant was discarded. The cell layer was washed with PBS 
                                                                                                       Chapter 2- Materials and Methods                  
62 
 
following incubation in 4% paraformaldehyde (PF) solution for 20 min for fixing the cells. 
After fixation, the cell layer was washed with PBS twice. The 8 well slides were then place on 
ice following treatment with 0.1% Triton-X for 1 min in-order to cause membrane porosity. 
Following Triton-X treatment, the cell layer was washed with PBS twice. Blocking solution of 
3% Porcein gelatin was added to the cell layer and the slide was incubated at 37oC for 1 h. 
Primary antibody, goat anti-bLf (Bethyl Scientific) was then added to the wells in the 
concentration of 1:100 using PBS for antibody dilution. The cells were incubated in primary 
antibody for 1 h at 37oC. Post-incubation, the primary antibody was discarded and the cell 
layer was washed with PBS thrice. Secondary antibody anti-goat IgG FITC (Sigma Aldrich, 
Australia) was added to the wells in the concentration of 1:100 using PBS for diluting the 
antibody. Secondary antibody incubation was done at 37oC for 1 h. After secondary 
antibody incubation the cell layer was washed with PBS thrice following which the chambers 
were detached from the slide. The slide was air dried and then one drop of DAPI solution 
(Sigma Aldrich, Australia) was added to each chamber and a coverslip was carefully placed 
on the slide to avoid formation of air bubbles. All the steps after primary antibody 
incubation were done in the dark. The slide was then left for air drying and viewed using a 
Leica SP5 confocal microscope and the images were processed using the LAS-AF software. 
Five images were taken from different fields for quantitative analysis.  
C) Analysis following treatments with Native-bLf, Apo-bLf and Fe-bLf 
2.3.1 Cell proliferation assay 
Cell viability studies were done to check the anti-cell proliferative effects of bLf on skin 
cancer cell lines. This study was done using the CyQUANT cell proliferation kit (Life 
Technologies, Australia) which is ideal for more sensitive and colorimetric based detection 
of proliferating cells as the GR dye component binds to the DNA of the proliferating cells. 
The melanoma cells were cultured at a cell density of 1x105 cells/mL in a 96 well plate. The 
cell layer was allowed to grow at 37oC at 5% CO2 for 48 h. The media was then discarded 
and the cell layer was washed with PBS. Cells were treated with varying concentrations  of 
Native-bLf, Apo-bLf and Fe-bLf as described in Table 2.4  for 24 h (SK-MEL-2 and SK-MEL-28) 
and 48 h (LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF 
G469E), (LM-MEL-24 (BRAF V600K) and Mel-007 (DR)).   The incubation was done at 37oC at 
5% CO2. Controls were maintained with a no treatment group. Another treatment group 
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included positive control that was incubated with 20% serum supplemented media to 
achieve maximum proliferation according to manufacturer’s instructions. After incubation 
with treatments, the 96 well plates were centrifuged at 4500 rpm for 5 min at RT. The 
supernatant was discarded. The cell layer was washed with PBS twice and air-dried for 30 
min. After drying the plate was covered in aluminium foil and stored at -80oC for a minimum 
of 48 h. To the frozen cell layer, 200 µL of the reaction mixture was added as per 
manufacturer’s instructions in table. Fluorescence was measured at excitation/emission of 
485/530 nm using a microplate reader.  
2.3.2 Tumour spheroid assay 
 
Figure 2.3. Showing the principle of tumour spheroids cultures. This diagram represents 
tumour spheroids can be formed by culturing cells in agarose-coated plates. These cultures 
mimic the natural environment of tumour in vivo by secreting extracellular matrix proteins, 
and are resistant to drugs (Nyga, Cheema & Loizidou 2011). 
To obtain 3D cultures of the melanoma cells being used for the study, tumour spheroids 
were formed. Tumour spheroid studies were studied as a treatment model. The cells were 
trypsinized using the routine protocol for trypsinization and 1000 cells/well were plated in 1 
% agarose-coated 96 well plates. The coated agarose plates were sterilised under UV for 1 h 
before plating out the cells. The cells were then allowed to form tumour spheroids for 7 
days. The media was changed every 3rd day to allow healthy spheroid formation from the 
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cells. After 7 days, the tumour spheroids were treated with varying concentrations of 
Native-bLf, Apo-bLf and Fe-bLf as described in Table 2.4. Untreated spheroids were 
maintained as positive controls. After incubation with treatments, the tumour spheroids 
were imaged by light microscopy and the surface area of the spheroids was calculated using 
Image J software (National Institute of Health, USA). The values were then plotted as a 
histogram.  
2.3.3 Clonogenic assay  
Colony forming ability of SK-MEL-2, SK-MEL-28, LM-MEL-1a (NRAS Q16K), LM-MEL-12 (WT 
BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) 
was studied. The cells were grown in 6 well plates at a cell density of 2x105 cells/mL and 
incubated at 37oC until desired confluence of 90% was achieved. After the cell layer was 
90% confluent, they were treated with varying concentrations of Native-bLf, Apo-bLf and Fe-
bLf as described in Table 2.4. Untreated cells were maintained as a positive control. The 
plates were then incubated at 37oC at 5% CO2 for 24 h. Duplicate control wells were 
maintained for each treatment. After incubation with the treatments, the supernatant was 
discarded, the cell layer was washed with PBS and the cell layer was subjected to 0.25% of 
trypsin-EDTA (Life Technologies, Australia). The cells were incubated with trypsin for 5 min 
at 37oC at 5% CO2. Once the cell layer was detached, the cells were collected in a 
microcentrifuge tube and then centrifuged at 1600 rpm for 6 min. The cell number for each 
treatment was counted using a haemocytometer by trypan blue (Sigma Aldrich, Australia) 
staining. For each treatment, 500 cells were plated into fresh 6 well plates and incubated at 
37oC at 5% CO2. The colonies were allowed to form for 14 days and media was changed 
every 3 days without disturbing the colony growth. After 14 days, the media was discarded 
and the cell layer was washed with PBS. The cell layer was fixed using 4% PF for 20 min at RT 
and then stained for 20 min using 1% crystal violet dissolved in PBS at RT. Stained cells 
colonies were counted using a colony counter and a graph was plotted for the number of 
colonies formed using untreated cells as a positive control. Colony forming efficiency was 
calculated using untreated as 100% clonogenic potential of the cell line.  
2.3.4 Cell cytotoxicity study 
The cytotoxic effects of the prepared bLf samples were tested using a lactate 
dehydrogenase (LDH) detection kit (Roche, Australia) as per the manufacturer’s instructions. 
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Dying cells due to changes in their membrane structure release LDH in the extracellular 
medium indicating the cytotoxic effects of bLf. Briefly, cells were plated out in 96 well plates 
at a cell density of 1x105 cells/mL and incubated for 48 h at 37oC in a humidified atmosphere 
of 5% CO2 in air. Post-incubation the media was removed and the cells were washed with 
PBS. After PBS was removed, the cell layers were treated with Native-bLf, Apo-bLf and Fe-
bLf in the concentrations as described in Table 2.4. The cells were then incubated at 37oC 
for 24 h (SK-MEL-2 and SK-MEL-28) and 48 h (LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a 
(NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-24 (BRAF V600K) and Mel-007 (DR)) at 5% 
CO2. Controls were set up as per the manufacturer’s instructions, with a positive control 
using 100 µL of cells and 100 µL of 1% Triton-X 100 (Sigma Aldrich, Australia), a negative 
control containing 200 µL of cells grown in media only and a background control. After 
incubation the plate was centrifuged at 4800 rpm for 5 min at RT to settle the cell debris. 
The supernatant from each well was then collected and transferred to a fresh 96 well plate. 
To this supernatant, 100 µL of reaction mixture (as per Table 2.2) (freshly prepared) was 
added and the plate was incubated in the dark for 30 min at RT. After incubation the 
absorbance was measured using a microplate reader (Corona electric) using a filter of 492 
nm, with a reference of 620 nm. Cytotoxicity (%) from the cell layer was calculated using the 
formula mentioned below 
                      Cytotoxicity (%) = Absorbance value-Negative control      X100 
                                                       Positive control- Negative control         
Table 2.2- Components of reaction mixture for LDH.  
Component Volume No. of tests 
Catalyst 250 µL 100 
Dye Solution 11.25 mL 100 
 
2.2.5 Morphological observations post treatments 
2X105cells/mL were seeded in 6 well plates and left incubated until   ̴80% confluency with 
frequent media change. The media was then completely aspirated and replaced with 
treatments media. After treatments, the plate was incubated at 37°C with 5% CO2 for 24 h. 
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Post incubation, cells were viewed under inverted microscope (Prism Optical) and images 
were captured by a digital camera. 
2.2.6 ANNEXIN-V staining  
Annexin-V staining is used to detect the apoptotic and necrotic cells from a population of 
cells that have been treated with bLf with the annexin-V labelling kit (Roche, Australia). 
Labelled annexin-V has a high affinity to bind to phosphatidylserine that is usually present 
on the outer layer of apoptotic cells. Propidium iodide (PI) is another stain used which stains 
DNA of damaged cells helping differentiate between necrotic cells and apoptotic cells. Cells 
were cultured in 6 well plates at a cell concentration of 2 x 105 cells/mL at 37oC at a humidity 
of 5% CO2. After the cells reached a desired confluency, the cell layer was washed with PBS. 
The cells were then treated with varying concentrations of Native-bLf, Apo-bLf and Fe-bLf as 
described in Table 2.4 , and incubated at 37oC at 5% CO2 for 24 h (SK-MEL-2 and SK-MEL-28 
and 48 h (LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF 
G469E), LM-MEL-24 (BRAF V600K) and Mel-007 (DR)). After incubation the supernatant was 
centrifuged at 1600 rpm for 6 min to collect any floating cells. The cell layer was washed 
with PBS and then subjected to 0.25% trypsin-EDTA. Cells were incubated with trypsin at 
37oC at 5% CO2 for 5 min, and centrifuged at 1600 rpm for 6 min. The centrifuged cells were 
then washed with PBS. To this cell pellet 100μL of reaction mixture was added and mixed 
well with the cells as per manufacturer’s instructions in Table 2.3. The cell pellet was 
incubated with the reaction mixture at 4oC for 30 min in dark. The cells were then sorted 
and analysed using a FACS-BD Canto II machine. Cells were sorted as unstained, early 
apoptotic, late apoptotic and necrotic cells depending on the stain they took. A graph was 
plotted using this information to check the percentage of apoptotic and necrotic cells when 
skin cancer cells were subjected to various concentrations of bLf.  
Table 2.3. Components of reaction mixture for Annexin-V staining. 
Component Amount (μL) No. of tests Stain for 
Propidium iodide (PI) 20  10 Necrotic cells 
Annexin-V 20  10 Apoptotic cells 
Incubation buffer 1000  10 ---- 
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2.2.7 Caspase-3 assay 
Caspase-3 activity was performed using spectrophotometric detection of cleaved 
chromophore p-nitroanilide (pNA) from DEVD-pNA substrate as described by Fujie et al. 
(Fujie et al. 2005). 1 x 104 cells/mL were seeded and allowed to reach confluency of about 
85-90% in 96 well plates. After 90% of confluency, cells were then treated with 20 nM and 
40 nM of Native-bLf, Apo-bLf and Fe-bLf for 24 h.  Briefly, cells were centrifuged in 50μL of 
chilled lysis buffer. Supernatant was then collected from the wells and Bradford assay was 
performed. To 100μg protein from the sample, 50uL of DTT in radio immunoprecipitation 
assay (RIPA) buffer solution was added to the samples. Finally, 5μL of 4mM DEVD-pNA 
substrate (200uM) was added to each sample and incubated at 37°C for 3 h. The reaction 
was then measured at 405 nm in a microplate reader. Caspase-3 activity in umol of pNA was 
calculated using the formula given below  
                                  Activity, umol pNA/min/mL = OD*d/ƐmM *t* v  
Where ƐmM = 10.5; v – volume of sample in mL; d – dilution factor; t – reaction time in min.  
2.2.8 Apoptotic array  
Apoptotic arrays were performed for the analysis of 35 key proteins involved in apoptosis 
pathway including various pro-apoptotic and anti-apoptotic molecules. Cells were plated in 
6 well plates at a concentration of 1x106 cells/mL. These cells were allowed to grow until 
90% confluent in a 5% CO2 incubator at 37
oC. Once confluent the cells were treated with 40 
nM of Native-bLf, Apo-bLf and Fe-bLf as per Table 2.4. Untreated cells were maintained as a 
control. After incubation with the treatments for 24 h the cell layer was washed with PBS, 
and the cell layer was lysed using RIPA buffer which contained protease inhibitor to prevent 
degradation of proteins. The assay was performed as per manufacturer’s instructions in the 
apoptotic array kit (R&D, Australia). The reagents were prepared according to the protocol 
provided. Two mL of array buffer which serves as a blocking agent was added into each well 
of the 4-well multi-dish provided in the kit. Flat-tip tweezers were used to remove each 
array to be used from between the protective sheets. One array was placed in one well and 
incubated in the blocking solution for 1 h at RT on a rocking platform. A desired quantity of 
lysate from the cells was added to 1.25 mL of array buffer 1. Aspirated array buffer 1 from 4-
well multi-dish and cell lysate-array buffer mixture was added in different wells. The plate 
was incubated overnight at 4oC on a rocking platform shaker. Each array was then removed 
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carefully and placed into plastic containers with 20mL of wash buffer. The multi-dish plate 
was rinsed with distilled water and dried. Each array was washed with wash buffer for 10 
min three times. 15 µL of reconstituted detection antibody cocktail was added to 1.5 mL 
with array buffer 2/3. The arrays were then placed in their respective wells in the multi-dish 
plate and reconstituted antibody was added per well and incubated for 1 h on a rocking 
platform shaker. The arrays were washed again as mentioned above. The streptavidin-HRP 
was diluted in array buffer 2/3 as per the instructions on dilution factor mentioned on the 
vial. 2mL of this mixture was added in each well of the plate and incubated for 30 min on a 
rocking platform. The arrays were then developed using chemidoc with XRS camera. Semi-
quantitative analysis of densitometry (Band density analysis) was done using the image J 
1.42 software and graphs were plotted showing the intensity of band density in pixels with 
respect to the control proteins.  
2.2.9 Migration and Invasion Assays 
 




Figure 2.4. Showing the steps involved in migration and invasion assays. This was drawn to 
represent the principle of migration and invasion assay where cells were allowed to grow in 
8 µm membrane chambers without extracellular matrix proteins (ECM) termed as migration 
assay and with ECM (Invasion assay) to check the migratory and invasive potential of cells 
and the effect of treatment on the metastatic potentials of cancer cells.  
To check the effects of bLf on tumour metastasis and its inhibition, migration and invasion 
assays were performed. Migration assay proves the capability of tumour cells to migrate 
through an 8 µm membrane. Twelve well plate thin-certs (Grenier BioOne) with a pore size 
of 8 µm were placed in a 24 well plate. Cells were plated out in the chambers with 
appropriate amount of media. To the wells, media with varying treatment concentrations of 
Native-bLf, Apo-bLf and Fe-bLf (as described in Table 2.4) were added including one well as 
a control with media alone. Cells were incubated with treatments for 24 h at 37oC with 5% 
CO2. Post-treatment the supernatant was discarded and the cell layer was washed with PBS 
both on top and bottom layers of the trans-well chambers. Cells were then fixed with 4% PF 
for 20 min at room temperature following which they were washed with PBS and then 
stained with 0.1% crystal violet. The top layer of cells was removed with the help of a cotton 
bud to only observe the cells that have passed through the 8µm membrane. The cells were 
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viewed and imaged using an inverted microscope. The same protocol was followed for 
invasion assay except that the trans-well chambers were coated with MaxGelTM ECM 
(extracellular matrix gel) (Sigma) that was allowed to solidify prior to plating out cells. This 
mimics the tumour vasculature and checks the ability of melanoma cell lines to invade into 
neighbouring tissues. The migratory and invasive cells were imaged and counted manually. 
The cells were counted from five different fields and average of the cells counted was 
plotted on a histogram with untreated cells as the control.  
2.2.10 Estimation of melanin content 
Melanin pigment is a very important component in skin cells. The amount of melanin 
pigment present in all the skin cancer cell lines was estimated using a standard protocol for 
melanin estimation that has been previously described (Hu 2008). Cells were grown in a 96 
well plate at a cell density of 1000 cells/well and allowed to grow for 48 h. The cells were 
then treated with 10 nM, 20 nM and 40 nM treatment of Native-bLf, Apo-bLf and Fe-bLf for 
24 h. Treated cells were trypsinized using the routine protocol for trypsinization and the 
cells were counted. 1x104 cells were taken and suspended in 1N NaOH. 300 µL of the cell 
suspension was added in a 96 well plates and 1N NaOH was used as a negative control. The 
absorbance was measured at 472 nm and amount of melanin present per cell was 
calculated.  
2.2.11 Extraction of cell lysates for Western blotting 
Cells were plated in 6 well plates at a cell number of 2x105 cells/mL and incubated at 37oC at 
5% CO2 until they reached 90% confluence. Once confluent the cell layer was washed with 
PBS and the cells were treated with 40 nM of Native-bLf, Apo-bLf and Fe-bLf. The cells were 
incubated with the treatments for 24 h at 37oC at 5% CO2. After incubation with the 
treatments, the supernatant was discarded and the cell layer was washed with PBS. 100 µL 
of RIPA buffer with 1x mini complete with EDTA (protease inhibitor) was added to each well 
and the plate was placed on ice for 20 min. The cell layer was scraped and collected in 
microcentrifuge tubes. The lysates were centrifuged at 13,000 rpm for 20 min at 4oC. The 
supernatants were collected after centrifugation and stored in a fresh microcentrifuge tube. 
Samples were then measured for their protein concentration using Bradford’s reagent.  
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2.2.12 Protein estimation 
Protein estimation was carried out using commassie plus –the better Bradford assay kit. 
Bovine serum albumin (BSA) (Sigma Aldrich, Australia) was used as a standard with 
concentrations ranging from 1 mg/mL to 25 mg/mL prepared in Milli-Q. Unknown protein 
samples were diluted in the concentrations of 1:10 and 1:100 in Milli-Q and 10 μL of the 
diluted samples were then added to a 96 well plate. Coommassie plus (300 μL) was added to 
each well with controls including Milli-Q, RIPA buffer and Coommassie plus alone. Plates 
were then shaken well and incubated for 10 min in dark. Readings were then taken using 
SH-1000 lab absorbance microplate reader (Corona Electric) at a wavelength 620 nm. 
Concentration of unknown proteins was then calculated by plotting a BSA standard curve 
and the linear equation obtained from the graph. 
Western blotting was performed for studying the marker expressions in cell lysate (as 
described earlier in the section) post treatments. The SDS-PAGE gels were prepared 
depending on the molecular weight of the protein of interest. For proteins that have a 
molecular weight more than 100 kDa, for example P-glycoprotein (P-gp), 8 % gels were 
used. 10 % gels were employed for analysing proteins such as GAPDH, p53, phospho-p53, 
MDM2 and Numb that had a molecular weight between 50 kDa- 100 kDa. For low molecular 
weight proteins such as survivin, Bax and Bcl-2, 12.5 % gels were used for analysis. Specific 
primary and secondary antibodies were used for probing the protein of interest (Table 
2.7).The other steps remained the same through the procedure.  
2.2.13 Flow cytometry analysis 
To check the expression patterns of various proteins when treated with bLf, flow cytometry 
analysis was done. The cells were plated out in 6 well plates at a cell density of 2x105 cells 
/mL and incubated at 37oC at 5% CO2 until the cells were confluent. After the cells reached 
90% confluence, growth media was discarded and the cell layer was washed with PBS. The 
cells were then treated with varying concentrations of Native-bLf, Apo-bLf and Fe-bLf as 
described in Table 2.4. All the treatments were prepared in 1% serum supplemented media. 
After incubation with the treatments, the supernatant was collected and centrifuged at 
1600 rpm for 6 min and floating cells if any were collected. The cell layer was then 
trypsinized using the routine procedure for trypsinization. Collected cells were centrifuged 
at 1600 rpm for 6 min and washed with PBS once. The cells were fixed with 4% PF for 20 min 
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at RT and then washed with PBS. After fixation, the cells were permeabilized using 0.1% 
triton-X100 for 1 min by placing all the microcentrifuge tubes on ice. The cells were then 
fixed using 3% bovine serum albumin (BSA) for one h at 37oC . The cells were incubated in 
primary antibody solution in the concentration of 1:100 at 37oC for one h. Appropriate 
secondary antibody was then added to the cells at a concentration of 1:100 and the cells 
were incubated at 37oC for 1 h. After each step, the cells were washed with PBS twice and 
centrifuged to collect the cell pellet and discard the supernatant. The cells were then 
suspended in 500 µL of PBS and analysed using FACS-BD Canto II. BD-FACS Diva software, 
version 5.0, was used for analysis; a uniform population of cells was gated from the parent 
population as P1 and is considered as the population of analysis. This population (P1) was 
kept constant (10,000 events) throughout the experiment. The distribution of cells in P1 was 
plotted as histograms and they were further divided into sub-populations gated as, P2, P3 
and P4 depending on the study.  
2.2.14 Gene silencing of p53 
SignalSilence p53 siRNA (Cell Signaling Technology, Australia) was used to silence gene 
expression of p53 in LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) 
cells. The cells were allowed to grow on a 12-well plate in media containing 10 % serum at a 
density that allows cells to reach 50 % confluence on day 2. On day 2, the media was 
removed from the cells and replaced with 500 µL of fresh serum-containing media. 100 µL 
of serum-free media was taken in a fresh tube and 2 µL of lipofectamine (Life Technologies) 
was used as the transfection agent. This solution was mixed well and incubated at RT for 5 
min. Appropriate volume of siRNA p53 was added to make the final concentration to 50 mM 
and 100 mM and the solutions were mixed well. The solution was incubated at RT for 5 min 
and 100 µL of the siRNA solution was added to the well containing 500 µL of fresh serum 
containing media. The media was agitated vigorously to allow uniform suspension of the 
mixture. The cells were allowed to be transfected with the siRNA for 24 h and 48 h.  
2.2.15 Softwares used 
Image J (http://imagej.nih.gov/ij/), a public domain with Java-based imaging processing 
program developed by National Institutes of Health was used in spheroid culture image 
analyses, Western blotting bands and apoptotic and cell stress array kit band density 
analysis. Adobe Photoshop, a graphics editing program developed by Adobe Systems was 
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used to enhance bright field images. Leica Application Suite Advanced Fluorescence (LAS-AF) 
software module was used to capture 3D images of samples through confocal microscopy. 
2.2.16 Statistical analysis 
 Each experiment/assay was performed three times in triplicates unless otherwise indicated, 
and representative data were shown. Data was presented as mean ± (SE), applying 
Student’s t-test for comparison between treatments and untreated controls. A value less 
than or equal to 0.05 and 0.01 was accepted as statistically significant and less than or equal 
to 0.001 was considered as highly significant. 
Table 2.4. Treatment conditions of bLf for melanoma cell lines. 
Cell lines SK-MEL-2 and SK-MEL-
28 
LM-MEL-12 (WT BRAF and NRAS), LM-
MEL-1a (NRAS Q16K), LM-MEL-62 
(BRAF G469E), LM-MEL-24 (BRAF 
V600K) and Mel-007 (DR) 
 
Treatments 
Native-bLf, Apo-bLf and Fe-bLf 
 
Represented as concentration in nM of bLf used for treatments 
(Treatment time) 
 






















20 nM (30 min, 4 h and 6 
h) 
20 nM (30 min, 2 h, 4 h and 6 h) 
CyQUANT 10 nM, 20 nM and 40 nM 
(24h) 
10 nM, 20 nM, 40 nM and 80 nM (48 h) 






10 nM, 20 nM and 40 nM 
(24 h) 
20 nM and 40 nM (48 h) 
Clonogenic 
assay 
10 nM, 20 nM and 40 nM 
(24 h) 
20 nM and 40 nM (48 h) 
LDH assay 10 nM, 20 nM and 40 nM 
(24 h) 
10 nM, 20 nM, 40 nM and 80 nM (48 h) 
Annexin-V/PI 
staining 





40 nM (24 h) 40 nM (48 h) 
Caspase-3 
assay 
20 nM and 40 nM (24 h) ---- 
Migration 
assay 
10 nM and 20 nM (24 h) 20 nM and 40 nM (48 h) 




5 nM, 10 nM, 12.5 n M, 
20 nM, 40 nM and 80 nM 
(48 h) 
20 nM, 40 nM and 80 nM (120 h) 
All the primers were purchased from Sigma Aldrich (Australia).  
Table 2.5. LIST OF PRIMERS USED FOR GENE EXPRESSION ANALYSIS. 
S.no. Primer Sequence (5ʹ to 3ʹ) Reference 
1.  Beta 
Actin 
F- 5’-CTC ACC GAG CGC GGC TAC A-3’ 
R- 5-CTC CTG CTT GCT GAT CCA CAT-3’ 
  
(Li et al. 2009) 
2.  Survivin F- 5’-CCA CCG CAT CTC TAC ATT CA-3’  
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R- 5’-TAT GTT CCT CTA TGG GGT CG-3’ (Sohn, Lee & Park 2010) 
3.  Bax F- 5’-GGCCCACCAGCTCTGAGCAGA-3’ 
R- 5’-GCCACGTGGGCGTCCCAAAGT-3’ 
 
(Gradilone et al. 2003) 
(Nilkaeo & Bhuvanath 2006) 
4.  Bcl-2 F- 5’-ATGTGTGTGGAGAGCGTCAA-3’ 
R- 5’-ACAGTTCCACAAAGCATCC-3’ 
 
(Leze et al. 2012) 
(Zhang et al. 2011) 
5.  FAS F- 5’-GAAGGACATGGCTTAGAAGTG-3’ 
R- 5’-ACTTAGTGTCATGACTCCAGC-3’ 
 
(Roh et al. 2002) 
6.  EpCAM F- 5’-AATGTGTGTGCGTGGGA-3’ 
R- 5’-TTCAAGATTGGTAAAGCCAGT-3’ 
 
(Subramaniam et al. 2013) 
7.  CD133 F- 5’-AGAGCTTGCACCAACAAAGTACAC-3’ 
R- 5’-AAGCACAGAGGGTCATTGAGAGA-3’ 
 
(van den Hoogen et al. 2010) 
8.  CD44 F- 5’-TGCCGCTTTGCAGGTGTAT-3’ 
R- 5’-GGCCTCCGTCCGAGAGA-3’ 
 
(Rüster et al. 2006) 
9.  LRP1 F- 5’-AGAAGTAGCAGGACCAGAGGG-3’ 
R- 5’-ACAGTACCCAGGCAGTTATGA-3’ 
 
(Demeule et al. 2008) 
10.  LRP2 F- 5’-CGGAGCAGTGTGGCATATTTTTC-3’ 
R- 5’-CAGGTGTATTGGGTGTCAAGGC-3’ 
 
(Demeule et al. 2008) 
11.  TfR F- 5’-TGTAGGCTGCCCATTGTAAC-3’ 
R- 5’-CAGAATTCCCACACATCCACT-3’ 
 
(Herbison et al. 2009) 
12.  TfR1 F- 5’-GTGGAGTATCACTTCCTGTCGC-3’ 
R- 5’-CCCCAGAAGATATGTCGGAAAGG-3’  
 
(Kollia et al. 2003) 
13.  TfR2 F- 5’-AGCTGGGACGGAGGTGACTT-3’ 
R- 5’- TCCAGGCTCACGTACACAACAG-3’ 
 
(Kollia et al. 2003) 
14.  LfR F- 5’- ACCCAAGGAAAGTGCAGCTGAGA-3’ 
R- 5’- GTTCCCTCCCACAAAACTCTCAACGA-3’ 
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Table 2.6. LIST OF PRIMARY AND SECONDARY ANTIBODIES USED FOR WESTERN BLOTTING 
AND IMMUNOFLUORESCENCE. 
S.no. Antibody Dilution Catalogue 
number 
Company 
1.  Goat anti-bovine 
lactoferrin 
1:1000 A10-126 Bethyl Laboratories 
2.  D-8, anti-human survivin 
mouse monoclonal 
antibody 
1:500 SC-17779 Santa Cruz, USA 
3.  Mouse monoclonal anti-
caspase-3 
1:1000 SC-65496 Santa Cruz, USA 
4.  Rabbit polyclonal anti-
GAPDH 
1:1000 SC-25778 Santa Cruz, USA 
5.  Rabbit monoclonal anti-
CD133 
1:100 3621-1 Epitomics, USA 
6.  Rabbit monoclonal anti-
CD44 
1:100 3381-1 Epitomics, USA 
7.  Mouse monoclonal anti-
EpCAM 
1:100 E144 (ab32392) Epitomics, USA 
8.  Mouse monoclonal anti-
EGFR 
1:100 SC-373746 Santa Cruz, USA 
9.  Mouse monoclonal anti-
ALDH1 
1:100 SC-166362 Santa Cruz, USA 
10.  Mouse monoclonal anti-
MDR-1 (P-gp) 
1:1000 SC55510 Santa Cruz, USA 
11.  Mouse monoclonal anti-
p53 
1:1000 MAB1355 R&D systems, USA 
12.  Mouse monoclonal anti-
Phospho-p53 
1:1000 MAB1839 R&D systems, USA 
13.  Goat polyclonal anti-Numb 1:1000 SC-23579 Santa Cruz, USA 
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14.  Mouse monoclonal anti-
MDM2 
1:1000 SC-965 Santa Cruz, USA 
15.  Bax- mouse monoclonal 
antibody 
1:1000 SC20067 Santa Cruz, USA 
16.  Bcl-2- mouse monoclonal 
antibody 
1:1000 SC-7382 Santa Cruz, USA 
17.  Anti-mouse IgG FITC 1:100 F9137 Sigma Aldrich, USA 
18.  Anti-rabbit IgG FITC 1:100 F1262 Sigma Aldrich, USA 
19.  Anti-goat IgG FITC 1:100 F2016 Sigma Aldrich, USA 
20.  Anti-mouse IgG TRITC 1:100 T2402 Sigma Aldrich, USA 
21.  Anti-rabbit IgG TRITC 1:100 T5268 Sigma Aldrich, USA 
22.  Phalloidin TRITC 1:100 P1951 Sigma Aldrich, USA 
23.  Anti-mouse IgG HRP 1:80,000 A2304 Sigma Aldrich, USA 
24.  Anti-rabbit IgG HRP 1:80,000 A3937 Sigma Aldrich, USA 
25.  Anti-goat IgG HRP 1:80,000 A5420 Sigma Aldrich, USA 
 







Anti-cancer activities of various 
forms of bLf in targeting cell 












Skin, being the largest organ in the body plays a critical role in the excretion of metabolic 
waste products and acts as the first protective barrier against environmental, physical, 
chemical and biological factors. An increase in body concentrations of oxidants, reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) can lead to chronic inflammation 
causing skin diseases including skin cancer (Kruk & Duchnik 2014). Melanoma accounts for 
the maximum deaths worldwide, due to skin cancer (Siegel et al. 2014). Despite extensive 
research, the exact molecular mechanism that leads to tumorigenesis in melanoma remains 
unclear. However, transformations due to the gene mutations are the main causes of 
tumorigenesis in melanoma (Davies et al. 2002) as described in Chapter 1 (Figure 1). 
Malignant transformation of cells is a multi-step process, and the mutations in p53 gene has 
been observed at different phases in this process leading to tumour initiation, promotion 
and metastasis (Rivlin et al. 2011). One of the molecules that has been associated most 
commonly to tumorigenesis is the p53 tumour suppressor protein (Oren 1992). A number of 
critical genes are implicated to play a role in tumorigenesis but p53 stands out as the most 
important in functioning as a tumour suppressor and a master regulator of various signaling 
pathways that play a role in tumour development and progression (Lane 1992).  
In normal conditions, p53 plays the role of a transcription factor in promoting apoptosis 
eliminating damaged cells suppressing the development of a tumour thereby maintaining 
homeostasis in the physiology (Levine & Oren 2009). It also plays a vital role in inducing DNA 
repair, cell cycle arrest, controlled apoptosis and senescence in its wild-type form (Aylon & 
Oren 2011). Functional inactivation and mutation in p53 has been a universal feature of all 
human cancers (Goh, Coffill & Lane 2011). Significant overexpression of mutant p53 was 
observed in mouse tumours and transformed cells,  identified in early 1983 (Rotter 1983) 
which was then confirmed in human tumours (Bartek et al. 1991; Iggo et al. 1990). Mutant 
form of p53 (induced by R270H and P2755 point mutations) has a dominant negative effect 
in tumorigenesis (Harvey et al. 1995) and unlike other genes the mutations in the p53 gene 
are usually missense mutations in which a single nucleotide is substituted with another 
(Hainaut & Hollstein 1999). Increased proliferation and inhibition of apoptosis are 
associated with the inactivation and/or mutation in the p53 expression which leads to 
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advantages in the growth and survival leading to chemoresistance (Brosh & Rotter 2009; 
Sigal & Rotter 2000).  
In the case of melanoma, studies indicate that human skin that is intermittently exposed to 
the sun contains a number of phenotypically intact cell compartments that bear missense 
and nonsense mutations in the p53 tumour suppressor gene. Deep sequencing of sun-
exposed skin revealed that 14% of all epidermal cells had accumulation of persistent p53 
mutations, showing no signs of growth advantage in the cell compartments that were 
affected (Ståhl et al. 2011). This result was attributed to the exposure of skin to ultra-violet 
(UV) radiation which has been linked to oxidative DNA damage in human non-melanoma 
and melanoma skin cancer (Pfeifer & Besaratinia 2012).  
Melanin content in melanoma cells is another aspect that has been studied to understand 
its role in skin cancer progression. Melanin pigment is classified into two types: eumelanin 
(responsible for skin colouration and is black/brown in colour) and pheomelanin 
(responsible for red hair and freckles). Eumelanin is more associated with melanoma when 
compared to dysplastic and benign nevi (Matthews et al. 2011). The melanin content of a 
cell can also predict the sensitivity of human skin cells to ultraviolet radiation, and the 
response of a skin cell towards UV radiation (Coelho et al. 2013). For example, the UVA 
component (320-400 nm) requires the presence of melanin pigment and initiates oxidative 
stress and DNA damage within melanocytes (Noonan et al. 2012). Further studies showed 
that a narrow bandwidth of UV radiation referred to as UVB (280-320 nm) initiates 
melanoma in a pigment-independent manner and causes a higher frequency of skin cancer 
(Yogianti et al. 2012). The roles of melanin both as a photoprotector and photosensitiser has 
been studied and it was established that the presence of melanin had no influence over the 
incidence of oxidative stress, and in contrary to this it protected cells against mitochondrial 
superoxide generation and DNA damage (Swalwell et al. 2012). In conditions where melanin 
content plays a role in protecting the skin against UVR and diverse free radicals, treatment 
strategies have employed the use of constituents to increase melanin content in B16F10 
melanoma cells. This was successfully achieved using 5, 7-dimethoxyflavone that induces 
melanogenesis by increasing cyclic adenosine monophosphate (cAMP) which activates Akt 
signaling (Kang et al. 2011b).  
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Melanin content of the cells holds great clinical importance and research has been focussed 
on targeting multiple aspects of melanoma to achieve therapeutics for metastatic and drug-
resistant melanomas. One of the most well-established pathways for treatment of 
cutaneous carcinomas is the administration of a light-activated drug following illumination 
of a light-activated area. Photodynamic treatment of B16F10 and B15G4F melanoma cells 
was performed, using 5-aminolevulinic acid (5-ALA), a photosensitiser that induces cell 
death pathway, which is dependent on the melanin content. The cell death in B16F10 and 
B15G4F cells corresponded to p53-dependent apoptotic signaling in the pigmented cells 
and, an autophagic response that leads to caspase-independent death is also known to be 
prominent in the non-pigmented melanoma cells. Combinatorial treatment of 5-ALA with 
photodynamic therapy (PDT) would be a promising approach to target metastatic 
melanoma (Sparsa et al. 2013). 
Reducing the iron content in the cancer cells by iron chelation therapy is another verified 
mechanism that can target cancer cells (Merlot, Kalinowski & Richardson 2013). Iron is 
required for many crucial processes like DNA synthesis, cell growth and proliferation making 
it an important target for anti-cancer therapeutics (Kalinowski & Richardson 2005). 
Significant suppression in metastatic mechanisms that get triggered due to the upregulation 
of iron-regulated metastasis suppressor called as N-myc downstream regulated gene 1 
(NDRG1), was observed when iron chelation therapies were used in neuroblastoma and 
melanoma cells in vitro (Le & Richardson 2004). Depleting the intracellular iron using 
chelators helps in regulating the downstream molecules that are involved in regulating cell 
cycles, angiogenesis and metastasis (Richardson 2005). 
The anti-cancer and multifunctional activities of bovine lactoferrin (bLf) have already been 
discussed in detail (Chapter 1, section 1.5). bLf is known to cause apoptosis or programmed 
cell death in cancer cells while sparing the normal cells, which has been shown in studies 
from our laboratory. This could be due to the possible difference in the iron metabolism 
between primary cells and tumour cells.  A number of cell death pathways and mechanisms 
including both the intrinsic and extrinsic pathways of apoptosis are known to be induced by 
bLf, which activates the caspase-cascades leading to an upregulation of the terminal 
caspase, caspase-3 (Furlong, Mader & Hoskin 2010; Gibbons, Kanwar & Kanwar 2010). 
mRNA expression levels of Bcl-2, Bax, Bid, Bak and Bcl-xL has been shown to be regulated by 
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bLf treatments causing caspase-dependent apoptosis in the case of colon cancer cells (Fujita 
et al. 2004; Tsuda et al. 2002). Further studies, by these researchers (Fujita et al. 2004) in 
colon cancer have revealed that the Fas-induced apoptosis in colon cancer cells  leads to the 
induction of caspase-1 and IL-8, thereby inhibiting carcinogenesis and metastasis in colon 
cancer. Studies from our laboratory also demonstrated that nanoencapsulated Fe-bLf, when 
delivered orally to xenografts mice bearing human colon cancer, showed a significant 
reduction in the tumour size and later complete inhibition of the tumour growth (Kanwar, 
Mahidhara & Kanwar 2012b). Further studies, also revealed that these Fe-bLf loaded 
nanocarriers were able to activate both extrinsic and intrinsic pathways of apoptosis leading 
to tumour cell death. An in depth analysis revealed that Fe-bLf loaded nanoformulations 
targeted survivin in cancer cells and cancer stem cells, in colon cancer xenograft model 
(Kanwar, Mahidhara & Kanwar 2012a; Kanwar et al. 2014). Downregulation of survivin 
expression is widely known to increase the p53 activity and induce apoptosis, since p53 
binds to survivin promoter region and regulates both mRNA and protein expression of 
survivin (Mirza et al. 2002). It also modulates p21 in order to regulate the survivin 
expression, survivin repression by p53. Previously publishes studies have reported that 
targeting survivin using the small molecule inhibitor YM155 leads to an increase in p53 
expression, inducing p53-dependant apoptosis (Tyner et al. 2011). 
Hence, studies from our laboratory and other research groups have shown that both Apo-
bLf and Fe-bLf induce apoptosis. However, their mode of action differs as Apo-bLf leads to 
iron chelation to induce apoptosis (Yoo et al. 1997) whereas; Fe-bLf directly inhibits survivin 
protein expression to induce apoptosis (Kanwar et al. 2014). However, this pathway has 
never been studied in melanoma cells with bovine lactoferrin treatments. 
Previous studies have substantiated the role of bLf as an adjuvant for mouse melanoma 
B16-F10 models (Kanwar et al. 2008). Administration of iron saturated bLf, along with 
chemotherapeutics in B16-F10 tumour models, in vivo, specifically helped in increasing the 
production of T helper immune cells leading to anti-tumour immune response as compared 
to native and iron free forms of bLf. Oral administration of bLf (1600 mg/kg per day) has also 
proved to attenuate the photodamage caused to the skin due to UVB radiation leading to 
protection of normal skin cells by helping decrease water loss from the skin (Murata et al. 
2014).  
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It has been established that Lf internalizes into the cells using lactoferrin receptors (LfR), 
transferrin receptors (TfR) and low-density lipoprotein receptor-related proteins-1 and -2 
(LRP-1 and LRP-2) (Naot et al. 2005). Presence of Lf receptors on cancer cells has been 
investigated and it has been proved that Lf enters the cancer cells via receptor-mediated 
internalisation using LRP and LfR (Legrand et al. 2008) which was further confirmed in colon 
cancer cells (Kanwar, Mahidhara & Kanwar 2012a; Kanwar et al. 2014). Clathrin-mediated 
endocytosis of both iron-free Apo-bLf and holo-bLf were confirmed in colon cancer cells 
(Jiang et al. 2011). Increase in the expression of LfR was also reported in the intestine of 
osteoarthritic models of mice with oral administration of Fe-bLf (Samarasinghe, Kanwar & 
Kanwar 2014). The status of Lf receptors and their modulation is not known in melanoma 
cell lines.  
3.2 HYPOTHESIS 
From the above listed findings, hypothesis tested for this phase of study is that bLf and its 
different forms will exhibit an anti-cancer effect in targeting growth and cell death of 
melanoma cells. It may induce the cell apoptosis by up regulating the p53 expression. 
It was believed that a difference in the iron saturation levels of the bLf forms (Native-bLf, 
Apo-bLf and Fe-bLf) might lead to anticancer activity by targeting p53 status. The three 
forms of bLf therefore might be able to target (i) varying aspects of melanoma tumour 
formation, growth, metastasis and melanoma progression and its survival, and (ii) induce 
cell death in the two melanoma cell lines with varying p53 status.  
Two well characterised cell lines, obtained from ATCC were employed. These include, SK-
MEL-2  (Landers, Cassel & George 1997) and SK-MEL-28 cells (Chen et al. 2001) .Additionally 
primary epidermal melanocytes were tested for bLf toxicity. Although, both SK-MEL-2 and 
SK-MEL-28 were p53 mutant cell lines, the type of p53 mutation in these cell lines were 
different. SK-MEL-2 was characterized by the G245S mutation in the p53 gene and SK-MEL-
28 harboured the L145R mutation 
(http://p53.free.fr/Database/Cancer_cell_lines/NCI_60_cell_lines.html). The p53G245S 
mutation is a conformational mutation in the L3 loop region, considered as a missense 
mutation and does not affect the functional activity of wild-type p53 (Olivier, Hollstein & 
Hainaut 2010; Solomon et al. 2012). The p53 mutation type in SK-MEL-28 is the p53L145R 
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mutation that has been associated with an alteration in the p53 activity leading to reduced 
apoptosis, DNA damage response and are also studied to be associated with drug-resistance 
due to alteration in the MAPK, TGF-β and other cell cycle pathways (Qin et al. 2004). It 
would thus be of interest to study the effect of the three bLf forms in melanoma cell lines 
with varying mutations in their p53 status and function.  
 3.3 AIMS  
 Preparation of endotoxin free, three different forms of bLf namely Native-bLf, Apo-
bLf and Fe-bLf. 
 Investigate the modulation of mRNA expression levels of Lf receptors in SK-MEL-2 
and SK-MEL-28 cell lines with bLf treatments.  
  Examination of the internalisation efficacy of all the three forms of bLf in SK-MEL-2 
and SK-MEL-28 cells.  
 To study the effects of bLf forms on the growth and metastatic potential of SK-MEL-2 
and SK-MEL-28. 
 To study the mechanism of apoptosis induced by various forms of bLf treatments in 
SK-MEL-2 and SK-MEL-28 cells. 
3.4 MATERIALS AND METHODS 
A detailed description of the materials and methods implemented in this study has been 
provided in Chapter 2 and its schematic representation is given below. 





3.5.1 SDS-PAGE and Western Blotting for bLf in prepared samples  
 The endotoxin free Australian bLf was prepared as described earlier (Kanwar 2008; Kanwar, 
Mahidhara & Kanwar 2012b).  To confirm the purity of all the three forms of bLf prepared, 
SDS-PAGE and Western blotting were performed. SDS-PAGE which was used to separate 
protein on the basis of its molecular weight showed the presence of a strong band at ~75 
kDa (Figure 3.1 A) proving the purity of bLf protein in Native-bLf, Apo-bLf and Fe-bLf 
samples. To further identify the protein, Western blotting was done and bLf showed 
immunoreactivity at ~75 kDa (Figure 3.1 B). Both SDS-PAGE and Western blotting confirmed 
the purity and integrity in all the three forms of bLf samples prepared.  




Figure 3.1. (A &B). Purity of three forms of bLf samples prepared and confirmed using SDS-
PAGE and Western blotting. SDS-PAGE (A) shows the presence of a strong band of bLf at 
~75 kDa in all the three types of bLf prepared. Western blotting (B) further confirms the 
presence of bLf when stained specifically with goat anti-bLf antibody (Bethyl laboratories, 
USA), and with secondary anti-goat IgG HRP-conjugate. The final immune reactivity was 
detected with chemiluminescence.   
3.5.2 Estimation of iron content in all the three forms of bLf samples 
To check the iron content in all the forms of bLf samples prepared, an estimation of 
percentage iron content in the samples was done using the ratio method (Yang et al. 2008). 
Native-bLf, Apo-bLf and Fe-bLf were diluted with milli-Q in 1:100 concentrations, 
respectively. The diluted samples were then checked for their iron content by measuring the 
absorbance of the samples at 280 nm and 465 nm using a spectrophotometer. The 
concentration of iron was calculated and a graph was plotted. Determination of iron content 
showed that Native-bLf had 19 % of iron content, Apo-bLf had a very low value of 2.3 % of 
iron content and Fe-bLf showed the highest % of iron saturation with 98.5 % of iron content. 
These values were plotted (Figure 3.2) in comparison with ferric ammonium sulphate which 
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is used (as a positive control) for preparation of iron standards. Fe estimation in the three 
forms of bLf samples was also confirmed with similar iron content values, using the 
traditional method of Fe estimation by preparing Fe-NTA standards (Ebrahim et al. 2014; 
Kanwar, Mahidhara & Kanwar 2012b). 
  
Figure 3.2. Percentage iron content in all the three forms of bLf samples when compared 
to iron standard. The percentage of iron present in Native-bLf, Apo-bLf and Fe-bLf with 
respect to the iron standard was analysed, and the values were plotted as a histogram. The 
experiment was done in triplicates and was repeated thrice independently. The results 
indicate that Apo-bLf is an iron-free form of lactoferrin containing only 2.3 % of iron in 
contrast to Fe-bLf which has 98.5 % iron saturation.  
3.5.3 Upregulation of lactoferrin receptors with bLf treatments 
To study the presence and involvement of Lf receptors in cellular uptake of  all the three 
forms of bLf in melanoma cells, real time PCR was used to study the gene expression 
analysis of low density lipoprotein receptor-1 (LRP-1), low density lipoprotein receptor-2  
(LRP-2), transferrin receptor (TfR), transferrin receptor -1 (TfR1), transferrin receptor-2 
(TfR2) and lactoferrin (LfR) receptor. Both endogenous expression, and modulation of 
expression of these receptors following bLf treatments, was studied and the results were 
represented in a histogram. Further tabular representation of the upregulation or 
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downregulation in gene expressions of various receptor genes with bLf forms is presented 
(Table 3.1). 
In case of SK-MEL-2 cells (Figure 3.3 A), it was observed that 40 nM (p< 0.05) of Native-bLf 
led to a significant increase in TfR1 expression, whereas its both 20 nM (p< 0.01) and 40 nM 
(p≤ 0.01) concentrations led to a significant increase in LfR expression. It was found that 40 
nM Apo-bLf led to a significant expression (p< 0.05) of only LRP-1. On the other hand, both 
20 nM and 40 nM of Fe-bLf led to significant increases in the gene expression levels of LRP-1 
(p≤ 0.01), LRP-2 (p≤ 0.01), TfR1 (p< 0.05) and LfR (p≤ 0.01). Interestingly, treatments with 
Native-bLf at 40 nM, Apo-bLf at 20 nM and 40 nM and Fe-bLf at 20 nM and 40 nM caused 
significant downregulation of TfR (p≤ 0.01). Lower treatment concentrations of 20 nM of 
Apo-bLf and Fe-bLf also caused significant downregulation of TfR2 (p≤ 0.01) in SK-MEL-2 
cells.  
In the SK-MEL-28 cells (Figure 3.3 B), both TfR1 and TfR 2 expression with Native-bLf 20 nM 
were significantly upregulated (p< 0.05) and Native-bLf 40 nM significantly upregulated TfR1 
(p< 0.05) and TfR2 (p≤ 0.01). Apo-bLf at 40 nM led to a significant increase (p< 0.05) in the 
TfR expression, whereas both TfR1 (p< 0.05) and TfR2 (p≤ 0.01) were significantly increased 
with its 20 nM and 40 nM treatments. Fe-bLf at 20 nM (p< 0.05) and 40 nM (p< 0.05) led to 
a significant increase in the TfR expression. However, only 20 nM of Fe-bLf treatment was 
able to significantly increase (p< 0.05) the TfR1 expression. As observed in SK-MEL-2 cells, 
SK-MEL-28 cells also showed downregulation of certain receptors with the bLf forms. For 
example, LRP-1 was downregulated with Fe-bLf at 20 nM and 40 nM concentrations. LRP-2 
was significantly downregulated with Native-bLf at 40 nM and Apo-bLf and Fe-bLf at 20 nM 
and 40 nM (p≤ 0.01). Fe-bLf 20 nM and 40 nM downregulated the expression of TfR2 (p≤ 
0.01) and LfR (p≤ 0.01) significantly. Native-bLf at 40 nM concentration also caused 
significant downregulation (p≤ 0.01) of LfR, LRP-2 and TfR in SK-MEL-28 cells. An interesting 
observation was that SK-MEL-28 when treated with Native-bLf was able to cause 
upregulation of TfR which was not upregulated with any other form of bLf. 




Figure 3.3. (A). Modulation of gene expression levels of Lf receptors by bLf treatments in 
SK-MEL-2 cells.  The relative mRNA expression of Lf receptors (LRP-1, LRP-2, TfR, TfR1, TfR2 
and LfR) in SK-MEL-2 cells was analysed after 24 h treatment with Native-bLf, Apo-bLf and 
Fe-bLf at 20 nM and 40 nM, by real time quantitative PCR (qRT-PCR).  One µg of the isolated 
RNA from untreated and treated cells was converted to cDNA by reverse transcriptase PCR.  
One hundred ng of cDNA, gene specific forward and reverse primers, RT2 SYBR Green qPCR 
mastermix was used for the analysis. The data was analysed using Livak method of relative 
quantification. The fold change was calculated by comparing the real time PCR values with a 
house keeping gene (GAPDH). All values are represented as mean ± SE and the experiments 
were done twice in duplicates. Student’s t test was performed to evaluate statistical 
significance. A significance level   of (p≤ 0.05) represented as * and (p≤ 0.01) as ** was 
considered when compared to untreated cells.   




Figure 3.3 (B). Modulation of bLf receptors in SK-MEL-28 cells with different bLf 
treatments. The relative mRNA expression of Lf receptors (LRP-1, LRP-2, TfR, TfR1, TfR2 and 
LfR) in SK-MEL-28 cells was analysed after 24 h treatment with Native-bLf, Apo-bLf and Fe-
bLf at 20 nM and 40 nM, by real time quantitative PCR. 1 µg of RNA that was isolated was 
converted to cDNA. 100 ng of cDNA, specific forwards and reverse primers, RT2 SYBR Green 
qPCR mastermix was used for analysis. The data was analysed using Livak method of relative 
quantification. All values are represented as mean ± SE and the experiments were done 
twice in duplicates. Student’s t test was performed to evaluate statistical significance. A 
value of (p≤ 0.05) represented as * and (p≤ 0.01) as ** was considered statistically 
significant when compared to untreated cells.   
Table 3.1. Comparative analysis of receptor expression patterns in SK-MEL-2 and SK-MEL-
28 with all three forms of bLf treatments. 




Where, - = No change, ↑= Non-significant increase, ↑↑= Significant increase (p<0.05), 
↑↑↑= Significant increase (p<0.01), ↓= Non-significant decrease, ↓↓= Significant 
decrease (p<0.05), ↓↓↓= Significant decrease (p≤ 0.01).  
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3.5.4 Time-dependent internalisation of Native-bLf, Apo-bLf and Fe-bLf in SK-MEL-2 and 
SK-MEL-28 
Laser-immunoconfocal microscopy was performed to investigate the internalisation efficacy 
of the bLf forms (Native, Apo and Fe-bLf) in SK-MEL-2 cells (Figure 3.4 A-D). The images 
taken from 5 different fields showing cells with positive immunofluorescence for the 
expression of bLf were counted and a graph was plotted to depict the percentage 
internalisation in these cells. The data indicated that all the three forms, i.e., Native-bLf, 
Apo-bLf and Fe-bLf was effective in internalising into SK-MEL-2 cells at all the time points. 
These results confirm that all bLf forms showed a significant (p≤ 0.01) internalization 
efficacy observed at 6 h in SK-MEL-2 cells and maximum internalisation occurred in a time-
dependent manner. However, comparatively lower internalisation was shown by Apo-bLf 
(p< 0.05) at 30 min.  
In case of SK-MEL-28 cells (Figure 3.4 E-H), a similar observation was made where; all the 
three forms i.e., Native-bLf, Apo-bLf and Fe-bLf showed significant (p≤ 0.001) internalisation 
efficacy in SK-MEL-28 cells at 6 h. However, 30 min interval, both Native-bLf (p< 0.05) and 
Fe-bLf (p≤ 0.01) showed comparatively lower internalisation efficacy when compared to 
Apo-bLf (p≤ 0.001) (Figure 3.4 E-H). Therefore, it could be understood that all the bLf forms 
were effective in internalising in SK-MEL-28 cells at a longer duration, while Apo-bLf was the 
most effective in the shorter time span. 
 




Figure 3.4 (A). Cellular internalisation of Native-bLf in SK-MEL-2.  Confocal images of SK-
MEL-2 cells showing positive staining for bLf when treated with Native-bLf 20 nM, further 
probed with specific goat anti-bLf primary antibody and anti-goat IgG FITC secondary 
antibody. When compared to control (untreated cells), an increase in the green 
fluorescence intensity with Native-bLf treatments, indicates successful internalisation of 
Native-bLf in SK-MEL-2 cells. Time-dependent uptake of the protein was observed and 100 
% of the cells stained positive for bLf after 6 h of treatment. 




Figure 3.4 (B). Cellular internalisation of Apo-bLf in SK-MEL-2. Immunofluorescence  
staining of SK-MEL-2 cells, with specific primary (goat anti-bLf) and secondary antibody 
(anti-goat IgG-FTIC) for bLf grown in 8 well slides showed time dependent internalisation of 
Apo-bLf (20 nM).  The maximum internalisation for Apo-bLf was noted after 6 h of 
treatment although Apo-bLf was able to enter SK-MEL-2 cells within 30 min of treatment. 
The control untreated cells’ image was shown in 3.4 (A). 




Figure 3.4 (C). Cellular internalisation of Fe-bLf samples in SK-MEL-2 cells. SK-MEL-2 cells 
were plated in 8 well slides at a cell density of 103 cells and treated with 20 nM of Fe-bLf for 
30 min, 2 h, 4 h and 6h. The cells were then stained with bLf specific goat anti-bLf primary 
and anti-goat IgG FITC secondary antibodies and the internalisation of bLf was visualised 
using confocal microscopy. Like Native-bLf and Apo-bLf, time-dependent internalisation of 
Fe-bLf was also observed in SK-MEL-2 cells. Interestingly, Fe-bLf showed better 
internalisation efficacy when compared to Apo-bLf in this cell line. The control untreated 
cells’ image was shown in 3.4 (A). 




Figure 3.4 (D). Semi-quantitative analysis of cellular internalisation of all the three forms 
of bLf in SK-MEL-2 cells. Internalisation of bLf was visualised by a confocal microscope (Leica 
TCS SP5). Five images per well were taken and the images were analysed using LAS-AF 
software. Cells that stained positive for bLf were counted manually and plotted. All values 
are represented as mean ± SE and the experiments were done twice in duplicates. Student’s 
t test was performed to evaluate statistical significance. A value of (p< 0.05) represented as 
* and (p≤ 0.01) as ** was considered statistically significant when compared to untreated 
cells.  A value of (p< 0.05) represented as † was considered statistically significant when 
compared amongst the treatments. NS represents non-significant difference between the 
treatments.  
 




Figure 3.4 (E). Cellular internalisation of Native-bLf in SK-MEL-28. SK-MEL-28 cells were 
grown at a cell density of 103 cells/well in an 8 well slide. The cells were treated with 20 nM 
Native-bLf for 30 min, 4 h and 6 h, and then stained for the presence of bLf with goat anti-
bLf antibody, followed by anti-goat IgG FITC. Internalisation of bLf was visualised by a 
confocal microscope (Leica TCS SP5). Native-bLf internalised into SK-MEL-28 cells within 30 
min of treatment but the maximum internalisation was observed after 6 h of treatment.  




Figure 3.4 (F). Cellular internalisation of Apo-bLf in SK-MEL-28. SK-MEL-28 cells were plated 
in an 8-well slide at a cell density of 103 cells. The cells were treated with Apo-bLf at 20 nM 
for 30 min, 4h and 6h, and stained with specific primary (goat anti-bLf) and secondary 
antibody (anti-goat IgG FITC) and the internalisation efficacy was visualised using confocal 
microscopy. Apo-bLf was efficiently internalised in SK-MEL-28 cells, in a time-dependent 
manner. After 6 h treatment Apo-bLf was taken up by 100% cells. The control untreated 
cells image panel was shown in 3.4 (E).  
 




Figure 3.4 (G). Cellular internalisation of Fe-bLf in SK-MEL-28 cells. Immunofluorescence 
assay was performed by plating cells at a density of 1000 cells/well in an 8 well slide. The 
cells were treated for 30 min, 4 h and 6 h with Fe-bLf at a concentration of 20 nM. Cells 
were then stained for bLf internalisation using goat anti-bLf and anti-goat IgG FITC. Confocal 
images show the time dependent internalisation of Fe-bLf in SK-MEL-28. The control 
untreated cells image panel was shown in 3.4 (E). 
 




Figure 3.4 (H). Semi-quantitative analysis of cellular internalisation of all the three forms 
of bLf in SK-MEL-28.  Internalisation of bLf was visualised by a confocal microscope (Leica 
TCS SP5). Five images per well were taken and the images were analysed using LAS-AF 
software. Cells that stained positive for bLf were counted manually and plotted. All values 
are represented as mean ± SE and the experiments were done twice in duplicates. Student’s 
t test was performed to evaluate statistical significance. A value of (p< 0.05) represented as 
*, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when 
compared to untreated cells. A value of (p< 0.05) represented as † was considered 
statistically significant when compared amongst the treatments. NS represents non-
significant difference between the treatments. 
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3.5.5 Anti-proliferative effects of Native-bLf, Apo-bLf and Fe-bLf  
CyQUANT cell proliferation assay (Life Technologies (Invitrogen), Australia) was used to 
detect the percentage cell proliferation of melanoma cells when treated with all the three 
forms of bLf. The Cy-Quant GR dye binds to DNA and therefore the DNA content of the cells 
can be directly quantified which is directly proportional to the cell proliferation. Therefore 
this method is considered as one of the most efficient methods to determine cell 
proliferation. In case of SK-MEL-2 cells (Figure 3.5), both Apo-bLf and Fe-bLf showed a dose 
dependant reduction in cell proliferation. Only  62 % (p< 0.05), 61 % (p< 0.05), 52 % (p≤ 
0.01) reduction in cell proliferation was observed with 10 nM, 20 nM and 40 nM of Apo-bLf, 
respectively; while Fe-bLf with  10 nM , 20 nM  and  40 nM  showed 34 % , 37 % and  26 % 
cell proliferation,  respectively (p≤ 0.001). On the other hand, 10 nM (72 %) and 40 nM (78 
%) treatments of Native bLf showed significant (p< 0.05) inhibitory effect on the cell 
proliferation, while 20 nM Native-bLf showed 92 % of cell proliferation.  
The results obtained showed that in case of SK-MEL-28 cells (Figure 3.5), both Native-bLf 
and Apo-bLf showed a dose dependant decrease in cell proliferation,  (10 nM-66% (p< 0.05), 
20 nM-57 % (p≤ 0.01), 40 nM- 48 % (p≤ 0.01) and 10 nM-73 % (p< 0.05), 20 nM-41 % (p≤ 
0.01), 40 nM-35 % (p≤ 0.001), respectively). There was no such trend observed in the Fe-bLf 
treated cells (10 nM-66 % (p≤ 0.01), 20 nM-78 % and 40 nM-79 % (p< 0.05)) even though the 
effects were significant when compared to the untreated cells. In conclusion it was 
observed that 40 nM treatment of Apo-bLf was the most effective in inhibiting cellular 
proliferation in SK-MEL-28 cells whereas, 40 nM treatment of Fe-bLf was the most effective 
in inhibiting the cellular proliferation of SK-MEL-2cells (Figure 3.5). 




Figure 3.5. Determination of cell proliferation using CyQUANT assay.  Cells were grown in 
96 well plates at a cell density of 1000 cells/ well and the percentage cell proliferation was 
quantified using CyQUANT reagent on SK-MEL-2 and SK-MEL-28 cells that were treated with 
varying concentrations of Native-bLf, Apo-bLf and Fe-bLf (10 nM, 20 nM and 40 nM) for 24 
h. Treatments were carried out in triplicates and the assay was performed thrice 
independently. The results are represented as mean ± SE values. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells. A value of (p≤ 0.01) represented as †, was considered statistically significant 
when compared amongst the treatments. 
3.5.6 Effect of bLf on 3D melanoma tumour spheroid formation 
The tumour spheroid assay is generally performed to evaluate the cytotoxic effects of 
potential anti-cancer therapeutics. The 3D tumour spheroid assay is able to closely mimic 
the tumour microenvironment and tumour growth, therefore it can be assumed that if an 
anti-cancer agent is able to induce significant growth inhibition in a multicellular tumour 
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spheroid model, it may prove to be a promising therapeutic in the actual scenario. In case of 
SK-MEL-2 cells (Figures 3.6 A & C), similar observations were made for 10, 20 and 40 nM 
treatments of Native bLf that lead to a significant increase (p< 0.05) in the tumour spheroid 
size. The increase in tumour spheroid surface area was not due to an increase in cell 
proliferation but mainly due to disruption of tumour spheroids due to possible cytotoxic 
effects of Native-bLf. Therefore, the cells were scattered and unable to form a spheroidal 
structure. On the other hand, 10 nM of Apo-bLf showed a significant reduction (p< 0.05, 1.4 
fold) in the tumour spheroid size. However, with increase in treatment concentrations i.e., 
20 nM and 40 nM, increases in the tumour spheroid surface areas were observed compared 
to 10 nM treatments. Fe-bLf showed a dose dependant decrease (10 nM-1.7 fold (p≤ 0.01), 
20 nM-3.3 fold (p≤ 0.001) and 40 nM-3.9 fold (p≤ 0.001) in the tumour spheroid size (Figure 
3.6 A).  
The results obtained from this assay revealed that, SK-MEL-28 (Figures 3.6 B & C) showed 
significantly better (p< 0.05) spheroid formation ability with 1000 cells on a 1% agarose 
coated plate after 7 days, when compared to the SK-MEL-2 cells under the same conditions 
(Figure 3.6 B). It was also noted that in case of SK-MEL-28 cells, the 10, 20 and 40 nM 
treatments of Native-bLf led to a non-significant increase in the tumour spheroid size. This 
increase in tumour size was not due to an increase in cell proliferation but mainly due to 
disruption of tumour spheroids due to effects of Native-bLf. Therefore, the cells were 
scattered and unable to form a spheroidal structure. The 40 nM treatment of Apo-bLf 
showed a significant decrease (p< 0.05, 1.5 fold) in tumour spheroid size whereas the 40 nM 
treatment of Fe-bLf led to the  significant (p≤ 0.01, 2.1 fold) and maximum decrease in the 
tumour spheroid size. Therefore, in conclusion, even though Native-bLf led to disruption of 
the tumour spheroid structure, it was Fe-bLf which showed the maximum cytotoxic effect in 
3D spheroid model in both SK-MEL-28 and SK-MEL-2 melanoma cells. 
 
 




Figure 3.6 (A). Inhibition of tumour spheroid forming ability of SK-MEL-2 with bLf 
treatments. SK-MEL-2 cells were allowed to grow on 1 % agarose-coated 96 well plates at a 
cell density of 1000 cells/well for 7 days. The 7 day old spheroids were treated with 10 nM, 
20 nM and 40 nM of Native-bLf, Apo-bLf and Fe-bLf for 24 h and the change in the surface 
area of the tumour spheroids was measured using Image J software. The experiment 
involved 6 spheroids for each treatment. Representative images from each treatment type 
are shown. 




Figure 3.6 (B.) Inhibition of tumour spheroid area post bLf treatments. SK-MEL-28 cells at a 
density of 1000 cells/well were allowed to grow on 1 % agarose-coated 96 well plates for 7 
days. The 7 day old spheroids were treated with 10 nM, 20 nM and 40 nM of Native-bLf, 
Apo-bLf and Fe-bLf for 24 h and the change in the surface area of the tumour spheroids was 
measured using Image J software. The experiment involved 6 spheroids for each treatment 
(n=6/treatment group). Representative images from each treatment type are shown.  




Figure 3.6 (C). Inhibition of tumour spheroid surface area. SK-MEL-28 and SK-MEL-2 cells 
were allowed to grow on 1 % agarose-coated 96 well plates for 7 days. The 7 day old 
spheroids were treated with 10 nM, 20 nM and 40 nM of Native-bLf, Apo-bLf and Fe-bLf for 
24 h and the change in the area of the tumour spheroids was measured using Image J 
software. The experiment involved 6 spheroids for each treatment. Data was represented as 
mean surface area values in pixels ± SE. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) 
as *** was considered statistically significant when compared to untreated cells. A value of 
(p≤ 0.001) represented as † was considered statistically significant when compared amongst 
the treatments. 
3.5.7 Native-bLf 40 nM significantly decreased clonogenic potential of both SK-MEL-2 and 
SK-MEL-28 cells 
 The clonogenic assay is generally performed in order to evaluate the colony forming 
efficacy or cell proliferation efficacy of cancer cells. The SK-MEL-2 and SK-MEL-28 cells were 
treated for 24 h and then 500 cells per treatment were grown in 6 well plates and observed 
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for colony formation efficacy. Untreated cells were maintained as control. The results 
revealed that SK-MEL-2 cells (Figure 3.7) had significantly higher cell proliferative potential 
(p< 0.05, 1.44 fold) when compared to SK-MEL-28 cells. In case of SK-MEL-2 cells, 40 nM 
treatments of all bLf forms i.e., Native-bLf (55.1 fold, (p≤ 0.001)), Apo-bLf (5.2 fold, (p≤ 
0.01)) and Fe-bLf (8.2 fold, (p≤ 0.01)) were effective in reducing the clonogenic potential of 
SK-MEL-2 cells. Native-bLf was the most effective in SK-MEL-2 cells in reducing the 
clonogenic potential when compared to Apo-bLf and Fe-bLf. In case of SK-MEL-28 cells 
(Figure 3.7), it was noted that the treatments of Native bLf showed a dose dependant 
decrease (10 nM-1.1 fold, 20 nM-1.3 fold) and a significant decrease in 40 nM-8.3 fold (p≤ 
0.001) was observed. Apo-bLf 20 nM treatment was more effective (2.7 fold decrease (p≤ 
0.01)) than both 10 and 40 nM that also showed significant decrease (2.1 fold (p≤ 0.01) and 
1.7 (p< 0.05) fold, respectively) in clonogenic potential of SK-MEL-28 cells. Fe-bLf 40 nM 
treatment was more effective than 10 nM and 20 nM (p< 0.05) in decreasing (3.5 fold, (p≤ 
0.01)) the clonogenicity of SK-MEL-28 cells. In conclusion it was observed that 40 nM 
treatments of Native-bLf was the most effective treatment to reduce the clonogenic 
potential of both SK-MEL-28 and SK-MEL-2 melanoma cells. Fe-bLf also showed promising 
inhibitory activity in both the cell types. 




Figure 3.7. Assessment of clonogenic potential of cells post treatments with bLf. The 
clonogenic survival assay was performed to investigate the ability of single cells to replicate 
and form colonies following treatments with all three forms of bLf for 24 h at 10 nM, 20 nM 
and 40 nM concentrations. 500 cells from each treatment were then plated out in a six well 
plate and allowed to grow for 14 days. The colonies were then stained with 0.1 % crystal 
violet and counted. This graph represents the reduction in colony forming ability of SK-MEL-
2 and SK-MEL-28 when compared to untreated cells. The results are presented as mean ± SE 
values and were repeated 3 times in triplicates. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) 
as *** was considered statistically significant when compared to untreated cells. A value of 
(p≤ 0.01) represented as † was considered statistically significant when compared amongst 
the treatments. Images are provided in the appendix section of the thesis.  
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3.5.8 Quantitative determination of cellular cytotoxicity exhibited by bLf in cancer cell 
lines using LDH reagent 
Lactate dehydrogenase (LDH) is a catalyst responsible for conversion of pyruvate to lactate 
and is hence is extensively found in body tissues. However, any damage to the membrane or 
cytotoxicity to the cells leads to release of LDH, therefore, making it an important marker 
for cellular cytotoxicity. In case of SK-MEL-2 (Figure 3.8 A) cells, all the three forms of bLf 
showed a dose dependant increase in cytotoxicity i.e., Native-bLf (10 nM-35 % (p≤ 0.01), 20 
nM-56 % (p≤ 0.01), 40 nM-74 % (p≤ 0.001)) Apo-bLf (10 nM-18 % (p< 0.05), 20 nM-21 % (p< 
0.05), 40 nM-56 % (p≤ 0.01)) and Fe-bLf (10 nM-38 % (p≤ 0.01), 20 nM-53 % (p≤ 0.01), 40 
nM-74 % (p≤ 0.001)).  
The LDH release assay results revealed that in case of SK-MEL-28 cells (Figure 3.8 A), both 
Native-bLf and Apo-bLf showed a dose dependant increase in cytotoxicity (10 nM-17 % (p< 
0.05), 20 nM-37 % (p≤ 0.01), 40 nM-76 % (p≤ 0.001) and 10 nM-9 %, 20 nM-76 % (p≤ 0.001), 
40 nM-85 % (p≤ 0.001), respectively. Whereas, all the three concentrations of Fe-bLf 
showed non-significant cytotoxicity when compared to the Apo-bLf and Native-bLf 
treatments in SK-MEL-28 cells (Figure 3.8 A). Therefore, it could be concluded that in the SK-
MEL-28 cells, 40 nM treatment of Native-bLf and Apo-bLf were the most effective 
treatment, whereas, in case of the SK-MEL-2 cells the maximum cytotoxicity was induced by 
40 nM treatments of both Native-bLf and Fe-bLf. The main advantages of using natural 
therapeutics over synthetic chemotherapeutic drugs are that they show little or no 
cytotoxicity in normal and healthy cells whereas the non-specific cytotoxic effects of various 
chemotherapeutics are widely known. Therefore, LDH release assay was conducted in order 
to evaluate the cytotoxicity induced by the bLf forms in primary epidermal melanocytes 
(Figure 3.8 B). 20 nM and 40 nM concentrations of all the three bLf forms were used as they 
proved cytotoxic to the SK-MEL-2 and SK-MEL-28 cells at that treatment concentration. The 
results revealed that there was no significant level of cytotoxicity induced by Native-bLf in 
any concentrations. 40 nM treatments of Apo-bLf showed significant cytotoxicity (15% (p< 
0.05)) when compared to the lower treatments of 20 nM. Even though this cytotoxic effect 
was significant in primary melanocytes, it is comparatively very less than the cytotoxicity 
observed by the same treatment in SK-MEL-28 (85 %) and SK-MEL-2 (56 %) cells. Fe-bLf 20 
nM and 40 nM did not show any significant cytotoxicity in primary epidermal melanocytes.  




Figure 3.8 (A). Cytotoxicity of bLf on SK-MEL-2 and SK-MEL-28. Cytotoxicity of all three 
forms of bLf in SK-MEL-2 and SK-MEL-28 cells was analysed using LDH reagent. SK-MEL-2 
and SK-MEL-28 cells were treated with various concentrations of Native-bLf, Apo-bLf and Fe-
bLf (10 nM, 20 nM and 40 nM) for 24 h.  Untreated cells were taken as negative control. All 
the values are represented as mean ± SE. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) 
as *** was considered statistically significant when compared to untreated cells. A value of 
(p≤ 0.01) represented as † and (p≤ 0.001) as †††, was considered statistically significant 
when compared amongst the treatments. 




Figure 3.8 (B). Cytotoxic effects of bLf in primary epidermal melanocytes (PEM). Cellular 
cytotoxicity in primary epidermal melanocytes was analysed using LDH reagent. PEM were 
treated with 20 nM and 40 nM concentrations of Native-bLf, Apo-bLf and Fe-bLf for 24 h. 
Untreated cells were taken as negative control. All the values are represented as mean ± SE. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) 
represented as * was considered statistically significant when compared to untreated cells.   
3.5.9 Annexin-V assay to identify the nature of cell death induced by bLf forms  
Annexin-V (also known as Annexin A5) is a cellular protein that competes for 
phosphatidylserine (PS) binding sites. In an event of apoptosis both PS and 
phosphatidylethanolamine (PE) are expressed on the cell surface. Therefore, annexin-V is 
used as a marker to detect event of apoptosis as it binds to both PS and PE. This assay was 
mainly performed in order to detect the nature of cell death necrosis versus apoptosis. SK-
MEL-28 cells were treated with Native-bLf, Apo-bLf and Fe-bLf in varying concentrations for 
24 h and then stained for annexin-V expression using flow cytometer. The effective 
concentrations i.e., 20 nM and 40 nM that have shown promising anti-cancer effect were 
used in this assay. A uniform population of the cells was selected and gating was done in 
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order to detect the cells that showed early apoptosis (annexin-V positive), late apoptosis 
(both annexin-V and PI positive) and necrosis (PI positive). The results were plotted in a 
graph showing percentage of cells with respect to the treatments. 
In case of SK-MEL-2 cells (Figure 3.9 A), it was observed that majority of the cells treated 
with 20 nM (30 %, p≤ 0.01) and 40 nM (41 %, p≤ 0.01) Native-bLf were in the necrotic region 
while some cells were also observed in the late apoptotic region with 20 nM (26 %, p≤ 0.01) 
and 40 nM (23 %, p≤ 0.01). On the other hand with 20 nM of Apo-bLf 10 % (p< 0.05) cells 
were observed in early apoptotic and 11 % (p< 0.05) of cells were observed in late apoptotic 
regions. With increase in concentration of Apo-bLf (40 nM), a shift in the expression was 
observed as 30 % (p≤ 0.01) of the cells were in the necrotic region while 26 % (p≤ 0.01) of 
cells were in the late apoptotic region. Fe-bLf was found to be the most effective in inducing 
apoptosis where at 20 nM, 40 % (p≤ 0.01) of cells were found in early apoptotic region while 
13 % (p< 0.05) cells were found in late apoptotic region, and at 40 nM, 64 % (p≤ 0.001) cells 
were found in early apoptotic region while 14 % (p< 0.05) cells were found in late apoptotic 
region.  
In case of SK-MEL-28 cells (Figure 3.9 B), majority of cells were found in necrotic and late 
apoptotic region with Native-bLf 20 nM (10 %, p< 0.05 and 27 %, p≤ 0.01 respectively) and 
40 nM (40 %, p≤ 0.01 and 36%, p≤ 0.01 respectively). Similar observations were made in 
case of Apo-bLf 20 nM, where 40 % cells (p≤ 0.01) were necrotic and 35% cells (p≤ 0.01) 
were in late apoptotic region, and 40 nM, where 45 % cells (p≤ 0.01) were in necrotic and 40 
% cells (p≤ 0.01) were in late apoptotic regions. Non-significant apoptosis was observed with 
20 nM where 3 % and 4 % and 40 nM (2 % and 6 %) cells were in necrotic and late apoptotic 
regions respectively, with Fe-bLf (Figure 3.9 B).  
 








Figure 3.9 (A). Increase in the % necrotic and late apoptotic cells with treatments of 
Native-bLf and Apo-bLf. Following 24 h of treatment with Native-bLf, Apo-bLf and Fe-bLf at 
20 nM and 40 nM, SK-MEL-2 cells were stained with annexin-V/PI and analysed by flow 
cytometry. Difference in the percentage viable cells between untreated and treatments 
were shown in representative quadrant images. Annexin-V and PI staining of 20 nM and 40 
nM treated, SK-MEL-28 cells were studied using flow cytometry. The difference in the 
percentage of apoptotic cells between the untreated (control) cells and the treatments are 
represented in this graph. The values were obtained from FACS-Diva software and plotted. 
Treatments were done in triplicates and the experiment was done thrice independently. All 
the values are represented as mean ± SE. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as **, and (p≤ 0.001) 
as *** was considered statistically significant when compared to untreated cells.  A value of 
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(p< 0.05) represented as † and (p≤ 0.001) represented as ††† was considered statistically 













Figure 3.9 (B). Induction of apoptosis in SK-MEL-28 with Apo-bLf treatments. Following 24 
h of treatment with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM, SK-MEL-28 cells 
were stained with annexin-V/PI and analysed by flow cytometry. Difference in percentage 
viable cells between untreated and treatments were shown in representative quadrant 
images. annexin-V and PI staining of 20 nM and 40 nM treated, SK-MEL-2 cells were studied 
using flow cytometry. The difference in the percentage of apoptotic cells between the 
                         Chapter 3- Induction of apoptosis in SK-MEL-2 and SK-MEL-28 with bLf forms                  
118 
 
untreated (control) cells and the treatments are represented in this graph. Treatments were 
done thrice and the experiment was done thrice independently. All the values are 
represented as mean ± SE. Student’s t test was performed to evaluate statistical 
significance. A value of (p≤ 0.01) represented as * and (p≤ 0.001) as ** was considered 
statistically significant when compared to untreated cells.  A value of (p≤ 0.01) represented 
as ††, was considered statistically significant when compared amongst the treatments. 
3.5.10 Caspase-3 mediated stimulation of cell death in bLf treated cells 
The caspase-3 protein is a member of the family cysteine-aspartic acid proteases (caspase) 
that plays a central role in execution of cell apoptosis. Therefore, in order to confirm the 
event of apoptosis, the caspase-3 activity was determined using the caspase-3 assay. The 
concentrations used for annexin-V assay were used in this study. From the results obtained 
(Figure 3.10) it was seen that Native-bLf at 20 nM and 40 nM concentration led to a 
significant increase in the caspase-3 activity when compared to other treatments. In SK-
MEL-2 cells, Native-bLf at 20 nM and 40 nM showed a 2.4 fold (p≤ 0.001) and 1.6 fold (p< 
0.05) increases in caspase-3 activity, respectively, when compared to untreated cells. In SK-
MEL-28 cells, a 1.8 fold (p≤ 0.01) and 1.4 fold (p< 0.05) increase in caspase-3 activity was 
observed with 20 nM and 40 nM Native-bLf, respectively. Apo-bLf did not show any 
significant caspase-3 activity in both SK-MEL-2 and SK-MEL-28 cells whereas, 40 nM 
treatment of Fe-bLf led to a significant increase (1.3 fold (p< 0.05)) in the caspase-3 activity 
in SK-MEL-28 cells and both 20 nM (1.6 fold (p≤ 0.01)) and 40 nM (1.7 fold (p≤ 0.01)) of Fe-
bLf showed significant increase in the caspase-3 activity in SK-MEL-2 cells.  




Figure 3.10. Measurement of active caspase-3 release from SK-MEL-2 and SK-MEL-28 
following bLf treatments. Caspase-3 release from SK-MEL-2 and SK-MEL-28 cells was 
measured in terms of activity using N-Acetyl-Asp-Glu-Val-Asp-p-nitroanilide substrate. Cells 
were grown in a 96 well plate at a cell density of 103 cells and treated with Native-bLf, Apo-
bLf and Fe-bLf at 20 nM and 40 nM concentrations. Supernatants were collected after 24 h 
and the amount of caspase-3 released was quantified. Untreated cells were included as 
negative control. Treatments were carried out in triplicates and the assay was performed 
thrice independently. Data has been expressed as mean values ± SE. Student’s t-test was 
performed to evaluate statistical significance.  A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells.  A value of (p≤ 0.01) represented as † was considered statistically significant 
when compared amongst the treatments. 
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3.5.11 Effect of bLf on mRNA expression of molecules involved in apoptosis and 
proliferation 
In order to detect the expression of key molecules involved in the apoptosis and the cell 
proliferation pathway induced by the three forms of bLf, gene expression analysis was 
carried out using real time polymerase chain reaction (qRT-PCR). The cells were treated with 
various forms of bLf for a 24 h period and RNA was extracted using TRIzol (Invitrogen, 
Australia) method. Post conversion of RNA into cDNA, q-RT-PCR analysis was carried out to 
calculate the gene expressions in terms of fold change (2^^ct).  
The results from SK-MEL-2 cells for real time gene expression studies, revealed that, Native-
bLf (40 nM) led to a significant (p< 0.05) increase in the survivin expression whereas both 
Apo-bLf (40 nM) and Fe-bLf (20 nM and 40 nM) led to a significant (p< 0.05) decrease in 
survivin gene expression (Figure 3.11 A). Even though Native-bLf showed a dose dependant 
reduction in Bcl-2 expression (20 nM (p< 0.05), 40 nM (p≤ 0.01), but lower concentrations 
(20 nM) of Apo-bLf and Fe-bLf were comparatively better in completely downregulating the 
Bcl-2 gene expression (p≤ 0.01). It was also observed that even though 40 nM Native-bLf led 
to a significant increase (p< 0.05) in Fas expression, it was Fe-bLf treatments (both 20 nM 
and 40 nM) that clearly showed a significantly better effect (p≤ 0.01) than the other two. 
Bax gene expression was also found to be upregulated in a dose dependant manner with Fe-
bLf (20 nM (p< 0.05) and 40 nM (p≤ 0.01) respectively). The cancer proliferation markers 
CD44 was found to be significantly lowered by 40 nM Native-bLf (p< 0.05), 20 nM Apo-bLf 
(p< 0.05) and 20 nM Fe-bLf (p≤ 0.01), whereas, EpCAM was also found to be significantly 
inhibited by 40 nM Native-bLf (p< 0.05), 20 nM Apo-bLf (p≤ 0.01), 20 nM Fe-bLf (p≤ 0.01) 
and 40 nM Fe-bLf (p< 0.05). Therefore, in conclusion it was Fe-bLf which showed the best 
overall anti-cancer activity in regulating the gene expressions of SK-MEL-2 cells. 
The gene expression studies revealed that in SK-MEL-28 cells (Figure 3.11 B), survivin was 
significantly inhibited by all the treatments i.e., Native bLf (20 nM-9.8 fold (p≤  0.01), 40 nM-
123.7 fold (p≤ 0.001)), Apo-bLf (20 nM-16.5 fold (p≤ 0.01), 40 nM-6.0 fold (p≤ 0.01)) and Fe-
bLf (20 nM- 3.7 fold (p≤ 0.01), 40 nM-5.7 fold (p≤ 0.01)) respectively. However, the most 
effective treatment against survivin gene expression was Native-bLf 40 nM. Native-bLf and 
Apo-bLf 40 nM also led to a significant decrease (p< 0.05) in Bcl-2 gene expression, whereas, 
Apo-bLf 20 nM (1.25 fold (p< 0.05)) and 40 nM (2.23 fold (p≤ 0.01)) led to a significant 
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increase in the Bax expression. Apo-bLf 40 nM (1.75 fold (p≤ 0.01)) also led to a significant 
increase in the Fas gene expression. CD44 and EpCAM common stem cell markers were 
chosen as cell proliferation markers and it was found that 20 nM of Apo-bLf led to a 
significant inhibition (p< 0.05) of both these markers. In conclusion, it was Apo-bLf which 
showed the best overall anti-cancer activity in regulating the gene expressions of SK-MEL-28 
cells. 
 
Figure 3.11 (A). Real time gene expression analyses of critical markers in SK-MEL-2. The 
relative mRNA expression of pro-apoptotic (Fas and Bax) and anti-apoptotic genes (survivin, 
Bcl-2, CD44, and EpCAM) in SK-MEL-2 cells was analysed by real time quantitative reverse 
transcriptase PCR. 1 µg of RNA that was isolated was converted to cDNA. 100 ng of cDNA, 
specific forwards and reverse primers, RT2 SYBR Green qPCR mastermix was used for 
analysis. The data was analysed using Livak method of relative quantification. The fold 
change was calculated by comparing the real time PCR values with a house keeping gene 
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(GAPDH). All values are represented as mean ± SE and the experiments were done twice in 
duplicates. Student’s t test was performed to evaluate statistical significance. A value of (p< 
0.05) represented as * and, (p≤ 0.01) as ** was considered statistically significant when 
compared to untreated cells. A value of (p≤ 0.01) represented as † was considered 
statistically significant when compared amongst the treatments. 
 
Figure 3.11 (B). Real-time gene expression analysis of critical markers in SK-MEL-28. The 
relative mRNA expression of pro-apoptotic (Bax and Fas) and anti-apoptotic genes (survivin, 
Bcl-2, CD44, and EpCAM) in SK-MEL-28 cells was analysed by real time quantitative PCR. 1 
µg of RNA that was isolated was converted to cDNA. 100 ng of cDNA, specific forwards and 
reverse primers, RT2 SYBR Green qPCR mastermix was used for analysis. The data was 
analysed using Livak method of relative quantification. The fold change was calculated by 
comparing the real time PCR values with a house keeping gene (GAPDH). All values are 
represented as mean ± SE and the experiments were done twice in duplicates. Student’s t 
test was performed to evaluate statistical significance. A value of (p≤ 0.01) represented as * 
and (p≤ 0.001) as ** was considered statistically significant when compared to untreated 
cells. A value of (p< 0.05) represented as †, (p≤ 0.01) as ††, was considered statistically 
significant when compared amongst the treatments. 
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3.5.12 Apoptosis array 
Gene expression analysis revealed that bLf forms led to change in gene expression levels of 
various key molecules involved in the apoptosis and cell proliferation pathway. Therefore, in 
order to evaluate the effect of bLf forms on protein expressions of 35 key molecules 
involved in apoptosis pathway, protein expression analysis using apoptosis array kit was 
performed. Some of the key pro-apoptotic molecules included in the array were Bad, Bax, 
pro-caspase-3, caspase-3, cytochrome-C, TRAIL R1, TRAIL R2, Fas-associated protein with 
death receptor (FADD), Fas/TNFRSF6 and second mitochondrial derived activator of caspase 
(SMAC)/direct inhibitor of apoptosis binding protein with low pI (Diablo). Anti-apoptotic 
molecules present in the array included Bcl-2, Bcl-xL, cAIP-1 and 2, claspin, clusterin, livin, 
survivin and x-linked inhibitor of apoptosis family (XIAP). The analysis of the array was done 
using image J software with assistance of microarray tool. The graphs were plotted to 
compare the relative expression between the untreated and the treated lysates. Since 
majority of the substantial results were obtained with the 40 nM concentrations in the 
previous assays, therefore, 40 nM treatments of all bLf forms were used this study. Since 
the importance of Bax/Bcl-2 ratio has been emphasized in several studies involving 
melanoma cells, the analysis of Bax/Bcl-2 ratio was also included in this study.   
In case of SK-MEL-2 cells (Figure 3.12 A), it was observed that Native bLf (p≤ 0.01), Apo-bLf 
(p< 0.05) and Fe-bLf (p< 0.05) led to a significant increase in the Bax/Bcl-2 ratio. Significant 
increase in Bad (Native-bLf (p< 0.05), Apo-bLf (p≤ 0.01) and Fe-bLf (p< 0.05)) was observed 
(Figure 3.12 A). The pro-caspase-3 expression was significantly upregulated by Apo-bLf (p< 
0.05) and Native-bLf (p< 0.05). The extrinsic apoptotic markers such as TRAILR 1 (Apo-bLf 
(p< 0.05) and Fe-bLf (p< 0.05)), TRAILR-2 (Fe-bLf (p≤ 0.01)), Fas (Apo-bLf (p< 0.05) and Fe-bLf 
(p< 0.05)), and FADD (Apo-bLf (p< 0.05) were found to be significantly upregulated. The 
phospho-p53 (S15) was also found to be upregulated by Apo-bLf (p< 0.05). The anti-
apoptotic markers such as Bcl-xl (Native-bLf (p< 0.05), Apo-bLf (p< 0.05) and Fe-bLf (p< 
0.05)), PON2 (Apo-bLf (p< 0.05) and Fe-bLf (p< 0.05)) and XIAP (Apo-bLf (p< 0.05) and Fe-bLf 
(p< 0.05)) were found to be significantly upregulated. HIF-1alpha was found to be 
significantly reduced (p≤ 0.01) by Fe-bLf (Figure 3.12 A). Survivin expression was 
significantly downregulated (p< 0.05) with both Native-bLf and Fe-bLf although maximum 
downregulation of survivin was observed with Apo-bLf (p≤ 0.01) treatments. Therefore, in 
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conclusion, even though Native-bLf showed the maximum increase in Bax/Bcl-2 ratio, both 
Apo-bLf and Fe-bLf proved to be most effective in upregulating the pro-apoptotic markers in 
SK-MEL-2 cells. 
In case of SK-MEL-28 cells (Figure 3.12 B), it was observed that Native-bLf (2.66 fold (p< 
0.05)), Apo-bLf (3 fold (p< 0.05)) and Fe-bLf (3 fold (p< 0.05)) led to a significant increase in 
the Bax/Bcl-2 ratio (pro-apoptotic molecule/anti-apoptotic molecule) (Figure 3.12 B). It was 
also seen that Bad expression was significantly (p< 0.05) increased by Native-bLf and Apo-
bLf. Even though, the pro-caspase-3 expression was significantly increased only by Native-
bLf (p< 0.05), the activated caspase-3 expression was significantly increased by Native-bLf 
(p≤ 0.01), Apo-bLf and Fe-bLf (p< 0.05). The death receptors involved in the extrinsic 
apoptotic pathway such as TRAILR1 and 2 (Native-bLf (p≤ 0.001), Apo-bLf (p< 0.05), Fe-bLf 
(p< 0.05)), FADD (Native-bLf and Apo-bLf (p< 0.05)) and Fas (Native-bLf, Apo-bLf and Fe-bLf 
(p< 0.05)) were also found to be significantly upregulated. Even though the SK-MEL-28 cells 
are p53 mutant, phospho-p53 levels (S15) were found to be significantly increased by 
Native-bLf (p≤ 0.01), Apo-bLf (p< 0.05) and Fe-bLf (p< 0.05). Phospho-p53 (S46) (p< 0.05) 
and phospho-p53 (S392) (p≤ 0.01) were also significantly upregulated with Native-bLf in SK-
MEL-28 cells. Apo-bLf and Fe-bLf also caused significant upregulation of phospho-p53 (S46) 
(p< 0.05). The SMAC/Diablo was also found to be significantly upregulated (p< 0.01) by 
Native-bLf.  The anti-apoptotic markers Bcl-xl (p< 0.05, p≤ 0.01, p< 0.05), cIAP-1 ((p≤ 0.01), 
(p≤ 0.01) and (p< 0.05) were significantly upregulated with Native-bLf, Apo-bLf and Fe-bLf, 
respectively), cIAP-2 (p≤ 0.01- Native-bLf and Apo-bLf, p< 0.05 for Fe-bLf), clusterin (p≤ 0.01- 
Native-bLf and Apo-bLf), p< 0.05- Fe-bLf). It was found that Native-bLf led to a significant 
decrease (p< 0.05) in expressions of HIF-1 alpha, livin, heame oxygenase (HO-1), HO-2, heat 
shock proteins (HSP) 27 and 60 while, it led to a significant (p≤ 0.01) increase in the HSP70 
expression. On the other hand the catalase expression was significantly increased by Native-
bLf (p< 0.05), while Apo-bLf (p< 0.05) and Fe-bLf (p< 0.05). It was also noted that survivin 
expression was significantly downregulated (p< 0.05) by Native-bLf and Fe-bLf, whereas, 
Apo-bLf did not cause a significant downregulation of survivin expression in SK-MEL-28 cells. 
To summarize the results, it was inferred that even though the Bax/Bcl-2 ratio was increased 
with all three bLf forms, it was Native-bLf that proved to the most effective in upregulating 
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the pro-apoptotic markers and inhibiting the anti-apoptotic markers in SK-MEL-28 cells 
(Figure 3.12 B). 
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Figure 3.12 (A). Involvement of bLf in increasing the expression of pro-apoptotic markers 
and decreasing the expression of anti-apoptotic markers in SK-MEL-2. Cells were treated 
with Native-bLf, Apo-bLf and Fe-bLf at 40 nM concentrations for 24 h and the lysates were 
subjected to analysis in a proteome profiler array for apoptotic regulators strips as per the 
manufacturer’s instructions (R&D). All values are represented as mean ± SE. Student’s t test 
was performed to evaluate statistical significance. A value of (p< 0.05) represented as * and 
(p≤ 0.01) as ** was considered statistically significant when compared to untreated cells. A 
value of (p≤ 0.001) represented as † was considered statistically significant when compared 
amongst the treatments.  
 





Figure 3.12 (B). Effect of bLf on some key pro-apoptotic and anti-apoptotic proteins in SK-
MEL-28 cells. Cells were treated with Native-bLf, Apo-bLf and Fe-bLf at 40 nM 
concentrations for 24 h and the lysates were subjected to analysis in a proteome profiler 
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array for apoptotic regulators as per the manufacturer’s instructions (R&D). All values are 
represented as mean ± SE. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was 
considered statistically significant when compared to untreated cells.  NS represents non-
significant statistical difference between the treatments.  
3.5.13 bLf causes downregulation of survivin protein expression in SK-MEL-2 and SK-MEL-
28 cell lines 
Flow cytometry studies were conducted in order to determine the effect of bLf treatments 
on survivin expression at 48 h period. In case of SK-MEL-2 cells, it was observed that all the 
three forms of bLf showed a decrease in survivin expression (Native-bLf 20 nM- 1.24 fold (p< 
0.05), 40 nM- 1.66 fold (p≤ 0.01), Apo-bLf 20 nM-no change, 40 nM-1.12 fold (p< 0.05), Fe-
bLf 20 nM-1.92 fold (p≤ 0.01), 40 nM-3.33 fold (p≤ 0.001)). Therefore, it was concluded that 
Fe-bLf was the most effective in downregulating survivin expression in the SK-MEL-2 cells. In 
case of SK-MEL-28 cells, it was observed that Native-bLf showed a dose dependant decrease 
in survivin expression (20 nM- 1.25 fold (p< 0.05), 40 nM-1.66 fold (p≤ 0.01)). Apo-bLf 
treatments also showed a dose dependant decrease in survivin expression (20 nM-2 fold (p≤ 
0.01), 40 nM-2.5 fold (p≤ 0.001)). Fe-bLf at both 20 (no change) and 40 nM (1.05 fold) failed 
to induce any change in expression of survivin. Therefore, it was concluded that 40 nM of 
Apo-bLf was the most effective in downregulating survivin expression in SK-MEL-28 cells 
(Figure 3.13).  
 
 












Figure 3.13. Quantification of survivin expression with bLf treatments using FACS. Cells 
were allowed to grow in 6 well plates at a cell density of 106 cells/well and treated with 20 
nM and 40 nM concentrations of Native-bLf, Apo-bLf and Fe-bLf for 48 h. Cells were then 
fixed using 4 % PF at RT for 20 min, following which they were blocked using 3 % serum for 1 
h at 37oC. The cells were then probed for survivin expression with mouse anti-human 
survivin monoclonal antibody at a dilution of 1:100 and incubated for 1 h at 37oC. Secondary 
antibody, anti-mouse IgG FITC was then added and the samples were incubated for 1 h at 
37oC in dark. The samples were then analysed through FACS for survivin expression. 
Untreated cells were used as control. The treatments were done thrice and the experiment 
was repeated thrice independently. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as ***, was 
considered statistically significant when compared to untreated cells.  A value of (p< 0.001) 
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represented as † was considered statistically significant when compared amongst the 
treatments.  
3.5.14 bLf and its effect on migration potential of SK-MEL-2 and SK-MEL-28 cells 
Cellular migration corresponds to the physical movement of cells from one site to the other 
and is considered as a measure of their metastatic potential. The higher concentration (40 
nM) was not considered because for the migration assay, the cells need to grow and migrate 
in the influence of the treatments. As seen in the cytotoxicity studies the 40 nM of bLf 
treatments led to a very high level of cellular cytotoxicity and disruption of their membrane 
hampering their normal capabilities. Therefore, in order to remove the bias, only 10 and 20 
nM treatments of all the three forms of bLf were considered. In case of SK-MEL-2 cells 
(Figure 3.14 A), the results from migration assay revealed that Native-bLf and Fe-bLf 
showed a dose dependant significant decrease (10 nM (p< 0.05) and 20 nM (p≤ 0.01)) in the 
migration potential. However, both 10 nM and 20 nM of Apo-bLf were equally effective in 
significantly downregulating (p≤ 0.01) the metastatic potential of SK-MEL-2 cells. There was 
no significant difference found between the efficacies of 20 nM treatments of Native-bLf, 
Apo-bLf and Fe-bLf. However, considering that the lower concentration of Apo-bLf (10 nM) 
showed a comparatively higher effect than the lower concentration of the other two and an 
equivalent effect as that of the higher treatments of the other two forms of bLf. 
Migration assay was performed in SK-MEL-28 cells after 24 h of treatments with varying 
concentrations of Native-bLf, Apo-bLf and Fe-bLf (Figure 3.14 B). The results from the 
migration assay in SK-MEL-28 cells revealed that only the 20 nM concentration of Native-bLf 
led to a significant reduction (p< 0.05), whereas, both Apo-bLf and Fe-bLf showed a dose 
dependant significant reduction (10 nM (p< 0.05) and 20 nM (p≤ 0.01), respectively) in the 
migration potential of SK-MEL-28 cells. Therefore, it was inferred from these results that 
both Apo-bLf and Fe-bLf worked better when compared to Native-bLf in inhibiting the 
migration potential of SK-MEL-28 cells. 




Figure 3.14 (A). Migratory potential of SK-MEL-2 with and without bLf treatments. SK-MEL-
2 cells were allowed to grow on trans-well membrane thin-certs containing pores of 8 µm 
diameter in a 12-well plate in the presence of Native-bLf, Apo-bLf and Fe-bLf at 10 nM and 
20 nM for 24 h. Cells grown in the presence of media alone were used as control. Number of 
cells that migrated through the 8 µm pores were stained with 1 % crystal violet and 
counted. Representative images from each treatment were shown. Number of cells that 
migrated through the 8 µm pores were stained with 1 % crystal violet and counted. The 
number of migratory cells that were counted in each treatment using a microscope was 
plotted on a graph. Treatments were done in triplicates and the experiment was performed 
thrice independently. All the values are represented as mean ± SE and the experiments were 
repeated thrice. Student’s t test was performed to evaluate statistical significance. A value 
of (p< 0.05) represented as * and (p≤ 0.01) as ** was considered statistically significant 
when compared to untreated cells.  NS represents non-significant difference between the 
treatments.  




Figure 3.14 (B). Migratory potential of SK-MEL-28 with and without bLf treatments. SK-
MEL-28 cells were allowed to grow on trans-well membrane thin-certs containing pores of 8 
µm diameter in a 12-well plate in the presence of Native-bLf, Apo-bLf and Fe-bLf at 10 nM 
and 20 nM for 24 h. Cells grown in the presence of media alone were used as control. 
Number of cells that migrated through the 8 µm pores were stained with 1 % crystal violet 
and counted. Representative images from each treatment were shown. The number of 
migratory cells that were counted in each treatment using a microscope was plotted on a 
graph. Treatments were done in triplicates and the experiment was performed thrice 
independently. All the values are represented as mean ± SE and the experiments were 
repeated thrice. Student’s t test was performed to evaluate statistical significance. A value 
of (p< 0.05) represented as * and (p≤ 0.01) as ** was considered statistically significant 
when compared to untreated cells.  A value of (p< 0.05) represented as † was considered 
statistically significant when compared amongst the treatments.  
3.5.15 Inhibition of invasive potential of SK-MEL-2 and SK-MEL-28 with bLf treatments 
The invasion assay is a semi-quantitative measure of the invasion potential of a cell type to 
penetrate a basement membrane barrier (extracellular matrix consisting of collagens, 
laminin, fibronectin, tenascin, elastin, glysocaminoglycans and a number of proteoglycans). 
Therefore, invasion assay was conducted in order to deduce the invasion potential of 
melanoma cells under influence of all three bLf forms. Treatment concentrations of Native-
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bLf, Apo-bLf and Fe-bLf were used in a similar fashion as that of the migration assay SK-MEL-
2 The results on invasion potential of SK-MEL-2 (Figure 3.15 A) cells revealed that all the 
three forms of bLf showed a dose dependant decrease in the invasive potential of these 
cells (Native-bLf 10 nM-1.2 fold, 20 nM-1.6 fold (p< 0.05), Apo-bLf 10 nM-1.3 fold (p< 0.05), 
20 nM-1.4 fold (p< 0.05) and Fe-bLf 10 nM-2.1 fold (p≤ 0.01), 20 nM-2.9 fold (p≤ 0.001)). 
Therefore, it was inferred that Fe-bLf had highest efficacy against invasion potential of SK-
MEL-2 cells. These results also correlated with the migration assay results from these cells 
where, Fe-bLf had shown significant downregulation of the migration potential.  
The results further revealed that, both Native-bLf and Apo-bLf showed a dose dependant 
significant decrease in the invasion potential of SK-MEL-28 cells (Figure 3.15 B), (10 nM-1.5 
fold (p< 0.05), 20 nM-2.4 fold (p≤ 0.01) and 10 nM-1.7 fold (p< 0.05), 20 nM-4.6 fold (p≤ 
0.001) respectively). Even though both 10 nM (1.3 fold) and 20 nM (0.6 fold) treatments of 
Fe-bLf showed a significant (p< 0.05) decrease in the invasion potential of SK-MEL-28 cells, 
its efficacy was comparatively lower than both Native-bLf and Apo-bLf. Apo-bLf was most 
effective.  




Figure 3.15 (A). Assessment of effect of bLf on invasive capacity of SK-MEL-2 cells. SK-MEL-
2 cells were allowed to grow on a trans-well membrane thin-certs containing pores of 8 µm 
diameter and coated with extracellular matrix (ECM) in a 12-well plate in the presence of 
Native-bLf, Apo-bLf and Fe-bLf at 10 nM and 20 nM for 24 h. Cells grown in the presence of 
media alone were used as control. Number of cells that migrated through the 8 µm pores 
were stained with 1 % crystal violet and counted. Representative images from each 
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treatment were shown. The number of migratory cells that were counted in each treatment 
using a microscope was plotted on a graph. Treatments were done in triplicates and the 
experiment was performed thrice independently. All the values are represented as mean ± 
SE and the experiments were repeated thrice. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) 
as *** was considered statistically significant when compared to untreated cells.  A value of 
(p≤ 0.01) represented as †, was considered statistically significant when compared amongst 
the treatments.  
 




Figure 3.15 (B). Semi-quantitative analysis of effect of bLf on invasive potential of SK-MEL-
28 cells. SK-MEL-28 cells were allowed to grow on a trans-well membrane thin-certs 
containing pores of 8 µm diameter and coated with extracellular matrix (ECM) in a 12-well 
plate in the presence of media alone were used as control. Number of cells that migrated 
through the 8 µm pores were stained with 1 % crystal violet and counted. Representative 
images from each treatment were shown. The number of migratory cells that were counted 
in each treatment using a microscope was plotted on a graph. Treatments were done in 
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triplicates and the experiment was performed thrice independently. All the values are 
represented as mean ± SE and the experiments were repeated thrice. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) represented as *** was considered statistically significant when 
compared to untreated cells.  A value of (p< 0.01) represented as † was considered 
statistically significant when compared amongst the treatments.  
3.5.16 Upregulation of melanin pigment production with bLf in SK-MEL-2 and SK-MEL-28 
cell lines 
Melanin is a natural pigment formed due to the oxidation of amino acid tyrosine mainly 
located in cells known as melanocytes. Melanin mainly protects skin cells from UV radiation 
induced DNA damage reducing the risk of cancer. However, when present in cancer cells it 
renders them more susceptible to chemotherapeutics. Therefore, the effect of bLf forms 
and their various concentrations was tested on melanin expression. In case of the SK-MEL-2 
cells (Figure 3.16), 20 nM (p< 0.05), 40 nM (p≤ 0.01) of Native-bLf and 40 nM (p< 0.05) of 
Apo-bLf led to significant increase in melanin content. Fe-bLf showed a non-significant 
increase in the melanin content compared to the untreated cells. The results revealed that 
10 nM of Fe-bLf significantly lowered (p< 0.05) the melanin content in the SK-MEL-28 cells 
whereas, 40 nM treatments of all the three bLf forms i.e. Native-bLf, Apo-bLf and Fe-bLf led 
to an non-significant increase in the melanin content. Therefore, it was concluded that 
Native-bLf was the most effective in increasing the melanin content of SK-MEL-2 cells, 
whereas all the three forms were equally effective in increasing the melanin content of the 
SK-MEL-28 cells.  




Figure 3.16. Estimation of melanin content with bLf treatments. Melanin content present 
per cell was quantified after treatment with Native-bLf, Apo-bLf and Fe-bLf at varying 
concentrations (10 nM, 20 nM, and 40 nM) for 24 h. The cells were then washed with 1X 
PBS after treatments and the cell layer was trypsinized and suspended in 1N NaOH and the 
absorbance was measured using a spectrophotometer at 472 nm. Melanin content per cell 
was calculated and untreated cells were kept as control. The treatments were done in 
triplicates and the experiment was done thrice independently. All the values are 
represented as mean ± SE and the experiments were repeated thrice. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as * and (p≤ 
0.01) as ** was considered statistically significant when compared to untreated cells.  A 
value of (p≤ 0.01) represented as † was considered statistically significant when compared 
amongst the treatments.  
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Table 3.2. Comparative analysis of effect of Native-bLf, Apo-bLf and Fe-bLf in SK-MEL-2 
and SK-MEL-28 cell lines. 
Name of the 
assay 
Native-bLf Apo-bLf Fe-bLf 










** ** ** *** *** ** 
Cell proliferation * ** ** *** *** * 
Tumour 
spheroid assay 
** * * ** *** *** 
Colony forming 
assay 
*** *** ** * ** ** 
Cell cytotoxicity *** *** ** *** *** * 
Annexin-V assay ** *** * *** *** * 





** ** * *** *** * 
Migration assay *** ** *** *** *** *** 





* *** ** ** *** * 
Survivin 
expression 
** ** * *** *** * 
Most effective treatment represented as *** 
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Effective treatment represented as ** 
Least effective treatment represented as * 
3.6 DISCUSSION 
Bovine milk derived lactoferrin, a milk whey protein, is known to restore the iron content in 
body to cure iron deficiency, enhance RBC count and also increase haemoglobin levels, in 
turn boosting inherent immune system of body to fight back against cancer and chronic 
diseases (Kanwar, Mahidhara & Kanwar 2012a). The main aim of this chapter was to study 
the effect of different forms of bLf with varying iron content in targeting cell death and 
growth of p53-mutant melanoma cell lines SK-MEL-2 and SK-MEL-2. The three different 
forms of bLf were used namely Native, Apo and Fe-bLf. The purity of the prepared protein 
forms was analysed using SDS-PAGE and confirmed by Western blotting. The iron content in 
the three forms of bLf samples prepared were 98.5 %, 2.3 % and 19 % in Fe-bLf, Apo-bLf and 
Native-bLf, respectively. The iron content in the three bLf samples were in range as reported 
earlier (Kanwar et al. 2008). Iron binding in bLf is a result of concomitant binding of two 
bicarbonate ions that keep the iron molecule attached to the bLf structure (Iyer & Lonnerdal 
1993; Levay & Viljoen 1995). Colour formation during the preparation of Fe-bLf was due to 
the addition of iron molecules. This is due to the presence of bicarbonate ions that aid in 
iron saturation of bLf. Binding of ferric ions is dependent on the open conformational state 
of the Apo-bLf protein. The ability of bicarbonate ions to bind to ferric ions onto two lobes 
(N- and C-) and their retention at low pH makes bLf acquire bacteriostatic, anti-oxidant and 
anti-tumor properties (Baker & Baker 2004).  
Several studies have investigated and reported presence of lactoferrin receptors in cancer 
and normal cells, it was reviewed  that bLf internalised through lactoferrin receptors and 
low-density lipoprotein receptors (LRP) in colon cancer cells (Legrand et al. 2008) which was 
further confirmed in colon cancer cells (Kanwar, Mahidhara & Kanwar 2012a; Kanwar et al. 
2014). Both Apo-bLf and hololactoferrin have been reported to be internalised via the 
clathrin-mediated endocytosis in Caco-2 cells, inducing ERK signaling and leading to 
apoptosis (Jiang et al. 2011). Increase in  the expression of LfR was also reported in the 
intestine of osteoarthritic models of mice with oral administration of Fe-bLf (Samarasinghe, 
Kanwar & Kanwar 2014). Since it has been reported that lactoferrin acts as a ligand for LRP 
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and TfR (Jeffrey et al. 1998), in the present study effect of bLf forms on gene expressions of 
all the forms of LRP receptors and TfR was studied. In SK-MEL-2 and SK-MEL-28 cells, 
treatments with bLf forms led to modulation of gene expression of lactoferrin receptors. 
This difference in the receptor expression patterns could be due to the 
structural/conformational variations between Apo-bLf and Fe-bLf, due to their metal 
saturation properties (Baker & Baker 2009) thereby resulting in differential interactions with 
receptors. The iron saturation in Fe-bLf leads to close conformation of the C lobe and the N 
lobe whereas the iron-free form of bLf (Apo-bLf) is characterised by open conformation of 
the N lobe. It has been reported that both Apo-bLf and holo-bLf internalise by LfR via 
clathrin-mediated endocytosis (Jiang et al. 2011; Kanwar et al. 2014).  
On basis of these findings and considering the receptor ligand chemistry, it could be 
concluded that bLf forms could internalise in the target cells using these receptors. No 
significant difference between the internalisation of Apo-bLf and Fe-bLf was observed 
between the two cell lines. All the three forms of bLf were able to internalise within 30 min 
but 100% internalisation was observed after 6 h of treatment in SK-MEL-2 and SK-MEL-28 
melanoma cells. Irrespective of this internalisation pattern, it was noted that Apo-bLf and 
Fe-bLf entered the melanoma cells by different Lf receptor activation indicating, that the 
two types of bLf employ different types of Lf receptors for their mechanism of 
internalisation. Although Native-bLf, Apo-bLf and Fe-bLf upregulated the expression of 
receptors as discussed above, a few Lf receptors were downregulated with bLf treatments 
(Figures 3.3 A & B). For example TfR and TfR2 were downregulated with Apo-bLf and Fe-bLf 
treatments in SK-MEL-2 and LRP-2, LfR were downregulated with Apo-bLf and Fe-bLf 
treatments in SK-MEL-28 cells. From the gene expression analysis of lactoferrin receptors on 
SK-MEL-28 cells’ analysis, it appears that for these cells TfR family of receptors (TfR, TfR1 
and TfR2) could be the dominant player for bLf internalisation. TfR1 was significantly 
upregulated with Native-bLf treatment, when compared to the other two bLf forms. It is a 
possibility that the Native-bLf could have preferred TfR1 for its internalisation thereby 
showing higher bLf immunofluorescence. Furthermore, different miRNA have been 
identified in targeting TfR1 including miR-320 (Schaar et al. 2009).It has been proved that 
the downregulation of TfR1 causes a decrease in the cell proliferation. There could be a 
                         Chapter 3- Induction of apoptosis in SK-MEL-2 and SK-MEL-28 with bLf forms                  
145 
 
possibility that the three forms of bLf might differentially regulate the expression of miR-320 
and other miRNAs that regulate the expression of TfR1.  
Internalisation of bLf through the receptors results in the activity of bLf enhancing its anti-
tumour response in xenograft models of colon cancer (Kanwar et al. 2014).  Therefore, the 
cytotoxic profile of all the three forms of bLf in SK-MEL-2 and SK-MEL-28 cell lines was 
evaluated. Interestingly, there was a significant difference between the effects of Apo-bLf 
and Fe-bLf in causing cytotoxicity to the melanoma cell lines tested which was dependent 
upon their ability to internalise via the receptors. In SK-MEL-2 cells, a dose-dependent effect 
of Fe-bLf was seen, and this was in accordance with the receptors study where the Fe-bLf 
treatments upregulated TfR 2 and LRP-1 receptors. On the other hand, upregulation of LfR 
and TfR1 in SK-MEL-28 cells with Apo-bLf treatments correlated with their increased 
cytotoxic effects in SK-MEL-28. Hence, the effect of Apo-bLf and Fe-bLf in SK-MEL-28 and SK-
MEL-2, respectively, could be related to their ability to enter the cells through receptor-
mediated internalisation. However the difference in their cytotoxic and anti-proliferative 
activities was mainly due to difference in the nature of these proteins. Even though Fe-bLf 
LDH release from SK-MEL-28 cells following Fe-bLf treatment could not be observed, other 
assays such as the cell proliferation, clonogenic and the tumour spheroid assay have shown 
that Fe-bLf is highly effective against these cancer cells. Therefore, further studies at varying 
time points must be conducted for LDH release assay in SK-MEL-28 cells.  
Apo-bLf is known to chelate free iron from the cells. Iron chelation has been linked with an 
increase in p53 activity (Liang & Richardson 2003). Interestingly, phospho-p53 (S15) was 
upregulated with Apo-bLf treatments in SK-MEL-2 cells (Figure 3.12 A) and its higher 
treatments have shown to induce more necrosis than apoptosis whereas, the nature of 
cytotoxicity induced by Fe-bLf was mainly due to apoptosis (Figures 3.9 A & B). All the three 
forms of bLf induced very low levels of cytotoxicity in primary melanocytes which is in 
accordance with previously published studies where Lf was reported to promote both 
granulation tissue formation and reepithelialisation thereby promoting proliferation of 
normal melanocytes without inducing any toxicity (Takayama 2012).  
Native-bLf showed a dose-dependent inhibition of cellular proliferation in SK-MEL-28. On 
the other hand, significant inhibition in the growth patterns of SK-MEL-2 cells with Fe-bLf 40 
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nM treatments, and SK-MEL-28 cells with Apo-bLf 40 nM treatments, respectively was 
observed. The activity of Fe-bLf in this study was in accordance with a previously published 
data where Fe-bLf was shown to reduce tumour volumes in colon, skin (B16), lung and 
breast cancer models when administered orally (Kanwar, Mahidhara & Kanwar 2012a; 
Kanwar et al. 2008). However, this effect of Fe-bLf could be attributed to the fact that iron 
saturation potentially increases the anti-cancer efficacy of bovine lactoferrin (Kanwar et al. 
2008; Yoo et al. 1998).  
To further establish the potential of all three forms of bLf in targeting 3D cultures of SK-
MEL-2 and SK-MEL-28 that closely resemble and replicate a tumour microenvironment were 
established. Tumour spheroids are considered as better models that in vitro cell culture 
models to predict the response of any drug as they mimic the tumour microenvironment 
more accurately and contains a heterogenic population of cells which is actually present in a 
tumour (Dufau et al. 2012). Bovine lactoferrin has also been reported to inhibit growth of 
solid tumours in several cancer types (Jonasch et al. 2008). Spheroids facilitate cell-cell 
interactions and represent a tumour microenvironment (Okochi et al. 2013). Native-bLf led 
to the disruption of tumour spheroid structures, whereas Fe-bLf showed maximum 
inhibition of tumour spheroid formation in both SK-MEL-28 and SK-MEL-2 cell lines. 
However, Apo-bLf‘s action on SK-MEL-28 in (2D cell monolayer), with respect to highest 
anti-cell proliferative activity was not replicated in 3D tumour spheroid assay. Though Apo-
bLf did affect the spheroid forming ability of these cells Fe-bLf showed the maximum 
cytotoxic effect in reducing spheroids' size.  These findings corroborate earlier findings by 
Kanwar al., 2008 which demonstrate that bLf needs to be saturated with iron to be effective 
for its higher anti-cancer activity against different tumours including B16 melanoma 
tumours (Kanwar 2008). Though all the three bLf forms of bLf, Native-bLf, Apo-bLf and Fe-
bLf were effective in inhibiting the tumour spheroid formation of SK-MEL-28, Fe-bLf has 
been considered most cytotoxic due to its ability to reduce the tumour spheroid size rather 
than causing disintegration of the tumour spheroids. This could be due to the ability of Fe-
bLf to internalise effectively and target stem cells in tumour spheroids. More recently, 
published studies from our laboratory prove that Fe-bLf is capable of targeting cancer stem 
cells (Kanwar et al. 2014) which might be prominent in a tumour spheroid model since 
spheroids mimic the 3Dtumour microenvironment to a large extent, contain necrotic core 
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and highly proliferating cell zones in periphery. Specific  molecular markers that are targeted 
by bLf forms in a tumour spheroid need to be studied in future along with gene expression 
profiling, to understand  the exact mechanism of action; since  as mentioned on page 83, SK-
MEL-2 and SK-MEL-28 differ in the mutational status of P53, the  guardian gene.  
Cellular sensitivity to treatments are measured by their ability to replicate and form colonies 
post-treatments, and for investigating this effect by clonogenic assay is still considered as 
the ‘gold standard’ method (Puck, Marcus & Cieciura 1956). To measure the growth rate 
and sensitivity of SK-MEL-2 and SK-MEL-28, clonogenic potential post-bLf treatments were 
measured. This would provide an indication of the sensitivity and decrease in growth rate as 
it provides an insight for long-term measurements on cell growth (Ramamoorthy et al. 
2013). Native-bLf at 40 nM was highly effective in reducing the clonogenic potential of SK-
MEL-2 and SK-MEL-28 cells. Higher concentrations of both Apo-bLf and Fe-bLf were also 
significant (p≤ 0.01) in reducing the clonogenic potential of both SK-MEL-2 and SK-MEL-28 
cells.  
One of the most critical hallmarks of cancer is their ability to resist induction of apoptosis; 
hence, inducing apoptosis is one of the main aims of anti-cancer therapeutics (Hanahan & 
Weinberg 2000). Apoptosis leads to changes in the cell morphology and causes destruction 
to the structural integrity of the cells. Phosphatidylserine (PS), a membrane phospholipid is 
commonly expressed on the cell membranes of damaged cell types. Annexin-V dye is 
capable of binding to this PS on the membrane of cells, hence providing a measure for 
apoptosis (Demchenko 2013). Propidium iodide (PI) binds to the DNA and core histones, 
through permeabilized or damaged plasma membrane structure in cells (Banerjee et al. 
2014). Both annexin-V staining and PI staining are indicators of apoptosis and necrosis, 
respectively; therefore, this technique was employed to confirm the role of bLf in causing 
apoptosis to SK-MEL-2 and SK-MEL-28 cells. bLf forms with less-least amounts of iron, 
Native-bLf and Apo-bLf appeared to induce significant necrosis in both the cell lines, though 
a large population of late apoptotic cells was also identified by flow cytometry. Fe-bLf on the 
other hand, induced cell death majorly by apoptosis only; however the cell population of 
apoptotic cells was relatively lower in SK-MEL-28. These results were not in accordance with 
the LDH release assay. The findings of the study are important and need further verification 
as the main of anti-cancer therapeutic development is to develop apoptosis inducing agents, 
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since removal of necrotic cells leads to inflammation. However, the results for SK-MEL-2 
cells are in correlation with the previous assays.  
The various effects of bLf on both SK-MEL-2 and SK-MEL-28 cells, and the ability of bLf to 
target the proliferation, survival and metastatic potential of melanoma cell lines both in 2D 
and 3D culture provided the much-needed information to test bLf a natural therapeutic for 
melanoma. To further elucidate the anti-cancer role of bLf extensively in SK-MEL-2 and SK-
MEL-28 cell lines, an apoptotic array kit that was further used to analyse the protein 
expression levels of 35 key molecules including pro-apoptotic and anti-apoptotic molecules 
involved in the apoptotic pathway.  
A number of studies have targeted melanoma cell line A375, by upregulating the Bad and 
Bax expression that leads to mitochondrial-related pathway of apoptosis by increasing the 
expression of caspase-3 (Li et al. 2013; Qin, Xin & Nickoloff 2012). B16F10 mouse melanoma 
cell lines and A375SM human melanoma cells have been targeted using hexane extract from 
the roots of Lithospermum erythrorhizon (LEH)  via the same pathway where an increase in 
the expression of Bad and Bax proteins caused significant cell death in melanoma cells 
(Rajasekar et al. 2012). Bcl-2 and Bcl-xL, on the other hand, are anti-apoptotic molecules 
that lead to survival and inhibition of apoptosis in melanoma cells (Mayola et al. 2011). Bcl-2 
and Bcl-xL proteins bind to Bax, inactivating Bax protein and avoiding the induction of 
apoptosis in cancer (Prasad et al. 2012). Expression of both pro-apoptotic molecules Bad 
and Bax was significantly upregulated with Fe-bLf samples used in SK-MEL-2 cell lines. Bcl-2 
and Bcl-xL, anti-apoptotic markers were slightly upregulated with bLf treatments, but the 
ratio of Bax and Bcl-2 was highest with Native-bLf 40 nM in SK-MEL-2 and all the three forms 
of bLf were effective in SK-MEL-28 helping cause apoptosis in SK-MEL-2 and SK-MEL-28 cells.  
A number of studies have investigated the regulation of wild-type p53 with an increase in 
Bax expression that together leads to apoptosis in cancer cell types. In human lung cancer 
cell lines A549, SK-LU-1 and SK-MES-1, ethanol extracts of Scutellaria baicalensis  (a Chinese 
medicine) has been used as an adjuvant to chemotherapy (Gao et al. 2011). Treatment with 
this adjuvant caused S phase and G0/G1 phase arrest and enhancement of apoptosis by 
overexpression of p53 and Bax. Wild-type p53 is believed to have a direct role in the 
induction of apoptosis. Tumour suppressor protein, p53 causes an upregulation of Bax 
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protein expression; naturally available tetranortriterpenoid, Nimbolide from Neem 
upregulated TRAIL mediated apoptosis by downregulating ERK1 and ERK2 pathway in 
melanoma by using (Gupta et al. 2011; Roy et al. 2007). Upregulation of p53 leads to 
increased expression of Bax and Bad proteins. This phenomenon was confirmed in both SK-
MEL-2 and SK-MEL-28 cells, where a significant upregulation in the phospho-p53 (S15) 
protein was observed with both Fe-bLf and Apo-bLf treatments. It is known that SK-MEL-28 
harbors a homozygous inactive p53 mutation. With homozygous loss of p53, DNA damage 
goes unrepaired, mutations become fixed in dividing cells and this leads to the malignant 
transformation of cells (Sun et al. 2014b). It has been reported that the wild-type p53 
activity can be restored by repairing the mutant p53 transcripts in osteosarcoma, colon and 
lung cancer cells. Activation of wild-type p53 has also been shown to cause downregulation 
in the promoter expression of the MDR1 gene (Watanabe & Sullenger 2000). An increase in 
the phospho-p53 (S15) activity observed in SK-MEL-28 cells suggests that Apo-bLf might 
have partially or completely restored the wild-type p53 activity in these cells. However, no 
specific claims can be made at this stage and further research work on the effect of the 
three forms of bLf on this particular p53 mutation needs to be studied in depth. As 
mentioned above, restoration of WT p53 activity in mutant p53 cells, might downregulate 
MDR1 gene expression, therefore, effect of various forms of bLf on the MDR1 (P-gp) 
expression would provide additional supporting information regarding this phenomenon 
and was studied in Chapter 5.  
SK-MEL-2 cells are well characterized for their mutation in p53 that does not lead to 
functional inactivation of p53 whereas; SK-MEL-28, mutation in the promoter binding region 
of p53 gene leads to its functional inactivation in SK-MEL-28 cell lines. In SK-MEL-28 cells, all 
the three forms of bLf upregulated the protein expression level of phospho-p53 (S15) 
significantly. Even though Apo-bLf and Fe-bLf significantly upregulated phospho-p53 (S15), 
Native-bLf at 40 nM was proved most effective in causing upregulation of phospho-p53 
(S15) in SK-MEL-28 where there was a 3 fold increase in the expression when compared to 
untreated cells. In SK-MEL-2 cells, Apo-bLf at 40 nM caused a 0.5 fold increase in the protein 
expression of phospho-p53 (S15). The Bax/Bcl-2 ratio in SK-MEL-28 was the highest with all 
the three forms of bLf treatment at 40 nM (p< 0.05) in the Bax/Bcl-2 ratio was observed and 
in SK-MEL-2 the most significant (p≤ 0.01) increase in the Bax/Bcl-2 ratio was noted with 
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Native-bLf at 40 nM showing a 4 fold increase in the Bax/Bcl-2 expression. Bad, an 
important pro-apoptotic molecule was upregulated by 2 fold with Native-bLf at 40 nM in SK-
MEL-28 cell lines and in SK-MEL-2 with Apo-bLf at 40 nM there was a 2 fold increase in Bad 
expression. All these pro-apoptotic markers that are downstream molecules for the p53-
dependent pathway of apoptosis were upregulated in both -SK-MEL-2 and SK-MEL-28 cell 
lines. This proves that the two melanoma cell lines with varying p53 showed upregulation of 
p53 dependent pathway of apoptosis proving the role of bLf in causing functional activation 
of p53 in SK-MEL-28 and in upregulating the activity of p53 in SK-MEL-2 cell line.  
Presence of survivin in the nuclear component has been associated with reduced survival 
and increased proliferative and metastatic potential of melanoma cells both in vitro and in 
vivo (Mckenzie & Grossman 2012; McKenzie et al. 2013a). The overexpression of survivin is 
linked to both downregulation of p53 and Bax protein in melanoma cells that ultimately 
leads to a decrease in the caspase-induced apoptosis in malignant melanomas when 
compared to melanocytic nevi (Kang et al. 2011a). YM155, a small-molecule inhibitor, 
targeting survivin shows that downregulation of survivin causes a 5.3 fold to 13.4 fold 
increases in the caspase-activities leading to cell death in A375 and SK-MEL-5 human 
malignant melanomas which was further confirmed in mouse xenograft models (Yamanaka 
et al. 2011). In SK-MEL-28 cells, treatment with Apo-bLf at 40 nM significantly 
downregulated the expression of survivin and caused a 2-fold increase in the expression of 
caspase-3 indicating the role of bLf in upregulating the p53-dependent pathway of apoptosis 
by downregulating survivin, Bcl-2 and increasing the expression of Bax, TRAIL and phospho-
p53. SK-MEL-28 is a p53 mutant characterized by the functional inactivation of p53 due to 
mutation in its promoter. Treatment with Native-bLf 40 nM, is able to cause functional 
activation of p53 leading to p53-dependent apoptosis in SK-MEL-28 cells. 
 Anti-apoptotic protein survivin was significantly downregulated with both Apo-bLf and Fe-
bLf treatments in SK-MEL-2 cells. A significant increase in the TRAIL receptors was observed 
with Fe-bLf treatments in SK-MEL-2 cell line. The mechanism of apoptosis in melanoma cells 
was proposed earlier through the inhibition of pro-survival transcriptional factor NF-κB that 
led to an increase in the expression of reactive oxygen species (ROS) upregulating TRAIL-
induced mitochondrial pathway of cell death in melanoma cells (D'Anneo et al. 2013). TRAIL 
belongs to the tumour necrosis factor family of ligands that initiate apoptosis by 
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engagement with its death receptors. It has been previously studied that, a natural 
compound, withaferin A (derived from a medicinal plant)  has anti-tumorigenic activity and 
it is capable of inducing apoptosis in human melanoma cells SK28, Mel501, Lu1205, M14 
and WM793 cells by downregulation of Bcl-2 that leads to the generation of ROS and 
release of cytochrome c from the mitochondria of the cells (Mayola et al. 2011). Another 
study using natural alkaloid named barbering has also shown activation of caspase-3, 4, 7, 8 
and 9 and the involvement of mitochondria by release of cytochrome c in being able to 
cause apoptosis in human melanoma cells (Burgeiro et al. 2011). Cytochrome c is 
significantly downregulated in SK-MEL-2 (p< 0.05) with Native-bLf, Apo-bLf and Fe-bLf 
treatments. In SK-MEL-28 cells, a significant decrease (p< 0.05) in cytochrome c was 
observed with Apo-bLf and Fe-bLf treatments. Both these results indicate that there might 
not be involvement of the mitochondrial induced cell death mechanism in the SK-MEL-2 and 
SK-MEL-28 melanoma cell lines.  
Development of brain metastasis occurs in approximately half of all cancer patients, with an 
incidence of 40-60 % of melanomas turning metastatic leading to poor prognosis and 
reduced overall patient survival (Nussbaum et al. 1996). Migration and invasion capacity of 
B16-F10, A375 and WM266-4 melanoma cells has been targeted to achieve a therapeutic 
strategy for metastatic melanoma using a potential natural anti-cancer compound, α-
mangostin (xanthone derived from Garcinia mangostana) (Beninati et al. 2014).  In the 
current study, all the three forms of bLf were able to reduce the migratory potential of SK-
MEL-2 cells whereas Fe-bLf 20 nM was most effective in reducing the invasive capacity of 
SK-MEL-2 cells. In SK-MEL-28 cells, both Apo-bLf and Fe-bLf effectively reduced the 
migratory potential whereas Apo-bLf was most significant (p≤ 0.001) in targeting the 
invasive potential of the cells. These results are also in accordance with previously published 
studies where it has been reported that oral administration of bLf demonstrated significant 
inhibition of lung metastasis in an allograft mice colon cancer model (Tsuda et al. 2000). 
However, the migration and invasion potential of cells differ from one another. Further 
studies conducted on time dependant effect of Fe-bLf on the invasion potential of SK-MEL-
28 cells would provide a better insight. Therefore, it was concluded from these results that 
Apo-bLf showed that maximum potential of inhibiting the invasion potential of SK-MEL-28 
cells. 
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Melanogenesis is the process of melanin pigment formation. Presence of melanin pigment 
in the skin cells forms a protective barrier when the skin is exposed to UV radiation reducing 
skin damage and occurrence of melanomas (Brenner & Hearing 2008) (Tong et al. 1987). 
Effect of milk derived proteins on melanin expression has been reported earlier where; milk 
derived protein such as β-lactoglobulin (BLG) has shown to possess a depigmenting effect 
(Solano et al. 2006). Other milk derived proteins such as k-casein have also been reported to 
suppress melanogenesis in B16F10 cells (Nakajima et al. 1997). Melanin pigment on the 
other hand is highly important for skin cells and has been reported to protect skin cells from 
UV-induced skin cancer and DNA damage (Brenner & Hearing 2008). Therefore, to further 
elucidate the effects of bLf in causing cell death in melanoma cell lines, the effect of bLf 
forms on melanin pigment content in SK-MEL-2 and SK-MEL-28 cells was investigated.  SK-
MEL-2 cells showed an upregulation in the melanin content of the cells with Native-bLf and 
Apo-bLf treatments. On the other hand, in SK-MEL-28 cells, Native-bLf, Apo-bLf and Fe-bLf 
at 40 nM concentration showed very little upregulation of the melanin content which needs 
to be further investigated for longer treatment times. This indicates a novel direction by 
which bLf can act as a melanin-targeting agent to sensitize melanomas to apoptosis 
whereas, other milk proteins don’t have this ability and therefore this provides bLf an upper 
hand over other milk derived proteins. Production of melanin pigment in the melanocytes 
leads to the formation of stage IV melanosomes that contain more melanin pigment. Stage 
IV melanosomes have weaker membranes when compared to stage II and stage III 
melanosomes, making the cells more susceptible to therapy with cisplatin (Chen et al. 
2009b). On the other hand, it has also been reported that low concentrations of Native-bLf 
(0.4-0.5 mg/mL) leads to lowering of the melanin expression in B16 cells (Nakajima et al. 
1997). 
Although, Apo-bLf and Fe-bLf were comparatively more effective towards one of the two 
types of cell lines studied, the role of Native-bLf as an anti-cancer agent in SK-MEL-2 and SK-
MEL-28 is worth mentioning as Native-bLf also proved effective against both melanoma cell 
lines tested. Native-bLf effectively downregulated the cell proliferative ability and 
upregulated cytoxicity in both SK-MEL-2 and SK-MEL-28 cell line when compared to Apo-bLf 
that was effective only in SK-MEL-28 and Fe-bLf that was able to downregulate cell 
proliferation in SK-MEL-2 cells only. Native-bLf was most effective in reducing the clonogenic 
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potential of SK-MEL-2 and SK-MEL-28 cells. Maximum release of caspase-3 was noted with 
Native-bLf treatment in SK-MEL-2 and it was most significant (p≤ 0.001) in causing apoptosis 
via upregulation of phospho-p53, Bax, TRAIL and Fas. The effect of Native-bLf in being able 
to function as an anti-cancer molecule could be due to its iron-saturation status (19 %). It 
has already been discussed that the presence of iron helps bLf in becoming a potential anti-
cancer agent.  
In order to summarise the findings from this study, we conducted a comparative analysis of 
the results obtained from the in vitro cell culture assays in both SK-MEL-2 and SK-MEL-28 
cell lines, with all the three forms of bLf (Native-bLf, Apo-bLf and Fe-bLf) (Table 3.2). Figure 
3.17 (A & B) concludes the possible mechanism(s) of action of bLf in SK-MEL-2 and SK-MEL-
28 cells.  
 




Figure 3.17 (A & B). Possible mechanism of action of bLf in SK-MEL-2 and SK-MEL-28 cells. 
This schematic is developed on the basis of the findings of the present study. Native-bLf, 
Apo-bLf and Fe-bLf enter the melanoma cell lines tested by receptor mediated 
internalisation. Upregulation of TRAIL, FADD and Fas was noted with Apo-bLf and Fe-bLf in 
SK-MEL-28 and SK-MEL-2, respectively. Upregulation of pro-apoptotic markers such as Bax, 
phospho-p53 and caspase-3 was noted and downregulation of Bcl-2 and survivin 
contributed to the induction of apoptosis in melanoma cell lines tested.  
3.7 CONCLUSIONS 
Bovine lactoferrin is a naturally occurring anti-cancer agent that has been used as a 
therapeutic regimen for a number of cancer studies conducted preclinically and clinically 
with colon cancer, Lewis lung carcinoma, mouse melanomas and lymphoma models. 
Different forms of bLf based on their iron content differed in their activities and anti-cancer 
efficacies that may be mainly due to difference in their iron saturation and structural 
conformation. As mentioned in section 1.5.2, there is a structural difference between the 
iron-containing and iron-free forms of bLf. Studies have shown that bLf has conformational 
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flexibility and that during its interactions with a range of cells and biomacromolecules 
(proteins, DNA) it oligomerises. Recently a study from our lab has also reported anti-cancer 
activity of high molecular weight-bLf oligomer. Therefore is could be a possibility that due to 
the structural conformation of iron-free and iron-containing forms (partially and fully 
saturated) may interact differentially with its receptors and the key regulatory 
proteins/genes involved in cell proliferation and cell death pathways. Secondly, the iron 
regulatory miRNA also play a role in its differential activities (Samarasinghe, Kanwar & 
Kanwar 2014). Cellular iron metabolism is regulated at the molecular level by several micro 
RNA’s such as miR-let7d, miR-584 etc. Several of these iron regulatory micro RNA are 
controlled by transcriptional regulation of the tumour suppressor protein p53, hence the 
iron metabolism of cells is in turn dependent on its p53 status. The variation in the 
mutational status of p53 in SK-MEL-2 and SK-MEL-28 might be the key reason as to why the 
iron metabolism status differs in these two cell lines hence allowing the action of iron-free 
and iron-saturated forms in differential ways. Also the differential regulation of gene 
expression of Lf receptors results in varied levels of their cellular internalisation which might 
cause an effect in their anti-cancer activity. In this study the use of specific bLf forms has 
shown a direct correlation with their upregulation of specific receptors that are involved in 
lactoferrin internalisation. The difference between the effects of Apo-bLf and Fe-bLf in the 
two cell lines, SK-MEL-2 and SK-MEL-28 was most likely due to the varying p53 mutational 
status of the cell lines and the iron saturation of the bLf forms. To further validate this, 
miRNA that could be involved in Fe metabolism pathways needs to be investigated which 
was presently beyond the scope of this project. bLf enhances the melanin expression in SK-
MEL-2 and SK-MEL-28 that helps in rendering the cell lines susceptible to chemotherapy. 
This IAP family survivin plays a central role in cell proliferation, drug-resistance and 
inhibition of apoptosis, and this protein was downregulated by Fe-bLf in SK-MEL-2 and Apo-
bLf in SK-MEL-28. Interestingly, a partial or complete reversal of wild-type p53 activity in the 
SK-MEL-28 cells was also observed. The three forms bLf forms showed significant decreases 
in the proliferative and metastatic potential of SK-MEL-28 and SK-MEL-2 cells which has 
never been reported and therefore is the most important aspect for the future of skin 
cancer therapy. This study clearly demonstrated the varied effects of iron-saturated and the 
iron-free forms of bLf on p53-mutant melanoma cell lines.
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Oncogenic mutations and accumulation of such mutations are one of the key mechanisms 
through which cancer arises. Oncogenic mutations are very rare mutations that induce 
excessive cell growth and division. The genes which undergo such mutations are generally 
referred to as oncogenes (Sharma et al. 2007). A number of melanomas become drug-
resistant due to oncogenic mutations in genes  whose encoded protein molecules are 
involved in various essential pathways, such as the mitogen-activated protein kinase (MAPK) 
pathway, that involves the proteins, rat sarcoma (RAS)/ rapidly accelerated fibrosarcoma 
(RAF)/ MAPK (also known as MEK)/ extracellular signal-regulated kinase (ERK) which play a 
critical role in regulating the growth of cutaneous melanomas (Lee, Choi & Kim 2011). 
Mutations in the RAS-RAF-MAPK pathway are shown to be activated during the early 
melanoma developmental stages, and have been reported to be preserved throughout the 
tumour progression (Omholt et al. 2003).  
RAS mutations are the most common oncogenic mutations, as they are observed in 15 % of 
all human cancers and, are also commonly associated with melanomas. KRAS, NRAS and 
HRAS genes play important roles in the regulation of RAS-regulated kinases that mediate cell 
growth and activation of malignant transformation kinase pathway and, a mutation in any 
of these RAS genes including BRAF and NRAS contribute to the development of oncogenesis 
in melanoma (Brose et al. 2002).  
All melanomas harbor two types of mutations namely, driver mutations (primary mutations) 
that are also termed as causative mutations and bystander mutations called as passenger 
mutations. Driver mutations in melanoma include mutations in subtypes including BRAF, 
NRAS, cluster of differentiation 117 (CD177), guanine nucleotide-binding protein G (q) 
subunit alpha (GNAQ) and guanine nucleotide-binding protein subunit alpha-11 (GNA11). In 
melanoma, the two most important molecular subtypes of mutations are BRAF and NRAS. 
As described in Chapter 1, BRAF mutations are the most common oncogenic RAF mutation 
observed in melanomas. BRAF belongs to RAF kinases and the gene is officially known as “B-
Raf proto-oncogene, serine/threonine kinase”, which is part of a signaling pathway known as 
the RAS/MAPK pathway. The MAPK is a signal transduction pathway responsible for 
transmitting mitogenic signals from the cell surface growth factor receptors in normal 
physiological conditions (Bamford, Dawson & Forbes 2004). It was reported that 41 out of 
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60 cases of melanoma metastases, showed BRAF, V599E mutations that helped in the 
initiation of tumour metastases and proliferation (Pollock et al. 2002).  
A number of BRAF inhibitors have been developed to target the above-mentioned BRAF 
mutations in melanoma. The U.S. Food and Drug Administration (FDA), approved 
vemurafenib as an inhibitor for BRAF mutant melanomas in 2011 (Bollag et al. 2012). 
Intermittent inhibition of BRAF by vemurafenib works better than continuous therapy when 
checked in genetically engineered mouse model of BRAF mutant melanomas (Thakur et al. 
2013). Other inhibitor, named dabrafenib was also approved in 2013 which when employed 
in phase II trials showed clinical responses in 59 % of patients with V600E/K mutation. Seven 
percent of these patients responded to the treatment completely (Ascierto et al. 2013a). 
Newer inhibitors like LGX818 are now in the early stages of trial.  
Treatment of BRAF mutations with vemurafenib is associated with paradoxical activation of 
the ERK1/2 pathways in cells that have wild-type BRAF status. Secondary treatment 
strategies to counteract these side-effects of vemurafenib for example targeting the ERK1/2 
pathway are being developed. PLX7904, a new BRAF inhibitor is able to target the ERK1/2 
pathway without leading to activation of BRAF in the cells that have wild-type BRAF gene (Le 
et al. 2013).  
A number of clinical trials have explored the use of MEK inhibitors that are downstream 
regulators helping BRAF mutant melanomas acquire resistance to chemotherapy. Phase I 
clinical trials with tratmetinib, a small molecule inhibitor showed that out of 36 patients 
with BRAF mutant melanoma, two complete response and ten partial responses were 
confirmed yielding a success rate of 33 % overall (Falchook et al. 2012a). Randomized phase 
III trials comparing tratmetinib with chemotherapeutics showed an increase in both 
progression free survival (PFS) and overall survival with the tratmetinib treatment (Flaherty 
et al. 2012). Combinatorial treatment using selumetinib with dacarbazine (DTIC) used in 
phase II randomized double-blind study showed improved PFS (Robert et al. 2013). Four 
phase III trials of combinatorial treatments of BRAF inhibitors with chemotherapeutics are 
now being explored (NCT01689519, NCT01597908, NCT01682083, NCT01682083).  
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Extensive research has been focussed on BRAF V600 mutations, however, a number of other 
mutations such as BRAF G469E, G466A and N581S have not been targeted specifically in 
clinical trials posing a need for therapeutic strategies for other BRAF mutant melanomas.  
The other most common mutation that occurs in melanoma is the NRAS mutation which 
accounts for 20 % of all mutations in melanoma. NRAS and BRAF mutations are almost 
mutually exclusive (Colombino et al. 2012). Targeting NRAS mutations has not been 
successful paving a way for combination treatments for downstream effectors of NRAS, for 
example, MEK, PI3K/mTOR and cell-cycle related targets (Posch et al. 2013). Monotherapy 
with MEK inhibitor MEK162 showed limited-partial response of 20 % and is the most active 
monotherapy that has been evaluated for NRAS and BRAF mutant melanomas (Ascierto et 
al. 2013b). GDC-0623, a new class of inhibitor that downregulates the activation of MEK due 
to RAS mutations is currently in phase I clinical trial and may prove efficient in targeting 
NRAS mutant melanomas (Hatzivassiliou et al. 2013). Cyclin-dependent kinase 4 (CDK4) has 
been pointed as an important molecule that causes activation of MEK and therapeutics have 
involved the use of pharmacological inhibition of MEK and CDK4 with its respective 
inhibitors, MEK162 and LEE011 in clinical phase I/II trials (NCT01781572).  
In BRAFV600E, BRAFG469E, BRAF D594G mutations it was observed that apoptosis is 
dysregulated by upregulation of Bcl-2 and inhibited phosphorylation of Bad. The same study 
also reported that use of BRAF inhibitors suppressed Bcl-2 expression leading to apoptosis 
(Smalley et al. 2008). Inhibition of TRAIL mediated apoptosis in melanoma is one of the most 
common properties seen in drug-resistant melanomas. In melanomas it was noted that 
reduced expression of TRAIL-R1 and TRAIL-R2 was due to which TRAIL mediate apoptosis 
was inhibited (Zhang et al. 1999). Upregulation of Bcl-2 as an oncogene and suppression of 
anti-apoptotic protein p53 have also been linked with drug resistance in melanomas 
(Johnstone, Ruefli & Lowe 2002; Soengas et al. 1999). Both intrinsic pathways and extrinsic 
pathways of apoptosis are involved in causing drug resistance in melanoma cells (Ashkenazi 
& Dixit 1998; Green & Reed 1998). Intrinsic pathway of apoptosis involves the mitochondrial 
pathway and involves molecules like cytochrome-c, Apaf-1 and caspase-3, 6 and 7 (Green & 
Kroemer 1998; Wang & Becker 1997). The extrinsic pathway which is also called as the 
death receptor pathway is also implicated in causing drug resistance towards cancer 
chemotherapy (Fulda et al. 2001). Both these pathways are equally important and can be 
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studied. It has been reported earlier that p53 expression is involved in induction of both 
intrinsic and extrinsic apoptotic pathways in melanoma (Haupt et al. 2003; Seitz et al. 2010). 
Therefore, p53 is a very important molecule and effect of current therapeutics against 
melanoma on p53 must be validated. 
Mouse double-minute 2 (MDM2) is an ubiquitin ligase that is responsible for the regulation 
of p53 expression, which in turn effects p53 activity. MDM2 targets p53 to the proteasome 
for degradation (Toledo & Wahl 2006). Therefore, MDM2 keeps p53 protein levels balanced 
in normal and unstressed cells, which if not controlled might  lead to cell cycle arrest and 
death even in the absence of any stress or damage to the cells (Ringshausen et al. 2006). 
MDM4 also known as MDMX is another regulator of p53 which inhibits p53 by direct 
interaction as it cannot mediate ubiquitination (Shvarts et al. 1996). Inhibition of p53 
expression by MDM2 activates the NOTCH signalling pathway which is essential for cell 
proliferation (Wade, Wang & Wahl 2010). However, the body has a homeostatic mechanism 
to control the NOTCH pathway through a protein called as Numb. Numb is an inhibitor of 
MDM2. It binds to the p53-MDM2 complex, inducing inhibition of MDM2 and an increase in 
p53 thereby antagonizing the NOTCH signalling pathway (Brooks & Gu 2006; Carter & 
Vousden 2008). Therefore, it is highly important to study the effect of all potential 
melanoma therapeutics on these regulatory molecules. 
Although extensive research on formulating therapeutics for BRAF/NRAS mutant, drug-
resistant and metastatic melanomas has been conducted, a number of side-effects limit the 
role of these therapeutic regimens. For example, BRAF inhibitors like vemurafenib lead to 
increase in progression-free survival (PFS) but are associated with numerous adverse skin 
reactions such as verrucous papilloma and hand-foot skin reaction as the two major 
cutaneous side-effects. Other side-effects such as photosensitivity, alopecia, epidermoid 
cysts, hyperkeratotic perifollicular rash and eruptive nevi were also associated with the use 
of BRAF mutant inhibitors (Boussemart et al. 2013). Dacarbazine, the only drug approved by 
the FDA for metastatic melanomas is also associated with sporadic myelosuppression, 
nausea, acute diarrhea, vomiting, headache, flu-like symptoms, and hypersensitivity 
reaction to sunlight (Buesa et al. 1984). Effective treatment of drug-resistant cancers 
through chemotherapy requires very high doses of drugs causing toxicity issues (Chabner & 
Roberts 2005). This in turn provides an upper hand to naturally derived cancer therapeutics 
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that have shown promising anti-cancer efficacy. The role of bLf in causing apoptosis in cell 
lines with varying p53 status was established in the earlier phase of this study as described 
in Chapter 3. The effect of bLf on melanoma cells with BRAF and NRAS mutations and drug-
resistant melanoma cells would therefore provide, much needed information for using bLf 
as a natural molecule for treating melanomas irrespective of their mutational and their 
drug-resistant status. This chapter focusses on providing a new dimension to using bLf for 
treating melanomas.  
The panel of cell lines that were employed in this study were received from “Ludwig 
Institute of Cancer Research” and were well-established for their BRAF and NRAS status 
(Behren et al. 2013), and a well-established cisplatin drug-resistant cell line Mel-007 that 
was kindly donated by Professor Peter Hersey, University of Sydney (Zhang et al. 2004). The 
importance of BRAF and NRAS mutations has been highlighted in Chapter 1. Role of bLf on 
BRAF and NRAS mutant melanoma cell lines has never been reported earlier making this, 
the first-of-its kind study to evaluate the potential role of bLf in inducing apoptosis in BRAF 
and NRAS mutant patient-derived primary melanoma cell lines. Studying the effects of bLf 
on cisplatin drug-resistant Mel-007 (DR) cell line would help in investigating the pathway of 
apoptosis and the mechanism of action of bLf in drug-resistant cancer cells.  
4.2 HYPOTHESIS 
All three forms of bLf samples will successfully be able to internalise in melanoma cells 
irrespective of their BRAF and NRAS mutational status and will also be able to internalise 
into drug-resistant Mel-007 (DR). Native-bLf, Apo-bLf and Fe-bLf will be able to reduce the 
tumour spheroid forming ability, migration capacity of melanoma cells. p53 dependent 
apoptosis may be upregulated and enhanced when melanoma cells are treated with bLf.  
4.3 AIMS 
 Study the modulation of Lf receptor expression with bLf treatments. 
 To study cellular internalisation of Native-bLf, Apo-bLf and Fe-bLf in melanoma cells 
with varying BRAF and NRAS mutations and drug-resistant cells. 
 To investigate the cytotoxic effects of bLf on 2D and 3D models of LM-MEL-1a (NRAS 
Q16K mutant, BRAF wild-type), LM-MEL-12 (wild-type BRAF and NRAS), LM-MEL-24 
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(BRAF V600K mutant, NRAS wild-type), LM-MEL-62 (BRAF G469E mutant, NRAS wild 
type) and Mel-007 (cisplatin drug-resistant). 
 To study the apoptosis induced by bLf and confirm p53-dependent pathway of 
apoptosis in cell lines varying in their mutational and drug-resistant status.  
4.4 MATERIALS AND METHODS 
A detailed description of the materials and methods used has been provided in Chapter 2. 
 
4.5 RESULTS 
4.5.1 Receptor-mediated internalisation of Native-bLf, Apo-bLf and Fe-bLf in LM-MEL-12 
(WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-24 
(BRAF V600K) and Mel-007 (DR) cell lines 
 The presence of various Lf receptors, as studied in Chapter 3, section 3.5.1, was 
investigated similarly by real time PCR studies. Cells were plated in 6 well plates, once 
confluent the cells were treated with 20 nM concentrations of bLf and RNA extraction was 
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performed using TRIzol RNA extraction reagent. RNA was then converted into cDNA which 
was used for real time PCR studies. Various Lf receptors known to involve in Lf 
internalisation, like TfR, TfR1, TfR2, LfR, LfR1, LfR2, LRP-1 and LRP-2, were studied for their 
gene expression patterns, when the cells were treated with Native-bLf, Apo-bLf and Fe-bLf. 
Interestingly, each cell line showed a different receptor expression pattern (Figure 4.1 A-E), 
with the expression levels of certain receptors were found to be significantly upregulated or 
downregulated following bLf treatments.   
Real time PCR data indicated that, in case of LM-MEL-12 (WT BRAF and NRAS) (Figure 4.1 A), 
Native-bLf led to a significant upregulation (p≤ 0.01) in TfR1 and LRP-1, while Apo-bLf 
significantly upregulated the expression of TfR1 (p≤ 0.01), TfR2 (p< 0.05) and LfR (p< 0.05). 
Fe-bLf led to the significant upregulation of (p≤ 0.01) in TfR1, LfR and (p< 0.05) LRP-2. In 
summary, while the gene expression levels of TfR were significantly downregulated by all 
the three forms of bLf, TfR1 expression was found to be upregulated by all the three bLf 
forms in LM-MEL-12 (WT BRAF and NRAS).  
Native-bLf failed to upregulate any receptor in LM-MEL-1a (NRAS Q16K) cells (Figure 4.1 B), 
Apo-bLf significantly upregulated (p≤ 0.01) the expression of LfR and Fe-bLf also significantly 
upregulated (p≤ 0.001) the expression of LfR and (p< 0.05) LRP-2. No specific trend was 
observed in these cells like LM-MEL-12 (WT BRAF and NRAS), except that all the three forms 
of bLf significantly downregulated TfR expression levels, however, it was noted that both 
Apo-bLf and Fe-bLf upregulated expression of LfR in LM-MEL-1a (NRAS Q16K) cells.  
In LM-MEL-62 (BRAF G469E) cells, (Figure 4.1 C) the three forms significantly downregulated 
LRP-1 and LRP-2 receptors expression, and significantly induced upregulation (p< 0.05) of 
LfR with all the three forms of bLf. While treatment with Fe-bLf caused significant 
upregulation (p< 0.05) of TfR and TfR2 expression it significantly caused downregulation of 
LfR1 (p≤ 0.01) and LfR2 (p< 0.05). It was concluded that all the three forms of bLf 
upregulated LfR expression in LM-MEL-62 (BRAF G469E) cells. Interestingly, all the three 
forms of bLf Native-bLf, Apo-bLf and Fe-bLf caused significant downregulation of TfR (p≤ 
0.01) and LfR1 (p≤ 0.01). Native-bLf caused downregulation of TfR1 (p≤ 0.01). 
In case of LM-MEL-24 (BRAF V600K) cells (Figure 4.1 D), the gene expression of LRP-1 alone 
was upregulated significantly (p< 0.05) with Native-bLf treatment, whereas, Apo-bLf 
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significantly upregulated (p≤ 0.01) TfR1, LfR-2 and (p< 0.05) LfR mRNA expression. Fe-bLf 
significantly upregulated (p< 0.05) the expression of LfR-2 and LRP-1. Significant 
downregulation (p≤ 0.01) of TfR and LfR1 was observed with all the three forms of bLf in 
LM-MEL-24 (BRAF V600K) cells. TfR2 expression was downregulated (p≤ 0.01) with Apo-bLf 
and Fe-bLf treatments, whereas; Native-bLf did not cause significant downregulation of TfR2 
in LM-MEL-24 (BRAF V600K) cells. Fe-bLf alone led to the downregulation of LfR (p≤ 0.01). 
In the cisplatin-resistant Mel-007 (DR) cells (Figure 4.1 E), Native-bLf also caused an 
upregulation (p< 0.05) of LfR-2 and LRP-2. A significant upregulation (p< 0.05) was observed 
in TfR, TfR1 and (p≤ 0.01) in LfR, LRP-2 with treatments of Apo-bLf. Fe-bLf treatments also 
significantly increased (p< 0.05), LfR2, LRP-1, LRP-2 and (p≤ 0.01) TfR and LfR. Therefore, it 
was observed that Apo-bLf and Fe-bLf upregulated TfR, TfR1, LfR and LRP-2. Native-bLf and 
Fe-bLf treatments led to an increase in LfR-2 in Mel-007 (DR) cells. Interestingly, here only 
TfR2 expression was observed to be significantly downregulated with Apo-bLf (p≤ 0.01) and 
Fe-bLf (p< 0.05).  
A tabular representation (Table 4.1) of the modulation of the various Lf receptors in the five 
melanoma cell lines was represented to clearly indicate and identify the receptor expression 
patterns with respect to both the cell lines and the bLf treatments.  




Figure 4.1 (A). Real time gene expression patterns of Lf receptors in LM-MEL-12 (WT BRAF 
and NRAS). The mRNA expression of Lf receptors in 48 h bLf treated, LM-MEL-12 (WT BRAF 
and NRAS) was analysed by real time quantitative reverse transcriptase PCR (qRT-PCR). One 
µg of RNA was converted to cDNA. 100 ng of cDNA, specific primers and RT2 SYBR Green 
qPCR Mastermix was used for analysis. Treatments were done in duplicates and the 
experiment was performed twice. Values are represented as fold change with GAPDH as the 
house-keeping gene using Livak’s method. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** was 
considered statistically significant when compared to untreated cells.   




Figure 4.1 (B). Upregulation of lactoferrin receptors in LM-MEL-1a (NRAS Q16K). 
Treatments in LM-MEL-1a (NRAS Q16K) with 20 nM concentration of Native-bLf, Apo-bLf 
and Fe-bLf were done to study the mRNA expression of Lf receptors by qRT-PCR. SYBR 
Green Mastermix was used for analysis with 100 ng of cDNA and specific primers. 
Treatments were done in duplicates and experiment was performed twice. Fold change of 
the receptors was calculated using Livak’s method and presented. GAPDH was used as the 
house-keeping control. Student’s t test was performed to evaluate statistical significance. A 
value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered 
statistically significant when compared to untreated cells.   




Figure 4.1 (C). Presence of Lf receptors on LM-MEL-62 (BRAF G469E). mRNA expression 
analysis of Lf receptors was performed in 20 nM bLf treated cells. Reaction mixture 
containing 100 ng of cDNA, SYBR Green Mastermix and specific primers were used, to 
perform qRT-PCR. Fold change in the receptor expression of treated cells when compared to 
untreated cells was plotted using GAPDH as the house-keeping gene. Treatments were done 
in duplicates and the experiment was repeated twice. Student’s t test was performed to 
evaluate statistical significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** 
was considered statistically significant when compared to untreated cells.   
 




Figure 4.1 (D). Upregulation of Lf receptors in LM-MEL-24 (BRAF V600K) with bLf.  Cells 
treated with 20 nM concentration of Native-bLf, Apo-bLf and Fe-bLf for 48 h were analysed 
for its Lf receptor expression patterns using qRT-PCR. The relative fold change in the Lf 
receptor expression between the untreated and the treated cells was plotted using GAPDH 
as the house-keeping gene. Treatments were done in duplicates and the experiment was 
performed twice. Student’s t test was performed to evaluate statistical significance. A value 
of (p< 0.05) represented as * and (p≤ 0.01) as ** was considered statistically significant 
when compared to untreated cells.   
 




Figure 4.1 (E). Expression of Lf receptors with bLf in Mel-007 (DR). Drug-resistant cell line 
Mel-007 (DR), treated with 20 nM concentration of Native-bLf, Apo-bLf and Fe-bLf for 48 h 
was investigated for its Lf receptor mRNA expression. cDNA, SYBR Green Mastermix and 
specific primers were used for qRT-PCR analysis. Relative fold change in the Lf receptors 
between untreated and bLf treated cells was calculated by Livak’s method. The fold change 
was plotted and GAPDH was used as the house-keeping control. Each treatment was done 
twice and the experiment was conducted twice. Student’s t test was performed to evaluate 
statistical significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** was 
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Table 4.1. Comparative gene expression analysis of various Lf receptors with bLf 
treatments. 
 
Where, ↑= Non-significant increase, ↓ = Non-significant decrease, ↑*= Significant 
decrease (p< 0.05), ↑**= Significant decrease (p≤ 0.01), ↑***= Significant decrease (p≤ 
0.001), --- = No change.  
4.5.2 All three forms of bLf successfully internalise in melanoma cell lines tested for bLf 
internalisation 
To establish that bLf was capable of internalising into drug-resistant cells and cell lines with 
BRAF and NRAS mutations, its internalisation efficacy was tested using the LM-MEL-12 (WT 
BRAF and NRAS), LM-MEL-1a (NRAS Q16K), , LM-MEL-62 (BRAF G469E) , LM-MEL-24 (BRAF 
V600K) and Mel-007 (DR) cell lines using immunofluorescence (IF) staining. Cells were plated 
in 8 well slides, and treated with 20 nM of all three forms of bLf samples in a time-
dependent manner. After treatment, the cells were fixed and stained with primary antibody 
specific to bLf which was then tagged using FITC labelled secondary anti -goat IgG antibody. 
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Green fluorescence was visualised using confocal microscopy to check for bLf 
internalisation. The internalisation pattern of bLf remained the same in most of the cell lines 
but a few interesting observations from this study are mentioned.  
In LM-MEL-12 (WT BRAF and NRAS) cells (Figure 4.2 A), a time-dependent increase in the 
uptake of Native-bLf was observed with maximum internalisation at 6h. More actin 
cytoskeleton (red fluorescence) was observed until 4 h due to lesser uptake of Native-bLf. 
Apo-bLf was also found to internalise in a time-dependent fashion in LM-MEL-12 (WT BRAF 
and NRAS) (Figure 4.2 B). A clear localisation of Apo-bLf could be seen on the membrane of 
the cells until 4 h, while, Apo-bLf also internalised in the nucleus after 6h. The maximum 
internalisation of Fe-bLf was at 6 h (Figure 4.2 C). Fe-bLf was also present on the cell 
membrane, however, no nuclear internalisation of Fe-bLf was observed in LM-MEL-12 (WT 
BRAF and NRAS) cells.  
A high cellular uptake of Native-bLf was observed in LM-MEL-1a (NRAS Q16K) cells in 30 min 
(Figure 4.2 D). Clear membrane localisation of Native-bLf was seen at 30 min while an 
increase in nuclear localisation was observed at 2 h, 4 h and 6 h. It was observed that 
Native-bLf was mainly present on the cell membrane until 4 h. A time-dependent increase in 
the internalisation of Apo-bLf was observed in LM-MEL-1a (NRAS Q16K) (Figure 4.2 E). 
However, an increase in nuclear internalisation of Apo-bLf was observed at 6 h. Fe-bLf also 
showed a time-dependent uptake in LM-MEL-1a (NRAS Q16K) cells (Figure 4.2 F). A time-
dependent increase in the nuclear internalisation of Fe-bLf was also observed from 30 min 
to 6 h.  
A time-dependent increase in Native-bLf was seen in LM-MEL-62 (BRAF G469E) cells (Figure 
4.2 G). An increase in the membrane localisation of Native-bLf was observed from 30 min to 
4 h whereas; at 6 h Native-bLf was found to be present in the nucleus of the cells. Time-
dependent internalisation of Apo-bLf (Figure 4.2 H) was observed. Apo-bLf was mainly 
localised on the cell membrane and very few cells showed nuclear internalisation of Apo-
bLf. An increase in the immunoreactivity of Fe-bLf with increase in treatment time indicated 
a time-dependent internalisation (Figure 4.2 I). Fe-bLf was highly localised in both, the cell 
membrane and the nucleus.  
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In LM-MEL-24 (BRAF V600K) cells it was observed that Native-bLf (Figure 4.2 J) showed 
effective internalisation within 30 min. However, no increase in the internalisation efficiency 
was noted upto 4 h. At 6 h, an increase in the immunoreactivity of Native-bLf was observed. 
Comparatively lower uptake of Apo-bLf was seen at all-time intervals (Figure 4.2 K) and the 
localisation was limited to the cell membrane (no nuclear localisation was observed). Higher 
uptake of Fe-bLf was observed in LM-MEL-24 (BRAF V600K) at 30 min (Figure 4.2 L). Fe-bLf 
was found to be present in both the cell membrane and the nucleus.  
Effective internalisation of Native-bLf was observed within 30 min in Mel-007 (DR) (Figure 
4.2 M). Both membrane and nuclear localisation was observed. Apo-bLf was able to 
internalise into the nucleus of Mel-007 (DR) within 30 min and the effect remained the same 
until 6 h (Figure 4.2 N). A similar observation with Fe-bLf was seen, where all the cells 
showed positive immunoreactivity for Fe-bLf within 30 min (Figure 4.2 O), a high 
internalisation in the nucleus was observed in majority of the cells.  




Figure 4.2 (A). Cellular internalisation of Native-bLf in LM-MEL-12 (WT BRAF and NRAS). 
Cells were grown in 8 well chamber slides and were treated with Native-bLf at 20 nM for 30 
min, 2 h, 4 h and 6 h. Cells were then fixed with 4 % PF for 20 min, permeabilized using 0.1 
% Triton-X100 on ice for 2 min. Cells were blocked with non-animal protein (NAP) blocker 
for 1 h at 370C. Cells were then probed with goat anti-bLf (1:100) primary antibody for 1 h at 
370C following which they were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was 
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used with mounting media and cells were visualised for bLf internalisation using Leica SP5 
confocal microscopy. Images were processed through LAS-AF version of the software and 
representative images were shown. 
 
Figure 4.2 (B). Cellular internalisation of Apo-bLf in LM-MEL-12 (WT BRAF and NRAS). 
Treatment of LM-MEL-12 (WT BRAF and NRAS) with 20 nM concentration of Apo-bLf was 
done to study the internalisation efficacy of Apo-bLf in a time-dependent manner. Cells 
were fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-X100 on ice for 2 min. 
Cells were blocked with NAP blocker for 1 h at 370C. Cells were then probed with goat anti-
bLf (1:100) primary antibody for 1 h at 370C following which they were tagged for bLf with 
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anti-goat IgG FITC (1:100). DAPI was used with mounting media and cells were visualised for 
bLf internalisation using Leica SP5 confocal microscopy. Images were processed through 
LAS-AF version of the software and representative images were shown. The control 
untreated cells image panel was shown in 4.2 (A). 
 
Figure 4.2 (C). Cellular internalisation of Fe-bLf in LM-MEL-12 (WT BRAF and NRAS). Fe-bLf 
treated LM-MEL-12 (WT BRAF and NRAS) cells at 30 min. 2 h, 4 h and 6 h were tested for 
internalisation of bLf. Cells were fixed with 4 % PF, following which they were permeabilized 
and blocked using NAP blocker. Cells were then probed with goat anti-bLf (1:100) primary 
antibody for 1 h at 370C following which they were tagged for bLf with anti-goat IgG FITC 
(1:100). Mounting media containing DAPI was used to visualise the internalisation patterns 
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of bLf, using Leica SP5 confocal microscopy. Images were processed through LAS-AF version 
of the software and representative images were shown. The control untreated cells image 
panel was shown in 4.2 (A). 
 
Figure 4.2 (D). Cellular internalisation of Native-bLf in LM-MEL-1a (NRAS Q16K). Cells were 
grown in 8 well chamber slides and were treated with Native-bLf at 20 nM for 30 min, 2 h, 4 
h and 6 h. Cells were then fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-
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X100 on ice for 2 min. Cells were blocked with NAP blocker for 1 h at 370C. Cells were then 
probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C following which they 
were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used with mounting media 
and cells were visualised for bLf internalisation using Leica SP5 confocal microscopy. Images 
were processed through LAS-AF version of the software and representative images were 
shown. 
 
Figure 4.2 (E). Cellular internalisation of Apo-bLf in LM-MEL-1a (NRAS Q16K). Apo-bLf 
treatments at 20 nM were done for 30 min, 2 h, 4 h and 6 h to study the internalisation 
efficacy of Apo-bLf. Following treatments, the cells were fixed with 4 % PF for 20 min after 
which they were permeabilized for 2 min on ice. Cells were blocked with NAP blocker for 1 h 
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at 37oC.  Cells were then probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C 
following which they were tagged for bLf with anti-goat IgG FITC (1:100). DAPI with 
mounting media was used and cells were visualised for bLf internalisation using Leica SP5 
confocal microscopy. Images were processed through LAS-AF version of the software and 
representative images were shown. The control untreated cells image panel was shown in 
4.2 (D). 
 
Figure 4.2 (F). Cellular internalisation of Fe-bLf in LM-MEL-1a (NRAS Q16K). Fe-bLf treated 
LM-MEL-1a (NRAS Q16K) cells at 30 min, 2 h, 4 h and 6 h were tested for internalisation of 
bLf. Cells were fixed with 4 % PF, following which they were permeabilized and blocked 
using NAP blocker. Cells were then probed with goat anti-bLf (1:100) primary antibody for 1 
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h at 370C following which they were tagged for bLf with anti-goat IgG FITC (1:100). Mounting 
media containing DAPI was used to visualise bLf internalisation using Leica SP5 confocal 
microscopy. Images were processed through LAS-AF version of the software and 
representative images were shown. The control untreated cells image panel was shown in 
4.2 (D). 
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Figure 4.2 (G). Cellular internalisation of Native-bLf in LM-MEL-62 (BRAF G469E). Twenty 
nM of Native-bLf was used to treat the cells for 30 min, 2 h, 4 h and 6 h to study time-
dependent internalisation of Native-bLf. The treated cells were fixed using 4 % PF for 20 min 
and then permeabilized using 0.1 % Triton-X 100 for 2 min on ice. The non-specific antigens 
were blocked using NAP blocker for 1 h at 37oC. Cells were then probed with goat anti-bLf 
(1:100) primary antibody for 1 h at 370C following which they were tagged for bLf with anti-
goat IgG FITC (1:100). DAPI with mounting media was used for nuclear staining and cells 
were visualised for bLf internalisation using Leica SP5 confocal microscopy. Images were 
processed through LAS-AF version of the software and representative images were shown. 
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Figure 4.2 (H). Cellular internalisation of Apo-bLf in LM-MEL-62 (BRAF G469E). Cells were 
grown in 8 well chamber slides and were treated with Apo-bLf at 20 nM for 30 min, 2 h, 4 h 
and 6 h. Cells were then fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-X100 
on ice for 2 min. Cells were blocked with NAP blocker for 1 h at 370C. Cells were then probed 
with goat anti-bLf (1:100) primary antibody for 1 h at 370C following which they were tagged 
for bLf with anti-goat IgG FITC (1:100). DAPI was used with mounting media and cells were 
visualised for bLf internalisation using Leica SP5 confocal microscopy. Images were 
processed through LAS-AF version of the software and representative images were shown. 
The control untreated cells image panel was shown in 4.2 (G). 
 
Figure 4.2 (I). Cellular internalisation of Fe-bLf in LM-MEL-62 (BRAF G469E). To study the 
internalisation patterns of Fe-bLf, cells were treated with 20 nM concentration of Fe-bLf for 
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30 min, 2 h, 4 h and 6 h. Treated cells were fixed and permeabilized using 4 % PF and 0.1 % 
Triton-X100, respectively. Blocking was done using NAP blocker for 1 h at 37oC. Cells were 
probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C following which they 
were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used with mounting media 
and cells were visualised for bLf internalisation using Leica SP5 confocal microscopy. Images 
were processed through LAS-AF version of the software and representative images were 
shown. The control untreated cells image panel was shown in 4.2 (G). 
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Figure 4.2 (J). Cellular internalisation of Native-bLf in LM-MEL-24 (BRAF V600K). 
Internalisation efficacy of Native-bLf was studied by treating LM-MEL-24 (BRAF V600K) cells 
with 20 nM of Native-bLf for 4 different time points (30 min, 2 h, 4 h and 6 h). Treated cells 
were fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-X100 on ice for 2 min 
and blocked with NAP blocker for 1 h at 370C. Cells were then probed with goat anti-bLf 
(1:100) primary antibody for 1 h at 370C following which they were tagged for bLf with anti-
goat IgG FITC (1:100). DAPI with mounting media was used to stain the nucleus and cells 
were visualised for bLf internalisation using Leica SP5 confocal microscopy. Images were 
processed through LAS-AF version of the software and representative images were shown. 
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Figure 4.2 (K). Cellular internalisation of Apo-bLf in LM-MEL-24 (BRAF V600K). Eight well 
chamber slides were used to grow and then treat cells with Apo-bLf at 20 nM for 
investigating the time-dependent internalisation patterns of Apo-bLf. The treated cells were 
fixed with 4 % PF for 20 min and permeabilized using 0.1 % Triton-X100 on ice for 2 min. 
Cells were blocked using NAP blocker for 1 h at 370C and then probed with goat anti-bLf 
(1:100) primary antibody for 1 h at 370C following which they were tagged for bLf with anti-
goat IgG FITC (1:100). DAPI was used with mounting media and cells were visualised for bLf 
internalisation using Leica SP5 confocal microscopy. Images were processed through LAS-AF 
version of the software and representative images were shown. The control untreated cells 
image panel was shown in 4.2 (J). 




Figure 4.2 (L). Cellular internalisation of Fe-bLf in LM-MEL-24 (BRAF V600K). Cells were 
grown in 8 well chamber slides and were treated with Fe-bLf at 20 nM for 30 min, 2 h, 4 h 
and 6 h. Cells were then fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-X100 
on ice for 2 min. Cells were blocked with non-animal protein (NAP) blocker for 1 h at 370C. 
Cells were then probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C following 
which they were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used for nuclear 
staining (with mounting media) and cells were visualised for bLf internalisation using Leica 
SP5 confocal microscopy. Images were processed through LAS-AF version of the software 
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and representative images were shown. The control untreated cells image panel was shown 
in 4.2 (J). 
 
Figure 4.2 (M). Cellular internalisation of Native-bLf in Mel-007 (DR). Eight well culture 
slides were used to grow cells which were treated with 20 nM of Native-bLf for 30 min. 2 h. 
4 h and 6 h following which the cells were fixed with 4 % PF for 20 min and permeabilized 
using 0.1 % Triton-X100 for 2 min on ice. Blocking was done using NAP blocker for 1 h at 
370C. Cells were then probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C 
following which they were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used 
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with mounting media and cells were visualised for bLf internalisation using Leica SP5 
confocal microscopy. Images were processed through LAS-AF version of the software and 
representative images were shown. 
 
Figure 4.2 (N). Cellular internalisation of Apo-bLf in Mel-007 (DR). Cells were grown in 8 
well chamber slides and were treated with Apo-bLf at 20 nM for 30 min, 2 h, 4 h and 6 h. 
Cells were then fixed with 4 % PF for 20 min, permeabilized using 0.1 % Triton-X100 on ice 
for 2 min. Cells were blocked with non-animal protein (NAP) blocker for 1 h at 370C. Cells 
were then probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C following 
which they were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used for nuclear 
staining and cells were visualised for bLf internalisation using Leica SP5 confocal microscopy. 
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Images were processed through LAS-AF version of the software and representative images 
were shown. The control untreated cells image panel was shown in 4.2 (M). 
 
Figure 4.2 (O). Cellular internalisation of Fe-bLf in Mel-007 (DR).  Fe-bLf at 20 nM was used 
to treat cells for 30 min, 2 h, 4 h and 6 h, in order to study the time-dependent 
internalisation of Fe-bLf on Mel-007 (DR) cell lines. The treated cells were fixed and 
permeabilized following which they were blocked with NAP blocker for 1 h. Cells were then 
probed with goat anti-bLf (1:100) primary antibody for 1 h at 370C following which they 
were tagged for bLf with anti-goat IgG FITC (1:100). DAPI was used with mounting media 
and cells were visualised for bLf internalisation using Leica SP5 confocal microscopy. Images 
     Chapter 4- Effect of bLf on melanomas with varying mutations and drug resistant status 
189 
 
were processed through LAS-AF version of the software and representative images were 
shown. The control untreated cells image panel was shown in 4.2 (M). 
4.5.3 Upregulation of the cell cytotoxicity in the melanoma cell lines tested for bLf 
treatments 
To quantify the cytotoxic effects of all three forms of bLf in the melanoma cells being 
studied, LDH release assay was done. The cells were plated in a 96 well plate and once 
confluent, the cells were treated with varying concentrations of all three forms of bLf 
tested. Post-treatments, the supernatants from the treated cells were collected and 
incubated with the LDH reaction mixture for 30 min. After incubation, absorbance from the 
samples was measured and % LDH release from the cells was calculated. 48 h treatment 
time was chosen to study the cytotoxic effects of Native-bLf, Apo-bLf and Fe-bLf in all the 
five melanoma cell lines. Following preliminary investigations, the best LDH release pattern 
was noted after 48 h of treatment, hence this incubation time was chosen for all further 
studies with these cells.  
Interestingly, all the three forms of bLf treatments at all concentrations (10, 20, 40 and 80 
nM) showed increased cytotoxicity in LM-MEL-12 (WT BRAF and NRAS) cells when 
compared to the untreated cells (Figure 4.3 A). The 80 nM concentration of Apo-bLf (p≤ 
0.001, 6.2 fold) and Fe-bLf (p≤ 0.001, 5.8 fold) proved most effective. Therefore, it was 
inferred that Apo-bLf and Fe-bLf were effective in inducing cytotoxicity in LM-MEL-12 (WT 
BRAF and NRAS) cells. 
In LM-MEL-1a (NRAS Q16K); only Fe-bLf treatments showed a dose dependant increase in 
the cell cytotoxicity (Figure 4.3 B). It was observed that with 80 nM treatments of both 
Native-bLf (3.8 fold , p≤ 0.001) and Fe-bLf (4.3 fold, p≤ 0.001) were the effective treatments 
against LM-MEL-1a (NRAS Q16K) cells, as compared to Apo-bLf (2.6 fold, p≤ 0.01). Both 
Native-bLf and Fe-bLf were able to induce significantly higher cytotoxicity by 1.46 fold (p< 
0.05) and 1.65 fold (p< 0.05), respectively when compared to Apo-bLf. 
On the other hand, in LM-MEL-62 (BRAF G469E) cells (Figure 4.3 C), a dose-dependent 
response with all the treatments was missing. The highest levels of cytotoxicity induced by 
80 nM treatments of Native-bLf, Apo-bLf and Fe-bLf were 5 fold, 4.4 fold and 4.6 fold, 
respectively, and found to be equally significant (p≤ 0.001).  
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In case of LM-MEL-24 (BRAF V600K) cells (Figure 4.3 D), Native-bLf at 20 nM (4.6 fold) and 
80 nM (5.2 fold) induced an equally significant cytotoxicity (p≤ 0.001). 80 nM treatments of 
all three bLf forms were equally effective in inducing a significant cytotoxicity (p≤ 0.001). 
However, the cytotoxicity induced by 40 nM treatment of Fe-bLf (p< 0.05) was significantly 
lower when compared to both Native-bLf (p≤ 0.01) and Apo-bLf (p≤ 0.01).  
In Mel-007 (DR) cells (Figure 4.3 E) all the three forms of bLf induced a dose-dependent 
increase in the cytotoxic effect, however, the cytotoxicity of Native-bLf was more 
pronounced among the three bLf forms. The lower treatment of Apo-bLf (10 nM) failed to 
induce any significant cytotoxicity (p> 0.05), 80 nM (p≤ 0.001) of Native-bLf treatment was 
found to be the more effective concentration against drug-resistant Mel-007 (DR) cells. 
 
Figure 4.3 (A). Effect of bLf as a cytotoxic agent in LM-MEL-12 (WT BRAF and NRAS) cells. 
Cellular cytotoxicity in LM-MEL-12 (WT BRAF and NRAS) cells was analysed using LDH 
reagent. LM-MEL-12 (WT BRAF AND NRAS) cells were treated at 48 h of treatment, with 
various concentrations of Native-bLf, Apo-bLf and Fe-bLf (10 nM, 20 nM, 40 nM and 80 nM). 
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Untreated cells were taken as control. Treatments were done thrice and the experiments 
were performed three times independently. All the values are represented as mean ± SE. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) 
represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
significant when compared to untreated cells. A value of (p< 0.05) represented as † was 
considered statistically significant when compared amongst the treatments.   
 
Figure 4.3 (B). Cytoxicity of bLf in LM-MEL-1a (NRAS Q16K) cells. Treatments of 10 nM, 20 
nM, 40 nM and 80 nM of Native-bLf, Apo-bLf and Fe-bLf for 48 h was studied for their cell-
cytotoxic effects using LDH assay quantification of cell cytotoxicity. Untreated cells were 
used as control. All the treatments were carried out thrice and the experiments were 
performed thrice independently. All the values are represented as mean ± SE. Student’s t 
test was performed to evaluate statistical significance. A value of (p< 0.05) represented as *, 
(p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared 
to untreated cells.  A value of (p< 0.05) represented as † was considered statistically 
significant when compared amongst the treatments.  




Figure 4.3 (C). Cellular cytotoxicity with bLf in LM-MEL-62 (BRAF G469E) cells. Cellular 
toxicity of three forms of bLf at 48 h treatment time at treatment concentrations of 10 nM, 
20 nM, 40 nM and 80 nM was quantified using LDH assay. The treatments were done in 
triplicates and the experiment was performed thrice indepdently. Untreated cells were 
maintained as control. All the values are represented as mean ± SE. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells. NS represents non-significant statistical difference between the treatments.  
 




Figure 4.3 (D). Cytotoxic effects of bLf in LM-MEL-24 (BRAF V600K) cells. Native-bLf, Apo-
bLf and Fe-bLf (10 nM, 20 nM, 40 nM and 80 nM) treated cells for 48 h were analysed for 
their cell cytotoxic effects on LM-MEL-24 (BRAF V600K) cell line. Each treatment was done in 
triplicates and the experiment was conducted three times, independently. Untreated cells 
were used as control. All the values are represented as mean ± SE. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells. NS represents non-significant statistical difference between the treatments. 




Figure 4.3 (E). Increase in cellular cytotoxicity with bLf in Mel-007 (DR) cells. LDH reagent 
was used to quantify the cell cytotoxic effects of all the three forms of bLf at 10 nM, 20 nM, 
40 nM and 80 nM treatment concentrations for 48 h of treatment. Untreated cells were 
used as control. The treatments were done in triplicates and the experiment was performed 
thrice independently. All the values are represented as mean ± SE. Student’s t test was 
performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells. A value of (p< 0.05) represented as † was considered statistically significant 
when compared amongst the treatments.  
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4.5.3 bLf treatment proves cytotoxic and induces morphological changes in LM-MEL-12 
(WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-24 
(BRAF V600K) and Mel-007 (DR) cells 
Since disruption of the actin structure was observed in melanoma cells during studies on Lf 
internalisation, further to observe the morphological changes indicating cytotoxic shock 
leading to cell death in these cells, microscopic images were taken 48 h post-treatment with 
Native-bLf, Apo-bLf and Fe-bLf. Cells were cultured in 6 well plates and treated with all three 
forms of bLf (20 nM, 40 nM and 80 nM) to check the effect of bLf on the morphology of the 
melanoma cell lines being tested.  Morphological images (Figure 4.4 A-E) showed overall the 
dose dependent effect of the treatments; presence of floating dead cells/apoptotic bodies, 
cell debris and depletion of cell monolayers, was observed mostly with higher 80nM 
concentration of bLf treatments. 




Figure 4.4 (A). Changes in cell morphology with bLf in LM-MEL-12 (WT BRAF and NRAS). 
bLf treated cells were checked for their effect on morphological disruptions by treating cells 
for 48 h, with 20 nM, 40 nM and 80 nM of Native-bLf, Apo-bLf and Fe-bLf,  at a cell density 
of 105 cells (grown in 6 well plates). The cells that were treated were viewed at 40X 
magnification. Treatments were done in duplicates and the experiment was performed 
thrice. Representative images from each treatment were shown. Untreated cells were 
maintained as control cells.  




Figure 4.4 (B). Changes in cell morphology of LM-MEL-1a (NRAS Q16K) with bLf. Cells were 
grown in 6 well plates at a concentration of 105 cells. Morphological changes in the cells 
without treatment and with Native-bLf, Apo-bLf and Fe-bLf treatment at 20 nM, 40 nM and 
80 nM for 48 h was viewed at 40X magnification. Treatments were done in duplicates and 
the experiment was performed thrice. Representative images from each treatment were 
shown. Untreated cells were maintained as control cells. 




Figure 4.4 (C). Morphological changes in LM-MEL-62 (BRAF G469E) with bLf. Six well plates 
were used to grow cells at a cell number of 105 cells. Treatments with 20 nM, 40 nM and 80 
nM of all the three forms of bLf was done for 48 h. Morphological changes in the cells 
without treatment and with treatments was viewed at 40X magnification. Treatments were 
done in duplicates and the experiment was performed thrice. Representative images from 
each treatment were presented. 




Figure 4.4 (D). Morphological observations of LM-MEL-24 (BRAF V600K) cells after bLf 
treatment.  Cells were treated with Native-bLf, Apo-bLf and Fe-bLf at varying concentrations 
of 20 nM, 40 nM and 80 nM for 48 h. The treated cells and a control of untreated cells were 
viewed at 40X magnification. Treatments were done in duplicates and the experiment was 
performed thrice. Representative images from each treatment type were shown.  




Figure 4.4 (E).  Morphological changes in Mel-007 (DR) with bLf. Cells were grown in 6 well 
plates at a concentration of 105 cells. Morphological changes in the cells without treatment 
and with Native-bLf, Apo-bLf and Fe-bLf treatment at 20 nM, 40 nM and 80 nM for 48 h was 
viewed at 40X magnification. Treatments were done in duplicates and the experiment was 
performed thrice. Representative images from each treatment were shown.  
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4.5.5 bLf causes apoptosis in LM-MEL-1a (NRAS Q16K), LM-MEL-12 (WT BRAF and NRAS), 
LM-MEL-24 (BRAF V600K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) 
To check the nature of cytotoxic death induced by of bLf, annexin-V staining was done to 
differentiate between apoptotic and necrotic melanoma cells. The staining was performed 
on cells that were plated, treated for 48 h, fixed and then stained annexin-V kit  was 
employed to differentiate  among  both PI  and annexin-V  stain  positive (late apoptotic 
cells), PI only positive (necrotic) and annexin-V only positive (early apoptotic) cells. The 
stained cells were acquired using FACS and the population of cells counted in the Q1, Q2, Q3 
and Q4 region are represented and plotted in a graph. The shift in population from the Q3 
region or live cells to the Q1 (early apoptosis), Q2 (late apoptotic) and Q4 (necrotic region) 
was checked for.  
In case of LM-MEL-12 (WT BRAF AND NRAS) cells (Figures 4.5 A & B), it was observed that 
majority of cells treated with all the three forms of bLf were in the early apoptotic region. 
Both Apo-bLf (p≤ 0.001, 5.3 fold) and Fe-bLf (p≤ 0.001, 4.8 fold) at 40 nM were significantly 
more effective than Native-bLf (p≤ 0.01, 3.7 fold).  
Majority of the LM-MEL-1a (NRAS Q16K) cells, treated with all the three forms of bLf were in 
the late apoptotic region (Figures 4.5 C & D). When compared to untreated cells, Native-bLf, 
Apo-bLf and Fe-bLf induced significant apoptosis p≤ 0.001 (2.6 fold), p< 0.05 (1.8 fold) and 
p≤ 0.01 (2.3 fold), respectively and it was revealed that Native-bLf was the most effective 
treatment. Fe-bLf 20 nM significantly increased (p< 0.05) the number of cells in the necrotic 
region when compared to untreated cells in LM-MEL-1a (NRAS Q16K) cells.  
In LM-MEL-62 (BRAF G469E) cells, it was observed that cells treated with all the three bLf 
forms were in both the late apoptotic and necrotic regions (Figures 4.5 E & F). A 2.9 fold (p≤ 
0.01) increase in necrotic cells were observed with Native-bLf 40 nM whereas, both Apo-bLf 
and Fe-bLf 40 nM, failed to show any significant increase in the necrotic cell population. 
However, a 1.9 fold (p< 0.05) increase with Apo-bLf and 2.1 fold increase (p< 0.05) with Fe-
bLf at 40 nM, in late apoptotic cells was observed. Native-bLf did not show any significant 
increase in apoptotic cells.  
Majority of LM-MEL-24 (BRAF V600K) cells (Figures 4.5 G & H) were observed in the early 
apoptotic region post treatment with the three forms of bLf. The results indicated a 
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significantly higher increase with Native-bLf (p≤ 0.01, 3.5 fold) and Apo-bLf (p≤ 0.01, 3.9 
fold) when compared to Fe-bLf (p< 0.05, 2.4 fold) 40 nM.  
In case of Mel-007 (DR) cells, it was observed that all the three forms of bLf led to an 
increase in early apoptotic cells (Figures 4.5 E & F). Native-bLf (p≤ 0.001, 5.8 fold) showed 
comparatively higher effect than Apo-bLf (p< 0.05, 2.7 fold) 40 nM. Fe-bLf failed to show any 
increase in the early apoptotic cells. However, a dose-dependent significant increase (40 
nM- p≤ 0.01, 3.7 fold) with Fe-bLf was observed in the late apoptotic cell which was 
comparatively higher than both Native-bLf and Apo-bLf that failed to show any significant 
increase in the late apoptotic cells.  
 
 








Figure 4.5 (A & B). Cell death quantification by Annexin-V/PI staining of LM-MEL-12 (WT 
BRAF and NRAS) cells treated with bLf. Annexin-V/PI staining was performed for cells 
treated with 20 nM and 40 nM of Native-bLf, Apo-bLf and Fe-bLf for 48 h to study the cell 
death mechanism caused by bLf treatments. Quantification of cell death mechanisms was 
done by analysing the annexin-V/PI stained cells using FACS-Diva software on a flow 
cytometer. Untreated cells were used as control. Treatments were done in triplicates and 
the experiment was performed thrice independently. Representative graph plots indicating 
the upregulation of apoptosis were shown. All the values are represented as mean ± SE and 
the experiments were repeated twice. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was 
considered statistically significant when compared to untreated cells. A value of (p< 0.05) 
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represented as † was considered statistically significant when compared amongst the 
treatments.  
 




Figure 4.5 (C & D). Quantification of apoptosis in LM-MEL-1a (NRAS Q16K) with bLf 
treatment. Following 48 h of treatment with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 
nM for 48 h, LM-MEL-1a (NRAS Q16K) cells were stained with annexin-V/PI and analysed by 
flow cytometry. Untreated cells were used as control. Treatments were done in triplicates 
and the experiment was performed twice. Representative FACS plots showing a shift in the 
population from the Q3 region to the Q1/Q2 and/or Q3 region were shown. All the values 
are represented as mean ± SE and the experiments were repeated twice. Student’s t test 
was performed to evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 
0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared to 
untreated cells. A value of (p≤ 0.01) represented as † was considered statistically significant 
when compared amongst the treatments. 








Figure 4.5 (E & F). Induction of apoptosis in LM-MEL-62 (BRAF G469E) with bLf treatments. 
Treatments with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM concentrations for 48 h 
was performed to quantify the cell death caused by bLf using the annexin-V Fluos assay. 
Treated cells were stained with annexin-V and PI and analysed through FACS using the FACS-
Diva software. Untreated cells were used as control. Treatments were done in triplicates 
and the experiment was performed twice. Representative FACS plots showing a shift in the 
population from the Q3 region to the Q1/Q2 and/or Q3 region were shown. All the values 
are represented as mean ± SE and the experiments were repeated twice. Student’s t test 
was performed to evaluate statistical significance. A value of (p< 0.05) represented as * and 
(p≤ 0.01) as ** was considered statistically significant when compared to untreated cells. A 
value of (p≤ 0.01) represented as † was considered statistically significant when compared 
amongst the treatments.  








Figure 4.5 (G & H). Effect of bLf in causing cell death in LM-MEL-24 (BAF V600K) cells. 
Annexin-V/PI staining was used to quantify the cell death caused by Native-bLf, Apo-bLf and 
Fe-bLf after 48 h of treatment at concentrations of 20 nM and 40 nM. The cells were 
acquired through FACS for studying the cell death mechanism and the results were analysed 
using FACS-Diva software. Untreated cells were used as control. Treatments were done in 
triplicates and the experiment was performed twice. Representative FACS plots showing a 
shift in the population from the Q3 region to the Q1/Q2 and/or Q3 region were shown. All 
the values are represented as mean ± SE and the experiments were repeated twice. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) is 
represented as * and (p≤ 0.01) as ** was considered statistically significant when compared 
to untreated cells. A value of (p< 0.05) represented as † was considered statistically 
significant when compared amongst the treatments.  








Figure 4.5 (I & J). Induction of apoptosis in Mel-007 (DR) with bLf treatments. Following 
treatments with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM concentrations for 48 
h, the cell death mechanism that is upregulated by bLf was studied using the annexin-V/PI 
staining. Treated, stained cells were analysed using the FACS-Diva software for 
quantification of the stained cells. Untreated cells were used as control. Treatments were 
done in triplicates and the experiment was performed twice. Representative FACS plots 
showing a shift in the population from the Q3 region to the Q1/Q2 and/or Q3 region were 
shown. Treatments were done in triplicates and the experiments were performed thrice, 
independently. All the values are represented as mean ± SE and the experiments were 
repeated twice. Student’s t test was performed to evaluate statistical significance. A value of 
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(p< 0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
significant when compared to untreated cells. A value of (p≤ 0.001) as †† was considered 
statistically significant when compared amongst the treatments.  
4.5.6 Inhibition of cell proliferation of melanoma cell lines treated with Native-bLf, Apo-
bLf and Fe-bLf 
To check the effect of bLf on cellular proliferation of all the melanoma cell lines being tested 
for bLf, CyQUANT cell proliferation assay was performed.  CyQUANT assay is based on the 
binding of green fluorescent dye (CyQUANT GR) to the cellular nucleic acids which in turn 
exhibits strong fluorescent enhancement that allows rapid and sensitive detection of density 
of cells in culture.   
As shown in Figure 4.6 A, LM-MEL-12 (WT BRAF and NRAS) cells showed significant 
inhibition of cell proliferation, over the used concentration range of all the three forms of 
bLf treatments.  When compared to the untreated cells’ proliferation, 2.7 fold (p≤ 0.01), 2.9 
fold (p≤ 0.01) and 3 fold (p≤ 0.01) inhibition of cell proliferation was observed with 40 nM of 
Native-bLf, Apo-bLf and Fe-bLf treatments, respectively. This anti-proliferative effect did not 
reduce significantly further with 80 nM concentration of these bLf forms.  
As seen in Figure 4.6 B all the three forms of bLf showed a dose-dependent decrease in cell 
proliferation of LM-MEL-1a (NRAS Q16K) cells. At 80 nM concentrations, Native-bLf (2.1 fold, 
p≤ 0.01), Apo-bLf (2.0 fold, p≤ 0.01) and Fe-bLf (2.0 fold, p≤ 0.01) showed significant 
reduction in cell proliferation. It was observed that 40 nM of Apo-bLf (2 fold, p≤ 0.01) was 
comparatively more effective than Native-bLf (1.56 fold, p< 0.05) and Fe-bLf (1.72 fold, p< 
0.05).  
In case of LM-MEL-62 (BRAF G469E) cells (Figure 4.6 C), it was noted that both Native-bLf 
and Apo-bLf showed a dose-dependent reduction in the cell proliferation. 80 nM of Native-
bLf (2.63 fold, p≤ 0.01), Apo-bLf (2.85 fold, p≤ 0.01) were equally effective. However, 80 nM 
of Fe-bLf (5.26 fold, p≤ 0.001) was the most effective concentration in reducing the cellular 
proliferation in LM-MEL-62 (BRAF G469E) cells.  
In LM-MEL-24 (BRAF V600K) cells (Figure 4.6 D), a dose-dependent decrease in cell 
proliferation was observed with all the three forms of bLf treatments. A comparison 
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between 80 nM of Native-bLf (1.72 fold, p≤ 0.01), Apo-bLf (2.0 fold, p≤ 0.01) and Fe-bLf (2.1 
fold, p≤ 0.01) were significant in reducing the cell proliferative ability.  
A similar observation was made in Mel-007 (DR) cells (Figure 4.6 E), where 80 nM 
treatments of Native-bLf (2.08 fold, p≤ 0.01), Apo-bLf (2.0 fold, p≤ 0.01) and Fe-bLf (2.22 
fold, p≤ 0.01) were equally significant in reducing the cell proliferative ability.  
 
 
Figure 4.6 (A). Quantitative analysis of anti-cell proliferative effects of bLf in LM-MEL-12 
(WT BRAF and NRAS). Percentage cell proliferation was quantified using CyQUANT kit 
(Invitrogen) on LM-MEL-12 cells (WT BRAF and NRAS) that were treated with varying 
concentrations of Native-bLf, Apo-bLf and Fe-bLf (10 nM, 20 nM, 40 nM and 80 nM) for 48 
h. Untreated cells were used as a positive control for this assay. Treatments were carried 
out in triplicates and the assay was performed thrice independently. All values are 
represented as mean ± SE. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** was considered 
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statistically significant when compared to untreated cells. NS represents non-significant 
statistical difference among the treatments with three forms of bLf.   
 
Figure 4.6 (B). bLf inhibits cell proliferation of LM-MEL-1a (NRAS Q16K). Native-bLf, Apo-
bLf and Fe-bLf at 10 nM, 20 nM, 40 nM and 80 nM were used to treat cells (plated out in 96 
well plates) for 48 h, to study the anti-cell proliferative effects of bLf. This assay was 
performed using CyQUANT assay for cell proliferation where untreated cells were used as 
controls. Treatments were carried out in triplicates and the assay was performed thrice 
independently. Data has been represented as mean ± SE. Student’s t test was performed to 
evaluate statistical significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** 
was considered statistically significant when compared to untreated cells. NS represents 
non-significant statistical difference among the treatments with the three forms of bLf.   




Figure 4.6 (C). Inhibition of cell proliferation of LM-MEL-62 (BRAF G469E) cells with bLf 
treatments. The anti-cell proliferative effects of Native-bLf, Apo-bLf and Fe-bLf were studied 
by treating cells grown in 96 well plates with 10 nM, 20 nM, 40 nM and 80 nM of the three 
forms of bLf for 48 h. CyQUANT assay for quantification of cell proliferation was used for 
this assay and untreated cells were used as a control. Treatments were carried out in 
triplicates and the assay was performed thrice independently. All values are represented as 
mean ± SE. Student’s t test was performed to evaluate statistical significance. A value of (p< 
0.05) represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
significant when compared to untreated cells. A value of (p< 0.05) represented as † was 
considered statistically significant when compared amongst the treatments.  




Figure 4.6 (D). bLf inhibits the cell proliferative ability of LM-MEL-24 (BRAF V600K) cells. 
Percentage cell proliferation of all the three forms of bLf at treatment concentrations of 10 
nM, 20 nM, 40 nM and 80 nM for 48 h time point was quantified using CyQUANT kit 
(Invitrogen) on LM-MEL-24 cells (BRAF V600K). Untreated cells were used as a positive 
control. Treatments were carried out in triplicates and the assay was performed thrice 
independently. LM-MEL-24 (BRAF V600K) cells also showed a dose-dependent effect of 
Native-bLf, Apo-bLf and Fe-bLf in reducing the cell proliferative ability. All values are 
represented as mean ± SE. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as * and (p≤ 0.01) as ** was considered 
statistically significant when compared to untreated cells. NS represents non-significant 
statistical difference between the treatments.   




Figure 4.6 (E). Reduction in cell proliferation in Mel-007 (DR) with bLf treatments. 
CyQUANT assay for quantification of % cell proliferation of Mel-007 (DR) cell lines when they 
were subjected to 48 h of Native-bLf, Apo-bLf and Fe-bLf at 10 nM, 20 nM, 40 nM and 80 
nM treatment concentrations was performed to study the anti-cell proliferative abilities of 
the bLf forms. Treatments were carried out in triplicates and the assay was performed thrice 
independently and untreated cells were used as a control. All values are represented as 
mean ± SE. Student’s t test was performed to evaluate statistical significance. A value of (p< 
0.05) is represented as * and (p≤ 0.01) as ** was considered statistically significant when 
compared to untreated cells. NS represents non-significant statistical difference among the 
treatments with three forms of bLf.   
4.5.7 bLf downregulates  tumour spheroid formation in melanoma cell lines following 
treatment 
The effectiveness of bLf in reducing tumour spheroid forming ability of LM-MEL-1a (NRAS 
Q16K), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 (BRAF 
G469E) and Mel-007 (DR) was further evaluated, considering 3D culture studies of 
melanoma cells provide a better insight on the effectiveness of bLf in a tumour 
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microenvironment. The tumour spheroids were formed by plating 1000 cells per well in a 
1% agarose-coated 96 well plate. The spheroids were allowed to grow for 7 days after which 
they were treated with all three forms of bLf samples. Post-treatment of 48 h, the tumour 
spheroids were imaged and the area of the tumour spheroids was measured using Image J 
software.  
In case of LM-MEL-12 (WT BRAF AND NRAS) cells (Figures 4.7 A &F), Native-bLf was the 
most effective treatment against LM-MEL-12 (WT BRAF and NRAS) cells. It was found that 
both 20 nM  and 40 nM of Native-bLf reduced the tumour spheroid area by  2.50 fold and 
3.33 fold, respectively (p≤ 0.01). Apo-bLf  even at 40 nM had a very  little effect  and 20 nM  
of Fe-bLf  could reduce the tumour area  by 1.33 fold (p< 0.05). However, an increase in the 
necrotic cellular zones was observed with Apo-bLf and Fe-bLf treatments which was absent 
in untreated and Native-bLf treated spheroids.  
Interestingly,  in  LM-MEL-1a  (NRAS Q16K) cells (Figures 4.7 B & F),  Native-bLf treatments 
proved comparatively least effective than both Apo-bLf and Fe-bLf. The 40 nM of Native-bLf  
reduced  tumour spheroid size by 1.95 fold (p< 0.05), while at the same concentration  Apo-
bLf  and Fe-bLf showed significant and highly significant decreases i.e. 3.30 fold (p≤ 0.01) 
and 5.37 fold (p≤ 0.001), respectively in the tumour spheroid area. Overall, Fe-bLf was found 
to be the most effective treatment against LM-MEL-1a (NRAS Q16K)  tumour spheroids. 
For LM-MEL-62 (BRAF G469E) cells (Figures 4.7 C & F), the 20 nM of Native-bLf  and 40 nM 
treatment of Fe-bLf were able to show a significant reduction in tumour spheroid sizes by 
1.43 fold (p< 0.01)  and 1.80 (p≤ 0.01), respectively. Therefore, it was inferred that Fe-bLf 
was comparatively effective against the LM-MEL-62 (BRAF G469E) tumour spheroids. 
 While Apo-bLf and Fe-bLf proved effective in downregulating the tumour spheroid size of  
LM-MEL-24 (BRAF V600K) cells, Native-bLf was found to be most effective bLf form targeting 
its 3D tumour spheroids (Figures 4.7 D & F).  It was found that both Apo-bLf and  Fe-bLf 
reduced the size by 2.33 fold and 2 fold, respectively (p≤ 0.05) at 40 nM concentration. 
However, 40 nM of Native-bLf showed 8.75 fold decrease in size (p≤ 0.001) of tumour 
spheroids and a higher central necrotic zone formation was observed with 20 nM and 40 nM 
Fe-bLf. 
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In Mel-007 (DR) tumour spheroids (Figures 4.7 E & G) when treated with different bLf forms, 
at 48 h, 40 nM of both Native-bLf and Apo-bLf induced highly significant inhibition (p≤ 0.01) 
in tumour spheroids area by 2.75 fold and 4 fold, respectively. However, 40 nM of Fe-bLf  
was the most effective treatment (p≤ 0.001) against the Mel-007 (DR) showng 8-fold 
reduction in the tumour spheroid size and unlike 20 nM treatments with Native-bLf and 
Apo-bLf, there was no reduction in spheroid size with 20 nM Fe-bLf.  




Figure 4.7 (A). Effect of bLf forms on spheroid of LM-MEL-12 (WT BRAF and NRAS) in 3D 
cultures. Cells (103) were allowed to form spheroids in agarose coated plates and then 
treated with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM concentrations for 48 h. 
Images of the tumour spheroids were taken at 40X magnification. Area of the tumour 
spheroids was then measured using Image J software. Untreated spheroids were used as 
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control. Treatments were done in triplicates and the experiment was performed thrice. 
Representative images from the experiment are shown. 
 
Figure 4.7 (B). Effect of bLf forms on spheroid of LM-MEL-1a (NRAS Q16K) in 3D cultures. 
Tumour spheroids were allowed to form for 7 days on 1 % agarose-coated 96 well plates at 
a cell density of 103 cells. After 7 days the cells were treated with 20 nM and 40 nM 
concentrations of Native-bLf, Apo-bLf and Fe-bLf for 48 h following which the tumour 
spheroids were imaged using an inverted micrscope at 40X magnification. Area of the 
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tumour spheroids was then measured using Image J software. Untreated spheroids were 
used as control. Treatments were done in triplicates and the experiment was performed 
thrice. Representative images from the experiment are shown. 
 
Figure 4.7 (C). Effect of bLf forms on spheroid of LM-MEL-62 (BRAF G469E) in 3D cultures. 
103 cells were allowed to grow on a 96 well plates coated with 1 % agarose for 7 days. The 
spheroids formed were then treated with 20 nM and 40 nM concentrations of all the three 
forms of bLf for 48 h. The effect of bLf on the spheroids was visualised and imaged using an 
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inverted micrscope at 40X magnification. Area of the tumour spheroids was then measured 
using Image J software. Untreated spheroids were used as control. Treatments were done in 
triplicates and the experiment was performed thrice. Representative images from the 
experiment are shown. 
 




Figure 4.7 (D). Effect of bLf forms on spheroid of LM-MEL-24 (BRAF V600K) in 3D cultures. 
Spheroids were formed by plating out 103 cells on 1 % agarose coated 96 well plates. The 
spheroids were allowed to form for 7 days following which they were treated with Native-
bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM treatment concentration for 48 h. The 
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spheroids were imaged at 40X magnification using an inverted micrscope. Area of the 
tumour spheroids was then measured using Image J software. Untreated spheroids were 
used as control. Treatments were done in triplicates and the experiment was performed 
thrice. Representative images from the experiment are shown.  
 
Figure 4.7 (E). Effect of bLf forms on spheroid of Mel-007 (DR) in 3D cultures. Cells were 
allowed to form spheroids in 1 % agarose coated plates for 7 days, and then treated with 
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Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM concentrations for 48 h. The effect of 
bLf on the spheroids was visualised and imaged at 40X magnification using an inverted 
microscope.Area of the tumour spheroids was then measured using Image J software. 
Untreated spheroids were used as control. Treatments were done in triplicates and the 
experiment was performed thrice. Representative images from the experiment are shown.  
 
Figure 4.7 (F). Reduction in tumour spheroid area with bLf treatments in LM-MEL-12 (WT 
BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-24 (BRAF 
V600K) and Mel-007 (DR). Calculations from the Image J analysis of tumour spheroids area 
was plotted for all the treatments when compared to untreated cells. Treatments were 
done in triplicates and the experiment was performed thrice. All values were represented as 
mean ± SE and the experiments were repeated thrice. Student’s t test was performed to 
evaluate statistical significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and 
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(p≤ 0.001) as *** was considered statistically significant when compared to untreated cells.  
A value of (p≤ 0.01) represented as † was considered statistically significant when compared 
amongst the treatments.  
4.5.8 Native- bLf and Fe-bLf proved more effective in targeting the clonogenic potential of 
the melanoma cells  
To study the effects of bLf on the colony forming potential of melanoma cells, clonogenic 
assay was done. As described in Chapter 3, the cells were first plated in 6 well plates. The 
cells were treated with all three forms of bLf at 20 nM and 40 nM concentrations for 48 h. 
Post-treatment, the cells were trypsinized and counted. 500 cells were plated out per 
treatment in 6 well plates and the cells were allowed to grow for 7 days. After 7 days, the 
cells were fixed, washed and stained with 0.1% crystal violet to visualise and count the 
number of colonies formed. The colony forming ability of all the melanoma cell lines that 
were tested was reduced significantly with bLf treatments.  
The results of clonogenic assays revealed that amongst the 5 cell lines LM-MEL-1a (NRAS 
Q16K) (p≤ 0.05), LM-MEL-62 (BRAF G469E) (p≤ 0.001) and Mel-007 (DR) (p≤ 0.001) showed 
significantly higher clonogenic potential than LM-MEL-12 (WT BRAF and NRAS) and LM-MEL-
24 (BRAF V600K) cells. Higher clonogenic potential of the three melanoma cell lines 
mentioned might be an indication of their higher cell proliferation and tumorigenic 
potential.  
In the case of LM-MEL-12 (WT BRAF and NRAS) cells, it was observed that all the bLf 
treatments showed highly effective dose dependant reduction in the clonogenic potential. 
At 40 nM (p≤ 0.001), Native-bLf, Apo-bLf and Fe-bLf showed an equally significant (p≤ 0.001) 
decrease in the clonogenic potential of cells (Figures 4.8 A & F). Importantly, treatment with 
Fe-bLf 40 nM reduced the number of colonies to zero. Therefore, it was inferred that all 
three types of bLf were equally effective against the LM-MEL-12 (WT BRAF and NRAS) cells. 
Further  again though all the bLf forms, significantly inhibited the colony forming activity of 
the LM-MEL-1a (NRAS Q16K) cells at 20 nM and 40nM, the 40 nM treatment of Native-bLf 
was found to be the most effective treatment for these cells as it led to the most significant 
reduction (p≤ 0.001) in  their clonogenic potential (Figures 4.8 B & F). 
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In case of LM-MEL-62 (BRAF G469E) cells (Figures 4.8 C & F), it was observed that the effects 
of 40 nM treatments of both Native-bLf and Fe-bLf were significant (p≤ 0.001), in 
downregulating the clonogenic potential, when compared to Apo-bLf which failed to show 
any significant reduction. Therefore, it was inferred that both the iron containing bLf forms, 
Native and Fe-bLf were most effective against the LM-MEL-62 (BRAF G469E) cells. 
In LM-MEL-24 (BRAF V600K) cells 40 nM of Native-bLf, Apo-bLf and Fe-bLf were effective in 
reducing the colony forming potential within 48 h of treatment where the number of 
colonies were reduced to zero in all treatments with all the three bLf forms (p≤ 0.001) 
(Figures 4.8 D & F).  
The clonogenic potential of Mel-007 (DR) cells as shown in Figures 4.8 E & F was found to be 
lowered significantly in a dose dependant manner by all the three forms of bLf. However, 40 
nM concentrations of both Native-bLf and Fe-bLf were found to be equally effective (p≤ 
0.001) in significantly reducing the clonogenic potential of these cells as compared to Apo-
bLf (p≤ 0.01). Therefore, it was concluded that again both iron-saturated forms Native-bLf 
and Fe-bLf were comparatively more effective in targeting the colony forming ability of the 
drug resistant Mel-007 (DR) cells.  




Figure 4.8 (A). Assessment of clonogenic potential with bLf treatments in LM-MEL-12 (WT 
BRAF and NRAS). Colony forming ability of LM-MEL-12 (WT BRAF and NRAS) was used to 
determine the ability of single cells to replicate and form colonies with and without bLf 
treatments at 20 nM and 40 nM. 500 cells from each treatment were plated and allowed to 
grow on a new plate for 14 days. Colonies were fixed with 4 % PF for 20 min and then 
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stained with 0.1 % crystal violet. Untreated cells were used as control. Treatments were 
carried out in triplicates and assay was performed thrice independently. Representative 
images from the assay are shown. 
 
Figure 4.8 (B). Assessment of clonogenic potential of LM-MEL-1a (NRAS Q16K) cells post-
bLf treatments. Following treatments with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 
nM for 48 h, clonogenic assay was performed to evaluate the effects of all the three forms 
of bLf on colony forming ability of LM-MEL-1a (NRAS Q16K) cells. Five hundred cells from 
each treatment were allowed to grow for 14 days after which they were fixed with 4 % PF 
for 20 min and stained with 0.1 % crystal violet for 2 min. Untreated cells were used as 
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control. Treatments were carried out in triplicates and assay was performed thrice 
independently. Representative images from the assay are shown.  
 
Figure 4.8 (C). Evaluation of clonogenic potential with bLf treatments in LM-MEL-62 (BRAF 
G469E). Colony forming ability of cells was evaluated following treatments with 20 nM and 
40 nM of Native-bLf, Apo-bLf and Fe-bLf for 48 h. The treated cells were plated at a cell 
density of 500 cells and allowed to grow for 14 days after which they were fixed and stained 
with 0.1 % crystal violet. Untreated cells were used as control. Treatments were carried out 
in triplicates and assay was performed thrice independently. Representative images from 
the assay are shown. 




Figure 4.8 (D). Evaluation of clonogenic potential with bLf treatments in LM-MEL-24 (BRAF 
V600K). The clonogenic assay signifies the ability of single cells to replicate and form 
colonies. Microscopic images represent the stained colonies which formed after 7 days from 
the plated cells following treatments with Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 
nM concentrations for 48 h. The treated cells were trypsinized and 500 cells per treatment 
were added onto a fresh plate and allowed to grow for 14 days. The colony forming units 
were fixed and stained with 0.1 % crystal violet for 2 min. untreated cells were used as 
control. Treatments were carried out in triplicates and assay was performed thrice 
independently. Representative images from the assay are shown. 




Figure 4.8 (E). Assessment of clonogenic potential with bLf treatments in Mel-007 (DR). 
Colony forming ability of Mel-007 (DR) was used to determine the ability of single cells to 
replicate and form colonies with and without bLf treatments at 20 nM and 40 nM. 500 cells 
from each treatment were plated and allowed to grow on a new plate for 14 days. Colonies 
were then fixed using 4 % PF for 20 min and then stained with 0.1 % crystal violet. 
Untreated cells were used as control. Treatments were carried out in triplicates and assay 
was performed thrice independently. Representative images from the assay were shown.  




Figure 4.8 (F). bLf reduces the number of colonies formed post-treatment in all the 
melanoma cell lines tested.  Following treatment with Native-bLf, Apo-bLf and Fe-bLf at 20 
nM and 40 nM for 48 h, the cells were plated and allowed to grow for 14 days. Number of 
colonies formed in the untreated and treated wells was counted using a colony counter and 
the values were plotted in the form of a histogram. All the three forms of bLf samples tested 
significantly reduced the number of colonies formed in all the melanoma cell lines. 
Untreated cells were used as control. Treatments were carried out in triplicates and the 
assay was performed thrice independently. All the values are represented as mean ± SE. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) 
represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
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significant when compared to untreated cells. A value of (p< 0.05) represented as †, and (p≤ 
0.001) as ††† was considered statistically significant when compared amongst the 
treatments. NS represents non-significant statistical difference between the treatments.  
4.5.9 bLf was successful in downregulating the migratory potential of melanoma cells  
bLf had proved to reduce the migratory capacity of SK-MEL-2 and SK-MEL-28 cells that was 
tested in Chapter 3. To confirm if bLf has the same effect on the patient-derived melanoma 
cells with BRAF and NRAS mutations and in drug-resistant melanoma cells, migration assay 
was performed. The cells were plated out in 12 well plates with 8 µm pore thin-certs, 
allowing cells to grow under the influence of bLf containing treatment media. This allows 
investigating the migratory potential of the cells under the influence of the three forms of 
bLf as a therapeutic. The cells were allowed to grow in the 8 µm pore chamber well in the 
presence of bLf for 48 h. The number of cells that migrated through the pores was counted 
by staining membrane containing migratory cells, with 1% crystal violet, and was imaged 
using a camera on an inverted microscope.  
It was observed that amongst the 5 cell lines, both LM-MEL-12 (WT BRAF and NRAS) and 
LM-MEL-24 (BRAF V600K) were found to have significantly higher (p≤ 0.05) migration 
potential under untreated conditions, when compared to LM-MEL-1a (NRAS Q16K), LM-
MEL-62 (BRAF G469E) and Mel-007 (DR). This implies that both LM-MEL-12 (WT BRAF and 
NRAS) and LM-MEL-24 (BRAF V600K) have migratory capability when compared to the other 
cell lines under normal conditions.  
In case of LM-MEL-12 (WT BRAF and NRAS) (Figures 4.9 A & F), a dose-dependent 
downregulation in the migratory potential with all the three forms of bLf was observed. 
Apo-bLf (45 fold, p≤ 0.001) and Fe-bLf (45 fold, p≤ 0.001) were found to be more effective in 
downregulating the migration potential at 40 nM when compared to Native-bLf (6.42 fold, 
p≤ 0.01). Therefore both Apo-bLf and Fe-bLf were equally effective against LM-MEL-12 (WT 
BRAF and NRAS) cells.  
As shown in Figures 4.9 B & F, both 20 nM and 40 nM of Fe-bLf (p≤ 0.001) completely 
downregulated the migratory potential of LM-MEL-1a (NAS Q16K) cells. Both 20 nM and 40 
nM of Apo-bLf 18 fold, p≤ 0.01 and 22 fold, p≤ 0.01, respectively showed comparatively 
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better downregulation in migration potential than Native-bLf 20 nM (9 fold, p< 0.05) and 40 
nM (10 fold, p< 0.05).  
In case of LM-MEL-62 (BRAF G469E) cells, a dose-dependent downregulation in the 
migratory potential with all the three forms of bLf were observed (Figures 4.9 C & F). Fe-bLf 
led to a complete inhibition of migration potential at 40 nM (p≤ 0.001) while Native-bLf 
caused a 9 fold (p≤ 0.001) decrease. Native-bLf was the least effective treatment (2 fold, p< 
0.05) when compared to Apo-bLf and Fe-bLf.  
LM-MEL-24 (BRAF V600K) cells (Figures 4.9 D & F) showed a dose-dependent decrease in 
the migration potential with all the three forms of bLf. Apo-bLf (32.8 fold, p≤ 0.001) 40 nM 
was more effective when compared to Native-bLf (7.80 fold, p≤ 0.01) and Fe-bLf (8.63 fold, 
p≤ 0.01).  
Drug-resistant Mel-007 (DR) cells (Figure 4.9 E & F) showed a dose-dependent decrease 
with Native-bLf. Apo-bLf at 20 nM and 40 nM led to complete inhibition (p≤ 0.001) of 
migration potential while 40 nM of Native-bLf (12 fold, p≤ 0.01) and Fe-bLf (10 fold, p≤ 0.01) 
were found to be equally effective.  




Figure 4.9 (A). Effect of bLf on migratory potential of LM-MEL-12 (WT BRAF and NRAS) 
cells. Cells were allowed to grow in 8 µm pores sized 12-well inserts in the presence of 
Native-bLf, Apo-bLf and Fe-bLf at 20 nM and 40 nM for 48 h. Cells grown in the presence of 
media alone were used as control. Number of cells that migrated through the 8 µm pores 
were fixed with 4 % PF and stained with 1 % crystal violet and imaged. Treatments were 
done in triplicates and the experiment was performed twice independently. Representative 
images from each treatment were shown.  




Figure 4.9 (B). Effect of bLf on migratory potential of LM-MEL-1a (NRAS Q16K) cells. 12 
well, 8 µm pore thin-certs were used to grow cells in the presence of media containing 20 
nM and 40 nM of Native-bLf, Apo-bLf and Fe-bLf for 48 h and in the presence of media alone 
as the untreated control. Migrated cells were fixed with 4 % PF and stained using 1 % crystal 
violet for 20 min and imaged. Treatments were done in triplicates and the experiment was 
performed twice independently. Representative images from each treatment were shown. 




Figure 4.9 (C). Effect of bLf on migratory potential of LM-MEL-62 (BRAF G469E) cells. Cells 
were checked for their migratory potential by allowing them to grow in 12 well plates, on 8 
µm pore thin-certs. Cells were allowed to grow for 48 h either in media alone and media 
containing Native-bLf, Apo-bLf or Fe-bLf treatments at 20 nM or 40 nM. After 48 h, the cells 
that migrated through the pores were fixed with 4 % PF and stained using 1 % crystal violet 
and imaged. Treatments were done in triplicates and the experiment was performed twice 
independently. Representative images from each treatment were shown. 




Figure 4.9 (D). Effect of bLf on migratory potential of LM-MEL-24 (BRAF V600K) cells. 
Treatments of 20 nM and 40 nM of Native-bLf, Apo-bLf and Fe-bLf for 48 h were checked for 
their effects on the migratory potential of cells using 8 µm pores sized 12-well inserts. Cells 
that migrated through the pore under the influence of one of the above mentioned 
treatments and media alone were fixed with 4 % PF and stained with 1% crystal violet and 
imaged. Treatments were done in triplicates and the experiment was performed twice 
independently. Representative images from each treatment were shown. 




Figure 4.9 (E). Effect of bLf on migratory potential of Mel-007 (DR) cells. Cells were allowed 
to grow in 8 µm pores sized 12-well inserts in the presence of Native-bLf, Apo-bLf and Fe-bLf 
at 20 nM and 40 nM for 48 h. Cells grown in the presence of media alone were used as 
control. Number of cells that migrated through the 8 µm pores were fixed with 4 % PF and 
stained with 1 % crystal violet and counted. Treatments were done in triplicates and the 
experiment was performed twice independently. Representative images from each 
treatment were shown. 




Figure 4.9 (F). Assessment of the effect of bLf on the migratory potential of melanoma cell 
lines. Number of cells that migrated through the 8 µm pores were stained with 1 % crystal 
violet, imaged and counted from five different fields. The number of migratory cells that 
were counted in each treatment using a microscope was plotted on a graph. Untreated cells 
were used as control. Treatments were done in triplicates and the experiment was 
performed thrice independently. All the values are represented as mean ± SE and the 
experiments were repeated thrice. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) represented as *, (p≤ 0.01) as ** and p≤ 0.001 as *** was 
considered statistically significant when compared to untreated cells. A value of (p≤ 0.01) 
represented as † is considered significant amongst the treatments.  
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4.5.10 Nuclear localisation of p53 with bLf treatments  
Apoptotic array results from SK-MEL-2 and SK-MEL-28 cell lines (Chapter 3) showed an 
increase in the phospho-p53 expression post-bLf treatments. To evaluate the effect of bLf 
on p53 expression in the patient-derived mutational melanoma cell lines, 
immunofluorescence studies were performed. The cells were plated in 8-chambered slides 
and treated with 40 nM of all the three forms of bLf (Native, Apo and Fe-bLf) for 48 h. After 
treatment, the cell layer was washed, fixed and stained specifically for p53 expression. The 
expression patterns of p53 was visualised using a confocal microscope (Figure 4.10 A-E).  
It was observed among the five cell lines tested, that Native-bLf, Apo-bLf and Fe-bLf were 
able to increase the p53 expression that was indicated by an increase in the green 
fluorescence intensity, while the untreated cells had very low expression of p53, and this 
expression was limited mainly to the cytoplasm. With bLf treatments, p53 expression was 
found to be upregulated and localised in both cytoplasmic and nuclear regions. Native-bLf 
and Apo-bLf treatments were the only exceptions, in the case of LM-MEL-62 (BRAF G469E), 
LM-MEL-24 (BRAF V600K) and Mel-007 (DR), where the expression of p53 was increased but 
remained only in the cytoplasmic region of the cells. Fe-bLf was convincingly the most 
effective in inducing higher p53 expressions in nearly all the 5 cell lines.  




Figure 4.10 (A). p53 expression patterns in LM-MEL-12 (WT BRAF and NRAS) with bLf 
treatments. Cells were allowed to grow on an 8 well culture slide at cell density of 103 cells. 
The cells were treated with Native-bLf, Apo-bLf and Fe-bLf at 40 nM for 48 h to study 
cellular localisation patterns of p53 with bLf treatments. The treated cells were fixed with 4 
% PF for 20 min, permeabilized using 0.1 % Triton-X100 for 2 min on ice and then blocked 
using 3 % rabbit serum for 1 h at 37oC. The cells were probed with specific mouse anti-
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human p53 antibody and mouse IgG FITC (secondary antibody) for 1 h each. DAPI with 
mounting media was used to stain the nucleus. The p53 staining was visualised using 
confocal Leica SP5 microscopy and the representative images were shown (processed using 
LAS-AF software). 
 
Figure 4.10 (B). p53 expression patterns in LM-MEL-1a (NRAS Q16K) with bLf treatments. 
Treatment of LM-MEL-1a (NRASQ16K) cells, with Native-bLf, Apo-bLf and Fe-bLf at 40 nM 
concentration was done after the cells were allowed to grow on 8 well chambered slides. 
Cells were treated for 48 h, fixed with 4 % PF and then permeabilized using 0.1 % Triton-
X100 for 2 min on ice. Cells were blocked with 3 % rabbit serum for 1 h at 37oC, following 
which they were stained with specific mouse anti-human p53 primary antibody for 1 h at 
37oC. Secondary antibody anti-mouse IgG FITC at 1:100 concentrations was then added and 
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cells were incubated for 1 h at 370C.  Nucleus was stained using DAPI with mounting media. 
p53 expression was visualised using Leica SP5 confocal microscopy and representative 
images were shown. 
 
Figure 4.10 (C). p53 expression patterns in LM-MEL-62 (BRAF G469E) with bLf treatments. 
Effect of bLf on the expression patterns of p53 was studied by treating the cells with 40 nM 
concentration of Native-bLf, Apo-bLf and Fe-bLf for 48 h. The treated cells were fixed for 20 
min using 4 % PF following which they were permeabilized with 0.1 % Triton-X 00 for 2 min 
on ice. The permeabilized cells were blocked with 3 % rabbit serum for 1 h at 37oC, and 
stained with specific mouse anti-human p53 primary antibody for 1 h at 37oC. Secondary 
antibody anti-mouse IgG FITC at 1:100 concentrations was then added and cells were 
incubated for 1 h at 370C. Nuclear staining was done using DAPI with mounting media. p53 
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expression was visualised using Leica SP5 confocal microscopy and representative images 
were shown.  
 
Figure 4.10 (D). p53 expression patterns in LM-MEL-24 (V600K) with bLf treatments. To 
study and visualise the p53 expression, cells were treated with 40 nM concentrations of 
Native-bLf, Apo-bLf and Fe-bLf for 48 h. After treatments, the cells were fixed and 
permeabilized using 4 % PF and 0.1 % Triton-X 100, respectively. Blocking was performed 
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using 3 % rabbit serum for 1 h and the cells were stained with specific primary antibody 
(anti-human p53 at 1:100) and secondary antibody (anti- mouse IgG FITC) at 1:100 for 1 h at 
37oC. DAPI was used as a nuclear stain with mounting media and the cells were visualised 
using Leica SP5 confocal microscopy. Representative images were shown.  
 
Figure 4.10 (E). p53 expression patterns in Mel-007 (DR) with bLf treatments. Following 
treatments with all the three forms of bLf at 40 nM for 48 h, the cells were fixed with 4 % PF 
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and permeabilized using 0.1 % Triton-X100 for 2 min on ice. The cells were then blocked 
with 3 % rabbit serum for 1 h at 37oC. Cells were then probed with specific primary antibody 
anti-human p53 at 1:100 concentrations and then stained with anti-mouse IgG FITC at 1:100 
concentrations for 1 h at 37oC. Nucleus staining was done using DAPI with mounting media. 
The p53 expression was visualised using Leica SP5 confocal microscopy and the 
representative images were shown.  
4.5.11 p53 dependent apoptosis is induced by Apo-bLf and Fe-bLf treatments in LM-MEL-
1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) 
 From the results in Chapter 3 it was observed that all the three forms of bLf were able to 
cause significant upregulation of phospho-p53 in SK-MEL-2 and SK-MEL-28 cells. Further 
confirmatory studies with all the three forms of bLf on the modulation of p53 protein 
expression following bLf treatments was visualised in this chapter (Figures 4.10 A-E). 
Confocal visualisation of cellular localisation of p53 with bLf treatments was investigated, 
and its nuclear localisation with Apo-bLf and Fe-bLf was mainly observed as described 
above. 
To study the pathway of p53-dependent apoptosis with the iron-free and iron-saturated 
forms of bLf, Western blotting analysis was further carried out. A few important molecules 
involved in the p53-dependent pathway were analysed in three mutant cells namely, LM-
MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells. The molecules that 
were investigated for this pathway were p53, phospho-p53, Numb, MDM2, survivin, Bax 
and Bcl-2. Interestingly, the trend and pathway proteins were regulated according to the 
different mutational status and drug-resistant status of the cells (Figures 4.11 A & B). In LM-
MEL-1a (NRAS Q16K) cells, Apo-bLf showed an upregulation in the protein expression of 
phospho-p53, Numb and Bax (pro-apoptotic) and a downregulation of survivin and Bcl-2. 
However, Apo-bLf caused upregulation of MDM2 and downregulation of p53 in LM-MEL-1a 
(NRAS Q16K) cells. Fe-bLf 40 nM showed an increase in the expression of p53, phospho-p53, 
Numb and Bax, and Bcl-2, survivin and MDM2 were downregulated with Fe-bLf (Table 4.2).  
In LM-MEL-62 (BRAF G469E) cells (Table 4.2), Apo-bLf was able to upregulate the expression 
of p53 and Bax, cause downregulation of survivin, Bcl-2 but had no effect in the modulation 
of phoshpo-p53, Numb and MDM2. Interestingly, Fe-bLf was able to upregulate the protein 
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expression of p53, phospho-p53, Numb and Bax. Survivin and Bcl-2 were downregulated 
with Fe-bLf 40 nM at 48 h in LM-MEL-62 (BRAF G469E). However, in both LM-MEL-1a (NRAS 
Q16K) and LM-MEL-62 (BRAF G469E) cells, Apo-bLf and Fe-bLf, respectively caused 
upregulation of MDM2 (Figure 4.11, Table 4.2). 
Cisplatin drug-resistant Mel-007 cells showed an upregulation of p53, phospho-p53, Numb 
and Bax, and, downregulation of MDM2, survivin and Bcl-2 with both Apo-bLf and Fe-bLf 
(Table 4.2). 
 
Figure 4.11 (A). bLf induces p53-dependent pathway of apoptosis in melanoma cell lines. 
LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells were treated 
with Apo-bLf and Fe-bLf at 40 nM treatment concentrations for 48 h. Cell lysates were 
collected post-treatments and 100 µg of lysate was used for Western blot analysis. 3 % skim 
milk in TBST was used for blocking non-specific proteins. Specific primary and secondary 
antibodies were used and the immunoreactive bands were detected using ECL reagent. The 
samples were tested for equal protein loading with GAPDH. Relative fold change for each 
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protein was calculated using GAPDH as the house-keeping gene using Image J software 
analysis (Table 4.2).  
Table 4.2. Image J analysis of protein expression patterns. 
 
4.5.12 Downregulation of wild-type p53 expression prevents melanoma cells to undergo 
apoptosis post-bLf treatments 
To confirm that the p53-dependent apoptosis induced by bLf, a p53 another experiment 
was performed by silencing the p53 expression of melanoma cell lines. Cells were plated in 6 
well plates and specific siRNA for p53 was used to silence the expression of p53. To confirm 
the successful silencing of p53, Western blotting was done to check the siRNA activity. 
Western blot results confirm that p53 gene was silenced leading to no expression of the p53 
protein (Figure 4.12 A). The p53 silenced cells were then treated with Apo-bLf and Fe-bLf to 
confirm if the activity of bLf is through p53-dependent pathway alone. Annexin-V assay was 
done to confirm this hypothesis. Interestingly, none of the cells where p53 gene was 
silenced showed any form of apoptosis or necrosis in the bLf treated cells (Figure 4.12 B-D). 
     Chapter 4- Effect of bLf on melanomas with varying mutations and drug resistant status 
253 
 
However, in the p53 non-silenced cells, Apo-bLf and Fe-bLf were able to cause apoptosis as 
described in the results before. In the non-p53 silenced (Apo-bLf and Fe-bLf treated cells, a 
very high percentage of cells were observed in the apoptotic region proving the p53-
dependent effect of the two forms of bLf tested. The key finding from this study was the 
confirmation of Apo-bLf and Fe-bLf in causing apoptosis is p53-dependent in all the three 
cell lines studied. 
 
Figure 4.12 (A). P53 silencing in melanoma cell lines. Cells were grown in a 6 well plate and 
then transfected with 50 nM and 100 nM concentration of siRNA for p53 for 24 h, 48 h and 
72 h. Post-transfection, cell lysates were collected and 100 µg of lysate was used for 
Western blotting. Anti-human p53 mouse monoclonal antibody (1:1000) was used for 
immunoblotting. Secondary antibody, anti-mouse IgG HRP (1:100,000) was used and the 
immunoreactive bands were detected by the ECL method. The samples were tested for 
equal protein loading with GAPDH. Anti-human GAPDH rabbit monoclonal antibody (1:1000) 
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was used as primary antibody and anti-rabbit IgG HRP (1: 80000) was used as secondary 
antibody. The immunoreactive bands were detected using ECL reagent.  
 
Figure 4.12 (B). Analysis of p53-dependent apoptotic pathway in LM-MEL-1a (NRAS Q16K). 
Cells were treated with siRNA for p53 for the predetermined time-interval and subsequent 
treatments were done with Apo-bLf at Fe-bLf at 40 nM for 48 h to study the cell death 
patterns. Cells not treated with siRNA for p53 were used as controls. The treated and 
untreated cells were stained with annexin-V/PI and analysed through FACS. The results were 
quantified using FACS-Diva software. Treatments were done in triplicates and the 
experiment was performed thrice independently. Representative FACS plots were shown.  
 




Figure 4.12 (C). Analysis of p53-dependent apoptotic pathway in LM-MEL-62 (BRAF 
G469E). Following treatments with siRNA p53, cells were treated with 40 nM of Apo-bLf and 
Fe-bLf for 48 h. Untreated cells were maintained as control. The treated and untreated cells 
were stained with annexin-V/PI and analysed through FACS. The results were quantified 
using FACS-Diva software. Treatments were done in triplicates and the experiment was 
performed thrice independently. Representative FACS plots were shown.  
 




Figure 4.12 (D). Confirmation of p53-dependent apoptotic pathway in Mel-007 (DR). After 
treatments with siRNA for p53 and subsequent treatments with Apo-bLf and Fe-bLf at 40 
nM, the cells were stained with annexin-V/PI and the stained cells were counted and 
analysed using FACS. The treated and untreated cells were stained with annexin-V/PI and 
analysed through FACS. The results were quantified using FACS-Diva software. Treatments 
were done in triplicates and the experiment was performed thrice independently. 
Representative FACS plots were shown. 
4.6 DISCUSSION 
Drug resistance in melanoma is one of the most challenging and critical aspects that needs 
to be addressed when developing a therapeutic strategy for melanoma. BRAF mutations 
occur most commonly in melanomas leading to poor-survival and drug response in patients 
although it does not affect the prognosis of melanoma (Meckbach et al. 2014). NRAS 
mutations are also commonly related to melanoma and can occur alongside BRAF mutations 
(Chiappetta et al. 2014). Cell lines with BRAF and NRAS mutations were hence studied in this 
chapter. This will help to validate the anti-cancer efficacy of bLf on melanoma cells 
irrespective of their BRAF, NRAS and drug-resistant status.  
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      It was revealed from this study on primary patient derived cell lines that, under normal 
growth conditions, the WT BRAF and NRAS melanoma cells (LM-MEL-12) showed a high 
migratory potential but comparatively low spheroid forming ability. The BRAF V600K mutant 
melanoma cells (LM-MEL-24) were characteristically very similar to the WT BRAF and NRAS 
(LM-MEL-12) cells, as they too showed similar migratory and low spheroid forming 
capabilities. However, its spheroid forming ability was comparatively better than the WT 
BRAF NRAS melanoma cells. On the other hand, the BRAF G469E mutant melanoma cells 
(LM-MEL-62), the NRAS Q16K mutant (LM-MEL-1a) and the drug resistant (Mel-007) 
melanoma cells were found to be characteristically similar. They showed the same tumour 
spheroid forming potential. Also, the clonogenic potential of LM-MEL-62 (BRAF G469E) and 
Mel-007 (DR) was higher than LM-MEL-1a (NRAS Q16K), However, all the three cell types, 
i.e., LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) showed 
comparatively lower migration potential than LM-MEL-12 (WT BRAF and NRAS) and LM-
MEL-24 (BRAF V600K). Therefore, it was inferred from these results that the mutations of 
BRAF and NRAS genes and the induction of drug resistance enhances the tumour spheroid 
and clonogenic potential (cell proliferation) of melanoma cells, whereas, it also lowers their 
migration potential. Previously published studies have shown that BRAF and NRAS 
mutations increases cell proliferation in melanoma cells by activating the Akt pathway 
(Halaban et al. 2010). Although studies have reported that BRAF and NRAS mutations may 
lead to activation of Akt pathway and cause malignant transformation in melanoma (Brose 
et al. 2002), there are no studies that claim effect on migration potential of melanoma cells 
with BRAF G469E and NRAS Q16K mutations. Therefore, this is the first study to report that 
such mutations may lead to a decrease in the migration potential of melanoma cells. 
Further investigations regarding the invasive capacity of these cells should be carried out.   
It was imperative to check whether bLf was capable of internalising into the BRAF, NRAS 
wild type and mutant, as well as drug-resistant cells and target their growth and cell death , 
as a number of mechanisms do not allow the entry of anti-cancer agents into drug-resistant 
cell lines (Smalley et al. 2006). The inclusion of patient-derived cisplatin-resistant cell line 
Mel-007 (DR) formed an interesting aspect of this study.   
It was found earlier that, Native-bLf, Apo-bLf and Fe-bLf were all able to internalise via 
receptor mediated pathways in the SK-MEL-2 and SK-MEL-28 cells. In this phase of the 
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study, determination of the internalization efficiency of bLf forms in patient derived-mutant 
and drug resistant melanoma cells revealed that eventually by 6 h all the bLf forms, i.e., 
Native-bLf, Apo-bLf and Fe-bLf were efficiently internalised. In order to understand this 
effect, q-RT-PCR analysis was carried out to determine the gene expression levels of various 
lactoferrin receptors in all cell lines. It was revealed that all the three forms of bLf used 
different receptors to internalize in the melanoma cells. The difference in the modulation of 
the expression patterns of the receptors in the different cell lines indicate the possibility of 
the use of different receptors by the three forms of bLf as all the three forms were able to 
internalise into the melanoma cell lines after 6 h (Figure 4.2). Downregulation of Lf 
receptors was also observed with all the three forms of bLf which needs further 
investigations at the protein expression levels. It has been reported earlier that both Apo-
bLf and holo-bLf internalise by LfR via clathrin-mediated endocytosis (Jiang et al. 2011; 
Kanwar et al. 2014). On the other hand Fe-bLf may internalise via LRP, LfR and TfR (Kanwar 
et al. 2014; Samarasinghe, Kanwar & Kanwar 2014). It was found that in LM-MEL-12 (WT 
BRAF and NRAS), all the forms of bLf could have internalised via TfR1, in LM-MEL-62 (BRAF 
G469E) and LM-MEL-24 (BRAF V600K), LfR and LfR-2 could have been utilised, respectively. 
BRAF mutant melanomas are associated with upregulation of its downstream MEK/ERK 
pathway leading to survival and proliferation of melanoma cells (Joseph et al. 2010). It has 
also been reported that ERK signaling is regulated by LRP-1 expression (Bergeron et al. 
2010). In the present study, it was noted that LRP-1 expression was upregulated in the BRAF 
V600K mutant LM-MEL-24 cells. Internalisation efficiency of all the three forms of bLf was 
not as effective as seen in some cell lines possibly due to the significant downregulation of 
some Lf receptors as shown in Table 4.1. Further in depth conformational analysis of the 
receptors and their lactoferrin binding domains may provide a wider perspective on the 
interaction between the lactoferrin receptors and the bLf forms.  
This difference may be due to the structural difference between the bLf iron free and iron 
saturated forms because of the iron atom binding, leading to conformational changes. As 
described in Chapter 1 (section 1.5.2), iron saturation leads to close conformation of the C 
lobe and the N lobe whereas iron-free (Apo-bLf) is characterised by open conformation of 
the N lobe (Baker & Baker 2009). Since drug resistance is a prevailing problem with the use 
of chemotherapeutics denying the entry and effect of chemotherapeutic molecules in 
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cancer cells (Helmbach et al. 2001), bLf (a natural molecule) therefore, holds potential as an 
anticancer drug for melanoma since it’s internalisation is not restricted in drug-resistant 
melanoma cells. 
An interesting confocal microscopic observation was the interaction of bLf with the actin 
structure of the cells. bLf showed a high co-localisation with actin in cells. This could be a 
possible mechanism for bLf’s anti-tumour activity where it destroys the actin structure of 
the cell. An in vivo study on colon cancer has proved the role of both bLf and hLf on the 
degradation of the actin structure of the cells (Blais et al. 2014). More recently data from 
our laboratory also showed the effect of high molecular weight (HMW)-bLf on actin 
structure in colon and breast cancer cells (Ebrahim et al. 2014). Therefore, the effect of bLf 
on morphology of all melanoma cells was evaluated. Two most critical characteristics of 
apoptosis include membrane-blebbing (Ruben et al. 2014) and rounding of the cells (De Las 
Llagas, Santiago & Ramos 2014). Rounding of cells indicate the degradation of cell’s 
cytoskeleton proteins such as actin, which was noted with bLf treatments in all the 
melanoma cell lines. This indicated that bLf had the capability to induce cytotoxicity in these 
melanoma cell lines.  
There are reports that claim a decrease in cell proliferation in melanoma cells and tumours 
in vivo with treatments of bLf, in particularly with iron saturated lactoferrin (Kanwar et al. 
2008).  Another study demonstrated that nano-formulated Apo-bLf inhibited the cell 
proliferation of B16-F10 melanoma cells by affecting their cell cycle progression (Roseanu et 
al. 2010). In order to evaluate the cytotoxic effects of bLf in the melanoma cell lines, three 
forms of bLf with different iron status were used in this current study. All the three bLf 
forms at 80 nM induced significant levels (p≤ 0.001) of cytotoxicity inLM-MEL-24 (BRAF 
V600K), LM-MEL-62 (BRAF G469E) cells, while both Native-bLf and Fe-bLf were effective (p≤ 
0.001) in LM-MEL-1a (NRAS Q16K) cells. It was observed that both Apo-bLf and Fe-bLf were 
effective (p≤ 0.001) in LM-MEL-12 (WT BRAF and NRAS) cells. Only Native-bLf was found to 
be the most significant (p≤ 0.001) in causing cytotoxicity in Mel-007 (DR) cells. To confirm 
the apoptotic effect of bLf on the melanoma cell lines, annexin-V assay was performed. All 
the three forms of bLf samples tested largely indicated the cells to be in the early and/or the 
late apoptotic region. This proves the ability of bLf to cause apoptosis in all the melanoma 
cell lines as shown in other studies where bLf has proved to cause apoptosis in cancer cells 
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(Kanwar et al. 2014; Mader et al. 2005). In accordance with cytotoxicity results in, LM-MEL-
12 (WT BRAF and NRAS) cells though the three forms of bLf induced significant apoptosis, it 
was further determined that Apo-bLf and Fe-bLf were equally effective in causing apoptosis, 
while LM-MEL-1a (NRAS Q16K) was more sensitive to the bLf forms containing iron (Native-
bLf and Fe-bLf).  This again shows that the WT BRAF and NRAS cells, the effect of bLf is 
independent of its iron content. LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells showed 
maximum cell death with Native-bLf while LM-MEL-24 (BRAF V600K) was most susceptible 
to both Native-bLf and Apo-bLf.  
Cell proliferation studies revealed that all the three forms of bLf were equally effective in 
LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-24 (BRAF V600K) and 
Mel-007 (DR) cells. Interestingly, Fe-bLf was found to be most effective in reducing the cell 
proliferation of LM-MEL-62 (BRAF G469E) cells.  To further validate the effect of bLf on 
targeting melanoma cell growth, 3D culture of all the melanoma cells were checked for the 
effect of bLf on the tumour spheroids. The cultured tumour spheroids mimic the tumour 
microenvironment as it replicates the physiological environment of the tumour (Kempf et al. 
2013). The effect of bLf on the tumour spheroids formed led to significant reduction in the 
size of the tumour spheroids after 48 h. In case of LM-MEL-1a (WT BRAF and NRAS) and LM-
MEL-24 (BRAF V600K), Native-bLf was most effective while Fe-bLf was most effective in LM-
MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells. The 
pathophysiological gradients of a 3D tumour spheroid comprise of an inner dark zone or the 
quiescent zone with low nutrient levels and waste deposits making it a necrotic zone. The 
outer and transparent, nutrient rich region is the proliferating zone (Michael 2012). In case 
of LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-24 (BRAF V600K) 
and Mel-007 (DR) cells it was clearly observed that all the three forms of bLf substantially 
reduced the proliferating zone of the tumour spheroids, proving the role of bLf in being able 
to tackle the tumour spheroid growth hence proving its potential as a molecule that can 
effect in in vivo conditions and can act on tumour even in the presence of a complex tumour 
microenvironment. There are no published reports so far that show the anti-cancer efficacy 
of bLf forms in a 3D multicellular tumour spheroid model. However, a recent study from our 
laboratory has reported that nanoformulated form of Fe-bLf led to reduction in size and 
complete destruction of multicellular tumour spheroids at 96 h in colon cancer cells (Kanwar 
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et al. 2014). Therefore, in this study the anti-cancer efficacy of bLf forms with varying iron 
content   on patient derived melanoma spheroids is reported for the first time. 
Clonogenic potential of cancer cells is one of the reasons for the relapse of cancer. The cells 
that escape treatment and are capable of forming colonies are responsible for attributing 
the clonogenic potential to cancer cells (Cristóbal et al. 2014; Nagalingam et al. 2014). 
Colony forming ability of all the cells was significantly downregulated with bLf treatments. 
Native-bLf, Apo-bLf and Fe-bLf at 40 nM concentrations reduced the number of colonies 
formed to zero in the case on LM-MEL-12 (WT BRAF and NRAS) and LM-MEL-24 (BRAF 
V600K) cells. In the other 3 cell lines the clonogenic potential was also found to be reduced 
substantially with higher treatments of both Native-bLf and Fe-bLf.   
Previously published studies have reported that bovine lactoferricin (a peptide derived from 
bLf) led to inhibition of lung metastasis in B16 melanoma model and liver and lung 
metastasis of L5178Y-ML25 lymphoma cells thereby, suggesting that bLf has the capability 
to reduce the metastatic potential in melanoma cells (Yoo et al. 1998).  Another study 
reported that both iron-saturated and Apo forms of human lactoferrin substantially reduced 
lung metastasis of B16-F10 melanoma cells in syngeneic mice confirming that apart from 
tumour inhibition and its forms also possess anti-metastatic ability (Bezault et al. 1994). 
Metastatic potential of cancer cells can be checked by its ability to pass through membranes 
of 8 µm pore size. Migration assay replicates this phenomenon in vitro where the effect of 
Native-bLf, Apo-bLf and Fe-bLf was determined on the migratory potential of all the 
melanoma cell lines being tested for bLf. The potential of all the three forms of bLf samples 
were tested and confirmed in various melanoma cell lines proving the role of bLf in 
inhibiting the migratory potential of melanoma cell lines which is also in accordance with 
the above mentioned studies. 
BRAF mutations, for example BRAF V600E mutant melanomas are known to proliferate and 
cause melanocyte transformation due to inactivation of p53 function (Yu et al. 2009). 
Reports claim that the effects of BRAF inhibition in melanocytes are independent of the p53 
activity (Sala et al. 2008). Therefore, there are no studies that have shown that an increase 
in p53 activity has therapeutic effects in melanoma. Oncogenic NRAS mutations, for 
example NRAS Q16K have been insufficient to promote tumour formation alone. However, 
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loss of p53 function has been associated with NRAS mutations in the development of 
melanoma in zebra fish melanoma model (Dovey, White & Zon 2009). It has been reported 
that inhibition of survivin using YM155 leads to increase in p53 activity that further induces 
apoptosis in human malignant melanoma models (Yamanaka et al. 2011). It has been 
reported in normal human melanocytes that p53 binds directly to the survivin promoter and 
regulates survivin expression. It also effects survivin expression via activation of p21. The 
same study also reported that a mutation in p53 leads to an increase in survivin promoter 
activity suggesting the role of p53 in regulating survivin expression in melanoma (Raj et al. 
2008). Previously published studies from our laboratory have reported that Fe-bLf 
downregulates survivin in cancer and cancer stem cells to induce apoptosis (Kanwar et al. 
2014). 
Therefore in order to investigate the involvement of survivin and p53 in the pathway of 
apoptosis and confirm the exact mechanism by which bLf causes apoptosis, the p53 
pathway was studied. From results obtained in Chapter 3 where Apo-bLf and Fe-bLf caused 
upregulation of p53 in SK-MEL-2 and SK-MEL-28 cells, and from literature about hLf causing 
upregulation of p53 (Hoedt et al. 2014) this pathway was of interest. Initial confocal 
visualisation showed nuclear localisation of p53 with all the three bLf forms and nuclear 
localisation of p53 is essential for the activity of p53 WT protein (Shaulsky et al. 1991). 
Downstream molecules like MDM2, Numb, Bcl-2, Bax, survivin and phospho-p53 were 
studied in three cell lines. Out of the five cell lines studied, only three cell lines were chosen 
due to their status of mutations or drug-resistant status. Mel-007 (DR) was chosen as it is a 
drug-resistant cell lines, LM-MEL-62 (BRAF G469E) were chosen as it contains a BRAF gene 
mutation and LM-MEL-1a (NRAS Q16K) is positive for NRAS mutations. Further information 
from the Ludwig Institute of Cancer Research showed that LM-MEL-62 (BRAF G469E) cells 
are mutant for p53 (S/F exchange on AA position 127). The p53 status of the other two cell 
lines remains unknown. It was considered in this study that choosing one of each of the cell 
types with either BRAF or NRAS mutations would help in understanding the role of the two 
forms of bLf (Apo-bLf and Fe-bLf) in the three different aspects of mutations and drug-
resistance.  
Interestingly, all the three cell lines that were tested showed an upregulation of the p53-
dependent pathway of apoptosis.  
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Fe-bLf, is known to target and downregulate survivin expression and reduction in survivin 
expression (Kanwar et al. 2014), and known to cause an increase in the wild-type p53 
expression (Raj et al. 2008). Accordingly, both Apo-bLf and Fe-bLf induced downregulation 
of the survivin expression in all the three melanoma cell lines tested. LM-MEL-1a (NRAS 
Q16K) and LM-MEL-62 (BRAF V600K) cells showed downregulation of survivin with both 
Apo-bLf and Fe-bLf, whereas; in Mel-007 (DR) cells, Fe-bLf was most effective in 
downregulating survivin expression. For survivin targeting, no difference in the bLf forms 
with varying iron content was seen in LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF 
V600K) cells. In Mel-007 (DR) cells, the iron saturated form of bLf proved more effective. 
This could be due to the varying iron metabolism status in these cell lines. It has been 
previously reported that metal chelators, for example, pyrrolidine dithiocarbamate (PDTC)  
led to an increase in the wild-type p53 activity (Verhaegh, Richard & Hainaut 1997). 
Therefore, it can be explained that increase in the p53 activity due to Apo-bLf, could 
possibility be due to Apo-bLf being a metal (Fe) chelator (Yoo et al. 1998). The current study 
also made an interesting observation, as it pointed a future potential of using Fe-bLf in all 
melanoma cells, in being able to upregulate the expression of p53 thereby, leading to 
apoptosis in melanoma cells.  
p53 pathway is one of the most critical pathways and its activation has been pointed out as 
a critical phenomenon for developing therapeutics for malignant melanoma (Jochemsen 
2014) and breast cancer (AGBOOLA et al. 2014). To confirm that bLf acts through the p53-
dependent pathway of apoptosis and to confirm whether p53-pathway was the major 
pathway activated by bLf to cause apoptosis, an initial study was done by silencing the p53 
expression and then checking the effect of bLf on these cell lines. As hypothesised, on 
silencing the expression of p53 did not cause any apoptosis in the three melanoma cell lines 
tested even after treatment with high concentrations of bLf. This indicates that the activity 
of bLf is specifically by upregulating the expression of WT p53 leading to p53-dependent 
apoptosis in LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR). This is a 
very promising finding considering the different mutational status of cells and drug-resistant 
phenotype. However, further in-depth analysis about the endogenous p53 status of these 
cell lines is also required in the future, in order to identify whether these cells are p53 WT or 
p53 mutant. It will also help in developing a better understanding of the p53-dependent 
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pathway, the role of the iron-free and iron-containing forms of bLf and their relation to the 
mutational status of the cells.  
To conclude, all the findings presented in this chapter, a comparative analysis of all the in 
vitro assays was performed in order to determine which form of bLf was overall the most 
effective in which type of melanoma cells (Table 4.3). It was found that all the three forms 
of bLf were able to cause a significant effect on the cell growth and anti-cell proliferative 
properties of the melanoma cell lines tested. Therefore these results reveal that the WT 
BRAF and NRAS (LM-MEL-12) cells and the BRAF V600K mutant melanoma (LM-MEL-24) 
cells responded in a similar way to bLf. Apo-bLf (iron free form of lactoferrin) was found to 
be the most effective in targeting their cell death and cell growth mechanisms while, the 
NRAS Q16K mutant (LM-MEL-1a), the BRAF G469E mutant (LM-MEL-62) and the drug 
resistant (Mel-007) melanoma cells (as mentioned above) since, Fe-bLf (iron-saturated form 
of lactoferrin) was found to be the most effective against these cells. This inference 
therefore implies that the effect of the bLf forms could be related to the iron metabolism of 
the melanoma cells. Therefore, an in depth analysis of the iron metabolism pathways, the 
iron metabolizing enzymes and other key molecules involved in iron storage and transport 
will provide a wider perspective and a better understanding of this phenomenon. It is also 
worth exploring whether BRAF/NRAS mutations lead to changes in the way the cells 
metabolize iron for their growth and other regulatory pathways. This study therefore 
demonstrated the potential of using naturally derived glycoprotein bLf in its various forms 
and also provides a platform for further iv vivo research in order to establish lactoferrin as 
an effective therapeutic against metastatic melanomas with different mutational status. 
Table 4.3. Comparative analysis of the effect of three forms of bLf in patient-derived 
primary melanoma cell lines. 
Name of the assay Native-bLf Apo-bLf Fe-bLf 
LM-MEL-12 (WT BRAF and NRAS) 
Internalisation * *** ** 
Cell proliferation 
assay 
*** *** *** 
Cell cytotoxicity ** *** *** 






** *** *** 
Tumour spheroid 
assay 
*** --- --- 
Clonogenic assay *** *** *** 
Migration assay ** *** *** 
Upregulation of p53 
(WB- not done) 
*** ** *** 
LM-MEL-1a (NRAS Q16K) 
Internalisation * *** ** 
Cell proliferation 
assay 
* *** ** 
Cell cytotoxicity 
assay 
*** ** *** 
Annexin-V/PI 
staining  
*** * ** 
Tumour spheroid 
assay 
* ** *** 
Clonogenic assay *** * ** 
Migration assay * ** *** 
Upregulation of p53 * ** *** 
LM-MEL-62 (BRAF G469E) 
Internalisation * *** ** 
Cell proliferation 
assay 
** ** *** 
Cell cytotoxicity 
assay 
*** ** ** 
Annexin-V/PI 
staining  
*** * ** 
Tumour spheroid ** * *** 




Clonogenic assay *** * *** 
Migration assay * *** *** 
Upregulation of p53 * *** ** 
LM-MEL-24 (BRAF V600K) 
Internalisation ** *** *** 
Cell proliferation 
assay 
** *** *** 
Cell cytotoxicity 
assay 
*** *** ** 
Annexin-V/PI 
staining  
*** ** * 
Tumour spheroid 
assay 
*** ** ** 
Clonogenic assay *** *** *** 
Migration assay * *** ** 
Upregulation of p53 
WB-not done 
* ** *** 
Mel-007 (DR) 
Internalisation * *** ** 
Cell proliferation 
assay 
** *** *** 
Cell cytotoxicity 
assay 
*** ** * 
Annexin-V/PI 
staining 
*** * ** 
Tumour spheroid 
assay 
** ** *** 
Clonogenic assay *** ** *** 
Migration assay * *** ** 
Upregulation of p53 * ** *** 




The in vitro findings of this chapter provide confirmation of the promising potential of bLf as 
a natural therapeutic option in targeting melanoma cell growth and death. For the first time 
it provides new knowledge about bLf’s activities in p53 mediated apoptosis, to target drug-
resistant melanomas and melanomas that develop mutations that most commonly occur in 
melanomas. It would be interesting to study the effect of bLf on drug-resistant markers to 
observe the effects of bLf and to understand the mechanism by which it targets a particular 
drug-resistant marker(s). The key conclusions derived from this study were that: bLf forms 
(Native, Apo and Fe-bLf) were able to internalize in wild type as well as mutant melanoma 
cells and drug-resistant melanoma cells efficiently through modulation of expression of bLf 
receptors. . A dose dependant effect of bLf forms was observed in reducing the cell 
proliferation and in increasing the cell cytotoxicity in melanoma cells. This study is the first 
to demonstrate that though natural (Native-bLf), iron-free (Apo-bLf) and iron-saturated (Fe-
bLf) forms of bLf were highly effective in targeting the cell growth, of mutant melanoma and 
drug-resistant melanoma cells, when grown as cellular monolayers (2D) and tumour 
spheroids (3D). It will be interesting to carry out an in-depth analysis of regulation of cellular 
iron metabolism in cells with different mutational status. Overall, bLf forms showed 
promising anti-cancer efficacy by targeting melanoma cell death and by substantially 
reducing the size of tumour spheroids within 48 h. This is also the first study to reveal that 
Fe-bLf could lead to stabilization of p53 by increasing the Numb and lowering the MDM-2 
levels in the mutant and the drug-resistant melanoma cells, to induce a p53 regulated 
apoptosis. Hence, not only does this study reveal the importance of p53 in mutant and drug-
resistant melanoma cells but also provides important observations on the promising anti-
cancer potential of naturally derived bLf and its forms in melanoma therapy. 




Figure 4.1 Possible mechanism of action of bLf in melanoma cell lines. A schematic 
representation was drawn to show the mechanism of action of bLf in LM-MEL-1a (NRAS 
Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) indicates receptor-mediated 
internalisation of bLf. Once internalised, bLf upregulates the protein expression of wild-type 
p53, Numb, Bax and downregulation in the protein expression of survivin, Bcl-2 and MDM2 
leading to p53-mediated apoptosis in the melanoma cell lines tested. In cancer cells that are 
not treated with bLf, numb expression is reduced further leading to overexpression of 
MDM2 that binds to p53. MDM2 binding to p53, leads to ubiquitination of p53, deactivating 
the function of p53 (as a tumour suppressor protein). This pathway may be targeted with 
bLf treatments leading to apoptosis in melanoma cell lines.






















Melanoma is the most aggressive form of skin cancer and its incidence has doubled in the 
past few decades (Jemal et al. 2001b). A number of drugs ranging from dacarbazine (DTIC), 
vincristine, vinblastine, cisplatin, carboplatin and lomustine have been used for treating 
melanomas, but none of the above mentioned drugs have been able to prolong the patient 
survival (Becker, Kämpgen & Bröcker 2000). Chemotherapy available to the cancer patients 
is not 100% effective, as the cells become drug-resistant. The genes that undergo the 
oncogenic mutations vary among different forms of cancer; hence every cancer has its own 
mechanism of becoming drug-resistant (Goldie & Coldman 2009).  
The key reasons that help cancer cells in acquiring drug resistance are; insensitivity to drug 
induced apoptosis and induction of drug-detoxifying mechanisms (Gottesman 2002b). 
Extensive research has been undertaken in order to identify, and understand the potential 
mechanisms of drug resistance, as these mechanisms are not completely understood. A 
number of chemokines and apoptotic molecules in combination with other factors are being 
worked upon, to develop targets in drug-resistant cancer cells. Numerous factors contribute 
in making the cancer cells drug-resistant (Housman et al. 2014). Processes like DNA repair, 
apoptosis, drug delivery and metabolism are involved in the genetic basis of resistance and 
sensitivity of the cells to anti-cancer drugs (Rabik & Dolan 2007). Hence, drug-resistance is 
said to be a multi-factorial phenomenon. A number of mechanisms have been explained as 
prime factors for contributing to multi-drug resistance (MDR) keeping in mind the 
transporters and micro RNA as prime focus (Kanwar, Kanwar & Singh 2011). A few more 
factors that are dependent on the individual response to cytotoxic drugs are reduced 
absorption or rapid excretion of the drug from the cells which result in failure of the drug 
action on the cancer cells (Pleun et al. 2001). The most critical factor that plays a main role 
in helping the cell acquire to MDR is the P glycoprotein (P-gp). The role of this protein has 
been very critical in the extrusion of drugs from the cells. Overexpression of P-gp,  on the 
membrane of the cells can cause failure in the acceptance of chemotherapy (He et al. 2011).  
One of the first reasons to be identified for drug resistance in melanoma is the drug 
transport mechanism that is exhibited by the melanoma cells which were dependent on P-
glycoprotein (P-gp) and multidrug resistance associated proteins (MRPs) (Borst et al. 2000). 
Though, most of the melanoma cell lines do not express P-gp, exposure to 
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chemotherapeutic drugs leads to the induction of its expression, thus proving its role in 
drug-resistant melanomas (Berger et al. 1994; Munoz et al. 2014; Schadendorf, Herfordt & 
Czarnetzki 1995).  
Upregulation of P-gp has been linked with alteration in a number of apoptotic pathways 
because of which cells acquire MDR. The use of polycationic nanoparticles to deliver anti-
cancer drug doxorubicin (Dox) and siRNA against P-gp in adriamycin-resistant breast cancer 
cell lines have shown to help resistant-cells undergo apoptosis through upregulation of Bax 
and downregulation of Bcl-2 both in vitro and in vivo in xenograft models (Shen et al. 2014). 
These cells acquired the property of resistance due to overexpression of P-gp. Similar 
phenomenon of upregulation of Bax due to reduction in P-gp expression was observed 
earlier in gastric cancer cells (Han et al. 2007). 
A number of studies then focussed on understanding the role of P-gp in various cancers, as 
number of cancers develop resistance to chemotherapy induced stress. It has been reported 
that pancreatic cancer cells develop resistance to gemcitabine by overexpression of P-gp, 
Bcl-2 proteins and MDR1 gene that encodes for P-gp (Chen et al. 2013). Changes in the 
glucose availability of the cells leads to enhanced reactive oxygen species (ROS) content that 
increases the expression of HIF-1α leading to P-gp overexpression in the cancer cells further 
causing drug resistance (Seebacher, Richardson & Jansson 2013). P-gp is responsible for the 
limited availability of drugs that are to be delivered to the brain as it is overexpressed on the 
blood-brain barrier. Erlotinib which is a substrate for P-gp had very low bioavailability due to 
its efflux by P-gp and breast cancer resistance protein (BCRP). Interestingly, knockout of 
these two transporters led to increased uptake of erlotinib in the brain (de Vries et al. 2012). 
Cisplatin-resistant ovarian cancer cell lines showed very high expression of P-gp when cells 
were treated with cisplatin every 21 days for 6 months, leading to decreased cellular 
localisation of the drug (Stordal et al. 2012).  
When inhibitors were used for P-gp the phenomenon of drug resistance was reversed 
leading to sensitivity towards paclitaxel that was delivered using polymeric micelles in 
breast cancer cell lines, where increase in the P-gp expression causes resistance to 
treatment with Dox (Wang et al. 2011). P-gp has been the prime target in order to formulate 
treatment strategies for drug-resistant cancer cells. 
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Co-delivery of a siRNA to silence the expression of P-gp has been used in combination with 
Dox by using mesoporous silica nanoparticles. This strategy allowed electrostatic binding of 
the drug on the surface of KB-V1 cells improving drug sensitivity (Meng et al. 2010). Co-
delivery of P-gp inhibitor, tariquidar with cytotoxic drug, paclitaxel using long-circulating 
liposomes has been able to sensitize taxol resistant ovarian cancer cells SKOV-3 to 
treatment with the drug by decreasing P-gp expression in these drug-resistant cells (Patel et 
al. 2011).  
Three generations of P-gp inhibitors have been developed. The first generation of P-gp 
inhibitors are metabolites like verapamil, cyclosporine A, vincristine and tamoxifen etc. that 
are already being used in clinical trials. Very high concentrations on these drugs were 
required to inhibit P-gp (Lomovskaya & Bostian 2006; Lomovskaya et al. 2007). The second 
generation of P-gp inhibitors are compounds that have not been used as therapeutics but 
have a higher affinity for P-gp. A few second generation P-gp inhibitors used are, (R) - 
verapamil, valspodar (PSC-833), elacridar, biricodar and dofequidar. The limitations with 
these inhibitors are that they get metabolised quickly which leads to alteration in their 
pharmacokinetics thereby turn reducing their efficacy (Kuppens et al. 2007; Pusztai et al. 
2005). Third generation inhibitors of P-gp are compounds that were developed using 
structure-activity relationship to identify specifically the compounds that have low toxicity 
but high specificity to P-gp. Tariquidar, zosuquidar, laniquidar, annamycin and mitotane are 
a few third-generation P-gp inhibitors (Krishna & Mayer 2000; Varma et al. 2003).  
A number of natural products have also been used for targeting drug-resistant cancers. Tea 
tree oil has shown a decrease in the migration and invasion process of both drug-sensitive 
and drug-resistant melanoma cells by reducing the expression of P-gp (Bozzuto et al. 
2011b). Quercetin, a flavonoid has been used as an inhibitor of P-gp mediated drug efflux 
which helps in increasing the bioavailability of Dox in rats (Choi, Piao & Kang 2011). 
Leelamine was screened amongst a natural product library in being able to target PI3 kinase, 
MAP kinase and STAT3 pathways which are overexpressed in 50-60% of melanomas aiding 
in disease development (Gowda et al. 2014). Oleanolic acid, a triterpenoid found in 
Phytolacca amerciana has been used to check its inhibitory effect on P-gp. In a mouse 
metastatic model of melanoma that metastasizes into the lung, it was observed that 
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inhibition of P-gp inhibits the development of melanoma-induced lung metastasis in B16-
F10 mouse melanoma cells (Lúcio et al. 2011).  
The emerging use of natural products to reduce P-gp expression led to a basis for this 
chapter making bLf a potential agent for P-gp inhibition, and targeting drug-resistant cancer 
cells. The role of bLf in being able to downregulate P-gp expression has not been studied 
extensively and provides another aspect to using bLf as a potent natural agent for anti-
cancer therapeutics. Although, the importance of P-gp as a drug-resistant marker is 
highlighted in this study, a number of other markers have been associated with drug-
resistance and stem cell population in melanomas (Zabierowski & Herlyn 2008). Survivin, 
one of the most commonly associated proteins with drug resistance and cancer progression, 
and as described below has been studied in detail with relation to melanoma formation.  
Survivin is a multi-functional protein that has roles in mitosis, apoptosis, cell-motility, 
formation of chromosomal passenger complex (CPC) and in inhibiting caspase activity 
(Baratchi, Kanwar & Kanwar 2010; Kanwar, Kamalapuram & Kanwar 2013; Kanwar et al. 
2010; Mckenzie & Grossman 2012). Survivin is absent from normal primary melanocytes but 
is overexpressed in a broad spectrum of human melanomas and melanocytic nevi both in 
the cytoplasm and the nucleus (Florell et al. 2005; Grossman et al. 1999) when compared to 
dysplastic nevi where survivin is primarily localised in the cytosol (Gao et al. 2010; Nasr & El-
Zammar 2008). Positive nuclear immunoreactivity of survivin was observed in a large subset 
of melanoma patients and was related to poor survival (Chen et al. 2009c) and its function 
was induced when there was a disruption in the p53 tumor suppressor genes leading to 
melanocyte transformation (Raj et al. 2008). Survivin expression in the sentinel lymph nodes 
of melanoma patients is correlated with mortality in melanoma patients as 61.5 % of stage 
III patients who showed survivin-positive sentinel lymph nodes died from the disease 
(Gradilone et al. 2003).  
The minimal expression of survivin in most normal tissues and its overexpression in 
melanoma cells makes it an easy therapeutic target in cancer (Ryan, O’Donovan & Duffy 
2009). Metastatic potential of melanoma cells is attributed to survivin overexpression in 
these cells by activation of Akt and mitogen-activated protein kinase pathways which when 
targeted reduced the migration and invasion potential of melanocytic cells (McKenzie et al. 
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2010). Anti-tumoral vaccination strategies have been employed to induce survivin-specific T-
cell response for the treatment of melanoma. Amongst 61 patients who received peptide 
vaccination therapy against survivin, 55 patients showed response and survival in metastatic 
melanoma patients with HLA-A1/A2/B35 positive type (Becker et al. 2012). Overexpression 
of survivin in LOX and YUSAC2 human melanoma cell lines led to increase in colony 
formation by upregulation of the α5 integrin indicating the role of survivin in melanoma 
metastasis (McKenzie et al. 2013b). 
Apart from drug-resistant markers, the discovery of cancer stem cells (CSCs) has provided 
more insight of the mechanism of resistance to chemotherapy. Pluripotent stem cells have 
the capacity of self-renewal, ability to generate organ-specific or differentiated repertoire of 
cells that exist in organs (Dean, Fojo & Bates 2005). Cancer stem cells share the same ability 
to self-renew which indicates the role of cancer stem cells in preventing apoptosis due to 
overexpression of Bcl-2 oncogene (Domen, Gandy & Weissman 1998).  
CD133 is expressed in endothelial progenitor cells (Corbeil et al. 2000), hematopoietic stem 
cells, neuronal and glial stem cells (Sanai, Alvarez-Buylla & Berger 2005). In melanoma, 
CD133 expression is directly correlated to recurrence of cancer due to its property of self-
renewal and differentiation (Miyabayashi et al. 2011). Another study showed that CD133 
positive cells were involved with tumour initiation, progression that leads to 
chemoresistance in melanoma. It was proved that these CD133 positive cells were 
responsible for attributing resistance to taxol-induced apoptosis, that leads to activation of 
ERK and leads to increased proliferation was observed in human-melanoma cell line A375 
(El-Khattouti et al. 2014).  
Cell-surface receptor epidermal growth factor receptor (EGFR) has been upregulated and 
associated with a number of cancers including lung cancer (Walker et al. 2009). Positive 
expression of EGFR was associated with 6 out of 16 melanoma tumours that developed 
resistance to BRAF and/or MEK inhibitors. EGFR expression in melanoma was observed as a 
mechanism of adaptive resistance in melanoma (Sun et al. 2014a). Further studies with 
BRAFV600E mutant cutaneous melanoma cell lines showed that vemurafenib resistance was 
due to the upregulation of the EGFR pathway which increases proliferation of melanoma 
cells (Gross et al. 2014).  
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Aldehyde dehydrogenase (ALDH), catalyse the oxidation of aldehydes (Marchitti et al. 2008). 
ALDH has been associated with esophageal, gastric, colon, lung and oropharyngolaryngeal 
cancer (Yokoyama et al. 1998). When ALDH+ cells were isolated and transplanted into non-
obese diabetic/severe combined immunodeficiency (NOD/SCID) mice, showed a higher 
tumorigenic potential and has superior self-renewal ability (Boonyaratanakornkit et al. 
2010). On the other hand, malignant melanomas that had a highly aggressive clonogenic 
and tumorigenic potential did not show any expression of ALDH which proves that the 
expression of ALDH could be selective for particular cell-types (Prasmickaite et al. 2010). 
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that is involved 
in cell signaling, migration and proliferation that is related to an increase in the proliferation 
of cervical squamous cell carcinoma (Litvinov et al. 1996). EpCAM expression was analysed 
in 131 different tumour categories and 98 of the 131 tumour cells were stained positive for 
EpCAM expression (Went et al. 2004). Positive expression of EpCAM was formed in 
melanoma-specific circulating tumour cells (CTCs) which proves the involvement of EpCAM 
in increasing the migratory potential of cells leading to metastasis (Luo et al. 2014).  
This chapter focusses on targeting drug-resistant marker P-gp expression patterns in SK-
MEL-2, SK-MEL-28, LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a (NRAS Q16K), LM-MEL-62 
(BRAF G469E), LM-MEL-24 (BRAF V600K) and Mel-007 (DR) cell lines. Therefore, Native-bLf, 
Apo-bLf and Fe-bLf forms were employed to investigate the activity of bLf as a potential 
therapeutic agent for not only BRAF and NRAS mutant melanomas, but also for drug-
resistant melanomas.  
5.2 HYPOTHESIS 
The anti-cancer activity and the ability of bLf to cause apoptosis and target survivin have 
been confirmed in the previous chapters. The role of Fe-bLf in targeting stem cell markers in 
colon-cancer xenografts leading to tumour size reduction indicated the possibility of bLf in 
targeting other drug-resistant and stem cell markers. The three forms of bLf that showed 
anti-cancer potential may be able to target P-gp in melanoma cells. The effect of bLf in 
downregulating P-gp can be time and dose-dependent, and the use of bLf may have an 
added advantage over other chemotherapeutics drugs such as atenolol, Dox, DTIC and 
Melphalan.   




 Study the cellular expression localisation of drug resistant (survivin, P-gp, EGFR)  and 
stem cell markers (CD133, ALDH, EpCAM) in LM-MEL-1a (NRAS Q16K), LM-MEL-12 
(WT BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 (BRAF G469E) and Mel-
007 (DR). 
 Check the effect of bLf forms on the expression patterns of P-gp in all the melanoma 
cell lines tested. 
 Evaluate the advantages of using bLf as a P-gp inhibitor and compare the effects of 
bLf with verapamil and available chemotherapeutic regimens atenolol, Dox, DTIC and 
Melphalan. 
5.4 MATERIALS AND METHODS 
A detailed description of the materials and methods used has been provided in Chapter 2. A 
flow diagram of the materials and methods employed in this chapter is provided below. 
 




5.5.1 bLf successfully downregulated the expression of P-gp in SK-MEL-2 and SK-MEL-28 
To confirm and quantify the effect of bLf on P-gp expression, flow cytometric analysis was 
performed. The anti-cancer effect of bLf on various melanoma cell lines has been studied in 
Chapters 1 and 2. It was found that all the melanoma cell lines were highly susceptible to 
the cytotoxicity induced by Native-bLf, Apo-bLf and Fe-bLf treatments. Therefore, in order 
to decipher whether bLf treatments had any effect on the expression of drug resistance 
marker- Pg-p, this study was performed. Firstly, all the three forms of bLf were tested for 
their effect on P-gp expression in SK-MEL-2 and SK-MEL-28 melanoma cells.  
In case of SK-MEL-2 cells (Figure 5.1 A), it was observed that 5 nM to 80 nM treatments of 
Native-bLf and Fe-bLf led to significant (p≤ 0.01) downregulation in P-gp expression. The 
Apo-bLf treatments on the other hand led to an increase in the P-gp expression. Apo-bLf 
from 5 nM- 20 nM treatments led to a significant increase (p≤ 0.01) in the P-gp levels and, 
40 nM- 80 nM treatments led to a significant (p< 0.05) increase in the P-gp expression. 
Therefore, it was concluded that both Native-bLf and Fe-bLf were most effective (5 nM-80 
nM range) in downregulating P-gp expression in SK-MEL-2. 
A similar trend was observed in case of SK-MEL-28 cells (Figure 5.1 B), where lower 
treatments (5 nM, (p< 0.05), 10 nM (p≤ 0.01)) of Apo-bLf led to a significant increase in the 
P-gp expression while the higher treatments of 20 nM (p< 0.05) and 40 nM (p< 0.05) led to 
significant decreases in the P-gp expression. However, 80 nM of Apo-bLf failed to show any 
change in the expression of P-gp at 48h. On the other hand 80 nM treatments of both 
Native-bLf and Fe-bLf led to significant (p≤ 0.01) downregulation of P-gp expression, 
respectively. However, all treatments (5 nM- 40 nM) of Native-bLf and Fe-bLf showed a 
highly significant decrease (p≤ 0.01) in P-gp expression when compared to untreated, 80 nM 
of Fe-bLf (p≤ 0.001) proved significantly more effective than Native-bLf (p≤ 0.01). Therefore, 
it was inferred that Fe-bLf was the most effective amongst all three forms in downregulating 
the P-gp expression in SK-MEL-28 cells. 
In order to visualise the effect of bLf forms on the P-gp expression in both these cells, 
immunofluorescence was also performed. The expression patterns of P-gp after 48 h of 
treatment with 20 nM of Native-bLf, Apo-bLf and Fe-bLf were determined (Figure 5.1 C). 
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The rationale of using 20 nM concentration of bLf for confocal studies was to ensure that 
there is no cytotoxicity to the melanoma cells and to keep most of the cell monolayer intact 
for imaging purposes. Moreover, the 20 nM treatment was found to be the most effective in 
case of both Native-bLf and Fe-bLf in the flow cytometric analysis against P-gp expression. In 
untreated cells, positive P-gp expression was observed predominantly in the cell 
membrane/surface and cytoplasm of the cells, showing granular and diffuse effect.  In SK-
MEL-2 both Native-bLf and Fe-bLf showed a decrease in the expression of P-gp when 
compared to Apo-bLf, where an increase in the immunoreactivity of P-gp (green 
fluorescence) was observed. Similar observations were made in case of SK-MEL-28 (Figure 
5.1 D), where both Native-bLf and Fe-bLf showed effective downregulation of P-gp 
expression, while Apo-bLf led to an increase in the in the immunoreactivity of P-gp (green 
fluorescence). With treatments of Native-bLf, Apo-bLf and Fe-bLf, more nuclear localisation 
of P-gp was observed.   
In order to semi-quantify the effects of bLf on P-gp expression, cells from 5 different fields 
were counted and a graph was plotted for the percentage P-gp expressing cells Vs the 
treatments. From the graphical analysis of the confocal microscopic images (Figure 5.1 E), it 
was inferred that, in case of SK-MEL-2 cells, Native-bLf showed a significantly higher (p≤ 
0.01) downregulation in the P-gp expression than Fe-bLf (p< 0.05), whereas 20 nM of Fe-bLf 
was showed a significantly higher (p≤ 0.01) downregulation when compared to Native-bLf 
(p< 0.05) in SK-MEL-28 cells. On the contrary, an increase in P-gp expression was observed 
in case of both SK-MEL-2 and SK-MEL-28 cells with Apo-bLf treatments. 
The results of these two assays were in accordance with each other and reveal that both 
Native-bLf and Fe-bLf were equally effective against SK-MEL-2 and Fe-bLf was found to be 
most effective in downregulating P-gp expression in SK-MEL-28 cells. A third and 
confirmatory analysis for P-gp expression post bLf treatment using Western blotting was 
performed (Figure 5.1 F). A graphical representation of the Western blot analysis was 
shown by calculating the fold change in P-gp expression with respect to the GAPDH control 
among all the bLf forms. The results further confirmed the observations from confocal 
microscopy, that in case of SK-MEL-2 cells, Native-bLf was most effective in downregulating 
P-gp expression whereas, Fe-bLf was most effective in downregulating P-gp expression in 
SK-MEL-28 cells.   








Figure 5.1 (A). Flow cytometric analysis of P-gp protein expression in SK-MEL-2 cells with 
bLf.  Cells were allowed to grow in 6 well plates at a cell density of 106 cells and treated with 
varying concentrations of Native-bLf, Apo-bLf and Fe-bLf for 48 h. Cells were then fixed 
using 4 % PF at RT for 20 min, following which they were blocked using 3 % rabbit serum for 
1 h at 37oC. The cells were then probed with mouse anti-human P-gp monoclonal antibody 
at a dilution of 1:100 and incubated for 1 h at 37oC. Secondary antibody, anti-mouse IgG 
FITC (1:100) was then added and the samples were incubated for 1 h at 37oC in dark. The 
samples were then analysed through flow cytometry for P-gp expression. Untreated cells 
were used as control for baseline expression. The treatments were done thrice and the 
experiment was repeated thrice independently. The P4 population of cells were considered 
as P-gp positive population and the percentage of cells counted in this P4 population were 
plotted in the histogram. P3 represents P-gp negative population in the treatment type. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) is 
represented as * and (p≤ 0.01) as ** was considered statistically significant when compared 
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to untreated cells. A value of (p≤ 0.001) represented as † was considered statistically 
significant when compared amongst the treatments.  
 




Figure 5.1 (B). Flow cytometry analysis displayed the downregulation of P-gp protein 
expression in SK-MEL-28 with bLf treatments. Following treatments with varying 
concentrations of Native-bLf, Apo-bLf and Fe-bLf for 48 h, P-gp expression analysis was 
done. After treatments, the cells were fixed with 4 % PF and then blocked using 3 % BSA for 
1 h. The cells were stained with specific primary antibody with anti-human P-gp antibody 
and then stained with anti-IgG FITC at 1:100 concentrations for 1 h at 37oC. The samples 
were then analysed through FACS for P-gp expression. Untreated cells were used as control 
for baseline expression. The treatments were done thrice and the experiment was repeated 
thrice independently. The P4 population of cells were considered as P-gp positive 
population and the percentage of cells counted in this P4 population were plotted in the 
histogram. P3 represents P-gp negative population in the treatment type. Student’s t test 
was performed to evaluate statistical significance. A value of (p< 0.05) is represented as *, 
(p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when compared 
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to untreated cells. A value of (p≤ 0.001) represented as † was considered statistically 
significant when compared amongst the treatments.  
 
Figure 5.1 (C). Downregulation of P-gp protein with bLf treatments in SK-MEL-2.  Cells 
were treated with 20 nM concentrations of Native-bLf, Apo-bLf and Fe-bLf for 48 h. After 
treatments, the cells were fixed with 4 % PF for 20 min and then blocked for 1 h at 370C. The 
cells were stained with specific anti-human P-gp antibody at 1:100 concentration for 1 h. 
Secondary antibody anti-mouse IgG FITC at 1:100 concentration was then added and cells 
were incubated for 1 h at 370C. DAPI with mounting media was used for staining the 
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nucleus. P-gp expression was visualised using Leica SP5 confocal microscopy and images 
were processed using LAS-AF software. Representative images were shown.  
 
Figure 5.1 (D). Confocal images cellular localisation of P-gp expression with bLf treatments 
in SK-MEL-28. Treatment of SK-MEL-28 cells, with Native-bLf, Apo-bLf and Fe-bLf at 20 nM 
concentration was done after the cells were allowed to grow on 8 well chambered slides. 
Cells were treated for 48 h, fixed with 4 % PF, and then blocked with 3 % serum for 1 h at 
37oC, following which they were stained with specific mouse anti-human P-gp primary 
antibody for 1 h at 37oC. Secondary antibody anti-mouse IgG FITC at 1:100 concentrations 
was then added and cells were incubated for 1 h at 37oC. DAPI was used as the nuclear 
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stain. P-gp expression was visualised using Leica SP5 confocal microscopy and images were 
processed using LAS-AF software. Representative images are shown here. 
 
Figure 5.1 (E). Semi-quantitative analysis of P-gp protein expression visualised by confocal 
microscopy post-bLf treatments. Images taken from confocal microscopy were processed 
through the LAS-AF software. Treatments were done twice and the experiment was done 
thrice independently. 5 images were taken from every treatment well. Untreated cells were 
maintained as control. The number of P-gp positive cells from every field was counted and 
the average was plotted on a histogram. Data is represented as mean ± SE. Student’s t test 
was performed to evaluate statistical significance. A value of (p< 0.05) is represented as * 
and (p≤ 0.01) as ** was considered statistically significant when compared to untreated 
cells.  A value of (p≤ 0.01) represented as † was considered statistically significant when 
compared amongst the treatments.  




Figure 5.1 (F). Western blot confirms downregulation of P-gp expression in SK-MEL-2 and 
SK-MEL-28. 100 µg of protein sample was loaded and mouse anti-P-gp monoclonal antibody 
(1:500) was used for immunoblotting. Secondary antibody, anti-mouse IgG HRP (1:80,000) 
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was used. The protein lysates were tested for loading control, GAPDH. Anti-human GAPDH 
rabbit monoclonal antibody (1:1000) was used as primary antibody and anti-rabbit IgG HRP 
(1:80,000) was used as secondary antibody. The immunoreactive bands were detected by 
the ECL method.  
5.5.2 Verapamil functions as a P-gp inhibitor in a concentration dependent manner 
A commercially available P-gp inhibitor verapamil was used as a positive control for P-gp 
downregulation studies. The effect of verapamil on the status of P-gp in SK-MEL-2 and SK-
MEL-28 were determined. Briefly, the cells were plated in 6 well plates; once confluent, the 
cells was treated with verapamil. After treatments the cells were trypsinized, fixed and 
blocked as mentioned in the protocol in Chapter 2. The cell pellet was then stained for P-gp 
using a primary antibody and the presence was confirmed using a FITC tagged specific 
secondary antibody. P-gp expression was determined using flow cytometry and percentage 
cells expressing P-gp were plotted in a graph.  
 The flow cytometry plots representing the percentage cells expressing P-gp (shift in peak 
from the P3 region towards the P2 region) indicate that verapamil was highly effective in 
downregulating P-gp expression in both SK-MEL-2 and SK-MEL-28 cells (Figure 5.2 A). When 
compared to the P-gp expression of untreated cells in, SK-MEL-2, 25 µM of verapamil 
showed significant reduction (p≤ 0.01) in P-gp expression, while 50 µM treatments showed 
(p< 0.05) decrease in P-gp expression. However, both 75 µM and 100 µM treatments 
showed a highly significant (p≤ 0.001) downregulation of P-gp expression.  
In case of SK-MEL-28 cells, 50 µM treatment of verapamil failed to induce any significant 
decrease in P-gp expression, whereas the 25 µM (p< 0.05) and 75 µM (p≤ 0.01) and the 100 
µM (p≤ 0.001) treatments showed a dose dependant significant decrease in the P-gp 
expression (Figure 5.2 B). These results suggest that the SK-MEL-28 cells were more 
resistant to the P-gp inhibitor verapamil, as the 75 µM and 100 µM treatment of verapamil 
was effective in downregulating the P-gp in SK-MEL-28 however, the effect was 
comparatively more in case of SK-MEL-2. 




Figure 5.2 (A). Confirmation of verapamil treatments in downregulating P-gp in SK-MEL-2 
and SK-MEL-28. Cells treated with varying concentrations of verapamil for 48 h were fixed 
with 4 % PF, blocked using 3 % rabbit serum for 1 h, and stained with primary and secondary 
antibody specific for P-gp. The stained cells were analysed through FACS for P-gp expression 
patterns. The treatments were done thrice and the experiment was repeated thrice 
independently. Representative images from the FACS experiment show the shift in the P3 
population (P-gp positive cells) towards the P2 region (P-gp negative cells) of the graph 
indicating a shift towards the left end which confirms the decrease of P-gp expression in 
these treatments. Numerical values of percentage P-gp positive population (P3) of cells are 
mentioned on the FACS plots.  




Figure 5.2 (B). Flow cytometric analysis of P-gp expression in SK-MEL-2 and SK-MEL-28. 
Data from FACS was analysed using the FACS-Diva software. Treatments were done in 
triplicates and the experiments were repeated thrice independently. Values from the P3 
population of cells were plotted as histograms and represented as mean ± SE. Student’s t 
test was performed to evaluate statistical significance. A value of (p< 0.05) is represented as 
*, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically significant when 
compared to untreated cells. 
5.5.3 Downregulation of P-gp expression with cardioprotective agent-Atenolol 
Atenolol, an anti-hypertensive drug has been used in clinical studies to treat melanoma 
patients. In a study where most of the malignant melanoma patients were prescribed with 
β-blockers (used for hypertension), proved that use of atenolol increased the overall survival 
of these patients and reduced the risk of death was reduced by 38% (p≤ 0.001) (De Giorgi et 
al. 2013). Another interesting observation with the use of atenolol was that it was not a 
substrate for P-gp, hence it would allow easy entry of the drug in case of drug-resistant 
patients (Li et al. 2014). Therefore, it would provide an interesting aspect for future scope of 
atenolol based melanoma therapy, to check the effect of atenolol on P-gp expression in p53 
mutant melanoma cells.  
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      Varying concentrations of atenolol were used to investigate the effects of atenolol on P-
gp expression in SK-MEL-2 and SK-MEL-28. The flow cytometric analysis revealed that 
atenolol induced a significant downregulation of the P-gp expression in both SK-MEL-2 and 
SK-MEL-28 cells (Figure 5.3 A). It was observed from the graphical representation of the 
flow cytometry results that 100-500 µg/mL treatment of atenolol downregulated the P-gp 
expression in both SK-MEL-2 and SK-MEL-28 cells. The highest concentration of atenolol i.e., 
1 mg/mL showed comparatively lower effect on P-gp expression in SK-MEL-28 even though 
the effect was found to be significant (p< 0.05) when compared to the untreated cells 
(Figure 5.3 B). At concentrations of 250 µg/mL and 500 µg/mL, atenolol treatments 
significantly downregulated the expression of P-gp in SK-MEL-28 (p< 0.05) when compared 
to SK-MEL-2 cells. Interestingly, 1 mg/mL of atenolol was more effective (p< 0.05) in 
downregulating P-gp expression in SK-MEL-2 when compared to SK-MEL-28.  
 
Figure 5.3 (A). FACS analysis showing downregulation of P-gp protein expression with 
atenolol treatments. SK-MEL-2 and SK-MEL-28 cells were treated with atenolol with varying 
concentrations for 48h. After treatment, cells were fixed with 4 % PF for 20 min at RT. The 
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cells were then blocked with 3 % BSA for 1 h at 37oC. Primary antibody, anti-human P-gp 
mouse monoclonal antibody was added at a concentration of 1:100 and the cells were 
incubated for 1 h at 37oC. Anti-mouse IgG FITC (1:100) was added and incubated for 1 h at 
37oC. The stained cells were analysed through BD FACS Canto II. The treatments were 
carried out thrice and the experiment was done thrice independently. Representative 
images from FACS that shows the shift in the peak from P4 (P-gp positive cells) to P3 region 
(P-gp negative cells) when treated with atenolol were shown. The shift in the peak towards 
the left (reduction in the number of cells that were in the P3 region) represents the 
reduction in expression of P-gp in both the melanoma cell lines tested when compared to 
the untreated or control cells. The value of percentage P-gp positive cells without and with 
treatments is represented in the FACS plots.  
 
Figure 5.3 (B). Comparative analysis of the FACS data to show the effect of atenolol on P-
gp protein expression in SK-MEL-2 and SK-MEL-28. Quantification of the % expression of P-
gp in SK-MEL-2 and SK-MEL-28 when treated with atenolol was done from the FACS graphs 
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that were analysed by BD FACS-Diva software. A dose dependent decrease in the expression 
of P-gp was observed with increasing concentrations of atenolol. P4 population of cells that 
were represented as the P-gp positive cells and all values are represented as mean ± SE. 
Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) is 
represented as * and (p≤ 0.01) as ** was considered statistically significant when compared 
to untreated cells. A value of (p< 0.05) represented as † was considered statistically 
significant when compared amongst the treatments in the 2 different cell lines. NS 
represents non-significant statistical analysis between the cell lines.   
5.5.4 Baseline expression of drug-resistant and stem cell markers in melanoma cell lines 
To investigate if the patient-derived BRAF and NRAS mutant and wild-type cell lines (LM-
MEL-1a (NRAS Q16K, BRAF WT), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K 
mutant, NRAS WT), LM-MEL-62 (BRAF G469E mutant, NRAS WT)) and drug-resistant cell line 
(Mel-007) had an intrinsic expression of critical stem cell markers namely aldehyde 
dehydrogenase (ALDH), epidermal growth factor receptor (EGFR), epithelial cell adhesion 
molecule (EpCAM), P-gp, survivin and cluster of differentiation 133 (CD133), in the cell lines, 
the intrinsic expression levels was checked using immunofluorescence. The cells were plated 
in 8 well slides and once confluent were fixed. Melanoma cells were stained for the different 
markers using respective primary and secondary antibodies conjugated with fluorescent 
FITC. The slide was visualised by confocal microscopy.  
It was observed from the confocal images that, a faint expression of EGFR was observed in 
LM-MEL-62 (BRAF G469E) (Figures 5.4 C & F) and low expression was observed in LM-MEL-
1a (NRAS Q16K) (Figures 5.4 B & F) and LM-MEL-24 (BRAF V600K) (Figures 5.4 D & F) cells, 
while a very high expression of EGFR was observed in Mel-007 (DR) (Figure 5.4 E & F) cells. 
The expression of EpCAM was observed in case of LM-MEL-24 (BRAF V600K), Mel-007 (DR) 
cells and LM-MEL-62 (BRAF G469E). Both P-gp and survivin were highly expressed in all the 
five cell lines except, slightly lower levels of P-gp was observed in LM-MEL-62 (BRAF G469E) 
cells. LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF G469E) cells showed comparatively 
higher expression of CD133 than the other cells which showed faint expression of CD133. 
No expression of ALDH was found in any of the cells (Figure 5.4 A-E), Table 5.1). 




Figure 5.4 (A). Expression of various drug-resistant and stem cell markers in LM-MEL-12 
(WT BRAF and NRAS). LM-MEL-12 cells that were characterised as a BRAF and NRAS wild-
type cell line. To check the expression of the various stem cells and drug-resistant markers, 
the cells were grown in 8 well culture slides at a cell density of 103 cells. Cells were fixed, 
permeabilized and blocked after which they were stained with specific primary and 
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secondary antibodies for each marker. Blocking, primary antibody and secondary antibody 
(FITC tagged) incubations were done for 1 h at 37oC. Nucleus was stained using DAPI with 
mounting media. Expression of individual markers was visualised using Leica SP5 confocal 
microscopy and the images were analysed using LAS-AF software. Treatments were done in 
duplicates and the experiment was repeated thrice. Representative images were shown.   
 
Figure 5.4 (B). Baseline expression of stem cell and drug-resistant markers in LM-MEL-1a 
(NRAS Q16K). LM-MEL-1a (NRAS Q16K) were characterised as BRAF wild-type and NRAS 
Q16K mutant cell lines. Cells were plated at a cell density of 103 cells in 8 well culture slides 
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and allowed to form a monolayer. The cell monolayer was then fixed with 4 % PF and then 
permeabilized using 0.1 % Triton-X100 for 2 min on ice. Cells were blocked with 3 % serum 
for 1 h at 37oC, following which they were stained with specific primary antibodies for 
EpCAM, CD133, , P-gp, survivin, ALDH and EGFR. The cells were then stained with specific 
secondary antibodies tagged with FITC. Nucleus of the cells was stained using DAPI. 
Expression of individual markers was visualised using Leica SP5 confocal microscopy and the 
images were analysed using LAS-AF software. Treatments were done in duplicates and the 
experiment was repeated thrice. Representative images were shown.   




Figure 5.4 (C). Baseline expression of EpCAM, CD133, P-gp, survivin, ALDH and EGFR in LM-
MEL-62 (BRAF G469E). LM-MEL-62 cell lines were characterised as BRAFG469E mutations 
and wild-type NRAS mutant cells. Endogenous expression of the desired markers was 
studied using IF. Cells grown in 8 well culture slides were fixed, permeabilized and blocked. 
Specific primary and secondary antibodies (tagged with FITC) were used for staining and 
DAPI was used as the nuclear stain. The immunoreactivity of every marker was visualised 
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using confocal microscopy and the images were processed through LAS-AF software. 
Representative images from the experiment were shown.   
 
Figure 5.4 (D). Baseline expression patterns of stem cell and drug-resistant molecules in 
LM-MEL-24 (BRAF V600K). LM-MEL-24 was established a BRAFV600K mutation and wild-
types NRAS cell line. 8 well culture slides were used for studying the expression patterns of 
EpCAM, CD133, P-gp, survivin, ALDH and EGFR. Cells were fixed using 4 % PF for 20 min, 
permeabilized using 0.1 % Triton-X100 for 2 min on ice, and then blocked using 3 % BSA for 
1 h. Specific primary and secondary antibodies (tagged with FITC) were used to stain the 
     Chapter 5- Role of bLf in targeting critical drug-resistant marker P-glycoprotein (P-gp) 
298 
 
markers. DAPI with mounting media was used to stain the nucleus. The immunoreactivity of 
every marker was visualised using confocal microscopy and the images were processed 
through LAS-AF software. Representative images from the experiment were shown.  
 
Figure 5.4 (E). Analysis of various stem cell and drug-resistant markers in drug-resistant 
Mel-007 (DR). Mel-007 (DR), a well-established drug-resistant cell line was also screened for 
various drug-resistant and stems cell markers. Cells were plated at a cell density of 103 cells 
in 8 well chambered slides and allowed to form a monolayer. The cell monolayer was then 
fixed with 4 % PF and then permeabilized using 0.1 % Triton-X100 for 2 min on ice. Cells 
were blocked with 3 % serum for 1 h at 37oC, following which they were stained with 
specific primary antibodies for EpCAM, CD133, P-gp, survivin, ALDH and EGFR. The cells 
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were then stained with specific secondary antibodies tagged with FITC. DAPI, nuclear stain 
was used with mounting media. Expression of individual markers was visualised using Leica 
SP5 confocal microscopy and the images were analysed using LAS software. Treatments 
were done in duplicates and the experiment was repeated thrice. Representative images 
were shown.   
 
Table 5.1. Semi-quantitative analysis of endogenous expression of drug-resistant and stem 
cell markers in LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-12 (WT BRAF 
and NRAS), LM-MEL-24 (BRAF V600K) and Mel-007 (DR). Images obtained from the 
confocal microscope were analysed using LAS-AF software. Five images were taken from 
each well and the number of positively stained cells for each marker was counted and the 
expression was represented in Table 5.1. Endogenous protein expression patterns of various 
drug-resistant markers showed that cell lines with varying mutational status in their BRAF 
and NRAS gene did not show any EGFR expression. Mel-007 (DR) was stained highly positive 
for EGFR. However, all the cell lines showed strong positivity for P-gp and survivin. The 
representation of the expression patterns on the basis of immunofluorescence intensity 
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were as follows, --- indicates very little expression (1 %), + indicates weak expression (15-45 
%), ++ shows overexpression (45-75 %), +++ indicates very high expression (75-100 %).  
5.5.5 In patient-derived primary melanoma cell lines, all the three forms of bLf 
significantly downregulate P-gp protein expression upto 120 h of treatment 
To establish the role of bLf in being able to reduce the P-gp expression in patient-derived 
cell lines, the three different concentrations (20 nM, 40 nM and 80 nM) of Native-bLf, Apo-
bLf and Fe-bLf were employed in this study. It was observed from the flow cytometry 
analysis that the bLf forms were highly effective in reducing P-gp expression (Figure 5.5 A-
E).  The analysis from of the results from the graphical representation of the flow cytometry 
results revealed that bLf forms were highly effective in all the cell lines in downregulating 
the P-gp expression.  
Time-dependent study on the effect of all the three forms of bLf on P-gp expression was 
done from 48 h upto 120 h of treatment. The time points were chosen on the basis of 
preliminary analysis of P-gp expression patterns in SK-MEL-2 and SK-MEL-28.  The results 
from the maximum time point of treatment i.e. 120 h would provide an understanding on 
the effect of bLf at 120 h hence this time point was chosen for studies for P-gp expression 
with all the three forms of bLf and other chemotherapeutics tested, for comparison 
between the chemotherapeutic regimens and the role of bLf as a natural molecule that 
targets P-gp.  
In case of LM-MEL 12 (BRAF and NRAS WT) cells (Figures 5.5 A & F), a dose dependant 
significant decrease in the P-gp expression was observed with Native-bLf (20 nM-1.72 fold 
(p< 0.05), 40 nM- 11.11 fold (p≤ 0.001), 80 nM- 20 fold (p≤ 0.001) and Apo-bLf (20 nM-1.81 
fold (p< 0.05), 40 nM- 5.5 fold (p≤ 0.01), 80 nM- 22.2 fold (p≤  0.001). While Fe-bLf 20 nM-
3.3 fold (p≤ 0.01), 40 nM- 3.8 fold (p≤ 0.01) showed nearly the same effect, whereas at 80 
nM- 16.66 fold (p≤ 0.001) reduction in P-gp expression was seen. Though at higher 
concentration (80 nM) all the three bLf forms had highly significant effect but, both 40 nM 
and 80 nM of Native-bLf showed a highly significant (p≤ 0.001) effect on P-gp 
downregulation, it was considered as the most effective against LM-MEL-12 (BRAF and 
NRAS WT) cells. 
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It was observed that in the case of LM-MEL-1a (NRAS Q16K) cells (Figures 5.5 B & F), 20 nM 
(10 fold, p≤ 0.01), 40 nM (25 fold, p≤ 0.001) and 80 nM (33.33 fold, p≤ 0.001) of Native-bLf 
showed highly significant downregulation of P-gp. The 20 nM and the 40 nM (3.33 fold, p< 
0.05) treatment of Apo-bLf showed a significant effect whereas, the 80 nM (10 fold, p≤ 0.01) 
treatment of Apo-bLf was comparatively more effective. Fe-bLf had a dose-dependent 
effect, 20 nM (7.69 fold, p≤ 0.01) treatment of Fe-bLf was comparatively less effective than 
the 40 nM (10 fold, p≤ 0.01) and the 80 nM (25 fold, p≤ 0.001). Therefore, it was observed 
that Native-bLf again proved the most effective in downregulating P-gp expression in LM-
MEL-1a (NRAS Q16K) cells. 
In case of LM-MEL-62 (BRAF G469E) cells, it was found that the 80 nM treatments of both 
Native-bLf (5.55 fold, p≤ 0.001) and Fe-bLf (5.88 fold, p≤ 0.001) were equally effective in 
downregulating the P-gp expression (Figures 5.5 C & F). However, the 20 nM (14.28 fold, p≤ 
0.001) and 40 nM (20 fold, p≤ 0.001) of Native-bLf showed a significantly higher effect than 
20 nM (2.43 fold, p≤ 0.001) and 40 nM (1.72 fold, p< 0.05) of Fe-bLf. Apo-bLf was found to 
be the least effective in these cells. However, both 40 nM (1.47 fold, p< 0.05) and 80 nM 
(1.66 fold, p< 0.05) showed a significant reduction in P-gp expression when compared to the 
untreated cells. Therefore, it was inferred that Native-bLf was the most effective bLf form in 
downregulating P-gp expression of LM-MEL-62 (BRAF G469E) cells. 
All three forms of bLf again showed a dose dependant reduction in P-gp expression in case 
of LM-MEL-24 (BRAF V600K) cells (Figures 5.4 D & F). Both Native-bLf and Apo-bLf at 20 nM 
(2 fold p≤ 0.01, 1.25 fold p< 0.05), 40 nM (9.09 fold (p≤ 0.001), 5.26 fold (p≤ 0.001)) showed 
an equally significant reduction in P-gp expression. However, higher reductions were at 80 
nM of Native-bLf (14.28 fold p≤ 0.001) and Apo-bLf (7 fold p≤ 0.001). Similarly, 20 nM Fe-bLf 
(p< 0.05) was least effective when compared to 40 nM and 80 nM Fe-bLf (p≤ 0.001) in LM-
MEL-24 cells.  
In case of Mel-007 (DR) cells (Figures 5.5 E & F), it was observed that the 40 nM and the 80 
nM treatment of both Apo-bLf (4 fold p≤ 0.01, 7.69 fold p≤ 0.01) and Fe-bLf (3.33 fold p≤ 
0.01), 4 fold p≤ 0.01) were found to significant in downregulating the P-gp expression. Even 
though the effect of Native-bLf was found to be lower than both Apo-bLf and Fe-bLf, it was 
significant (p< 0.05) at all concentrations when compared to untreated cells. Therefore, it 
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was inferred that both Apo-bLf and Fe-bLf were equally effective in downregulating the P-gp 
expression in Mel-007 (DR) cells (Figure 5.5 F).  
From the flow cytometry analysis a clear understanding of the effect of iron-saturated and 
iron-free forms of bLf on P-gp expression could not be derived. Therefore, in order to 
understand the effect of iron-saturated (Fe-bLf) and iron-free (Apo-bLf) forms of bLf on P-gp 
expression, Western blotting assay was further performed. (Figure 5.5 G). A graph was 
plotted using the fold change in P-gp expression with respect to GAPDH in the Apo-bLf and 
Fe-bLf forms. It was revealed from this assay that in case of LM-MEL-12 (BRAF and NRAS 
WT) cells, Apo-bLf 40 nM was more effective when compared to Fe-bLf  thus confirming 
FACS findings, whereas; in case of LM-MEL-1a (NRAS Q16K) cells Fe-bLf was found to be 
effective. In case of LM-MEL-62 (G469E) cells Fe-bLf was comparatively more effective 
whereas, in case of and LM-MEL-24 (BRAF V600K) cells both Apo-bLf and Fe-bLf were 
effective. In Mel-007 (DR) cells, Fe-bLf proved comparatively more effective than Apo-bLf 40 
nM.   




Figure 5.5 (A). FACS plots showing P-gp expression in LM-MEL-12 (WT BRAF and NRAS) 
with bLf treatments. Evaluation of P-gp expression after 120 h of treatment in LM-MEL-12 
(WT BRAF and NRAS) with Native-bLf, Apo-bLf and Fe-bLf treatments at 20 nM, 40 nM and 
80 nM treatment concentrations was performed using FACS analysis. After treatments, the 
cells were trypsinized using the routine procedure of trypsinization. The cells were then 
fixed using 4 % PF for 20 min at RT following which the cells were blocked using 3 % rabbit 
serum for 1 h at 370C. P-gp specific primary and secondary antibodies, mouse anti-human P-
gp and anti-mouse IgG FITC respectively were used to stain the cells for 1 h at 37oC each. 
After staining, the cells were acquired through FACS and the data was analysed using the 
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FACS-Diva software. Treatments were done in triplicates and the experiment was performed 
thrice. Representative FACS plots are shown. The numbers on the FACS plots represent the 
P3 population of cells (P-gp positive) and the reduction of the P3 population with 
treatments of all three forms of bLf.   
 
Figure 5.5 (B). Effect of bLf treatments on P-gp in LM-MEL-1a (NRAS Q16K). FACS analysis 
was done after cells were treated with three different forms of bLf at 20 nM, 40 nM and 80 
nM treatment concentrations for 120 h. Treated cells were trypsinized and fixed using 4 % 
PF for 20 min. The cells were blocked using 3 % rabbit serum for 1 h at 37oC, followed by 
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incubation with primary antibody (mouse anti-human P-gp) at 1:100 concentrations for 1 h 
at 37oC. Staining was done using anti-mouse IgG FITC (1:100) for 1 h and the stained cells 
were acquired through FACS. Analysis was done using FACS-Diva software. Treatments were 
done in triplicates and the experiment was performed thrice independently. Representative 
FACS plots were shown. The numbers on the FACS plots represent the P3 population of cells 
(P-gp positive) and the reduction of the P3 population with treatments of all three forms of 
bLf.   
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Figure 5.5 (C). Analysis of P-gp expression in LM-MEL-62 (BRAF G469E) with bLf 
treatments. Native-bLf, Apo-bLf and Fe-bLf at 20 nM, 40 nM and 80 nM treatment 
concentrations were used to study the effect of all the three forms of bLf on P-gp expression 
after 120 h of treatment. Treated cells were trypsinized using the routine procedure and 
fixed using 4 % PF for 20 min at RT. The cells were then blocked using 3 % rabbit serum for 1 
h at 370C, followed by incubation with mouse anti-human P-gp antibody for 1 h at 370C. 
Staining was done with anti-mouse IgG FITC secondary antibody for 1 h at 370C. Stained cells 
were analysed through FACS using the FACS-Diva software. Treatments were done in 
triplicates and the experiment was performed thrice independently. Representative FACS 
plots were shown. The numbers on the FACS plots represent the P3 population of cells (P-gp 
positive) and the reduction of the P3 population with treatments of all three forms of bLf.   
 
 




Figure 5.5 (D). Downregulation of P-gp expression in LM-MEL-24 (BRAF V600K) with bLf 
treatments. Cells were plated in 6 well plates and treated with 20 nM, 40 nM and 80 nM 
concentrations of Native-bLf, Apo-bLf and Fe-bLf for 120 h. After treatment, the cell layer 
was trypsinized and the cells were fixed for 20 min using 4 % PF at RT. After fixing, the cells 
were blocked using 3 % rabbit serum. Primary and secondary antibody staining was 
performed using P-gp specific antibodies. Blocking, primary and secondary antibody 
incubations were done for 1 h each at 370C. The stained cells were acquired using FACS and 
analysed using the FACS-Diva software. Each treatment was done in triplicates and the 
experiment was performed three times independently. The numbers on the FACS plots 
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represent the P3 population of cells (P-gp positive) and the reduction of the P3 population 
with treatments of all three forms of bLf.   
 
Figure 5.5 (E). Drug-resistant Mel-007 and the effect of bLf on P-gp expression. Cells were 
treated with three different concentrations of Native-bLf, Apo-bLf and Fe-bLf for 120 h to 
check the P-gp expression patterns with 20 nM, 40 nM and 80 nM treatments of bLf. The 
treated cells were fixed with 4 % PF for 20 min and blocked with 3 % rabbit serum for 1 h. 
Mouse anti-human P-gp antibody was used at 1:100 concentration and staining was done 
using anti-mouse IgG FITC at 1:100 for 1 h at 370C. The stained cells were acquired through 
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FACS and the plots were analysed using FACS-Diva software. Treatments were done in 
triplicates and the experiment was performed thrice independently. Representative plots 
from each treatment were shown. The numbers on the FACS plots represent the P3 
population of cells (P-gp positive) and the reduction of the P3 population with treatments of 
all three forms of bLf.   
 
Figure 5.5 (F). Comparative analysis of P-gp protein expression with bLf treatments. Values 
that were obtained from FACS plots were analysed and plotted as a bar graph. The 
treatments were done in triplicates and the experiment was repeated thrice independently. 
The P3 population of cells from the gated P1 population was represented as percentage P-
gp positive cells in a histogram. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) is represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** 
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was considered statistically significant when compared to untreated cells. A value of (p< 
0.05) represented as † and (p≤ 0.01) represented as †† was considered statistically 
significant when compared amongst the treatments. NS represents statistically non-
significant difference between treatments.  
 
Figure 5.5 (G). Western blot confirms downregulation of P-gp protein expression in 
patient-derived melanoma cell lines. P-gp expression analysis in LM-MEL-1a (NRAS Q16K), 
LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 (BRAF G469E) and 
Mel-007 (DR) after  48 h of bLf treatment. A decrease in the expression of P-gp in all the 5 
melanoma cell lines tested. 100 µg of protein sample was loaded and anti-human mouse 
monoclonal antibody (1:500) was used for immunoblotting. Secondary antibody, anti-mouse 
IgG HRP (1:80,000) was used. The protein lysates were tested for loading control, GAPDH 
anti-human GAPDH rabbit monoclonal antibody (1:1000) was used as primary antibody and 
anti-rabbit IgG HRP (1:80,000) was used as secondary antibody. The immunoreactive bands 
were detected by the ECL method.  
     Chapter 5- Role of bLf in targeting critical drug-resistant marker P-glycoprotein (P-gp) 
311 
 
5.5.6 P-gp inhibitor verapamil downregulates P-gp expression in all melanoma cell lines 
To study the effect of verapamil as a P-gp inhibitor in the BRAF and NRAS mutant (LM-MEL-
1a (NRAS Q16K), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K) and LM-MEL-
62 (BRAF G469E) and drug-resistant cell Mel-007 (DR), was determined by flow cytometry 
analysis (Figure 5.6 A). It was observed that verapamil showed a dose dependant reduction 
in P-gp expression in all cell lines. Verapamil 25 µM induced significant (p< 0.05) 
downregulation in P-gp expression in all the cell lines at 120 h. A significant reduction (p≤ 
0.01) was observed in all cell lines at 50 µM, except LM-MEL-62 (BRAF G469E) (p< 0.05) 
cells. However, at 75 µM (p≤ 0.001) and 100 µM (p≤ 0.001) concentrations of verapamil a 
dose dependant significant reduction in P-gp expression was observed in all the cell lines. 
Therefore, it was inferred that verapamil successfully inhibited P-gp expression in the 
BRAF/NRAS mutant and the drug resistant melanoma cells. 








Figure 5.6 (A) FACS histograms showing the effect of verapamil on P-gp expression in 
melanoma cell lines. Cells treated with varying concentrations (25 µM, 50 µM, 75 µM and 
100 µM) of verapamil for 120 h were fixed with 4 % PF and stained with primary and 
secondary antibody specific for P-gp. The stained cells were analysed through FACS for P-gp 
expression patterns. The treatments were done thrice and the experiment was repeated 
thrice independently. Representative images from the FACS experiment show the shift in 
the P3 peak towards the P2 region of the graph indicating a shift towards the left end which 
confirms the decrease of P-gp expression in these treatments. Data from FACS was analysed 
using the BD-FACS-Diva software. Treatments were done thrice and the experiments were 
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repeated thrice independently. Percentage cells that were stained positive in the P3 region 
(P-gp positive cells) were indicated as numerical values in the FACS plots. 
 
Figure 5.6 (B). Verapamil downregulates P-gp in a dose-dependent manner. The 
percentage positive P-gp cells were analysed using FACS and the cells that were stained 
positive in the P3 region (P-gp positive cells) were represented as mean ± SE in the 
histogram. Student’s t test was performed to evaluate statistical significance. A value of (p< 
0.05) is represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
significant when compared to untreated cells.   
5.5.7 Atenolol inhibits P-gp expression at higher concentration in patient-derived BRAF, 
NRAS mutant and drug-resistant cell lines 
Atenolol was found to be efficient in downregulation of the P-gp expression in SK-MEL-2 and 
SK-MEL-28 melanoma cells. Its effect on P-gp expression was further evaluated in LM-MEL-
1a (NRAS Q16K), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 
(BRAF G469E) and Mel-007 (DR) (Figure 5.7 A).  
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Interestingly, it was observed that 100 µg/mL atenolol treatments failed to induce any 
significant decrease in the P-gp expression in LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a 
(NRAS Q16 K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cells. However, a significant 
reduction in the P-gp expression was observed in (p< 0.05) in LM-MEL-24 (BRAF V600K) 
cells. 250 µg/mL atenolol treatments a significant increase (p< 0.05) in P-gp in LM-MEL-12 
(WT BRAF and NRAS) cells was observed and significant decrease (p< 0.05) in P-gp 
expression was observed in LM-MEL-24 (BRAF V600K) cells. At 500 µg/mL, a significant 
increase (p< 0.05) was observed in LM-MEL-1a (NRAS Q16K) cells and,  a significant decrease 
(p< 0.05) was observed in the Mel-007 (DR) cells whereas, at 1 mg/mL significant decrease 
(p< 0.05) observed in the Mel-007 (DR) cells was observed. Therefore, it was inferred that 
overall atenolol failed to show any promising effect in the BRAF/NRAS mutant, WT BRAF and 
NRAS and drug resistant melanoma cells against P-gp expression (Figure 5.7 B). 








Figure 5.7 (A) FACS histograms representing the effect of atenolol on melanoma cell lines. 
LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-12 (WT BRAF and NRAS), LM-
MEL-24 (BRAF V600K) and Mel-007 (DR) cells were treated with atenolol in varying 
concentrations (100 µg/mL, 250 µg/mL, 500 µg/mL and 1 mg/mL) for 120 h. After 
treatment, cells were fixed with 4 % PF for 20 min at RT. The cells were then blocked with 3 
% BSA for 1 h at 37oC. Primary antibody, anti-human mouse P-gp monoclonal antibody was 
added at a concentration of 1:100 and the cells were incubated for 1 h at 37oC. Anti-mouse 
IgG FITC (1:100) was added and incubated for 1 h at 37oC. The stained cells were analysed 
through FACS BD-Canto II. The treatments were carried out thrice and the experiment was 
done thrice independently. No shift in the peak towards the left represents no effect on the 
expression of P-gp in the melanoma cell lines tested when compared to the untreated or 
control cells. Representative FACS plots from each experiment were shown. Percentage cells 
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that were stained positive in the P3 region (P-gp positive cells) in the untreated and bLf 
treated cells were indicated as numerical values in the FACS plots. 
 
Figure 5.7 (B). Effect of atenolol on patient-derived and drug-resistant melanoma cells. 
Quantification of the % expression of P-gp was done from the FACS graphs that were 
analysed by FACS-Diva software. Percentage cells that were stained positive in the P3 region 
(P-gp positive cells) were indicated as numerical values in the FACS plots. All values are 
represented as mean ± SE. Student’s t test was performed to evaluate statistical 
significance. A value of (p< 0.05) is represented as * was considered statistically significant 
when compared to untreated cells.   
5.5.8 DTIC modulates P-gp expression in LM-MEL-12 (WT BRAF and NRAS), LM-MEL-1a 
(NRAS Q16K), LM-MEL-62 (BRAF G469E) and LM-MEL-24 (BRAF V600K) 
To check the effect of an anti-cancer chemotherapeutic on the expression of P-gp, FDA 
approved drug for melanoma, dacarbazine (DTIC) was used. Time dependent effect (24-120 
h) of DTIC on LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E), LM-MEL-12 (WT BRAF 
and NRAS) and LM-MEL-24 (BRAF V600K) was determined (Figure 5.8).  
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In case of LM-MEL-1a (NRAS Q16K) (Figures 5.8 B & E) and LM-MEL-24 (BRAF V600K) 
(Figures 5.8 C & E), it was observed that the 24 h treatment of 1 mg/mL DTIC there was a 
non-significant effect in the P-gp expression when compared to the untreated cells. In LM-
MEL-12 (WT BRAF and NRAS) and LM-MEL-62 (BRAF G469E) (Figures 5.8 D & E) cells 
(Figures 5.8 A & E), there was a significant increase in P-gp expression (p< 0.05). However in 
all these cells, a highly significant downregulation (p≤ 0.001) of P-gp was observed at 48 h, 
72 h and 96 h. In case of LM-MEL-12 (WT BRAF and NRAS), LM-MEL-62 (BRAF G469E) and 
LM-MEL-24 (BRAF V600K) cells at 72 h, DTIC showed significant but comparatively less 
effective downregulation (p≤ 0.01) of P-gp. Interestingly, P-gp expression was found to 
increase in all the cell lines at the period of 120 h when compared to 48-96 h. A significant 
increase (p< 0.05) was observed in all the cells treated with DTIC at 120 h when compared 
to 96 h of treatment. Therefore, it was inferred from these results that at 120 h the P-gp 
expression starts to upregulate in the melanoma cells following single treatment of DTIC.  
Treatment time of 48 h and 120 h was compared for DTIC (1mg/mL) in all the four 
melanoma cell lines. At 48 h time point was chosen as the maximum downregulation of P-gp 
expression was observed when compared to untreated cells. All the four cell lines showed a 
significant increase (p≤ 0.01) in the P-gp expression at 120 h treatment when compared to 
48 h of treatment indicating increase in P-gp expression at this time point (Figure 5.8 E).  




Figure 5.8 (A). Analysis of P-gp expression with DTIC in LM-MEL-12 (WT BRAF and NRAS) in 
a time-dependent manner. Treatments with DTIC showed a time-dependent decrease in 
the P-gp expression until 96 h of treatment. Shift in the peak from P4 region in the 
untreated cells to the P3 region with treatments indicate a decrease in the expression of P-
gp. After 120 h of treatment the P-gp expression shift is towards the P4 region indicating an 
increase in the expression after 120 h. Percentage cells that were stained positive in the P4 
region (P-gp positive cells) from the total of 10,000 cells that were gated (P1) were indicated 
as numerical values in the FACS plots. 




Figure 5.8 (B). Time-dependent effect of DTIC on LM-MEL-1a (NRAS Q16K). Treatments 
with DTIC (1mg/mL) were done in a time-dependent manner, starting from 24 h, 48 h, 72 h, 
96 h and 120h. The cells were processed for FACS analysis and results were analysed using 
the FACS-Diva software. Treatments were done in triplicates and the experiment was done 
thrice. Shift in the peak from P4 region in the untreated cells to the P3 region with 
treatments indicate a decrease in the expression of P-gp and shift from the P3 region to the 
P4 region indicate an increase in P-gp expression. Representative images from each 
treatment were shown. Percentage cells that were stained positive in the P4 region (P-gp 
positive cells) from the total of 10,000 cells that were gated (P1) were indicated as 
numerical values in the FACS plots. 




Figure 5.8 (C). Time-dependent study of P-gp expression with DTIC in LM-MEL-62 (BRAF 
G469E). One mg/mL of DTIC was used for treating cells in order to check their effect on the 
P-g expression. The cells were treated for various time points and the treated cells were 
fixed and blocked after which they were stained with P-gp specific primary antibody and 
anti-mouse IgG FITC for 1 h each at 370C. Following staining, the cells were analysed through 
FACS and representative FACS plot from three repeats were shown. Percentage cells that 
were stained positive in the P4 region (P-gp positive cells) from the total of 10,000 cells (P1) 
that were gated were indicated as numerical values in the FACS plots. 




Figure 5.8 (D). FACS analysis representing P-gp expression with DTIC treatments in LM-
MEL-24 (BRAF V600K). Treatments with DTIC showed a time-dependent decrease in the P-
gp expression until 96 h of treatment. Shift in the peak from P4 region in the untreated cells 
to the P3 region with treatments indicate a decrease in the expression of P-gp. After 120 h 
of treatment the P-gp expression shift is towards the P4 region indicating an increase in the 
expression after 120 h. Percentage cells that were stained positive in the P4 region (P-gp 
positive cells) from the total of 10,000 cells (P1) that were gated were indicated as 
numerical values in the FACS plots. 




Figure 5.8 (E). Quantitative analysis of P-gp expression with DTIC treatments from 24 h 
upto 120 h. Quantification of the % expression of P-gp in the various melanoma cell lines 
tested, when treated with DTIC was done from the FACS graphs that were analysed by FACS-
Diva software. All values are represented as mean ± SE. Student’s t test was performed to 
evaluate statistical significance. A value of (p< 0.05) is represented as *, (p≤ 0.01) as ** and 
(p≤ 0.001) as *** was considered statistically significant when compared to untreated cells.  
Histogram represents the decrease in the P-gp positive cells (P4 region) in all the four cell 
lines upto 96 h of treatment. A value of (p≤ 0.01) represented as † was considered 
statistically significant when compared amongst the treatments.  
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5.5.9 P-gp protein expression reappears after 120 h following single treatment of DTIC, 
Dox and Melphalan in Mel-007 (DR) 
In order to determine the effect of drugs on the P-gp expression in Mel-007 (DR) three 
different drugs, namely DTIC, Doxorubicin (Dox) and Melphalan, flow cytometric analysis 
was performed. Since, Mel-007 is an established cisplatin-resistant cell line; it would be 
interesting to study the effect of diverse chemotherapeutic drugs. A time dependent study 
on the effect of the three drugs used was conducted from 24 h to 120 h in Mel-007 (DR) 
cells (Figure 5.9 A & B). At 24 h period, DTIC failed to induce any significant downregulation 
of P-gp as noted with other cell lines earlier in this study. However, both Dox and Melphalan 
significantly (p< 0.05) lowered the P-gp expression. Dox showed significantly higher (p≤ 
0.01) downregulation of P-gp expression at 48 h when compared to DTIC while Melphalan 
which showed an equally significant effect (p< 0.05) to DTIC when compared to untreated 
cells. At 72 h period all the three drugs induced an equally significant (p≤ 0.001) effect on 
downregulation of P-gp, whereas at 96 h period Dox showed comparatively lower effect (p≤ 
0.01) than the other two (p≤ 0.001) and when compared to its own effect at 72 h period. 
However, at 120 h the P-gp expression was found to be much higher in all treatments when 
compared to 96 h, even though the P-gp levels were found to be significantly lower than the 
untreated cells (p< 0.05). Therefore, these results imply that even though all the drug 
treatments were highly effective in downregulating the P-gp expression at 72- 96 h, the P-gp 
expression was found to increase significantly levels at 120 h, when compared to 72 h of 
treatment (where maximum downregulation of P-gp expression was observed when 
compared to untreated cells). With DTIC (p< 0.05), Dox (p≤ 0.01) and Melphalan (p≤ 0.01) a 
significant increase in P-gp expression was observed at 120 h when compared to 72 h of 
treatment in Mel-007 (DR) cells.  




Figure 5.9 (A). Time-dependent analysis of chemotherapeutic drugs (DTIC, Dox and 
Melphalan) on Mel-007 (DR). Mel-007 (DR) cells were treated with DTIC, Dox and 
Melphalan at 1 mg/mL for varying time points from 24 h, 48 h, 72 h, 96 h and 120 h. After 
treatment, cells were fixed with 4 % PF for 20 min at RT. The cells were then blocked with 3 
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% rabbit serum for 1 h at 37oC. Primary antibody, anti-human mouse P-gp monoclonal 
antibody was added at a concentration of 1:100 and the cells were incubated for 1 h at 
37oC. Anti-mouse IgG FITC (1:100) was added and incubated for 1 h at 37oC. The stained 
cells were analysed through FACS BD-Canto II. The treatments were carried out thrice and 
the experiment was done thrice independently. Representative images from FACS that 
shows the shift in the peak from P3 to P2 region when treated with the chemotherapeutic 
drugs were shown. The shift in the peak towards the left represents the reduction in 
expression of P-gp in both the melanoma cell lines tested when compared to the untreated 
or control cells. Percentage cells that were stained positive in the P4 region (P-gp positive 
cells) from the total of 10,000 cells (P1) that were gated were indicated as numerical values 
in the FACS plots. 
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Figure 5.9 (B). Comparative analysis of the effect of DTIC, Dox and Melphalan on P-gp 
protein expression. Quantification of the % expression of P-gp in Mel-007 (DR) cell line that 
was tested, when treated with DTIC, Dox and Melphalan was done from the FACS graphs 
that were analysed by FACS-Diva software. Percentage cells that were stained positive in the 
P4 region (P-gp positive cells) from the total of 10,000 cells (P1) that were gated were 
indicated as numerical values in the FACS plots and these values are represented as mean ± 
SE. Student’s t test was performed to evaluate statistical significance. A value of (p< 0.05) is 
represented as *, (p≤ 0.01) as ** and (p≤ 0.001) as *** was considered statistically 
significant when compared to untreated cells. A value of (p< 0.05) represented as † and (p≤ 
0.01) represented as †† was considered statistically significant when compared amongst the 
treatments.   
5.6. DISCUSSION 
A number of drug resistant markers play a critical role in the mechanisms conferring MDR to 
melanomas (Grossman & Altieri 2001). P-gp has been related to drug resistance directly and 
it has been shown that P-gp protects the cells from multiple forms of caspase-dependent 
apoptosis as it effluxes any drug that enters the cells (Smyth et al. 1998). P-gp is one of the 
most commonly studied clinical markers for understanding MDR in cancer cells, when they 
are treated with chemotherapeutic regimens (Gillet, Efferth & Remacle 2007). In the 
present study, P-gp was found to localise in the melanoma cells mainly in the cell 
membrane, surface and cytoplasm of the cells (Figure 5.4). Although, P-gp is a membrane 
protein that is restricted to the plasma membrane of the cells, it is also expressed in the 
membranes of various cytoplasmic components like the Golgi body (Wojtal et al. 2006) and  
intra-cytoplasmic vesicles (Fox & Smith 1995). Presence of P-gp along the plasma 
membrane, caveolae, coated vesicles and nuclear envelope in astrocyte culture was 
confirmed earlier by studying the accumulation of [3H] digoxin which is an established P-gp 
substrate (Ronaldson et al. 2004). It has been proved that redistribution of P-gp primarily 
arises as a mechanism of resistance to chemotherapeutic agents and cytotoxic drugs 
including Dox. This redistribution occurs from the plasma membrane to the cytoplasm 
leading to reduced nuclear localisation of any drug, which is hypothesised to be one of the 
mechanisms by which P-gp causes MDR (Abbaszadegan et al. 1996).  
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P-gp can be present in plasma membrane, intracellular membranes and nuclear envelope in 
drug resistant cell lines. Recently, it has also been proved that P-gp transporter can be found 
within the cell as a regulatory mechanism of drug resistance which holds extreme 
importance in the cancer cell survival (Szaflarski et al. 2013). The focus of this chapter was 
to observe the effects of bLf in being able to target and downregulate P-gp protein 
expression in a panel of melanoma cell lines.       
Although there are no studies that show effect of bLf on P-gp expression, studies from our 
laboratory have shown that Fe-bLf shows effective decrease in tumour volume without 
inducing any drug resistance, whereas both Taxol and Dox have shown an increase in the 
tumour volume which may imply to an increase in the drug resistance (Kanwar, Mahidhara 
& Kanwar 2012b; Kanwar et al. 2014). 
It has been previously reported that p53 mutant cells express high levels of P-gp and 
survivin (Shi et al. 2007). Studies have also claimed that p53 downregulation is highly 
essential for prevention of apoptosis and chemosensitivity in melanoma cells and thus, 
several drugs are unable to reduce P-gp and Bcl-2 expression in p53 mutant cells (Li, Bush & 
Ho 2000). It was observed from the results in this study on p53 mutant cells, that Native-bLf 
and Fe-bLf were efficient in downregulating the P-gp expression in SK-MEL-2 and SK-MEL-
28. It was found that in SK-MEL-28 both Native-bLf and Fe-bLf were equally efficient in 
downregulating the P-gp expression when compared to Apo-bLf, although Apo-bLf was able 
to induce a higher cytotoxicity than Fe-bLf in SK-MEL-28 cells (Chapter 3, Figure3.8).  On the 
other hand, Fe-bLf was the most effective in downregulating the P-gp expression in SK-MEL-
2 cells, which correlated its cytotoxicity (Chapter 3) where Fe-bLf was found to be the most 
cytotoxic in SK-MEL-2 cells.  
Studies have claimed that iron deprivation leads to downregulation of MDR genes (Fang et 
al. 2010) and commonly used iron chelator, desferrioxamine has shown to decrease P-gp 
expression (Cheng et al. 2011). Even though Apo-bLf was found to be more cytotoxic in SK-
MEL-28, no supporting evidences were found to prove or hypothesise why Apo-bLf led to an 
increase in P-gp expression. Interestingly, in SK-MEL-2 and SK-MEL-28 cells although Apo-bLf 
did not downregulate the expression of P-gp, it had significantly induced substantial 
translocation of P-gp to the nucleus after 48 h of treatment. P-gp has also been studied to 
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have a direct interaction with p53 which was confirmed in in vivo models of breast cancer. 
Immunoprecipitation assays of with siRNA transfected MCF-7 and p53 mutated MDA-MB-
231 cells showed that P-gp regulates the expression of pokemon (a critical factor in 
oncogenesis) through the presence of p53 (He et al. 2010). In breast cancer and 
osteosarcoma poor expression of wild-type p53, is reported to be associated with increased 
expression of P-gp in the cells leading to poor prognosis and reduced survival (Linn et al. 
1996; Park et al. 2001). Considering the p53 mutational status of SK-MEL-2 and SK-MEL-28, a 
further in depth investigation to delineate interactions of nuclear P-gp and p53, will be an 
interesting follow up of this study.  
The levels of P-gp have also been studied to be regulated by ROS. In prostate cancer cells it 
has been shown that maximum P-gp expression was observed in tumour spheroids with a 
high percentage of quiescent, reduced ROS levels and increased expression of CDK inhibitors 
(Wartenberg et al. 2001). Apo-bLf acts as an iron chelator, releasing free Fe from the cells 
(Oda et al. 2014). One possible explanation is that, a decrease in free iron content in the 
cells could lead to increase in the oxidative stress as a result of which there is an increase in 
the P-gp expression in both SK-MEL-2 and SK-MEL-28 when treated with Apo-bLf. Fe-bLf on 
the other hand, although saturated with 98 % of iron, is a more potent anti-cancer agent 
that directly targets wild-type survivin (Kanwar et al. 2014). Moreover, Fe-bLf has been 
previously demonstrated as an anti-oxidant agent in human gut epithelial cells (HT-29) by 
our laboratory, where Fe-bLf protects the cells against oxidative stress induced damage by 
the generation of free radicals (Burrow et al. 2011). It has been previously reported that 
downregulation of survivin leads to a decrease in P-gp expression (Liu et al. 2010). It was 
also seen from this study that Fe-bLf completely disturbed the cell shape and led to 
rounding in cell morphology (Chapter 2, Figure 4.4). Beta-III tubulin forms an integral part of 
the cytoskeletal framework that helps to hold the integrity of the cell structure and shape. 
Studies have claimed that reducing the beta-III-tubulin can lead to a decrease in P-gp 
expression (Cai et al. 2013). Hence, it is possible that Fe-bLf leads to downregulation in P-gp 
expression by two ways, lowering the survivin expression and altering the cell shape and 
morphology leading to a disruption of β-actin and β-III-tubulin (Beck et al. 1986). 
In Dox-resistant, highly metastatic, 4T1 breast cancer cells, there was reduced nuclear 
localisation of Dox due to overexpression of P-gp in nucleus of the resistant cells. The Dox-
     Chapter 5- Role of bLf in targeting critical drug-resistant marker P-glycoprotein (P-gp) 
331 
 
resistant cells when treated with verapamil, which is a known to be a general inhibitor of P-
gp, increased the nuclear localisation of Dox (Bao et al. 2011). Verapamil was used as a 
positive control to inhibit P-gp expression in both SK-MEL-2 and SK-MEL-28. Verapamil has 
been used extensively as an inhibitor of P-gp in in vitro and clinical studies (Fung et al. 2014). 
In this study verapamil showed, a dose dependent effect in the downregulating the P-gp 
expression in SK-MEL-2 and SK-MEL-28, when these cells were treated with varying 
concentrations of verapamil for 48 h. Atenolol, a cardioprotective drug that is also being 
used in various clinical trials to treat melanomas (McCourt et al. 2014), was tested as this 
would form an important aspect in drug repurposing for an added advantage of it being P-
gp inhibitor. Atenolol showed a significant effect in reducing the P-gp expression in both SK-
MEL-2 and SK-MEL-28 cells indicating the potential for using atenolol in the future as a 
treatment of metastatic drug resistant melanoma. However, before that, more in-depth 
studies are needed as with higher concentrations of atenolol P-gp expression started to 
increase.  
P-gp status was also studied extensively in order to understand its role and importance in 
varying melanoma cells with BRAF, NRAS mutations and in drug resistant melanoma cells. In 
order to understand its correlation with the other drug resistance and stem cell markers 
(EpCAM, CD133, survivin, ALDH and EGFR), the baseline expression patterns of these 
markers were investigated in recently established melanoma patient cell lines, LM-MEL-1a 
(NRAS Q16K), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 (BRAF V600K), LM-MEL-62 
(BRAF G469E) and Mel-007 (drug-resistant). Interestingly, irrespective of the BRAF and NRAS 
mutational status of the cells, both P-gp and survivin were highly expressed. However, it is 
still unclear whether BRAF mutation leads to an increase in P-gp or not, since the 
endogenous P-gp expression observed in the LM-MEL-12 (WT BRAF and NRAS) cells the 
same as that of the BRAF and NRAS mutant cells. From the IF experiments (Figure 5.4) it has 
been observed that the survivin and P-gp expression levels were almost the same in all the 
cell lines studied. Studies have shown that even though BRAF mutation may play a role in 
acquiring drug resistance, it doesn’t lead to an increase in P-gp expression in melanoma (Su 
et al. 2012a). Mel-007 (DR), drug resistant melanoma cells also showed a high expression of 
P-gp which was in accordance with earlier studies where P-gp overexpression was noted in 
drug-resistant cancers (Stordal et al. 2012). 
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        Effect of BRAF and NRAS mutations on endogenous survivin expression remains 
uninvestigated. Among the many genetic alterations that occur in melanomas, BRAF, NRAS 
and p53 are the most frequent, therefore the present study which comprehends extensive 
information on several stem cell markers and drug resistance markers may be highly 
promising and of great interest to the researchers and clinicians working in field of 
melanoma therapy. It was observed that LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF 
G469E) cells showed an increase in CD133 expression when compared to the LM-MEL-12 
(WT BRAF and NRAS) cells. The EpCAM expression was also found to increase in cells with 
BRAF mutations i.e., LM-MEL-62 (BRAF G469E) and LM-MEL-24 (BRAF V600K) cells. While, 
an increase in the EGFR expression was also observed in Mel-007 (DR) cells compared to all 
the other cell lines. These findings clearly implicate that oncogenic mutations lead to 
increased expression of several cancer stem cell markers such CD133 and EpCAM, whereas 
EGFR may have an important role in drug resistance. EGFR expression in melanoma, most 
commonly associated with progression and metastasis is expressed in patients with positive 
sentinel lymph nodes (SNL) (Boone et al. 2011). EGFR are also known to be associated with 
vemurafenib resistance where vemurafenib resistant cells showed a stronger P-gp 
expression when compared to tumour cells (Gross et al. 2014). There are several studies 
that claim that a mutation in EGFR may lead to increased drug resistance in cancers (Bell et 
al. 2005; Yun et al. 2008) and that targeting EGFR can over drug resistance in EGFR mutated 
cancers (Regales et al. 2009). Although EGFR is an important marker in drug-resistant 
melanomas, the role of all the three forms of bLf on EGFR has not been explored in this 
study due to its lack of expression in two of the melanoma cell lines tested (Figures 5.4 A 
&C).  
The unpublished work from our laboratory on breast cancer cell lines proves that Fe-bLf 
downregulates the EGFR expression leading to cell death in breast cancer cells. However, 
future studies could employ more patient-derived melanoma cell lines to study this aspect. 
The presence of P-gp, survivin and EGFR markers in the melanoma cell lines tested provided 
a model to study the effect of bLf on these drug-resistant markers in order to develop bLf as 
a potential therapeutic for targeting drug resistant melanomas and their stem cell markers. 
The most commonly expressed marker in the 5 melanoma cell lines tested, at baseline level 
were P-gp and survivin (Figure 5.4 A-E). The localisation of survivin was mainly found to be 
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cytoplasmic in most of the cell lines tested in this study. Cytoplasmic expression of survivin 
in melanoma has been related to attributing survivin the property to inhibit apoptosis by 
decreasing caspase-9 activity (Lewis et al. 2011). Cytoplasmic survivin also indicates the role 
of survivin in being able to increase phospho-Akt that leads to increase of α5 integrin. This 
integrin is mainly responsible for regulating cell motility which could help cancer cells 
acquire the property of being metastatic (McKenzie et al. 2010). It has been shown that 
overexpression of survivin leads to increase in the migration and invasion properties of 
melanoma cells. When wild-type survivin was targeted using a dominant negative mutant of 
survivin leads to loss of G2M DNA content in the melanoma cells leading to reduction of cell 
proliferation, both in vitro and in vivo was observed (Brennan et al. 2008; Grossman et al. 
1999). Presence of survivin in the nucleus, as noted in LM-MEL-24 (BRAF V600K) cells, that 
had a higher proliferative ability when compared to other melanoma cell lines studied in this 
chapter, indicated that survivin could play a role in its association with the chromosomal 
passenger complex (CPC) that helps in the microtubule assembly during metaphase of the 
cell cycle. This helps in the survival and proliferation of cells which is one of the most 
common property attributed to cancer (Mckenzie & Grossman 2012). Furthermore, survivin 
has been studied extensively as a drug resistant maker and it has been proved that 
inhibition of survivin has been able to reverse the phenomenon of drug resistant to drug 
sensitivity (Li et al. 1999). The effect of all the three forms of bLf on survivin expression has 
been investigated in the previous chapters (Chapter 3, Figure 3.13 and Chapter 4, Figure 
4.11), hence P-gp was chosen as the marker of interest for studying the effects of all the 
three forms of bLf.   
The effect of bLf forms on P-gp in mutant and drug resistant melanoma cells revealed that 
Apo-bLf was more effective than Fe-bLf in case of both LM-MEL-12 (WT BRAF and NRAS) 
and LM-MEL-24 (BRAF V600K) cells. It has already been shown in the previous chapter 
(Chapter 4) that both these cell lines showed characteristic similarities and that Apo-bLf was 
found to have a higher anti-cancer efficacy in these cells when compared to Fe-bLf. All the 
three forms of bLf at 80 nM were effective in downregulating the P-gp expression in LM-
MEL-12 (WT BRAF and NRAS) and LM-MEL-24 (BRAF V600K) cells. Native-bLf and Fe-bLf 
were found to be most effective in LM-MEL-1a (NRAS Q16K) and LM-MEL-62 (BRAF G469E) 
cells, whereas; Apo-bLf and Fe-bLf were the most effective in Mel-007 (DR) cells. The results 
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for Fe-bLf were also in accordance with the results of previous chapter (Chapter 4) where 
Fe-bLf was found to have a better anti-cancer efficacy in these cells which were found to 
have characteristic similarities. Hence, it could be claimed that Fe-bLf internalised in these 
cells and downregulated P-gp protein expression which could be a consequence of the 
downregulation of survivin protein expression and upregulation of apoptosis in the 
melanoma cell lines.  Therefore, it could be hypothesized that iron metabolism of cells has 
an important role in P-gp expression. An in depth analysis of the iron metabolism pathway 
of all the mutant and the drug resistant melanoma cells may provide a wider insight on 
effect of bLf on P-gp expression in these cells. 
             The only FDA approved drug, for treating metastatic melanoma is dacarbazine (DTIC) 
(Serrone et al. 2000). Although a number of studies have employed the use of DTIC alone, 
and in combination with other therapeutic options, the effect of DTIC on P-gp expression 
has not been studied in these cell lines. To investigate the effect of this drug on P-gp 
expression in five different patient-derived cell lines with varying BRAF, NRAS and drug 
resistant status were thus employed. No effect on P-gp expression was noted at 24 h 
incubation. However, after 48 h, 72 h and 96 h there was a significant decrease in the P-gp 
positive cells in LM-MEL-1a (NRAS Q16K), LM-MEL-12 (WT BRAF and NRAS), LM-MEL-24 
(BRAF V600K) and LM-MEL-62 (BRAF G469E). When the cells were treated for 120 h, it was 
observed that the P-gp expression reverted significantly. This shows that although DTIC is 
effective after 48 h of treatment, its effectiveness is reduced with longer incubations. It has 
been previously reported that post chemotherapeutic treatments, cells that are viable show 
a high expression of P-gp, which could further lead to survival of these cancer cell types 
(Tang et al. 2004).  
Since Mel-007 (DR) is an established drug resistant cell line, other anti-cancer drugs, Dox 
and Melphalan were also added to the study including DTIC. The same effect of all anti-
cancer drugs was noted in Mel-007 (DR) as well, where there was no effect in the P-gp 
expression with DTIC, but both Dox and Melphalan showed significant downregulation (p< 
0.05) of P-gp, when treated for 24 h. After 48 h of treatment, there was further decrease in 
the P-gp expression with DTIC, Dox and Melphalan which was more reduced at 72 h and 96 
h post treatment time. However, after 120 h of treatment, the P-gp expression was found to 
increase. This effect could be due to less availability of the chemotherapeutic drug to the 
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cancer cells after 120 h because of the increase in P-gp positive cells. P-gp expression in the 
remaining viable cells could help in the extrusion of the drug from the cells after 120 h 
which could lead to overexpression of P-gp in the cells (Schinkel 1997). Even though atenolol 
had shown promising results in both SK-MEL-2 and SK-MEL-28 cells, it was not 
comparatively effective for  substantial lowering of P-gp expression in mutant and drug 
resistant melanoma cells, whereas the standard P-gp inhibitor, verapamil showed a dose 
dependant efficient effect in downregulating the P-gp expression in all the five cell lines. 
The results from this chapter therefore present highly novel and key findings that may be 
helpful to form a platform for the future melanoma therapy. The insights provided by this 
chapter are not only beneficial to clinicians (since not only bLf, some other important 
chemotherapeutic drugs have been used in this stud), but also to researchers working in the 
field of natural therapy against melanoma.  
5.6 CONCLUSIONS 
In summary the key findings of this chapter showed that bLf forms, Native-bLf and iron-
saturated bLf (Fe-bLf) were more effective in downregulating P-gp in SK-MEL-2 and SK- MEL-
28 melanoma cells. Speculation of a possible relation between BRAF mutation and stem cell 
progression, since there was an increase in both CD133 and EpCAM in LM-MEL-62 (BRAF 
G469E) and LM-MEL-24 (BRAF V600K) could be made. The findings from this study indicate a 
possible relationship and interactions among iron metabolism, BRAF mutations and P-gp 
expression since, Apo-bLf was found to be more effective in downregulating P-gp and 
inducing higher anti-cancer activity (Chapter 4) in characteristically similar LM-MEL-12 (WT 
BRAF and NRAS) and LM-MEL-24 (BRAF V600K), while Fe-bLf was more effective in in 
downregulating P-gp and induced a higher anti-cancer activity (Chapter 3) in 
characteristically similar (LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 
(DR) melanoma cells. This chapter also presented the efficacy of atenolol as a potential P-gp 
targeting drug, whereas it also established that the P-gp inhibitor verapamil proved effective 
in targeting P-gp expression in BRAF, NRAS, p53  mutant and drug resistant melanoma cells. 
This chapter highlights the role of bLf as the most effective P-gp targeting agent as lower 
concentrations of Native-bLf and Fe-bLf (nM concentration) were more effective than 
verapamil (effective at µM concentrations) even after 120 h of treatment in downregulating 
the expression of P-gp. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
Although a number of chemotherapeutic regimes have been developed and understood in 
being able to target melanomas, their limited action and the development of multi-drug 
resistance (MDR) has posed continuing problems in formulating effective anti-melanoma 
therapeutics. To counteract the side-effects and other limitations associated with 
chemotherapy, a number of studies have focussed on developing natural therapeutic 
options for targeting melanoma. As described in Chapter 2, section 1.5 bovine lactoferrin 
(bLf) has been proved to be a potent natural biodrug for anti-cancer therapies by our 
laboratory and by a number of other studies worldwide. The three forms of bLf with varying 
iron saturation levels Natural bLf, termed as Native-bLf, iron-free (Apo-bLf) and iron-
saturated (Fe-bLf) were investigated for their activities in melanoma cell lines with varying 
p53 mutational status, SK-MEL-2 and SK-MEL-28, well-established patient-derived primary 
melanoma cell lines with varying BRAF and NRAS status, LM-MEL-12(WT BRAF and NRAS), 
LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and LM-MEL-24 (BRAF V600K)  and in 
drug-resistant cell lines, Mel-007 (DR).  
Main conclusions from this study are 
 All the three forms of bLf, Native-bLf, Apo-bLf and Fe-bLf were able to internalise 
into melanoma cell lines through receptor-mediated internalisation. At 40 nM 
concentrations bLf forms were able to cause significant cell death in all the 
melanoma cell lines tested. Fe-bLf was most effective in causing cell death in SK-
MEL-2 and Apo-bLf caused cell death in SK-MEL-28. The difference in the anti-cancer 
activities of Apo-bLf and Fe-bLf could be attributed to the p53 mutational status of 
the cell lines. However, further studies on iron metabolism specific micro RNA can be 
conducted to develop a better understanding on the difference of the iron-free and 
iron-saturated forms of bLf on the melanoma cell lines tested.  
 The three forms of bLf were not only effective in causing cell death in melanoma cell 
lines with varying p53 mutational status, but also in drug resistant cell line (Mel-007) 
and in cell lines with varying BRAF and NRAS status (LM-MEL-12, LM-MEL-1a, LM-
MEL-62 and LM-MEL-24). Because of the observed differences in the actions of iron 
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free and iron containing forms in targeting these cell lines growth and death, a 
possible relationship of the BRAF/NRAS mutations with the regulation of iron 
metabolism in the melanoma cell lines is hypothesized which can be investigated 
and will further explain these differences. 
 All the three forms of bLf were able to target a number of aspects in vitro including 
the clonogenic potential, tumour spheroid forming potential and the metastatic 
potential of melanoma cell lines. Though all the three forms proved equally effective 
at 80 nM in most of the assays, overall, Apo-bLf at 40 nM was most effective in SK-
MEL-28, LM-MEL-12 (WT BRAF and NRAS) and LM-MEL-24 (BRAF V600K) cells, 
whereas, Fe-bLf was most effective in SK-MEL-2, LM-MEL-12 (WT BRAF and NRAS), 
LM-MEL-1a (NRAS Q16K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) cell lines. This 
could be mainly due to varying p53, BRAF and NRAS mutational status and iron 
metabolism pathways involved.  
 Apo-bLf and Fe-bLf were able to significantly upregulate the protein expression of 
p53 and its downstream regulators causing p53-dependent apoptosis in patient-
derived melanoma cell lines. Silencing p53 expression in these cell lines did not allow 
upregulation of apoptosis confirming that Apo-bLf and Fe-bLf cause cell death in LM-
MEL-1a (NRAS Q6K), LM-MEL-62 (BRAF G469E) and Mel-007 (DR) majorly through 
the p53-mediated pathway of apoptosis.  
 Native-bLf, Apo-bLf and Fe-bLf also targeted the expression of some critical drug-
resistant studied. For example, all the three forms of bLf downregulated both gene 
and protein expression of survivin in all the melanoma cell lines tested. P-gp a critical 
drug-resistant marker in case of melanoma was also downregulated with Native-bLf, 
Apo-bLf and Fe-bLf treatments for upto 120 h of treatment.  
 Chemotherapeutic drugs tested in this study, namely, DTIC, Dox and Melphalan were 
all found to be effective in downregulating the P-gp protein expression. However, 
this effect was limited as the time-dependent studies upto 120 h revealed that P-gp 
expression was significantly (p< 0.05) increased after 96 h of treatment time 
whereas, the bLf forms were able to show marked decrease in the P-gp levels even 
at the 120 h time interval. Therefore, in future bLf can provide an added advantage 
over chemotherapeutics, in targeting P-gp making it a treatment strategy for robust 
and drug-resistant melanomas.  
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Thus this study, for the first time reports on the difference in the effects of iron-free 
Apo-bLf and iron-saturated Fe-bLf depending on the p53 mutational status and the 
BRAF/NRAS mutational status of the melanoma cell lines, and the ability of Native-bLf 
and Fe-bLf in targeting P-gp in drug-resistant melanomas. By employing melanoma cell 
lines from diverse patient range, it is also the first study to prove that bLf leads to 
upregulation of p53 by increasing the protein expression of Numb and Bax and 
downregulating the levels of MDM2, survivin and Bcl-2.  
 
Figure 6.1. Conclusive mechanism of action of bLf in melanoma cell lines. This schematic 
diagram is drawn to show that all the three forms of bLf internalise into the melanoma cell 
lines via receptor mediated mechanisms. After internalisation bLf has shown to 
downregulate the protein expression of anti-apoptotic markers such as survivin, Bcl-2 and 
MDM2. Pro-apoptotic markers such as Bax, p53, phoshpo-p53 and Numb were upregulated 
by bLf treatments. P-gp expression is also downregulated with bLf treatments. bLf also aids 
in nuclear localisation of p53. All these markers together contribute to induction of 
apoptosis in the melanoma cell lines being tested.  




At the preclinical level, by employing robust cell based assays, this study proves the role of 
bLf as an anti-cancer agent for melanoma, supporting previous studies from our laboratory. 
Further studies, investigating the exact mechanism by which iron-free and iron-saturated 
forms act on cell lines with varying p53 and BRAF/NRAS mutational status can be done by 
studying specific iron metabolism markers. Micro RNA (miRNA) expression profiling of 
markers that specifically regulate the iron metabolism in cancer cells and normal cells can 
be studied to form an understanding on the role of the iron-free and iron-saturated forms in 
causing cell death in melanomas.  
Furthermore, as the roles of bLf in targeting drug-resistant markers such as P-gp and 
survivin have been investigated in the current study. It will be worthwhile to study the effect 
of all the three forms of bLf on some other drug-resistant markers for melanoma such as 
livin, stathmin and multi-drug resistance related protein-1 (MRP-1). This will help establish 
the role of bLf in targeting an array of other drug-resistant markers including P-gp, CD133 
and survivin.  
Clinical samples for example, tumour biopsies can be screened for the presence of various 
markers like P-gp, survivin, CD133, livin, stathmin etc. to study and gain knowledge on the 
presence of these markers in a clinical scenario. Confirmation of the presence of these 
markers would help formulate anti-melanoma therapy directed towards targeting specific 
markers.  
To further evaluate and confirm the efficacy of bLf in targeting melanomas, these studies 
can be extended to more patient derived cell lines with different mutational and drug-
resistant status, and be performed using xenograft mouse models for melanoma. In vivo 
analysis of the activity of bLf in reducing tumour volume and its effect on key apoptotic, 
cancer proliferative and drug-resistant markers will provide a broader perspective on the 
exact mechanism(s) of bLf.
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Milli-Q 200 µL 
Concentrated HCl 50 µL 
Milli-Q To make upto 500 µL 
 
Table 2.7. Components of reaction mixture for CyQUANT 
Component Amount No. of tests 
CyQUANT GR dye 1 mL 100 
Cell-lysis buffer 50 μL 100 
Milli-Q water 19 mL 100 
 
Table 2.8 Buffer compositions 
Name of the reagent Reagent Quantity 
10XPBS (pH 7.4) Sodium Chloride (NaCl) 80 g 
Potassium chloride (KCl) 2 g 






Milli-Q  To make upto 1000mL  
Running Buffer (10x) 
(pH 8.3) 
Tris base 33 g 
Glycine 144 g 
SDS 10 g 
Milli-Q To make upto 1000mL 
Towbin transfer buffer Tris base 30.3 g 
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(10x) Glycine 144 g 
SDS 10 g 
Milli-Q To make upto 1000mL  
TBS (10x) (pH 7.4) Sodium chloride (NaCl) 80 g 
Potassium chloride (KCl) 2 g 
Tris base 30 g 
Milli-Q  To make upto 1000mL 
TBST (10x) (pH 7.4) Sodium chloride (NaCl) 80 g 
Potassium chloride (KCl) 2 g 
Tris base 30 g 
Tween-20 500 μL 
Milli-Q To make upto 1000mL  
TBE (10x) Tris base 108 g 
Boric acid 56 g 
0.5M EDTA 20 mL 
Milli-Q To make upto 1000mL 
Staining solution Commassie Brilliant Blue R-250 250mL 
10% glacial acetic acid (CH3COOH) 10 mL 
Methanol 45 mL 
Milli-Q To make upto 500mL 
Destaining solution 10% glacial acetic acid (CH3COOH) 50 mL 
Methanol 45 mL 
Milli-Q To make upto 500mL 
Sample loading buffer Glycerol 4 mL 
o.5M Tris pH 6.8 2.5 mL 
10% SDS 5 mL 
β-mercaptoethanol 1 mL 
Bromophenol blue 10% v/v CH3COOH 
RIPA buffer (pH 7.5) Tris base 0.6507 g 
Sodium chloride (NaCl) 0.877 g 
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Nonident P-40 10mL 
10% sodium deoxycholate 1mL 
10% SDS 1mL 
Milli-Q To make upto 100mL 
Alkaline acetate NaOH 500 µL 
Sodium acetate 0.25 g 
Ascorbic acid Ascorbic acid 25 µL 
HCl (freshly prepared) 275 µL 
 
Table 2.9 LIST OF CHEMICALS AND REAGENTS 
S.no. Reagent/Chemical/Antibody/Buffers Purchased From 
1.  Acetone  Chem Supply Australia 
2.  Acetyl-Asp-Glu-Val-Asp P-nitroanilide  Sigma Aldrich Australia 
3.  Acrylamide  Sigma Aldrich Australia 
4.  Agarose  Sigma Aldrich Australia 
5.  Ammonium per-sulfate (APS) Sigma Aldrich Australia 
6.  Annexin-V staining kit  Roche Australia 
7.  Anti-Goat-FITC  Sigma Aldrich Australia 
8.  Anti-mouse IgG horse radish peroxidise (HRP) Sigma Aldrich Australia 
9.  Anti-Rabbit-FITC  Sigma Aldrich Australia 
10.  Anti-Rabbit-TRITC  Sigma Aldrich Australia 
11.  Apoptotic array kit  R & D Australia 
12.  Anti-Phalloidin Fluorescein-isothyocyanate (FITC) 
antibody  
Sigma Aldrich Australia 
13.  Bradford-Coommassie plus protein assay reagent  Thermo Scientific 
14.  Bovine serum albumin (BSA) Sigma Aldrich Australia 
15.  Chloroform  Sigma Aldrich Australia 
16.  Crystal violet  Sigma Aldrich Australia 
17.  CyQUANT cell proliferation kit  Life Technologies 





diphenyltetrazolium bromide (MTT) reagent  
Sigma Aldrich Australia 
19.  Dithiothreitol (DTT) Sigma Aldrich Australia 
20.  Dimethyl sulfoxide (DMSO) Sigma Aldrich Australia 
21.  DNA ladder  Bio-Rad Australia 
22.  DNA loading dye  Bio-Rad Australia 
23.  DNase RNase free water  Life Technologies 
Australia 
24.  Doxorubicin (Dox) Nishchay life sciences 
25.  Dulbecco Modified Eagles’ Media (DMEM) high 
glucose  
Gibco Australia 
26.  Ethanol  Chem Supply Australia 
27.  Ethylenediamine tetra acetic acid (EDTA) Sigma Aldrich Australia 
28.  Eosin  Fronine lab supplies 
Australia 
29.  Fetal bovine serum (FBS) Bovogen Australia 
30.  Fluoro shield 4’,6-diamidino-2-phenylindole (DAPI) Sigma Aldrich Australia 
31.  Glacial acetic acid  Panreac Australia 
32.  Glycerol Sigma Aldrich Australia 
33.  Glycine  Sigma Aldrich Australia 
34.  Goat anti-CD133 monoclonal antibody  Santa Cruz USA 
35.  Goat anti-bLf antibody Bethyl Scientific, Australia 
36.  Haematoxylin  Fronine lab supplies 
Australia 
37.  Isopropyl alcohol  Chem Supply Australia 
38.  Lactate dehydrogenase cytotoxicity kit  Roche Australia 
39.  Low molecular weight chitosan  Sigma Aldrich Australia 
40.  1M Bicarbonate solution  Sigma Aldrich Australia 
41.  0.1M DTT  Sigma Aldrich Australia 
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42.  Mitochondrial depolarization assay kit  Sigma Aldrich Australia 
43.  25mM magnesium chloride  Life Technologies 
Australia 
44.  Mouse anti-Bad monoclonal antibody  Santa Cruz USA 
45.  Mouse anti-Bax monoclonal antibody  Santa Cruz USA 
46.  Mouse anti-Bcl2 monoclonal antibody  Santa Cruz USA 
47.  Mouse anti-Bcl-xl monoclonal antibody  Santa Cruz USA 
48.  Mouse-anti-beta actin monoclonal antibody  Santa Cruz USA 
49.  Mouse anti-Caspase-3 monoclonal antibody  Santa Cruz USA 
50.  Mouse anti-Caspase-8 monoclonal antibody  Santa Cruz USA 
51.  Mouse anti-Caspase-9 monoclonal antibody  Santa Cruz USA 
52.  Mouse-anti-Cytochrome-C monoclonal antibody  Santa Cruz USA 
53.  Mouse anti-EGFR monoclonal antibody  Santa Cruz USA 
54.  Mouse anti-EpCAM monoclonal antibody  Santa Cruz USA 
55.  Mouse-anti-MDR1 monoclonal antibody  Santa Cruz USA 
56.  Mouse D-8 (anti-survivin) monoclonal antibody  Santa Cruz USA 
57.  MTT solvent  Sigma Aldrich Australia 
58.  Paraformaldehyde  Sigma Aldrich Australia 
59.  Polyvinylidene difluoride (PVDF) membrane  GE Healthcare Australia 
60.  Propidium Iodide (PI) stain  Sigma Aldrich Australia 
61.  Protein ladder  Bio-Rad Australia 
62.  Rabbit serum  Sigma Aldrich Australia 
63.  Rabbit anti-ALDH1 monoclonal antibody  Epitomics USA 
64.  Rabbit anti-CD44 monoclonal antibody  Epitomics USA 
65.  Rabbit anti-G6PDH monoclonal antibody  Epitomics USA 
66.  Radioimmunoprecipitation assay (RIPA) buffer  Made in Laboratory 
67.  Rhodamine  Sigma Aldrich Australia 
68.  RNase H  Life Technologies 
Australia 
69.  RNase OUT  Life Technologies 




70.  RNase ZAP  Life Technologies 
Australia 
71.  Roswell park memorial institute (RPMI) media  Life Technologies 
Australia 
72.  10X RT buffer  Life Technologies 
Australia 
73.  Skim milk  Coles Australia 
74.  Sodium azide  Sigma Aldrich Australia 
75.  Sodium Chloride Sigma Aldrich Australia 
76.  Sodium do-decyl sulphate (SDS) Sigma Aldrich Australia 
77.  Sodium tri-poly phosphate (STPP) Sigma Aldrich Australia 
78.  Superscript-III  Life Technologies 
Australia 
79.  SYBR green premix  Life Technologies 
Australia 
80.  Taxol  Nishchay life sciences 
81.  Tris base Sigma Aldrich Australia 
82.  Triton X-100 Sigma Aldrich Australia 
83.  TRIzol reagent  Life Technologies 
Australia 
84.  Trypan Blue  Sigma Aldrich Australia 
85.  Trypsin/EDTA (0.25%) Life Technologies 
Australia 
86.  Tween-20 Sigma Aldrich Australia 
 
Table 2.10 LIST OF INSTRUMENTS  
S.no. Instrument Model Company name 
1. Biosafety Cabinet Safemate 1.2 Laf technologies 
2. 5% CO2 incubator Heracell 150i Thermo Scientific 
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3. Chemidoc XRS XRS Bio-Rad 
4. SDS-PAGE setup Powerpac Hc Bio-Rad 
5. Gel electrophoresis setup Major Science MP 300N 
6. Protein transfer system Trans-blot turbo Bio-Rad 
7. Fumehood - Conditionaire 
8. Sample Heater HB-2 Wealtec Corp 
9. Colony Counter 570 Suntex 
10. pH meter - Labchem pH 
11. Confocal Microscope LASaf Leica 
12. Inverted Microscope - Prism Optical 
13.  q-RT-PCR iQ5 Bio-Rad 
14. Gradient PCR - Takara 
15. Sonicator Vibra-cell Sonics 
16.  Microplate Reader SH-1000 Corona electric 
17. Fluorescent Reader MTO-601F Corona electric 
18. Flow cytometer CantoII BD biosciences 
19. Centrifuge CT15RT Techcomp 
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